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ABSTRACT 
Human immunodeficiency virus (MV), which is the etiologic agent of the acquired 
immunodeficiency syndrome (AIDS), is mainly spread by heterosexual 
transmission. Therefore, initial exposure to HIV occurs most frequently at the 
genital mucosa and thus the induction of mucosal immune response may be 
important in protection against HIV infection. The finding that some individuals are 
highly exposed to HTV infection, but remain persistently seronegative (HEPS) 
suggests that there may be a natural immune protection mechanism possibly 
involving mucosal immunity. The aim of this thesis was firstly to investigate the 
possibility of local antibody in urine samples from REPS individuals to evaluate the 
theory that such individuals may develop a protective local anti-HIV-1 antibody 
response, detectable in urine. Since elicitation of mucosal immunity is important in 
preventing viral infection by sexual transmission, development of a vaccine which is 
effective for the induction of mucosal immune responses may provide protection to 
mucosal surfaces against HIV-1 transmission. Transgenic plants expressing foreign 
protein have been demonstrated to be an inexpensive and easily delivered system for 
the production of animal and human vaccines which can effectively induce a 
mucosal immune response. The second aim of this work was to develop a transgenic 
plant system expressing HIV-1 gp160 protein to exploit the feasibility of HIV-1 oral 
vaccine. 
The specificity of IgG, IgA and sIgA anti-HIV antibodies to different HIV-1 viral 
proteins present in paired urine and serum samples from 3 HIV-1 seropositive and 9 
REPS individuals were profiled using Western blot immunoassay. Specific sIgA 
antibodies to HIV-1 gpl60, p65, gp4l, p31 and p24 were detected in urine or the 
corresponding vaginal swab samples from HIV-1 seropositive individuals, which 
suggested that a local mucosal immune response was induced by HIV-1 infection. 
For samples from REPS individuals, specific IgG antibodies to HIV-1 gpl60, gpl20 
and pSi, and IgA antibody to HIV-1 p51 were detected in 1 of 9 urine but not the 
corresponding serum samples, respectively. These results suggested that local 
mucosal immune responses may be elicited in those REPS individuals. Furthermore, 
IgG are the predominant isotype of anti-HIV antibodies present in the genitourinary 
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tract of those HEPS subjects and may be associated with a natural protection 
mechanism in some individuals. 
In order to express HIV-1 gp160 protein in transgenic plants, recombinant plant 
expression vectors containing 1HV-1 env16O and leaf specific cauliflower mosaic 
virus (CaMV) 35S promoter or potato tuber specific expression promoter patatin 
were constructed. This first required amplifying the full-length of HIV-1 env16O and 
cloning this into plant plasmids pIBT210.1, behind plant leaf specific promoter 35S, 
and pIBT240.1, behind potato tuber specific promoter patatin. The final 
recombinant expression vectors were obtained by cloning DNA fragments 
containing env160 gene-35S promoter or env16O gene-patatin promoter into the 
plant binary vector pGPTV-KAN which contained the plant selectable marker gene 
nptll, which confers kanamycin resistance to plants. 
The required DNA segment containing HIV-1 env16O associated with the 
appropriate promoter was introduced into tobacco (Nicotiana tabacum "sumsun"), 
potato (Solanum tube rosum, variety "Frito-Lay (FL) 1607") and tobacco NT 
(Nicotiana tabacum)-1 cell line by Agrobacterium-mediated plant transformation 
system. The integration of HIV-1 env160 into tobacco "sumsun" transformants was 
verified by PCR using 3 paired 1-TV-1 env primers, respectively. 29 out of 30 tested 
transformants showed the correctly sized PCR products, which indicated the target 
gene had been successfully introduced into the host genome. To investigate the 
transcription of integrated env160 gene in tobacco transformants, the presence of 
mRNA was analysed by RT-PCR. 14 out of 17 transformants showed specific 
transcription of env16O genes, which indicated the presence and proper processing 
of mRNA of gpl60 gene in the leaves of tobacco plantlets. The expression of HIV-1 
gpl60 protein in transformed tobacco plantlet leaves, potato microtubers and NT-1 
cells was detected by gpl60/120 ELISA using monoclonal antibody to HIV-1 
gpl20. Results showed that HIV-1 gpl60 protein was expressed in 84 out of 96 
kanamycin-resistant tobacco plantlets with the expression level ranging from 0.03 to 
15.88 ng/mg total soluble protein, corresponding to gp160 protein accumulated in 
the leaves of tobacco transformants from 0.000003 to 0.002% of the total soluble 
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leaf protein. The presence of HIV-i gp16O protein was also detected in 8 out of 32 
tested potato microtubers and 6 out of 32 tested NT-1 cell transformants, with the 
expression level up to 14.92 ng/mg total soluble protein in potato microtubers and 
2.76 ng/mg total soluble protein in NT-i cell transformants, corresponding to about 
0.002% and 0.0003% gpl60 of the total soluble protein, respectively. These results 
demonstrate the feasibility of expressing the HIV-1 gpl60 protein in transgenic 
tobacco, potato and tobacco NT-i cell systems. Such transgenic plants may provide 
a valuable tool for the development of edible oral vaccines. 
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1.1 Human immunodeficiency virus 
1.1.1 Discovery 
The first cases of what later became known as acquired immunodeficiency syndrome 
(AIDS), manifested as Pneumocystis carinii pneumonia (PCP) were reported in June 
1981 in the United States (Gottlieb et al., 1981). The other immunodeficiency-associated 
conditions such as Kaposi's sarcoma, mucosal candidiasis, disseminated 
cytomegalovirus infection, and chronic perianal herpes simplex virus ulcers were 
described in next several months. All the affected patients had the common features of 
T-lymphocyte dysfunction. By the end of 1982, the outbreak of this immunodeficiency 
syndrome was reported in over 30 states and different populations hemophiliacs, 
transfusion recipients, sex partners of risk-group people, and children born to mothers at 
risk. This all pointed to a transmissible agent which spread through genital secretions 
and blood. 
Several infectious agents were suggested as possible etiologic agents for this newly 
described immunodeficiency syndrome such as human cytomegalovirus (CMV), 
hepatitis B (HBV) and human T-cell leukaemia virus type 1 (HTLV-1). However, all 
three viruses were excluded as there was limited evidence of infection with these viruses 
in the AIDS affected patients, particularly children. Barre-Sinoussi et al. (1983) 
recovered a reverse transcriptase-containing virus, suggestive of a retrovirus, from the 
lymph node of a man with persistent lymphadenopathy syndrome (LAS). This first 
isolation of a retrovirus, later called lymphadenopathy-associated virus (LAy), was 
initially believed to be a member of known human retrovirus groups such as human T -
cell leukemia virus (HTLV), until Montagnier et al. (1984) found that this human 
retrovirus had some quite distinct properties from HTLV. They found that it grew 
substantially in peripheral blood mononuclear cells (PBMC), killing CD4 lymphocytes, 
not immortalising them. In 1984, Gallo et al. and Levy et al. reported another two 
human retrovirus HTLV-III and AIDS-associated retroviruses (ARV) respectively. Both 
of them confirmed that these two viruses had the same properties as LAV and greatly 
expanded the evidence linking these three retrovirues (LAV, HTLV-HI, ARV) to the 
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immunodeficiency syndrome. 
In 1986, the three prototype viruses (LAy, HTLV-111 and ARV) were recognised as 
members of the same group of retroviruses, and the International Committee on 
Taxonomy of Viruses recommended giving the AIDS virus a separate name, the human 
immunodeficiency virus (HIV). 
Subsequently a second human immunodeficiency virus (HIV-2) was isolated in West 
Africa and North America. It appeared that individuals infected with HIV-2 also develop 
AIDS, but with a longer clinical latency period and lower morbidity (Clavel et al., 
1986). 
1.1.2 Transmission 
According to new estimates from the Joint United Nations Program on HIV/AIDS 
(UNAIDS) and the World Health Organization (WHO) (HiVinSite 1999), 33.6 million 
people were living with HIV/AIDS by the end of 1999. By the end of 1999, it is 
estimated that total number of AIDS deaths was 16.3 million since the summer of 1991. 
Approximately, 22% of these deaths occurred in children and 38% in women. In 1999, 
2.6 million people died from HIV/AIDS, a figure that is higher than for any year since 
the beginning of the epidemic. With the HIV-positive population expanding, the annual 
number of HIV/AIDS deaths can be expected to increase for many years. Clearly, AIDS 
represents an international health crisis that threatens to overwhelm even the best 
systems of health care delivery. 
HIV is spread by sexual contact, by exposure to infected blood or blood products and 
perinatal transmission from mother to child. Heterosexual transmission remains by far 
the predominant mode of transmission worldwide (Quinn et al., 1996). 
1.1.2.1 HIV-1 transmission by blood and blood products 
HIV transmission by blood was first reported in 1983 (Jaffe et al., 1983). It is clear that 
both free infectious HTV and HIV-infected cells are present in blood, although HIV- 
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infected cells appear to be more infectious. Transfusion recipients and hemophiliacs 
have been infected by HIV present in blood and blood products such as factors Vifi and 
IX, although heat treatment processes have virtually eradicated HIV transmission 
through this route (Levy et al., 1984b). Studies have demonstrated that the time period 
before development of AIDS in the donor can influence the risk of transmission (Perkins 
et al., 1987; Ward et al., 1989). Those who received blood transfusions from individuals 
who had already developed AIDS progressed to disease much more rapidly than those 
who received blood from an asymptomatic individual. In rare instances, transfusion 
recipients of contaminated blood do not become infected (Ward et at., 1989), possibly 
reflecting a very low virus load in the donors. 
The use of illicit intravenous drugs is an efficient way of spreading HIV due to sharing 
of needles or syringes without sterilizing (Jarlais et al., 1992). Where drug-injecting 
equipment sharing is common, HIV infection may spread through drug-injecting 
populations. 
Among health care workers, needle stick injury has not been considered a major risk 
factor, although it is still appreciable. About 1 in 800 puncture wounds have led to 
transmission (Gerberding, 1994). 
1.1.2.2 HIV-1 transmission from mother to child 
On average, vertical transmission leads to infection in about 25% of children born to 
MV-positive mothers (Louis et al., 1993). The first children with HIV-1 infection were 
described in 1983. Reports suggest that if the mother is symptomatic with a 
characteristic high level of virus in the blood (virus load), transmission of HTV to their 
child can occur during pregnancy, at the time of delivery or even from breast feeding 
(Rossi et al., 1989; Scarlatti et al., 1991; Van de Perre et al., 1991; Weiser et at., 1994). 
Antiviral therapy taken by an HIV infected mother late in pregnancy significantly 
reduces transmission to her offspring (Louis et al., 1994). This latter finding has offered 
encouraging approaches to limiting I-HV transmission to newborns. 
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1.1.2.3 HIV-1 in urine and other body fluids 
It is unlikely that urine could serve as a vehicle for HIV-1 transmission. It has been 
shown urine contain none or only very few virus (Levy et al., 1985; Skolnick et al., 
1989; Li et al., 1992). Skolnick et al. (1989) reported the absence of infectious HIV-1 in 
urine. However, a study reported HIV-1 DNA proviral sequences were detected in 53 of 
80 (66.25%) fresh urine pellets from HIV-i-seropositive individuals (Li et al., 1992). 
Nevertheless, so far, there is no report showing transmission of HIV by urine (Flint et 
al., 2000). 
HIV-1 was isolated from the saliva of HIV-1 infected patients. Early study showed the 
presence of low level of free REV-i particles or infected cells in saliva (Groopman et al., 
1984; Ho et al., 1985; Levy et al., 1988). It was believed to be associated with the 
presence of large molecular weight glycoprotein in this body fluid, which could block 
REV infection at the cell surface or lack of virus infection of salivary glands (Archibald 
and Cole, 1990; Amory et al., 1992). However, high prevalence of HIV-1 RNA in saliva 
has been demonstrated by using PCR method (Liuzzi et al., 1997; Pilcher et al., 2001, 
Shugars et al., 2000; 2001). A recent study showed REV-i RNA was detected in 44% of 
unfiltered saliva samples, 16% of filtered saliva samples, and 59% of saliva-derived cell 
pellets. Morphological characterization of cell pellets identified lymphocytes as a likely 
HIV-1 source. Thus substantial quantities of HIV-1 could be shed in the oral cavity, 
particularly when inflammatory conditions are present (Shugars et al., 2001). Therefore, 
the possibility that REV can be transmitted by saliva should be considered. In addition, a 
small quantity of virus has been also found in tears but there has not been detection of 
virus in sweat and faeces (Levy, 1993c). 
1.1.2.4 HIV-1 sexual transmission 
There is no doubt that the most common way of spreading HIV is sexual transmission. 
Worldwide the vast majority of cases of REV-i infection have been acquired 
heterosexually (Overbaugh et al., 1999), despite the first case of AIDS being observed in 
the homosexual population. It has been demonstrated that HIV-1 virus can be cultured 
from the mononuclear cell fraction of semen from HIV-1-infected men (Zagury and Ho, 
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1984) and subsequently HIV-1 cell free virus was detected in semen of HIV-1-infected 
patients (Borzy et at., 1988). Studies on artificial insemination demonstrated that semen 
could transmit FITV-1 (Stewart et al., 1985; Araneta et al., 1995). The first reports of the 
culture of HIV-1 from cervical and vaginal secretions of HIV-1 infected women 
demonstrated that virus was present in the female genital tract both as cell-associated 
and cell-free virus (Wofsy et al., 1986; Vogt et at., 1986). Generally, 10-57% of seminal 
and vaginal fluid samples were shown to have free infectious virus and/or virus-infected 
cells (Henin et al., 1993; Milman et al., 1994). A number of studies present evidence 
that both cell-associated and cell-free virus can be transmitted (Tan et al., 1996; Zhu et 
al., 1996; Sodora et al., 1998). However, whether HIV-1 is predominantly transmitted as 
a cell-free virus or in a cell associated form is not known. 
It was reported that transmission rate is approximately two to three times higher from 
infected males to females than from infected females to males (Nicolosi et al., 1994). 
The reason for this phenomenon is not fully understood. It is possibly due to the fact that 
the transformation zone which is located between the squamous and glandular 
epithelium of penile urethra has a much smaller surface area compared to that in the 
female genital tract (Milman and Sharma, 1994). Sexual acts also play an important role 
in the efficiency of transmission of HIV-1. The risk of vaginal intercourse is 
considerably less than insertive anal intercourse (Lazzarin et al., 1991; Seidlin et al., 
1993). 
1.1.2.5 Mechanisms of HIV-1 mucosal transmission 
1.1.2.5a Cellular target(s) for HIV-1 mucosal transmission 
CD4 lymphocytes, monocytes and macrophages are the principal cells for 1HIV-1 
infection (Levy, 1993). In addition, HIV can also infect CD4 cells, including epithelia 
(Zachar et at., 1991). Recently, it was reported that epithelial, stromal, and dendritic 
cells, as well as cells with CD14CD4, CD14CD4, and CD4CD14phenotypes from 
the human female reproductive tract are infectable with HIV-1 (Yeaman et at., 1998), 
suggesting that multiple cell types may be targets for the initial infection by HIV-1. 
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However, little is known about potential target cells in the male genital tract (Pudney et 
al., 1993). In females, dendritic cells (DC) are localized in the skin and mucosal tissues 
such as uterus and cervix. There have been conflicting reports regarding the infection of 
DC with HIV-1. Langerhans cells (LCs), phagocytic dendritic cells found in the 
epidermis, have reported to be infected in vitro by HIV and can present HIV antigens to 
helper T cells (Tschachler et al., 1987; Ramazzotti et al., 1995; Spira et al., 1996). It has 
also been demonstrated that only early HIV genes are transcribed, indicating that 
incomplete replication of HIV-1 occurs in DC. 
A model of virus dissemination during the sexual transmission of HIV is shown in 
Figure 1.1. For transmission of HIV-1 infection to occur, HIV-1 has to be disseminated 
from sites of infection on mucosal surfaces to secondary lymphoid tissues where viral 
replication can take place in T cells (Fauci et al., 1996a). A hypothetical model of the 
role of mucosal LCs in HIV infection has been proposed (Zambruno et al., 1995). This 
model suggested that for transmission to occur, HIV-1 penetrates through the mucosal 
epithelium (columnar or squamous) and infects LCs. These infected cells then migrate to 
the lamina propna and lymph nodes where they initiate a vigorous productive infection 
of T cells, allowing systemic dissemination of HIV. However, a recent study of mucosal 
infection with SW showed that DCs were poorly infected (Granelli-Piperno et al., 
1999). An in vitro study of HIV-1 infection also indicated that the virus poorly infects 
DC derived from skin and blood (Cameron et al., 1992; 1996). It has been proposed that 
DC have a unique ability to catalyze infection of T cells with HIV but do not become 
infected (Cameron et al., 1992). Recently, a Dc-specific  C-type lectin, DC-SIGN (DC-
specific ICAM-3 grabbing nonintegrin) was found normally to be highly expressed on 
DC present in mucosal tissues but also binds to the HIV-1 gpl20 (Geijtenbeek et al., 
2000a; 200b). However, DC-SIGN does not act as a receptor for viral entry into DC. 
During transmission of HIV, it is proposed that mucosal DC capture HIV-1 through DC-
SIGN. These cells, carrying HIV, then migrate to secondary lymph nodes where they 
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Figure 1.1 Virus dissemination during the genital transmission of HIV. Adapted from 
Miller et at. (1992c). 
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1.1.2.5b Mechanism for cell-associated HIV-1 infection. 
It was proposed that transmission of HIV-1 is mediated by 1-TV-1-infected T 
lymphocytes or macrophages in genital tract secretions (Phillips et al., 1994). In this 
model, the HIV infected T lymphocytes or macrophages in semen or vaginal secretions 
first adhere to the epithelium of the genital tract of the sexual partner. Adherence 
triggers rearrangement of cell cytoskeletal elements (microtubules and microfilaments) 
and results in directional secretion of HIV-1 onto the surface of the epithelium. HIV-1 
particles are taken up by nonspecific phagocytosis into the epithelial cell, which then 
becomes infected. New virions released basally from the epithelial cell can infect CD4 
T cells or macrophages in the connective tissue below. It has been demonstrated that 
HIV-1 can infect vaginal epithelial cells by a CD4 independent mechanism (Furuta et 
al., 1994). This mechanism suggests that the HIV-1 envelope gp120 initially interacts 
with a cell-surface glycosphingolipid which could be blocked by antibodies raised 
against gpl2O. 
1.1.2.5c Mechanism for cell-free HIV-1 sexual transmission 
By comparing HIV-1 gp120 sequences in longitudinal samples from five acute 
seroconvertors with those from their corresponding sexual partners (transmitters) as well 
as compartmentalization of the virus in blood and genital secretions, Zhu et al. (1996) 
proposed a multiple-step process of HIV-1 sexual transmission: first, compart-
mentalisation occurs between blood and semen within the donor, and then the selection 
for viral genotypes occurs between the donor semen and the recipient mucosa and blood. 
That is, those variants which have an advantage in infecting cells at entry can 
disseminate the virus in the new host and those strains which can replicate efficiently 
may become the dominant variants in blood as the virus spreads systematically from the 
mucosa. This hypothesis is also supported by the study in the SIV-Rhesus Macaque 
model (Miller, 1998). After intravenous inoculation of rhesus macaques, all the 
vaginally transmitting viruses produced plasma antigenemia and high levels of plasma 
viral RNA. In contrast, the infection that occurs after intravenous inoculation of 
non transmitting viruses is characterized by a lack of viral antigen in plasma and low 
levels of plasma viral RNA. It is likely that the primary target cells for HIV heterosexual 
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infection in the recipient's genital tract and HIV-1 envelope sequences play an important 
role in this selection mechanism (Soto-Ramirez et al., 1996; Lu et al., 1996). Some 
authors found that the non-syncytia-inducing (NSI) isolates of HIV are preferentially 
transmitted (Roos et al., 1992) whereas others could not show a preferential 
transmission of HIV-1 NSI isolates (Albert et al., 1995). 
1.1.3 Structure of HIV-1 
HTV is a virus of the retroviral subfamily Lentivirinae, the members of which include the 
simian, bovine and feline immunodeficiency virus, caprine arthritis encephalitis virus 
(CAEV) and maedi-visna virus (MVV). HIV is an enveloped virus, with an RNA 
genome, and exhibits typical retrovirus morphology (Figure 1.2). The mature virion has 
a diameter of approximately 80-130 nm with a cone-shaped core composed of the viral 
gag protein p24. This nucleoid contains two identical RNA strands with which the viral 
RNA-dependent DNA polymerase (also called reverse transcriptase) (p66, p55), 
integrase (p32) and nucleocapsid protein (p7, p6) are closely associated. Gag protein p17 
that provides the matrix (MA) for the viral structure lies just beneath the lipid membrane 
of the virus and is vital for the integrity of the virions. The viral surface is surrounded by 
72 "knobs" consisting of the viral envelope glycoproteins, the external surface protein 
gpl20 and the gp41 transmembrane protein (TM) (Ozel et al., 1988). Parts of the central 
and NH2-terminal portions of gp41 are found on the outside of the virions and the central 
region of gp4l binds to the external viral gp120 in a noncovalent manner. The virion 
gpl20 located on the viral surface contains the binding site for the cellular receptors and 
the major neutralising domains (Dalgleish et al., 1988). 
1.1.4 The Structure of HIV-1 envelope glycoprotein 
The MV envelope glycoprotein plays a pivotal role in the early events of virus 
attachment and entry into the target cell. Neutralising antibodies found in the sera of 
infected individuals are primary directed against this glycoprotein. The HIV env gene 
encodes a single-chain precursor gp160 that is cleaved by a cellular protease to yield the 
mature surface and transmembrane glycoproteins known as gpl20 and gp4l, 











Figure 1.2 Schematic diagram of the HIV-1 virion. 
Each of the vinon proteins making up the envelope (gpl20 and gp4l), capsid (p24), 
matrix (p17) and nucleocapsid (p9 and p7) is identified. In addition, the diploid RNA 
genome is shown associated with reverse transcriptase, an RNA-dependent DNA 
pol ymerase. 
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heterodimer, forming an oligomeric structure that probably comprises three gp12O-gp4l 
heterodimers (Rao et al., 1995). However, there are multiple intra-gpl20 disulfide bonds 
that keep the molecule in its proper conformation (Leonard et al., 1990). Even though 
the predicted molecular weight of the polyprotein is 88 kDa, the actual molecular weight 
of 160 kDa can be explained by its extensive glycosylation (Allan et al., 1985). There 
are 24 glycosylation sites in gpl20 and four in gp41 so that the fully modified envelope 
is at least 45% carbohydrate in mass (Geyer et al., 1988). 
gp120 consists of 551 amino acids and is delineated by eight disulfide bridges located 
within the primary amino acid sequence of the protein at highly conserved positions 
(Figure 1.3 and 1.4). Comparison of the gene sequence of divergent HIV-1 isolates 
showed significant diversity concentrated primarily in the gpl20 coding region env, in 
five discrete regions named hypervariable regions (V1-V5). The regions between the 
variable regions are more conserved and were named constant (Cl-CS) domains (Levy 
1994). Immunisation with purified envelope proteins leads to neutralising antibodies 
capable of binding to the V3 hypervariable region, a loop of 33-35 amino acids confined 
by a conserved disulfide bond (V3 loop). The viral gp41 protein consists of a N-amino-
terminal glycosylated extracellular region (Allan et al., 1985), a transmembrane region 
and an unusually long carboxy-terminal cytoplasmic region which anchors env in 
membranes. 
The gpl20 is involved in recognition and binding to the target cell receptors, and has 
therefore been identified as an antigenic target during immune responses to HIV 
infection. The gpl20 molecule mediates the attachment of the virus to the cell-surface 
CD4 receptor, an interaction that is thought to trigger a series of conformational changes 
in the virus glycoproteins. This is hypothesized to result in exposure of the fusion 
peptide of gp4l and allows the fusion between the virion and the cell (Sattentau et al., 
1993) (For 111EV receptors, see section 1.1.6.2). Interactions between gpl20 and CD4 
have been extensively studied (Lasky et al., 1987; Leonard et al., 1990). Variable 






Figure 1.3 Secondary structure of HIV-1 envelope protein gpl20. Location of variable 
[V1-V5] and constants [C1-05] domains are shown. N+ is the N-terminus and C+ is the 
C-terminus of the protein. Y indicates complex carbohydrates. (Taken from Levy, 1994). 
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Figure 1.4 Genome organization of human immunodeficiency virus-1. Location of 
regions encoding precursors for known virion proteins are shown. 
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V4 and V5 can block gpl20-CD4 complex formation (Capon and Ward, 1991). 
1.1.5 Molecular biology of HIV-1 
HIV, like other lentiviruses, has a positive-stranded RNA genome that is approximately 
9.7 kilobase (Kb) long and exists within the virion as a dimer, with two identical RNA 
strands (Muesing et al., 1985). An outline of HIV genome is shown in Figure.1.4. The 
genome of the virus contains the structural genes (gag, pol and env) common to all 
retroviruses. In addition to these genes, HIV genomes also encode regulatory genes tat, 
rev and the accessory genes nef, vif, vpu and vpr. SlY and FHV-2 genomes also encode a 
second, related gene, vpx, which appears to have arisen as a duplication of vpr (Tristem 
et al., 1990). 
The genome of HIV-1 contains a repeated region (R) at the 5' and 3' ends, and 
untranslated 5' and 3' sequences (U5 and U3) that are important in the process of 
reverse transcription of the genomic RNA into DNA. These regions consist of the long 
terminal repeats (LTR) found in all other retroviruses (Figure 1.4). The viral RNA 
transcripts initiate transcription at the 5' LTR and terminate in the 3' LTR, at the 
polyadenylation signal. 
1.1.5.1 Structural genes of HIV-1 
The viral gag, poi and env, which are flanked by LTR, encode proteins required for 
production of infectious virus particles. 
The gag gene encodes a 55 kD non-glycosylated precursor core polypeptide (p55) which 
is cleaved after translation from unspliced transcripts to form nucleocapsid: p17 (matrix, 
MA), p24 (capsid, CA), p7/9 and p6 (nucleocapsid, NC). The principal gag product p24 
noncovalently associates with the viral genomes to form a nucleoid shell. The p55 Gag 
precursor alone is required for the assembly and release of viruslike particles (Gheysen 
etal., 1989). 
The p01 gene encodes the highly conserved enzymatic protein protease, reverse 
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transcriptase (RT), integrase (IN), and nbonuclease H. Because the gag and p01 genes 
overlap and the pol gene is encoded in a different reading frame from gag, translational 
frame shifting must occur to produce the Gag-Pol polyprotein precursor p106 (Wilson et 
al., 1988). The p106 is cleaved by the viral protease to yield plO (protease), p66/55 
(RT), and p32 (integrase). Both the Gag and Gag-Pol precursors are cleaved by the viral 
protease during or after virus budding. 
The env gene of fly encodes an 88-kDa precursor that is translated from a singly 
spliced mRNA. This precursor is glycosylated to give gpl60 during its passage through 
the endoplasmic recticulum and the Golgi complex of the host cell. The gp160 is cleaved 
to produce an external glycoprotein (gpl20) involved in recognition and binding to 
target cell receptors and a smaller, hydrophobic transmembrane protein (gp4l) involved 
in membrane fusion (Barr et al., 1991). The gpl20 is noncovalently bound to gp4l to 
form the knobs that coat the virion surface. 
1.1.5.2 Regulatory and accessory genes of HIV-1 
In addition to three structural genes, HIV-1 has six regulatory and accessory genes (vif, 
tat, rev, vpr, vpu, and nef). Two regular genes (tat and rev) encode proteins Tat and Rev 
that are essential for viral replication. The remaining four accessory genes (vif, vpr, vpu 
and nef) encode the accessory proteins (Vif, Vpr, Vpu and Net) which are essential for 
efficient virus production in vivo. However, their precise roles remain ill defined. 
The tat (trans-activator of transcription) gene is believed to be necessary for efficient 
viral replication and enhanced viral transcription (Greene, 1991). It encodes a 14 kD 
protein which is synthesised early after infection (Arya et al., 1985). In HIV (as in SIV 
and EIVA), tat protein enhances HIV genes expression by interacting with cellular 
factors and binds to a stem-loop structure known as trans-activation-responsive element 
(TAR) RNA sequences located in the 5' end of all HIV transcripts (Barry et al., 1991). 
The recent identification of cyclin-T revealed a new mechanism by which Tat co-opts 
cyclin-T to increase processivity of LTR-driven transcription (Wei et al., 1998). 
18 
The rev (regulator of expression of virion proteins) gene encodes a protein (19 kD) 
translated from multiply-spliced RNAs (Sodroski et at., 1986). The Rev protein 
functions to facilitate the export of unspliced and singly spliced viral mRNA from the 
nucleus. The rev protein binds to viral RNA in the nucleus through a highly structured 
RNA element known as the Rev-responsive element (RRE) located within the env gene 
(Greene, 1991, Levy, 1993). The Rev-responsive element is only present in unspliced 
and singly spliced viral mRNAs whose expression is regulated by rev. Consequently, 
Rev is required for the expression of structural proteins and indirectly downregulates its 
own expression, as well as that of tat and nef. 
The nef (negative effector function) gene is present in all primate lentiviruses and is 
highly immunogenic. Nef was proposed as a specific repressor of HIV transcription 
(Ahmed et at., 1988), although this result was not reproduced by others (Hammes et at., 
1989; Kim et al., 1989). It has been shown that the Nef protein is not essential for viral 
replication in cell culture (Hammers et at., 1989), although SW Nef protein is required 
for efficient virus replication in vivo (Kestler et al., 1991). It has been reported that the 
expression of fly Nef protein results in reduction of CD4 expression on the cell surface 
(Aiken et al., 1994). The Nef protein may, therefore, be associated with membrane 
structure and may function to downregulate surface expression of CD4 on infected cell 
by inducing endocytosis and degradation of CD4 in lysosomes (Garcia et al., 1991; 
Aiken et al., 1994). Therefore, Nef may be involved in both protein transport and 
transmembrane signaling. HIV-1 sequences containing deletions in nef were found in 
multiple blood samples over a period of 10 years in a patient with nonprogressive HIV-1 
infection, suggesting that nef deficient strains are attenuated (Kirchhoff et al., 1995). 
The mechanism for this function of nef has not been defined. 
The vif (viral infectivity factor) gene encodes a late gene product found to be essential 
for the spread of HIV-1 in peripheral blood lymphocytes, primary macrophages (von 
Schwedler et al., 1993) and some established cell lines (Sakai et al., 1993). In addition 
to a role in viral particle formation, Vif appears to be important for both cell-to-cell and 
cell-free transmission (Fisher et al., 1987). Three different functions of Vif have been 
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described. First, Vif is required for the complete synthesis of viral DNA, which could be 
due to its effects on the internalization of the nucleocapsid, virion uncoating, activation 
of RT, or RNA processing (von Schwedler et al., 1993). The second proposes that Vif is 
a cysteinyl protease, which could play a role in the processing or conformation of Env 
(Guy et al., 1991). Finally, Vif might be required in the maturation process, since, in its 
absence, only low amounts of Env are expressed on the virion (Sakai et al., 1993). 
The vpr (virion protein R) gene encodes a 15-kD protein associated with the 
nucleocapsid protein p6 (Paxton et al., 1993). Although dispensable for replication in 
CD4 lymphocytes (Dedera et al., 1989; Balotta et al., 1993), Vpr appears to augment 
both HIV-1 and HIV-2 replication in macrophages (Westervelt et al., 1992) and has 
been implicated in nuclear localization of viral nucleic acids in nondividing cells 
(Heinzinger et al., 1994). Additionally, Vpr has weak transactivation properties for the 
HIV long terminal repeat (LTR) and other promoters (Cohen et al., 1990). 
The vpu (virion protein U) gene is present in HIV-1 but not HIV-2 or SIV. Vpu is 
necessary for intracellular dissociation of gp160 and CD4 through degradation of CD4 
in the endoplasmic reticulum (Willey et al., 1992a; 1992b). Vpu may play a role in 
proper and efficient virion assembly and release (Geraghty et al., 1993), and also 
facilitate the export of Env and the budding of mature virions (Yao et al., 1993). 
1.1.6 Life cycle 
1.1.6.1 HIV-1 life cycle 
The genomes of HIV are single-stranded, positive-sense RNA. The virus replication is 
similar to that of other lentiviruses, which involves a requirement for RT enzymatic 
action and reverse transcription of the viral RNA, a multistep process involving "jump" 
or strand transfers (Goff, 1990; Kupiec and Sonigo, 1996), to produce double-stranded 
DNA provirus (Figure 1.5). 
HIV infection is initiated by binding of the viral envelope to a cellular receptor, the CD4 
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molecule and coreceptor (see section 1.1.6.2). CD4 is expressed on the surface of the T -
helper lymphocyte subset and, in lesser quantities, on mononuclear phagocytes. These 
are thus the principal target cells in vivo. There may be other cell surface molecules 
involved in virus binding and entry as HIV-1 infection has been detected in a variety of 
non-CD4-bearing cells in infected individuals (Nelson et al., 1988; Pomerantz et al., 
1988). After the binding events, HIV enters cells through a pH-independent membrane 
fusion mechanism (Sinangil et al., 1988). During membrane fusion, the lipid molecules 
of the viral envelope and those of the cell plasma membrane can freely intermix and the 
two membranes eventually coalesce, allowing the viral nucleocapsid to 
enter the cell cytoplasm. Although FITV-cell binding and membrane fusion are 
prerequisite events in HIV infection, their occurrence does not guarantee infection 
(Potash et at., 1992; Stamatatos and Duzgunes, 1993). 
Once inside the cell, virion-associated reverse transcriptase synthesizes a linear, double-
stranded DNA copy of the viral genome. Then the viral core is actively transported to 
the cell nucleus through interactions with the gag matrix protein (p17), possibly 
involving Vpr (Bukrinsky et at., 1993; Heinzinger et at., 1994). Integration of full-length 
viral DNA occurs by colinear insertion into chromosomal DNA to form the provirus. 
Viral genes are replicated along with host chromosomal DNA and therefore persist for 
the life of the cell. Like other lentiviruses, HIV is able to replicate in non-dividing 
terminally differentiated cells as well as in dividing cells. It is still an open question 
whether this may require specific functions, supplied by the viral accessory genes, to 
permit translocation of the preintegration complex and integration into nonreplicating 
genomic DNA. 
Expression of fly genes involves both cellular and viral proteins. The retroviral DNA 
("provirus") uses the cellular transcription machinery to express the viral RNA that has 
two essential roles. Firstly, it serves as the genomic RNA that is incorporated in the 
virion and secondly as the messenger RNA that produces all the viral proteins. Signals 
for initiation of transcription are found in the 5' LTR (long terminal repeats) region, 
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Figure 1.5 HIV-1 life cycle. After binding to the surface of the cell, the viral core enters 
by virus-cell membrane fusion. A double-stranded DNA copy is synthesized from 
genomic RNA by virion-associated reverse transcriptase. The viral core is transported to 
the nucleus, and the provirus is formed by integration into the host genome. Viral RNA 
can be expressed from the provirus, typically after cell activation, and viral proteins are 
synthesized on host ribosomes. Progeny virions are formed by budding through the 
membrane of infected cells (Adapted from O'Brien and Pomerantz, 1997). 
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precursor proteins are proteolytically cleaved and the vinons, which are assembled in the 
cytoplasm are released from the cell by budding through the cell surface membrane. 
Cellular proteins have been found in association with virions and may be important for 
viral infectivity (Benkirane et al., 1994). 
1.1.6.2 Viral co-receptors and cellular tropisms 
The ability of HIV-1 to infect different types of cells vanes from isolate to isolate and is 
referred to as cellular tropism (Figurel.6 and 1.7). All HIV-1 strains infect primary 
CD4 T lymphocytes. Many strains of HIV-1 replicate well in monocytes, but not in 
established T-cell lines (Cheng-Mayer et al., 1988), and are classified as monocyte-or 
macrophage-tropic (M-tropic). Other isolates, particularly those that have been passaged 
in lymphoid cells in vitro (T-cell-line-adapted strains), infect primary T lymphocytes but 
not monocytes or macrophages, and are referred to as T-cell-tropic (T-tropic) virus. M - 
tropic viruses are usually noncytopathic, that is, NSI, and T-tropic viruses are generally 
found to induce syncytia formation in vitro and are thus termed as syncytia-inducing 
(SI). Dual-tropic viruses that are M-tropic with SI characteristics may be produced 
during transition from M-tropiclNSl to T-tropic/SI (Doranz et al., 1996). Cellular 
tropism of HTV appears to be determined primarily by the gp120 subunit of the HIV-1 
Env protein, particularly the third variable region (V3 loop) of gp120 (Cheng-Mayer, 
1990). 
Studies to investigate the basis of cellular tropism led to the identification of the co-
receptor for HIV-1. In early 1996, Feng et al. reported that the receptor CXCR4 (also 
termed fusin) was an HIV-1 entry co-receptor (or cofactor) with CD4 for T-tropic 
strains. The sequence of CXCR4 indicated that it was a GTP-protein (G-protein)-
coupled receptor with seven transmembrane helices. Shortly afterwards, several groups 
found that cysteine-cysteine (C-C)-linked chemokine receptor CCR5 (also called CC-
CKR5, CKR5) functioned as a coreceptor for M-tropic HIV-1 but not for T-tropic IIIV-
1 strains (Alkhatib et al., 1996; Dragic et al., 1996). The C-C or j3-chemokine receptors 
consist of seven transmembrane domains and typically contain no introns (Choe et al., 
1996, Combadiere et al., 1996, Samson et al., 1996a). Primary CD4 T lymphocytes 
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Figure 1.6 Coreceptors for M- and T-tropic strains of HIV-1. The T-tropic HIV-1 strain 
can infect host cells expressing CXCR4. The M-tropic HIV-1 strain can infect host cells 














Figure 1.7 The interaction of HIV-1 with CD4 receptor and coreceptor. The envelope 
glycoprotein of HIV exists as a heterodimer with the extra cellular component (gpl20) 
interacting with the receptor and the transmembrane component (gp4l) inducing fusion 
with the host membrane. Following HIV gpl2O binding to CD4 a conformational change 
facilitates the interaction of gp120 with the chemokine receptor, exposes the fusogenic 
peptide on gp4l and allows it to insert into the cell membrane. 
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express both CXCR4 and CCR5, and transformed T-cell lines express CXCR4 but not 
CCR5 (Figl.6 and 1.7). Other -chemokine receptors (CCR2b and CCR3) can also act 
as co-receptors for M-tropic and dual-tropic HIV-1, but they are little used by M-tropic 
strains. Although HIV-1 isolates utilize both CXCR4 and CD4 as entry receptors, some 
HIV-2 isolates were found to use CXCR4 as an alternative receptor in the absence of 
CD4 (Endres et al., 1996). 
Before the HIV-1 entry coreceptors were identified, the C-C chemokines RANTES, 
macrophage inflammatory protein (MTP)-la, and MT1P-1, which are ligands for CCR5, 
were found to block infection with M-tropic HIV-1 (Cocchi et al., 1995). Then, the CXC 
chemokine stromal cell derived factor (SDF)-1 was shown to be the ligand for CXCR4 
and to block infection with T-tropic but not M or dual-tropic MV-1 strains (Bleul et al., 
1996; Oberlin et al., 1996). Oravecz et al (1996) showed that the -chemokines seem to 
inhibit infection by blocking or down-regulating the receptor they share with virus. 
However, the role of intracellular signaling activated by co-receptors in HIV-1 entry is 
still poorly understood. 
Although CD8 cells are not considered to be prime targets of HIV-1 infection, several 
studies have demonstrated that HIV-1 is able to infect these cells. The presence of viral 
DNA in CD8 cells of HIV-1-infected patients has been demonstrated (Livingstone et 
al., 1996). Flamand et al. (1998) showed that stimulation of CD8 T cells with mitogens 
including plant phytohemagglutinin (PHA), bacterial staphylococcal enterotoxin B and 
anti-CD3 mAb, led to de novo expression of the CD4 antigen at the cell surface of CD8 
I cells, which results in susceptibility of CD8 T cells to HIV-1 infection. Other study 
demonstrated that activated neonatal CD8 T cell can be productively infected in vitro 
by M-tropic HIV-1 isolates, which are responsible for disease transmission (Yang et al., 
1998). A recent study showed that mature CD8 lymphocytes can be productively 
infected with 1-TV-1 in patients with AIDS (Saha et al., 2001). Infection of naïve CD8 
cells (CD3CD8CD45RA) with HIV-1 in vivo has been also demonstrated (McBreen 
et al., 2001). These findings indicate that direct HIV-1 infection of CD8 T lymphocytes 
may contribute to the decline in CD8 T cells frequencies and functions on disease 
26 
progression in 1-IIV-1 infected individuals. 
1.2 The immune response to HIV-1 
1.2.1 The humoral immune response to HIV-1 
The humoral immune response, which is characterised by the production of large 
numbers of antibody molecules specific for antigenic determinants (epitopes) on a 
foreign pathogen, is uniquely adapted to the elimination of extracellular pathogens. This 
process requires the participation of macrophages, activated helper T cells and B cells. 
Antibodies to FIIV proteins can appear as early as 2 weeks and as late as 6 month after 
infection (Allain et al., 1986; Gaines et al., 1988), but generally within 1 to 3 months 
(Flint et al., 2000). Detection of serum antibodies to FIIV is a common method of 
demonstrating HIV infection (Schochetman et al., 1989; Mylonakis et al., 2000; Flint et 
al., 2000). It was shown that the viral gpl20 and gp160 proteins were the major targets 
for human antibody response (Allan et al., 1985; Barin et al., 1985, Moore et al., 1994; 
Binley et al., 1998; Parren et al., 1999). Antibodies specific for other FHV proteins, 
including p66, p55, gp4l, p32, p24, and p17, have also been detected (Carlson 1988; 
Lewis et al.,1998). 
1.2.1.1 Neutralising Antibodies to HIV-1 
The most effective type of antiviral antibody is "neutralising" antibody, which usually 
binds to the viral envelope or capsid proteins and prevents the virus from binding and 
gaining entry to the host cell. HIV-1-infected people mount and sustain a vigorous 
antibody response to HIIV-1. A portion of this response is neutralising. Neutralising 
antibody is first detectable in the serum within 1-2 months after infection. A variety of 
different observations show that early neutralising antibodies tend to be of low titer, are 
not present in all patients after primary infection, and are only able to neutralise a 
limited range of isolates (Moore and Ho 1995; Legrand et al., 1997; Moog et al., 1997; 
Pilgrim et al., 1997; Stamatos et al., 1998). Even following many years of HIV 
infection, most infected subjects mount only weak neutralising responses against 
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primary HIV-1 isolates (Sattentau et al., 1996; Burton et al., 1997). However, this does 
not mean that antibodies are powerless in controlling HIV infection. In the presence of 
natural killer (NK) effector cells FHV-1 specific antibody from patient with acute HIV-1 
infection can inhibit HIV-1 replication (Forthal et al., 2001). Passive immunotherapy 
with IgG monoclonal antibodies against the HIV-1 gpl20 CD4 binding region and the 
gp4i neutralising epitope protected intrarectally SHIV-infected macaques (Baba et al., 
2000). Passive transfer of IgG from an SIV-infected long-term nonprogressor can delay 
disease progression when given to macaques at the time of SIV infection (Haigwood et 
al., 1996). Neutralising antibody against the HIV-1 Env glycoprotein is capable of 
protecting macaque monkeys from chimeric SIVJFIIV-1 (SHIV-1) infection (Shibata et 
al., 1999). In vitro study showed that IgG 3 from plasma of HIV-1 infected donors has 
more potency in neutralising HIV-1 compared to that of IgG I and IgG2 . The result that 
IgG3 F(ab')2 was still more efficient in neutralisation than F(ab')2 of IgG i indicated that 
the IgG3 hinge region confers enhanced HIV-1 neutralising ability (Scharf et al., 2001). 
These results suggested that antibody specificity, such as subclass, may be crucial for 
neutralisation of HIV-1. 
The vast majority of neutralising antibodies bind to gpl20 and gp4l (Parren et al., 
1999). Experimental stimulation of neutralising antibodies to HIV was first achieved by 
inoculation of animals with either genetically engineered or purified natural gp120 
(Lasky et al., 1986; Robey et al., 1986). Matthews et al. (1986) found that HIV-specific 
neutralising antibodies react predominantly with the Env glycoproteins, similar to that 
observed in other retroviral systems. It has also been demonstrated that antibodies to p17 
Gag protein and the immunodominant epitope of gp4l have neutralising activity (Sarin 
et al., 1986; Schrier et al., 1988; Parren et al., 1999). 
The gpl20-specific neutralising antibodies appear to be type specific when raised in 
goats immunised with either recombinant or purified viral gp120 (Matthews et al., 1986; 
Rusche et al., 1987). However, group-specific neutralising antibodies have been 
detected in human sera from HIV-infected individuals (Weiss et al., 1986) and 
chimpanzees (Goudsmit et al., 1988). Type specific antibody is only capable of 
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neutralising the viral strains used for immunisation, whereas the group-specific antibody 
can react with a range of viral strains. 
The presence of neutralising antibodies has been shown to select for FHV variants in 
vivo (Robert-Guroff et al., 1986). Sera from an infected individual did not neutralise the 
recovered virus, however, they neutralised previous autologous virus or heterologous 
laboratory strains, reflecting the appearance of escape variants (McKeating et al., 1989). 
Emergence of these resistant strains may contribute to disease progression. 
1.2.1.2 Neutralising epitopes of HIV-1 
Epitopes or antigenic determinants are the immunologically active regions of an 
immunogen that bind to antigen-specific membrane receptors on lymphocytes or 
secreted antibodies. Epitopes are divided into two categories, sequential and 
conformational, depending on whether they are formed by the primary sequence or the 
three-dimensional conformation. 
The elucidation of the X-ray crystal structure of HIV gp120 (Kwong et al., 1998), 
together with the mutagenic and antibody competition studies (Moore and Sodroski, 
1996; Ditzel et at., 1997) make it possible to precisely characterise the neutralising 
epitopes on the gp120 molecule. Neutralising epitopes on gpl20 map to the surface of 
the envelope glycoprotein and face the target cells. For T cell line adapted virus (TCLA) 
HIV isolates, the neutralising epitopes on the gp120 include the CD4 and co-receptor 
binding-sites, the V2 and V3 loops and the unique 2G12 epitope (Burton et at., 1994, 
Roben et at., 1994, Mo et at., 1997). 
The V3 loop of gp120 was originally termed as the principal neutralising domain (PND) 
because of its role in the neutralisation of TCLA strains by sera from HIV-1 infected 
patients and gp120 vaccine recipients. PND contains a central amino acid sequence 
GPGRAF (amino acid 308-322) which is shared by many distinct HJV isolates (see 
Figure 1.8) (Broliden et at., 1991). Although monoclonal antibodies (mAbs) to V3 loop 
have a dominant role in neutralising TCLA strains, their role in neutralisation of primary 
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isolates is not significant (VanCott et al., 1995, Spenlehauer et al., 1998). Because of the 
hyper-variability of the V3 loop, neutralisation by mAb directed to this epitope is strain-
specific. Some studies have shown that a broader neutralising response can be obtained 
when it is directed either to a relatively conserved motif at the crown of the loop (Conley 
et al., 1994), or to a discontinuous epitope spanning both sides of the loop (Moore et al., 
1995). Anti-V3 loop antibodies neutralise TCLA stains by blocking the virus attachment 
to the target cells (Ugolini et al., 1997; Valenzuela et al., 1997). In addition, it was 
reported that mAb against the V3 loop inhibits the interaction of gp120-CD4 with co-
receptor, suggesting neutalisation at a post-attachment stage (Wu et al., 1996; Trkola et 
al., 1996; Hill et al., 1997). 
A second cluster of neutralising epitopes is located in the V1IV2 region, which 
constitutes a complex, disulfide-bonded arm of gp120. MAbs specific for this segment 
generally recognise conformational epitopes which are located in the centre region of the 
V2 loop (Gomy et al., 1994), and have been shown to neutralise TCLA viruses 
relatively well (Warner et al., 1994). Two mAbs to the V2 loop have been reported to be 
able to neutralise primary isolates (Gomy et al., 1994; Vijh-Warrier et al., 1996) but the 
range of isolates that can be neutralised is limited (Pinter et al., 1998). So far mAbs 
directed against the Vi loop have not been identified. 
A third epitope cluster that was first defined by Lasky et al. (1987) is a relatively well-
conserved linear epitope within the C4 region, the gp120-CD4 binding domain. MAbs 
directed to this epitope neutralise a relatively broad panel of TCLA HIV-1 isolates (Sun 
et al., 1989), but neutralisation of primary isolates has not been observed. Mabs against 
this epitope was shown to block the interaction of the gp120-CD4 with CCR5 (Wu et at., 
1996; Trkola et al., 1996), indicating that the epitope is located in or near the co-receptor 
binding sites. 
A unique epitope defined by a single mAbs 2G12, termed 2G12-binding site, has been 
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Figure 1.8 Principal binding domain of neutralising antibodies on the V3 loop of the 
viral envelope gp120. Sequences between amino acids 296-331 are shown. The 
cysteines are joined by a disulfide cross-bridge (bar). The amino acid sequences in the 
box (crown) is neutralising region of V3. (Taken from Levy, 1994). 
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residues at the base of the V3 loop and the NH 2-terminal flank of the V4 loop; 
suggesting that the 2G12-binding site is adjacent to both the V3 loop and the C4 region. 
This mAbs potentially neutralises a percentage of primary isolates (Trkola et al., 1995; 
1996). 
An antigenic surface map has also been proposed for gp4l (Binley et al., 1996; Earl et 
al., 1997). Two neutralising epitopes have been described on gp4l. One epitope is 
defined by the neutralising mAb 2F5 and is located in the membrane proximal part of 
the ectodomain of gp4l, which is highly conserved in a broad spectrum of TCLA and 
primary isolates (Muster et al., 1993), and is generally accepted as having specific 
neutralising activity (D'Souza et al., 1995). The other epitope of gp4l is within the 
cyoplasmic domain of gp4l (Chanh et al., 1986), and mAbs to this domain of gp4l have 
been shown to bind equally to HIV-infected and uninfected cells, implying a non-HIV-
related mechanism of neutralisation (Sattentau et al., 1995). 
1.2.1.3 Mechanism of HIV-1 Neutralisation 
The mechanism of antibody-mediated neutralisation for HIV-1 is to block the virus 
attachment to the target cells (Ugolini et al., 1997). For attachment of virus to the target 
cells to occur, multiple interactions in a localised area are required. Coating of virus 
surface with antibodies obstructs the virus approach to the target cells, thereby 
preventing attachment and initiation of a fusion event (Parren et al., 1998). It was found 
that the antibody-mediated neutralisation for HIV-1 is independent of the epitope cluster 
recognized by the neutralising mAb (Parrent et al., 1998). 
For neutralisation of HIV-1, both blockage of gp120-CD4 binding and direct 
inactivation of HIV-1 infectivity after binding have been described (Layne et al., 1990; 
Moore et al., 1991; Orloff et al., 1993; McDoug et al., 1996) (Fig.1.9). 
1.2.1.3a Inhibition of gp120-CD4 binding 
Some reports have shown that antibodies neutralise HIV-1 by inhibiting gp-120-CD4 
binding. These neutralising antibodies compete with monomeric gp120 binding to CD4 
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(Layne et al., 1990; Moore et al., 1991). It has been reported that most of the effective 
HIV-1 neutralising mAbs inhibit the attachment of the virus to the target cells by 
blocking the interaction with CD4 or co-receptor (Wu et al., 1996; Trkola et al.,1996; 
Ugolini et al.,1997). If the principal mechanism of neutralisation is not simply steric 
inhibition of virus binding to CD4 cells, these mAbs may prevent recruitment of a 
sufficient number of CD4 molecules to form a fusion-competent complex, or may 
trigger a more complex pathway of antibody-induced conformational rearrangement 
within the envelope glycoproteins. Indeed it has been demonstrated that mAbs such as 
IgG1bl2 which blocks the interaction of CD4 with monomeric gp120 can neutralise a 
TCLA HIV-1 clone without inducing any obvious conformational changes in the 
envelope glycoproteins (Poignard et al., 1996b). 
1.2.1.3b Inhibition after gp120-CD4 binding 
It is well-established that V3 mAbs inhibit TCLA HIV-induced fusion of CD4 cells at a 
stage after virus binding (Nara et al., 1991). It has been shown that these neutralising 
antibodies increase gp4l exposure and induce dissociation of gp120 from gp4l in TCLA 
HIV-1 viruses (Poignard et al., 1996b) which, by analogy with sCD4-induced 
dissociation, will result in irreversible inactivation of the virus (Orloff et al., 1993). 
1.2.1.4 Enhancing antibodies 
Enhancing antibodies, i.e. those which enhance virus infectivity, have been found in 
HTV-infected individuals, particularly those at the late stage of disease (Homsy et al., 
1988, 1990; Robinson et al., 1988). These antibodies were found to bind to gp120 and 
gp4l (Jiang et al., 1991). Mechanisms of enhancement for viral entry involve 
complement and Fc receptors (Homsy et al., 1989; Robinson et al., 1990; Takeda et al., 
1990, 1992; Kliks et al., 1993). The neutralising and enhancing effects of anti-HIV 
antibody depend on the HJV strain involved and the concentration of the antibodies 
employed (Kliks et al., 1991). In some cases, a particular monoclonal antibody to gp120 
will enhance virus infection, while another may neutralise it. It is also suggested that 
enhancing antibodies may induce gp120 conformational changes which can improve the 
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Figure 1.9 Scheme for potential mechanism of HIV neutralisation and enhancement. 
Conformational changes induced in the envelope glycoproteins mimic receptor 
binding and activate the fusion pathway. In the situation where this state is relatively 
stable, virus entry will be rendered more efficient, leading to enhancement of infectivity. 
Conformational changes induced in the envelope glycoproteins prevent virus binding 
or fusion, resulting in neutralisation. (c) Antibody-induced dissociation of gp120 from 
gp4l leads to inappropriate exposure of the gp4l fusion domain and virus inactivation. 
(Taken from Poignard et al., 1996a). 
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1.2.2 Cellular immune response to HIV-1 
The cellular immune response is mediated by T lymphocytes that release cytokines and 
lyse target cells expressing foreign antigens. Cytotoxic T lymphocytes (CTLs) are major 
contributors to the antiviral T cell immune response. This T-cell population carries the 
CD8 cell surface glycoprotein and recognises peptide antigens which have been 
synthesised within cell's nucleus or cytosol, and which have been degraded. They are 
presented at the cell's surface as short peptides associated with self class I major 
histocompatibility (IvIHC) molecules of the immune system (Zinkernagel and Doherty, 
1975). However, CD4 CTL directed to HIV-1 specific antigens in a MHC-class II 
restricted fashion have also been described in the blood of infected patients (Liu et al., 
1992), but their role in HIV infection is not clear. 
1.2.2.1 T lymphocytes 
T cells interact with invading antigens, in association with the MHC proteins, via their T 
cell receptor (TCR). Two classes of MHC exist, class I and class II. MI-IC class I is 
expressed on the majority of cells. In contrast, MHC class II is restricted to B cells, 
macrophages, monocytes, DC and activated T cells. CD4 T cells respond to exogenous 
antigens presented in association with MHC class H in the surface of antigens presenting 
cells (APC). CD8 T cells recognise endogenous antigens presented on cells in 
association with MHC class I. 
1.2.2.2 HIV-1 specific cytotoxic CD8 Cells 
CTLs have two antiviral activities: First, they can kill virus-infected cells, and they can 
release cytokines and chemokines with antiviral activity (Morris et al., 1982; 
Zinkernagel et al., 1986; Cocchi et al., 1995; Guidotti et al., 1996; 1999; Appay et al., 
2000). 
HIV-specific CTLs were initially described in 1987. A remarkable feature was that 
human leukocyte (HLA)-restricted CTLs could be readily detected in freshly separated 
peripheral blood mononuclear cells or in alveolar lymphocytes from HIV-infected 
individuals, without prior in vitro stimulation with antigen (Plata et al., 1987; Walker et 
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al., 1987; Flamand et al., 1998; McBreen et al., 2001). Subsequent studies demonstrated 
that HIV-1 specific CTLs could be isolated from infected organs, such as spleen 
(Cheynier et al., 1994), lymph nodes (Hadida et al., 1995; Kuroda et al., 1999), and even 
from the vaginal mucosa of SIV-infected macaques (Lohman et al., 1995; Wilson et al., 
2000). HIV-specific CTLs were also found in individuals exposed but not infected by 
HIV. The latter may reflect the ability to control virus early in infection (Langlade-
Demoyen etal., 1994; Rowland-Jones et al., 1995; 1998; 2001; Kaul et al., 2001). 
Studies of CD8 CTL response at the different stages of disease provides evidence of the 
importance of HIV-1 specific CD8 CTL in controlling HIV-1 replication and disease 
progression. Borrow and coworkers (1994) reported that the level of HIV-1-specific 
CTL activity in HIV-1 infected patients paralleled the efficiency of control of primary 
viremia. Patients with strong gp160-specific CTL responses showed rapid reduction of 
acute plasma viremia and antigenemia, while in contrast, primary viremia and 
antigenemia were poorly controlled in patients in whom virus-specific CTL activity was 
low or undetectable. This observation is consistent with other studies (Ariyoshi et al., 
1992; Koup et al., 1994, Pantaleo et al., 1994), which demonstrated that the early 
decline in plasma viral levels shortly after HIV-1 infection coincides with the 
appearance of HIV-specific CD8 CTLs. In addition, inverse correlations between 
frequency of peripheral blood HIV-1-specific CTL and plasma HIV load have been 
reported (Ogg et al., 1998). A recent study showed that during acute HIV-1 infection, 
broader HIV-1 specific CTL responses were correlated with lower viral load (Altfeld et 
al., 2001a). Similarly, in non-human primates models, the CD8 CTL response is the 
best correlate of viremia control after SIV primary infection in macaques (Yasutomi et 
al., 1993; Reimann et al., 1994; Chen et al., 1995). Depletion of CD8 cells results in 
SW replication being uncontrolled during primary infection and high virus load in 
chronically infected rhesus monkeys (Schmitz et al., 1999; Jin et al., 1999). These data 
indicate the importance of CD8 CTL responses that arise in response to HIV-1 infection 
in controlling FIIV replication during primary infection and a role for cellular immunity 
in protection to HIV- 1 in vivo. In addition to resolving the viremia of acute infection, 
early generation of HIV-specific CD8 CTLs may influence subsequent disease course 
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(Koup et al., 1994; Borrow et al., 1994). It was reported that a more broadly directed 
CTL response correlates with slower disease progression (Pantaleo et al., 1997). There is 
an inverse correlation between disease progression and HIV-1-specific CTL activity in 
HIV-1 infected subjects (Musey et al., 1997). Moreover, HIV-1 infected long-term 
nonprogressors (LTNPs) maintained the established CTL precursors pool and the 
frequency of gag-specific CTL precursors were inversely correlated with virus load 
(Pontesilli et al., 1998). On the other hand, viral mutation in CTL epitopes can result in 
viral escape from CTL recognition, which contributes to disease progression 
(McMichael 1998; Goulder et al., 1997). 
CD8 class I-restricted CTLs have been demonstrated against a wide variety of the HIV-
1 gene products, predominantly directed against Gag, Pol and Env but also targeting 
some regulatory proteins such as Nef, Tat, and Vif (McMichael and Walker, 1994; 
Autran et al., 1991, Novitsky et al., 2001). Within the envelope, both conserved and 
variable domains serve as CTL targets whereas those within Gag, Nef and Vif are 
relatively conserved. A striking feature of HIV-specific CTLs is that these effector cells 
from an infected person can be directed toward multiple epitopes in HIV viral proteins, 
but the range of HIV Cli epitopes recognised by infected individuals varies (Johnson et 
al., 1994). Phillips et al., (1991) reported that HIV-specific CTLs from an infected donor 
could be directed against three peptide epitopes in Gag. However, CTLs from HIV-1 
infected hemophiliacs directed toward a single epitope in Gag were also reported 
(Goulder et al., 1997). It has been demonstrated that anti-HIV CTLs could switch from 
one epitope to the other in HIV infected individuals (Nowak et al., 1995) and that CTL 
activity may decline as disease progresses (McMichael and Walker, 1994; Wolinsky et 
al., 1996). Individuals who progress to AIDS may lose the CTL activity directed against 
the HIV Env, Gag, Pol, and Nef proteins despite maintaining a broad cytolytic function 
against other non-HIV antigens (Pantaleo et al., 1990). The loss of CTL activity is 
probably secondary to the loss of CD4 T-cell population and impairment of their 
function (Fauci et al., 1996b). A recent study in the SW macaques model of AIDS 
infection showed that initial immune pressure was directed mainly through an epitope in 
Tat, whereas on in Gag did not appear to be under strong immune selection pressure 
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(Allen et al., 2000). During primary and late HTV infection in human, differences 
between the specificity of HIV-1 specific CD8 responses has been noted (Altfeld et al., 
2001a; Goulder et al., 2001). In subjects with early HIV infection, there were no 
detectable CTL responses towards the p17 Gag epitope which is recoginsed in majority 
of subjects with chronic infection (Goulder et al., 2001). HIV-1 infected long-term 
survivors presented a persistently predominant gag-specific CTL response (Pontesilli et 
al., 1998). In addition, recent date suggests that CTL responses directed against 
regulatory proteins Tat and Rev (Walker and Goulder, 2000; Allen et at., 2000; Addo et 
at., 2001) and accessory protein Vpr (Aitfeld et al., 2001b) may also play a role in the 
HIV-1 specific immune responses. The identification of the regions of HIV-1 which 
induce HIV-1 specific CTL response may help better understand immune control of 
viremia and for the development of potential HIV vaccines. 
1.2.2.3 CD8 cell-mediated suppression of HIV-1 replication 
In addition to the anti-HIV cytotoxic activity, CD8 cells are capable of controlling HIV 
infection by a direct effect on viral replication. This was first demonstrated by Walker et 
al., (1986), who showed that HIV could be recovered from PBMCs of asymptomatic 
individuals only after the CD8 cells were removed, and that adding back the CD8 cells 
suppressed virus production in a dose-dependent manner. This anti-ITV activity is 
mediated by a nonlytic mechanism (Walker et al., 1991), is not MHC-restricted 
(Brinchmann et al., 1990; Levy et al., 1996), and can occur without contact between the 
target and effector cells (Walker and Levy 1989). However, the suppression of HIV 
replication is more efficient when the effector and target cells are in contact with one 
another (Levy et al., 1996; Brinchmann et al., 1990; Mackewicz et al., 1995). HIV-
suppressing CD8 cells have been shown to express certain cell surface markers: CD28 
(Landy et al., 1993), CD29, CD45RA, (Tsubota et al., 1989), suggesting that CD8 
clones with antiviral activity are phenotypically heterogeneous (Toso et al., 1995). 
It was found that the suppression of HIV replication can occur across a semipermeable 
membrane that excludes cells but not fluids or by transfer of the supernatant from CD8 
cells, suggesting that it is mediated by release of soluble factor which is referred as 
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CD8 antiviral factor (CAF) (Walker and Levy, 1989; Brinchmann et al., 1990; 
Mackewicz et al., 1994). CAF is active against a wide variety of HIV-1 isolates (both SI 
and NSI) and can suppress HIV-2 and SIV strains (Levy, 1993b). Furthermore, The 
suppression of HIV replication has been demonstrated to be at the level of viral 
transcription (Mackewicz et at., 1995). 
Although cytokines, such as interferon-gamma (IFN-y) and IL-16 produced by CD8 
cells, have viral-suppressive activity (Emilie et al., 1992; Baier et al., 1995), they do not 
have the properties attributed to CAF. Reports have identified the CC chemokines MW-
la, MIP-113, and RANTES as potent suppressive factors produced by CD8 T-cells 
(Cocchi et al., 1995). This anti-REV suppressive activity can be explained by the 
blocking of HIV entry by competition for the viral coreceptor. IFIIV-1 T-tropic strains 
use the C-X-C chemokine receptor CXCR4 (Feng et al., 1996), the ligand for which 
SDF-1, blocks entry of T-tropic HIV isolates (Bleul et al., 1996; Oberlin et al., 1996). 
M-tropic isolates predominantly use CCR-5, a CC chemokine receptor that binds 
RANTES, MIP-la, and MIP-113 which block entry of these isolates (Cocchi et al., 1995; 
Alkhatib et al., 1996). However, these chemokines cannot account for all the properties 
of CAF, such as the ability to suppress HIV replication by an effect on LTR-driven 
transcription (Mackewicz et al., 1995) and this process needs to be more fully explored. 
1.2.2.4 CD4 cell response 
CD4 T helper cells play a critical role in regulating production of antibodies, induction 
and maintenance of CTL responses, and activation of macrophages and natural killer 
cells (Abbas et al., 1996; Zajac et at., 1998; Walter et al., 1995; Ridge et al., 1998). 
CD4 cell response can be decreased early in HIV-1 infection (Levy, 1993; Rosenberg et 
al., 1997; Oxenius et at., 2000). The vast majority of REV-i infected individuals have 
weak or undetectable proliferative responses to HTV-1 antigens (Schrier et al., 1989; 
Clerici et al., 1989; Musey et al., 1999; Valentine et al., 1998; Rosenberg et al., 1998). 
But a minority of HIV-infected patients, who maintain high blood CD4 T cell counts, 
have good proliferative responses to Gag p24 (Rosenberg et at., 1997; Pitcher et al., 
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1999). HIV-1-specific CD4 T helper responses were observed in long-term 
nonprogressors and initiation of potent antiretroviral therapy early in the course of 
primary infection resulted in generation of strong HIV-1 specific CD4 T helper 
responses to HIV-1 Gag 24 (Rosenberg et al., 1997; Musey et al., 1999; Aitfeld et al., 
2001a). This observation is consistent with the finding that HIV-1 specific CD4 T cells 
were detected in early infection but disappeared in untreated patients (Oxenius et al., 
2000). 
Analysis of functional HIV-1-specific memory CTL precursor frequencies and p24.-
specific proliferative responses counts showed that levels of p24-specific proliferative 
responses positively correlated with levels of Gag-specific CTL precursors in a cohort of 
infected untreated persons with a wide range of viral loads and CD4 cell, indicating that 
association between T helper cell and strong HIV-specific CTL responses (Kalams et 
al., 1999). An inverse relation between HIV-specific CD4 T cell responses to HIV-1 
p24 and viral load was also observed in persons with chronic infection (Rosenberg et al., 
1997). HIV-1 long-term non-progressors have showed relatively strong CD4 T cell 
antiviral activity compared with responses in disease progressors (Picker et al., 2000). 
These findings suggest that HIV-1 specific CD4 cell response may contribute to the 
control of HIV-1 replication and be likely to be important in immunotherapeutic 
interventions and vaccine development. This concept is also supported by a study in 
non-human primates, which has shown that the level of SIV-specific CD4 T cell 
responses induced during anti-viral treatment associated with the degree of control of 
viral replication (Lifson et al., 2000). A key feature of HIV-1 is its ability to infect and 
kill (either directly or indirectly) CD4 T cells, particularly, activated CD4 T cells 
(Veazey et al., 2000). There are several mechanisms proposed to explain HIV-mediated 
depletion of CD4 cells including accelerated killing of mature T cells, altered 
movement leading to the appearance of circulating CD4 T cell loss, impaired 
production of new T cells; HIV-1 associated apoptosis (reviewed in McCune 2001). 
Loss of these cell help may be responsible, in part, for the subsequent insufficient 
control of HJV infection by CTL (Picker et al., 2000). 
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The interaction of CD 4 T cells with MEC class H and peptide results in the activation 
of the cell, which in turn induces the secretion of cytokines. Cytokines represent major 
factors in development of immune responses including activation of B cells, CTLs and 
macrophages. Similar to the situation in mice, human CD4 T cells can be separated into 
two distinct subsets of Th cell: TO and Th2. The different subsets differ in cytokine 
profiles and the subsequent immune response they aid. TO cells produce IFN-y, IL-2, 
TNF-a/, which promote cell-mediated immunity and delayed-type hypersensitivity 
(DTH) (Mosmann et al., 1986; Mosmann and Coffman, 1991; Romagnani, 1994). TO 
cells secrete 11L-4, IL-5, IL-6, EL-9, EL-10 and IL-13, which favour allergic reactions and 
provide the most efficient help for B cells (antibody production) (Mosmann et al., 1986; 
Romagnani, 1994). On the basis of the pattern of cytokines expressed, immune response 
can be divided into TO and TO (Clerici and Shearer, 1993). It has been reported that in 
certain pathologic conditions different patterns of cytokine expression may be related to 
different types of immune response (Mosmann et al., 1986; Romagnani, 1994). 
With regard to HIV infection, a switch from TO to Th2 cytokine responses has been 
suggested to represent a critical step in the disease based on the pattern of cytokines 
production from PBMCs from HTV-infected individuals at different stages of disease 
progression (Clenci and Shearer, 1993). Patients with a Thi-type  response, characterised 
by production of IL-2 and IFN-y remain asymptomatic whereas those that switch from 
TO to TO, as indicated by decreased secretion of IL-12 and increased production of IL-
4, go on to be symptomatic (Clerici and Shearer 1993, Chehimi et al., 1994; Klein et al., 
1997; Clerici et al., 2000). It is known that one cytokine which may contribute to 
sustaining and augmenting both HIV-specific CTL-activity and TO function is IL-12 
(McFarland et al., 1998; Young et al., 2001). In vitro production of IL-12 in PBMC 
from HIIV-1 infected patients has been shown to be decreased compared to that in HIV-1 
seronegative individuals (Chehimi et al., 1994; Clerici et al., 2000; Ma et al., 2000). 
Dysregulation in IL-12 secretion by neutrophils from HP/-infected patients has been 
also observed (Vecchiarelli et al., 2000). Thus, it is possible that a primary IL-12 defect 
may contribute to the inability of HIV-infected individuals to sustain an effective 
antiviral immune response (Uherova et al., 1996; Nagy-Agren and Cooney 1999). 
41 
1.2.2.5 ADCC 
Virus-specific antibodies may direct the effector cells which bear Fc receptors, such as 
natural killer (NK) cells and monocytes/macrophages, to lyse the infected cell through a 
process known as antibody-directed cellular cytotoxicity (ADCC). Infected cells 
expressing the HIV envelope or CD4 cells pulsed with the gpl20 molecule are 
effectively lysed by this process (Lyerly et al., 1987; Ahmad et al., 1994). Antibodies 
capable of triggering ADCC are predominantly of the IgGi class and are directed 
against the envelope proteins (Ljunggren et al., 1988). Antibodies directed against Gag 
proteins are not as effective at inducing ADCC (Koup et al., 1989). HIV-1-specific 
antibodies capable of inducing ADCC decline as disease progresses. This may be related 
to the level of effector cell function (Tyler et al., 1990). 
In addition, NK cells represent a discrete lymphocyte subset defined by CD16/56 
expression. NK cells are spontaneously cytotoxic to tumor and virally infected targets. 
As such, they may play a role in natural resistance to HIV-1-associated disorders and 
other opportunistic infections. NK cells have been shown to be effective in killing HIV -
infected cells (Brenner et al., 1993; Ullum et al., 1999; Hultstrom et al., 2000). 
However, peripheral blood NK activity is frequently reduced in HIV-1 infected-patients 
with HIV-1-induced disease (Brenner et al., 1993) and the impairment of NK cells 
function is observed throughout the course of 1-TV-1 infection (Cai et al., 1990; Hu et 
al., 1995). The causes of NK cell dysfunction in AIDS-related disorders remain 
unknown. An altered expression of important regulatory receptors have been observed 
on NK cells from HIV-infected patients. The inhibitory NK receptor CD94 was 
upregulated (Andre et al., 1999) and the NK activation molecule CD16 and CD56 
downregulated (Hu et al., 1995). These phenotypical changes as well as the decreased 
number of NK cell in HIV infection may contribute to the decreased NK activity. This 
reduction in NK cells function may be one of reasons to cripple the immune response to 
infection. A recent study of HIV-1 exposed but uninfected individuals (HEPS) among 
Vietnamese showed the increased NK cell cytotoxicity present in these Vietnamese 
HEPS when compared to low-risk donors, indicating that NK cells may, in part, 
contribute to natural protection against WV-i (Scott-Algara et al., 2001). 
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1.3 Mucosal immunity to HIV-1 
There is now evidence suggesting that the mucosal and systemic immune responses are 
elicited and regulated with a considerable degree of independence (Alley et al., 1988). 
Mucosal immune responses play an important role in protection against HTV infection. 
However, the immune response to this virus at the mucosal surface is poorly understood. 
1.3.1 Overview of the mucosal immune system 
The existence of a protective local immune system in humans was initially suggested by 
Davies (1922) based on his observation that bacterial agglutinins could appear in 
dysentery stools several days earlier than in the blood. The molecular basis for local 
immunity was established after the discovery of secretory IgA in external secretions 
(Tomasi et al., 1965). 
The mucous membranes which in humans have a combined surface area of about 400m 2 , 
are the major sites of entry for most pathogens (Miller et al., 1992c). The defence of 
these vulnerable membrane surfaces is provided by organised lymphoid tissues known 
as mucosal -associated lymphoid tissue (MALT). The mucosal immune system (termed a 
compartment) consists of the tissues, cells and effector molecules that protect mucous 
membranes (Figurel.10). This immune system can be divided into two sites: inductive 
sites where antigen is encountered and initial responses are induced and effector sites 
where the production of secretory IgA (sIgA) results in local immune protection. The 
lamina propria of the gastrointestinal (GI) tract and upper respiratory tract are major 
mucosal effector sites. The mucosal inductive sites include gut-associated 
lymphoreticular tissues (GALT), brochus-associated lymphoreticular tissues (BALT), 
genital tract and secretory glands such as salivary gland. 
The mucosal immune response is initiated by the uptake of antigen by microfold (M) 
cells in the columnar epithelium of the Peyer's patches (PP) which consist of 30-40 
lymphoid nodules on the outer wall of the intestines. M cells then pass the antigen to 
antigen presenting cells (APCs) in the lamina propria. The APCs process and present the 












Figure 1.10 The mucosal system and its cellular components. Adapted from Cruse and 
Lewis (2000). 
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activated B and T cells enter the efferent lymphatic, pass through the thoracic duct and 
reach the systemic circulating blood and distant mucosal sites. The activated B and T 
cells enter mucosal tissues by specific binding to adhesion molecules (addressins) on the 
cytoplasmic membranes of lymphocytes and the endothelium of postcapillary venules. 
This concept that immune responses may occur at mucosal surfaces which are distinct 
from the site of mucosal immunisation is known collectively as common mucosal 
immune system (Bienenstock, 1979; Mayer, 1997; Kelsall et al., 1998). 
Since the lower female reproductive tract can initiate an immune response (Lehner et al., 
1992; Parr et al., 1992; Hocini et al., 1995, Czerkinsky et al., 1999), the genital tract is 
part of a common mucosal immune system. The mechanism of immune response to 
antigen in the female reproductive tract has recently been elucidated. Langerhans cells 
(LCs), which are abundant in the vaginal and ectocervical mucosa have dendritic 
processes which extend to the lumen of the vagina, both LCs and macrophages act as 
APCs (Miller et al., 1992b; Lechner et al., 1999). To generate a primary immune 
response in the female genital tract, APCs take up the antigen, and migrate to the 
draining lymph nodes, where they activate B and T cells. These then enter the 
circulating blood stream via the efferent lymphatic and thoracic duct, and reach the 
genital tract. When re-exposed to the antigen, these cells induce a secondary immune 
response. The mucosal effector sites in the mucosal immune system of the female 
genital tract consist of Fallopian tubes, ectocervix, endocervix and perhaps the vagina 
(Mestecky et al., 1994; Yeaman et al., 1998; Czerkinsky et al., 1999). 
In addition to antibody response, cell mediated immune responses, including CTLs, 
APCC and NK cells are also involved in protection of mucosal tissues. It has been 
demonstrated that functional CTL activity has been observed in subsets of intraepithelial 
lymphocytes (IELs) in lamina propria (Mayer, 1997; Yeaman et al., 1998). Induction of 
effective mucosal response to microbial attack is obviously a benefit to the host, since 
mucosal elimination of invading pathogens is the first line of immune defence to prevent 
subsequent systemic infection. 
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1.3.2 Secretory immunoglobulin A (sIgA) 
1.3.2.1 Structure of sIgA 
Although IgA constitutes only 10-15% of the total immunoglobulin (Ig) in serum, it is 
the predominant Ig class in external secretions including breast milk, saliva, tears, and 
secretions of the bronchial, genitourinary and digestive tracts. In contrast to IgG, human 
IgA displays a unique heterogeneity in its molecular forms. There are known to be two 
subclasses of IgA, IgA 1 and IgA2. Serum IgA is predominantly monomeric IgA i . The 
IgA in external secretions, called secretory IgA (sIgA), consists of a dimer or tetramer 
with a relative increase in the proportion of IgA 2. Monomeric IgA, like IgG, comprises 
two heavy and two light chains. The heavy or cc chain is made up of four domains, a 
variable domain and three constant domains (CHI, CH2 and C113). The heavy chains of 
human IgA 1 and IgA2 differ in only 22 amino acids. 
The molecules of sIgA contain a J-chain polypeptide and a polypeptide chain called 
secretory component (SC). SC is a 50 to 90 kDa polypeptide produced by the epithelial 
cells of the mucus membrane (Figure 1.11). It is found in secretions not only complexed 
to IgA and also as a free glycoprotein. SC consists of five immunoglobulin-like domains 
that covalently bind to the Fc regions of the IgA dimer. Immunochemical studies (Kerr, 
1990) have suggested that SC interacts with CH2 and CH3 domains of both pairs of 
heavy chains. The fifth domain of the SC is disulphide-linked to the CH2 domain of one 
of the IgA monomers. This model indicates that much of the Fc region might be 
exposed. 
1.3.2.2 Production of sIgA antibodies 
Daily, humans produce 5-15g of IgA in mucous secretions, greater than that of any other 
Ig class. The production of sIgA involves the selective transport of sIgA to external 
secretions (Rudzik et al., 1975; Mestecky et al., 1987; Brandtzaeg, 1989; Mestecky et 
al., 1994; Cruse and Lewis, 2000) (Figure 1.12). Induction of the mucosal IgA response 
is known to be highly dependent on cognate help provided by T cells. In vitro studies 
46 
Figure 1.11 Theoretical model of secretory IgA. Secretory component (dark shading) 
interacting with CH2  and CH3 domains of both pairs of heavy chains. The fifth domain of 
the secretory component is disuphide-linked to the CH2  domain of one of the IgA 










Figure 1.12 Production of secretory IgA (adapted from Cruse and Lewis, 2000). The 
precusor of glycosylated transmembrane SC is produced on the rough endoplasmic 
reticulum, matured in the Golgi apparatus, and expressed on the basolateral plasma 
membrane of the mucosal epithelial cells as the poly-Ig receptor. J-chain containing 
polymeric IgA (pigA) released by subepithelial plasma cells interacts with poly-Ig 
receptor on the surfaces of epithelial cells. This membrane complex is then endocytosed 
and transported in the form of a vesicle across the cells. These vesicles fuse with the 
plasma membrane at the luminal surface. Then the sIgA and free SC are released by 
cleavage. 
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indicated that cloned CD4 T cells in MALT are able to induce sIgA B cells to become 
sIgA and enhance the production of IgA (Kawanishi et al., 1983; Mayer et al., 1985; 
Murray et al., 1987). These effects occur through either the direct contact between 
responding B cells and T cells or activated antigen-specific CD4 cells (Hodgkin et al., 
1991). The T cells can lead to secretion of appropriate cytokines for B cell responses and 
Ig synthesis. Th l-type cells selectively produce JFN-y, IL-2, and TNF-13. Both IFN-y and 
TNF-a can upregulate functional SC expression (Brandtzaey et al., 1988). Transforming 
growth factor 13 (TGF-13), mainly produced by macrophage and platelets, can induce 
sIgM B cells to switch to sIgA expression. TO cells produce IL-4, IL-5, IL-6 and IL-
10, important lymphokines for IgA synthesis. 11L-5 induces sIgA B cells to differentiate 
into cells secreting IgA. IL-6 induces increased numbers of IgA secreting B cells at 
higher levels of total IgA synthesis than IL-5, probably because of its known ability to 
stimulate the differentiation or proliferation of plasma cell precursors arriving at 
mucosal sites (Mulligan et al., 1993; Ramsay and Kohonen-Corish, 1993). In mice, both 
IL-4 and IL-6 are required for the development of a specific IgA response to T cell 
dependent antigens (Vajdy et al., 1995). The finding that the cytokines produced by cells 
isolated from mucosal lymphoid tissue are strongly geared towards a TO type response 
which promotes antibody responses may explain the predominance of the IgA in 
mucosal effector tissues (Else et al., 1994; Xu-Amano et al., 1994). Although it is clear 
that cytokines are essential for IgA expression and production, the role of cytokines in 
regulating mucosal immunity is not fully understood. 
1.3.2.3 Function of sIgA antibodies 
sIgA antibodies serve an important effector function in mucosal immunity, because they 
are present at mucous membrane surfaces, which represent the main entry sites for most 
pathogenic organisms. Since it is polymeric, sIgA can prevent virus attachment to 
epithelial cells by cross-linking antigens with multiple epitopes, then transporting these 
immune complexes from the lamina propna across the epithelium into the secretion, thus 
blocking their subsequent penetration (Mazanec et al., 1993). Another important 
function of sIgA is intracellular neutralisation of viruses in epithelial cells. The 
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mechanism of neutralisation is a transcriptional block of virus replication in the infected 
epithelial cells. For influenza virus the mechanism for this transcriptional block may 
involve a conformational change in hemagglutinin (HA) following sIgA antibody 
binding, which results in transmission of a signal to the transcriptase complex inside the 
virus (Dimmock, 1984). The epithelial cells infected by virus are involved with IgA 
transport, and are therefore the site of antigen-IgA neutralisation that results in blocked 
viral nucleotide transcription. The unique characteristics of sIgA, such as its polymeric 
nature, avidity for mucus and resistance to proteolytic enzymes which is reinforced by 
its association with SC, all contribute to the apparent efficiency of this antibody in virus 
neutralisation. In addition to virus, sIgA antibodies also neutralise other biologically 
active antigens such as bacterial toxins and enzymes. sIgA is also secreted in breast 
milk, and plays an important role in protecting the new-born during the first month of 
life (Miller et at., 1992c). 
In summary, the mucosal immune response is a combination of humoral and cellular 
mechanisms. Exploitation of the origin of secretory antibodies and of specific antibody-
containing cells in mucosal layers and of the development of a vaccine which is 
effective for the induction of mucosal immune responses may assist in reducing the 
incidence of many infectious disease, including AIDS. 
1.3.3 HIV-1 mucosal immunity 
1.3.3.1 Mucosal immune response to HIV-1 in the female genital tact 
The investigation of mucosal immunity to HIV-1 has been mainly focused on the 
immune response to 1-HV-1 in genital tract of HIIV-1 infected women. An early study 
(Archibald et al., 1987) has reported that antibodies to HIIV-1 env proteins gp160, gp120 
and p01 proteins p55, p38  and gag protein p24 were detected by ELISA, Western 
blotting (WB) and radioimmunopreciptation assay (RIPA) in cervical samples from 
fly-i seropositive women. But the presence of serum in the secretions did not have any 
apparent effect on the results of the RIPA. This finding suggest that these antibodies 
were of IgA class and produced locally. Later, IgA antibodies to HIV- glycoproteins 
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gp160, gp120 and core proteins p18, p24 were detected in female vaginal secretions 
from healthy HIV-1 seropositive women, HIV-1 sreonegative exposed women and 
AIDS patients. However IgA antibodies to HTV-1 glycoprotein gpl20 in female vaginal 
secretions were rarely recovered (Bélec et al., 1989a, 1994a; Lu et al., 1991). Further 
investigations on the effects of HIV-1 infection on cervical/vaginal IgA synthesis were 
performed. Bélec et al., (1995a) have evaluated total IgA, IgA 1 , IgA2 in paired sera and 
cervical/vaginal secretions from HIV-1 infected women. The results showed that total 
IgA, IgA i , IgA2 increased proportionately in sera and cervical/vaginal secretions from 
early HIV-1 infection stages. However, the secretion rates of total IgA, IgAl and IgA2 
were markedly reduced in AIDS women. The data also demonstrated that healthy HIV-1 
infected women contained higher IgA 2 subclass than IgA 1 in vaginal washings. The 
author suggested that the decreasing rate of secretion for IgA 2 subclass at early stage of 
HIV infection indicated impairment of IgA class-specific immunoglobulin production in 
the cervical/vaginal mucosa during HIV infection. Similar selective reductions in 
salivary IgA and in intestinal IgA-producing plasma cells have also reported (Kotler et 
al., 1987; Jackson et al. 1990; Sun et al., 1990; Muller et a1991; Janoff et al., 1994). 
Since CD4 T helper (TH) cells are essential to both induce and maintain appropriate IgA 
response in mucosa-associated tissue and since HIV-1 infection causes a loss of mucosal 
CD4 lymphocytes (McGhee et at., 1989), it is conceivable that the number of CD4 
lymphocytes and subsequently IgA-bearing plasma cells within the cervical/ vaginal 
mucosa of HIV-1 infected women may be reduced. Overall, these findings are in 
keeping with the fact that female cervical/vaginal mucosa belongs to the mucosal 
immune system, with a predominance of IgA-producing cells and the IgA2 plasma cells 
being more numerous than the IgAl plasma cells within vaginal mucosa (55% versus 
45%) (Kutteh et al., 1994). Local antibodies in female genital tract could therefore play 
an efficient role in neutralising ITV-1 virus and limiting the virus infectivity on normal 
mucosa. 
1.3.3.2 Mucosal immune response to HIV-1 in the male genital tract 
Heterosexual intercourse is the major route of infection worldwide (Overbaugh et al., 
1999). HIV-1 transmission from men to women has been well documented, whereas 
, Uiv7 4.  
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studies for female-to-male transmission remain limited. Similar to the immune response 
pattern to HIV-1 in female genital tract secretions, both IgG and IgA antibodies to HIV-
1 were detected in semen samples from healthy male HIV-1 seropositive individuals and 
male patients with AIDS-related complex (ARC) or with AIDS. 73% of these semen 
samples contained IgA antibodies to HIV-1 env glycoprotein gp160, although 
surprisingly, only 9% semen samples possessed IgA antibodies to gp120. Since HIV-1 
env glycoproteins are the most external antigens, IgA antibodies to gp160 may 
significantly inhibit transmission of HIV-1 having been implicated in the neutralisation 
process (Bélec et al., 1989a; O'Shea et al., 1990; Wolff et al., 1992). 
1.3.3.3 Mucosal immune response to HIV-1 in urine and other body fluids 
Investigations into the mucosal immunity to REV using urine samples from HIV-1 
seropositive or exposed seronegative individuals are very limited. Most research on 
urine samples from HIV-1 infected subjects has been focused on the development of 
methodology for diagnosis of HIV-1 infection to replace the use of serum. The presence 
of antibodies to HIV-1 antigens p17, p24, p33, gp4l, p5i, p55, p61, gpl20, and gp160 
has been reported in unconcentrated and concentrated urine samples of HIV-1 
seropositive individuals using ELISA kits and Western blot assay, the highest 
prevalence being in antibodies to HIV-1 gp120 and gpi60 (Cao et al., 1989). The titre of 
the antibodies to HIV-1 in the urine specimens was parallel with the titre of antibodies to 
REV-1 in the corresponding serum. IgA was also found in some urines of HIV-1 
seropositive individuals by immunodiffusion analysis; 1gM was not detected. IgG 
antibodies to HIV-1 (TuB) gp160 were also found in the urine of children of HIV-1 
infected women and it has been suggested that this could be an early indicator of 
vertically transmitted infection (Bauer et al., 1992). Constantine et al. (1994) reported 
that all tested urine samples in their study consistently exhibited reactivity to gp160. In 
common with semen (Wolff et al., 1992) and parotid saliva (Sun et al., 1990), many 
urine samples showed no, or very weak reactivity to p24, in contrast to the generally 
strong p24 reactivity found in serum samples. It is possible that antibodies to p24 may 
be either complexed with viral antigen and may not pass through the kidney glomerulus, 
or may be sequestered by reacting with cross-reactive antigens in the reproductive tract. 
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Testing antibodies to HIV in urine samples using enzyme immunoassay was more 
sensitive than conventional methods (Hashida et al., 1993, 1994a, 1994; Sterne 1993; 
Urnovitz et al., 1993; Conell et al., 1990; 1993). These results suggest that such assays 
may be used either as a primary screen in populations or as an alternative test for 
individuals unwilling to or with difficulty in providing a serum sample. 
1-HV-1 neutralising activity in serum and concentrated urine from HIV-1 seropositive 
individuals was also reported (Cao et al., 1990). HIV-1 neutralisation activity was 
detected in 23 of 56 of the serum samples and in 19 of 56 of the urine samples. The 
neutralising activity in the urine concentrates was generally associated with high titres of 
neutralising antibody in the corresponding serum samples. However 11 urine samples 
contained HIV-1 neutralising antibodies but the corresponding sera lacked neutralising 
activity. On the other hand, one urine concentrate lacked neutralising antibody, but the 
corresponding serum had high titres of neutralising antibody. The reason for the 
discrepancy between the frequency of neutralising antibodies in paired concentrated 
urine and serum is unclear. 
Antibodies to HIV-1 in urine from seropositive or exposed seronegative subjects can 
reflect the mucosal immune response as well as systemic immune response to HIV-1. In 
spite of this, little work has been done in this area and further research is required. 
Mazzoli et al. (1997) reported that MV-1 specific IgA but not IgG was present in urine 
and vaginal wash samples from 10 (5 males and 5 females) out of 16 (63%) HIV-
exposed seronegative individuals, whereas both IgA and IgG were observed in their HIV 
infected partners; antibodies were not demonstrable in the urine of low-risk controls. 
These data indicating that the mucosal immune response is triggered when exposed to 
HIV-1, raise the possibility of a protective role for mucosal IgA in resisting I-ITV 
transmission and infection. 
In addition to genital secretions and urine samples from HIV-1 infected subjects, 
specific antibodies to FIIV-1, predominantly of the IgA isotype, have also been detected 
in other body fluids, such as tears, milk, nasal washing, intestinal fluid, cervicular fluid 
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and saliva (O'shea et al., 1990; Sun 1990; Thongcharoen et at., 1992; Janoff et at., 1994; 
Mestecky et al., 1994). All these findings indicate that following HIV-1 infection, a 
mucosal immune response induced at one site, results in antibody secretion in a variety 
of external secretions. 
1.3.3.4 Local IgG antibodies to HIV-1 within the genital tract 
HIV-1-specific antibodies have been detected in the both male and female genital tract 
(Archibald et at., 1987; Bélec et at., 1989a; Wolff et at., 1992; Lu et at., 1993; Bélec et 
al., 1994b). Bélec et al. (1995b) have investigated local synthesis of IgG antibodies to 
REV-i within the genital tract of HIV-1 infected, clinically asymptomatic women and 
men. The results showed that the mean specific activities of IgG to gp4l and p24 in 
cervical/vaginal secretions and in seminal fluids were about 33-fold and 16-fold higher 
respectively than that of the corresponding sera, and the mean specific activities of IgG 
to gp160 in genital secretions were correspondingly about 17-fold and 10-fold higher 
than that of the sera. IgG antibodies to HIV-1 have been detected in genital secretions 
from HIV-1 infected individuals, and appear to be largely synthesised in situ within the 
genital tract of both genders. The authors therefore suggested that a strong, specific local 
production of IgG antibodies to HIV-1 occurs within the genital tract of both HTV-i 
infected men and women. This hypothesis can fit with the fact that HIV specific IgGs 
are found in cervical/vaginal secretions of HIV infected women and seminal fluid of 
HIV infected men (Bélec et al., 1989b; O'Shea et at., 1990; Wolff et al., 1992; Lu et at., 
1993). This concept was further supported by the another study by the same authors 
(Bélec et at., 1995c). Paired sera and cervicovaginal secretions (CVS) from 30 women 
infected with REV-i were analyzed for IgG and IgA antibodies to MV and for IgG, IgA, 
and human serum albumin. The results showed that cervicovaginal immunoglobulins 
were markedly increased, and IgG predominated in HIV-infected women compared with 
that of the healthy controls. Furthermore, IgG excretion by reference to albumin was 
increased 1.9-fold, whereas the IgA secretion tended to decrease, suggesting a possible 
enhanced local IgG synthesis. 
This is however in contrast to other opinions (WoIlf et at., 1992) who claimed that HTV- 
1 IgG antibodies in semen of infected men were transudated from serum primarily via 
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the prostate. Thus, analysis of the different abilities of serum and local IgG antibodies to 
block transmission of HIV-1 is particularly important in the understanding both the basic 
mucosal immunology of HIV infection and the design of an HIV vaccine. 
1.3.3.5 Cellular mucosal immune response to HIV-1 
Little is known concerning the induction of an effective cell mediated immune response 
in the mucosal immune system. It has been demonstrated that HIV infection leads to a 
reduction in the number of CD4 cells in mucosal sites. A lower ratio of CD4:CD8 
cells also occurs in the intestinal lamina propria of subjects with either lymphadenopathy 
syndrome or AIDS (Rodgers et al., 1986). Data concerning the number of Langerhans 
cell (LC) in mucous membranes of 1-HV-1 infected patients are conflicting. One early 
study showed that the number of LC in oral mucus of HIV infected patients had not been 
reduced (Becker et al., 1988). However, a study reported a statistically significant 
reduction of LC (CD1a) found in oral mucosal washings of HIV-1 seropositive patients 
compared with healthy controls (Sporri et al., 1994). These abnormalities at mucosal 
surfaces may explain the pathogenesis of opportunistic infection in the gastrointestinal, 
respiratory and genitourinary tracts of infected patients. Miller et al. (1996) 
demonstrated that, in SW-infected female rhesus monkeys, the vaginal CD8 
intraepithelial lymphocyte (EEL) population is moderately increased and more widely 
distributed compared with uninfected monkeys, and persistently infected monkeys had 
greater numbers of CTL precursors than the ones which were infected for only two 
weeks. Sly specific CTL have also been found in the vaginal mucosa of monkeys 
(Lohman, 1995). The above results may suggest that this immune effector function 
might provide a first-line defence against sexually transmitted intracellular pathogens. 
In conclusion, although considerable progress has been made recently in understanding 
the mucosal immune response to HIV infection and in developing mucosal HIV 
vaccines, and it is generally accepted that mucosal immunity might be important in 
protection against HTV transmission, the types of anti-WV mucosal immune responses 
required are still not fully understood. 
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1.4 HIV-1 HEPS individuals (EUs) 
During the past ten years, AIDS researchers have recognised that some individuals are 
persistently HIV seronegative despite documented exposure to HIV, defined as highly 
exposed, persistently seronegative (HEPS) individuals or exposed uninfected individuals 
(EUs). 
1.4.1 Host factors in HEPS individuals 
Population analyses have shown that individuals homozygous for the 32-bp deletion in 
the gene encoding CCR5, which has been identified as a major coreceptor for M-tropic 
HIV-1 entry (see section 1.1.6.2) are rarely present in HIV infected populations, 
indicating that mutant CCR5 confers resistance to HIV-1 infection in vivo as well as in 
vitro (Dean et al., 1996; Samson et al., 1996b). It has been demonstrated that the mutant 
alleles harboured a 32-bp deletion (32) in CCR5 gene which lead to a premature stop 
codon and encoded for a nonfunctional protein. 
In 1996, Liu et al. reported that homozygous defect in CCR5 gene was found in two 
HEPS individuals. The encoded protein is severely truncated and cannot be detected at 
the cell surface. Furthermore, this defect had no obvious phenotype in the affected 
individuals. These data indicate that a CCR5A32 allele present in the human population 
appears to protect homozygous individuals from sexual transmission of HIV-1. 
Subsequent studies supported this conclusion by demonstrating that people who are 
homozygous for the deleted allele (32) are highly resistant to 1-IIV-1 infection in vivo 
(Dean et al., 1996; Huang et al., 1996; Samson et al., 1996b; Michael et al., 1997), and 
cells from such people are resistant to the infection by HIV-1 M-tropic strains in vitro 
(Connor et al., 1996; Liu et al., 1996; Rana et al., 1997). The hypothesis, that people 
who carry one deleted and one normal allele (heterozygous) i32 genotype can be 
partially protected against FIIV-1 infection, is suggested and demonstrated by a couple 
of studies (Samson et al., 1996b; Hoffman et al., 1997). Recently, it has been confirmed 
that the presence of two CCR5wth32 heterozygous genotypes among 139 HEPS 
individuals, and PBMCs from these two heterozygous individuals were also found to be 
less susceptible to HIV-1 M-tropic isolates infection in vitro (Kokkotou et al., 1998). 
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This result supports a role for 32-bp CCR5 deletion in HIV-1 resistance. However, 
despite the substantial protection it affords, the CCR5 i32 still fails to account for most 
HEPS cases (Dean et al., 1996; Huang et al., 1996; Smith et al., 1997; Zimmerman et 
al., 1997). 
1.4.2 Systemic immune response in HEPS population 
HIV-1-specific immune responses in HEPS population have been detected at both the 
cellular and humoral level. Several studies have demonstrated the presence of an HIV 
specific T cell response, in the form of T cell proliferation, interleukin 2 (IL-2) 
production induced by HIV peptide, detection in vitro of HIV specific cytotoxic T 
lymphocytes by HIV peptide and generation in vitro of HIV specific CTLs in cohorts of 
these individuals (Shearer et al., 1996). It was also reported that NK cells play a role in 
resistance to HIV infection (Krowka, 1996). In addition high levels of neutrophils and 
C138 cells were found in repeatedly exposed seronegative homosexual men (Detels et 
al., 1994), suggesting a hypothesis that C138 cells may modulate the outcome of HIV-1 
exposure. It has been demonstrated that the anti-HIV-1 activity from C138 lymphocytes 
in multiple high-risk sexually exposed HIV-1 seronegative individuals was greater that 
that of CD8 lymphocytes from nonexposed controls and their purified CD4 
lymphocytes were relatively resistant to HIV-1 infection in vitro (Paxton et al., 1996). 
This relative resistance did not extend to T cell line adapted strains, but was associated 
with the activity of the C-C chemokines RANTES, MIP-la and MIP-113. Therefore the 
authors suggested that this relative resistance of CD4 lymphocytes may block HIV-1 
transmission and contribute to protection from HIV-1 in multiply exposed HIV-1 
seronegative persons. It also reported that anti-CD4 antibodies specific for defined 
epitopes of the CD4 molecule were detected in 6 of 18 individuals who were persistently 
seronegative, despite exposure to HIV-1. These antibodies could block HIV-1 driven 
syncytia formation, and inhibit the ability of CD4 binding to specific anti-CD4 
monoclonal antibodies, but did not interfere with the CD4-gpl2O interaction. The result 
indicated that these autoantibodies to CD4 may play a protective role in HIV-1 EUs. The 
possible mechanism for the resistance against I-IIV infection in multiply exposed 
individuals who exhibit strong HIV specific T cell immune activity, suggested by 
57 
Shearer and Clerici (1996), is acquired immunity through natural immunisation. 
Accidentally acquired immunity may therefore protect from HIV infection. 
1.4.3 Mucosal immune response in HEPS population 
Another clue to the explanation of natural resistance against HTV in HEPS individuals 
comes from studies in rhesus macaques and chimpanzees of resistance to low doses of 
HIV or Sly given intrarectally or intravaginally, indicated that there may be local 
cellular mucosal immune responses capable of protecting against low dose mucosal HIV 
or SW challenges (Haynes et al., 1996). Recently, Mazzoli and his colleagues (1997) 
examined 16 Italian couples discordant for HIV infection, in which one member was 
HEPS. It was found that HIV-specific IgA but not IgG was present in urine and vaginal 
wash samples from HEPS individuals, whereas both IgA and IgG were observed in their 
HIV seropositive partners, Also, Env peptide-stimulated PBMCs from HEPS individuals 
produced more IL-2 and less IL-10 compared to those of HIV-infected individuals. 
These data demonstrated that a compartmentalised immune response to HIV is possible 
in humans, and mucosal IgA in the genital tract could offer a potent first-line defence 
against HIV sexual transmission. Recently, Kaul et al. (1998) reported that HIV-1 
specific IgA was detected in the genital tract of 16 out of 21(76%) 1-HV-1 EUs, 5 out of 
19 (26%) infected women, and 3 out of 28 (11%) lower risk women (P<0.0001). T-
helper lymphocyte response did not correlate with the presence or titre of HIV-1 specific 
mucosal IgA. These data suggest a role for mucosal 1-TV-1 specific response in HIV-1 
resistance, independent of a systemic cellular response. 
Since the development of vaccine which induces a specific mucosal immune response in 
genitourinary tract has far reaching implications for the prevention of HIV transmission, 
the need for determining the specificity of protective mucosal antibodies and 
understanding mucosal immunity status in multiply exposed HIV seronegative 
individuals is vital for developing HIV mucosal vaccines. 
1.5 Vaccine development 
The majority of HIV-seropositive individuals acquired their infection via mucosal 
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surfaces (Miller et al., 1992c; Phillips et al., 1994), which strongly implies that HIV-
specific sIgA with neutralising activity in secretions on the mucosal surface is critical for 
control of infection in individuals exposed to HIV. Therefore, the ability of candidate 
I-ITV vaccines to induce mucosal responses is likely to be an essential feature of an 
effective IJJV vaccine, not only because of the importance of mucosal transmission of 
HTV, but also because of the large pool of activated T cells in the gastrointestinal tract 
which are susceptible to HIV infection. Systemic immunisations are unable to efficiently 
induce immune responses in mucosal sites because of compartmentalisation of systemic 
and mucosal immune system, prompting an intensive effort to develop novel vaccine 
approaches able to induce a mucosal immune response. There is evidence showing that 
sIgA not only prevents viral adhesion to the mucosal receptors but also neutralises the 
virus (Mazanec et al., 1993). 
1.5.1 Mucosal HIV-1 vaccines development 
Mucosal HIIV vaccines designed to be given by mucosal routes (oral, rectal, intranasal 
and intravaginal) to induce both mucosal and systemic immune response to HIV 
antigens are under development, although at present most are still restricted to animal 
models. 
Oral vaccination is useful not only because of the generation of mucosal immunity but 
also because of the ease of administration and applicability for mass vaccination. Recent 
evidence demonstrates that oral immunisation can elicit sIgA. It has been reported that 
when mice and rabbits were orally immunised with HIV-immunsomes (gp160-coated 
liposomes) followed by parenteral immunisation with a low dose of the same antigens, 
high titres of serum IgA, 1gM and IgG against HIV gp160, and sIgA in the saliva were 
detected (Thibodeau et al., 1992). These data suggest that oral immunisation can 
effectively induce a mucosal immune response upon re-exposure to antigen. The concept 
has been supported by other studies (Lehner et al., 1992; Mestecky et al., 1994; Morrow 
et al., 1994; Bond et al., 1995). There are recent studies showing that oral immunisation 
can induce systemic and mucosal immune responses to H1V (Bukawa et al., 1995; Wu et 
al., 1997). When mice were immunised orally with a multiple macromolecular peptide 
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vaccine candidate (VC1), composed of peptides from the V3 region of four subtypes of 
HIV-1, one CD4 binding site and one Gag region linked to cholera toxin, it stimulated a 
specific systemic and mucosal immune response to HIV. Strong and prolonged 
production of serum IgG as well as faecal and serum IgA antibodies were detected 
(Bukawa et al., 1995). The secretory component titre of HIV-1 specific faecal IgA 
antibody was 1:2 11 , which strongly implies that the HIV specific faecal IgA to VC1 
vaccine was mainly in the secretory form. Neutralisation tests showed that this HIV 
specific faecal IgA was capable of neutralising HIV-1 IIIB, HIV-15F2 and H1IV-1MN. 
Moreover, the faecal IgA antibody response was greater that that of serum IgG. This 
result indicates that env-peptide delivered orally in combination with cholera toxin 
adjuvant can effectively induce HIV-specific immune response in mucosal tissues which 
may provide protection to mucosal surfaces against HIV-1 transmission. 
The intranasal route of immunisation has been reported to induce mucosal immune 
responses (Muster et al., 1995; VanCott et al., 1998; Staats et al., 1996; 1997) as well as 
cellular immune responses (Morris et al., 2000) against the immunising antigen. 
Intranasal immunisations with oligomeric HIV-1 gp160 vaccine formulated with several 
adjuvants can elicit serum and vaginal IgG/IgA titres in mice (VanCott et al., 1998) and 
long-lasting sIgA was detected in the genital and intestinal tracts in mice after intranasal 
immunisation with chimeric virus that can express gp4l of HIV-1 (Muster et al., 1995). 
In 1996, Staats et al. reported that intranasal immunisation with hybrid HIV-1 peptide 
vaccine candidate T1SP1OMN(A) and cholera toxin (CT) induced long-lived systemic 
and mucosal antibody responses as well as cell-mediated immunity to HIV. It has been 
further demonstrated that the intranasal route of immunisation is superior to gastric, 
vaginal and rectal routes for induction of specific anti-HIV immune responses by the 
same author (Staats et al., 1997). However, recent evidence demonstrates that rectal and 
vaginal immunisation with a multiple macromolecular peptide vaccine candidate VC1, 
mixed with cholera toxin strongly induces IgA antibody in faecal extract solution and 
vaginal washing (Kato et al., 2000). 
A great deal of attention has focused on HIV DNA vaccines (Okuda et al., 1995; Askura 
et al., 1997; Okada et al., 1997; Barouch et al., 1998, Kaneko et al., 2000). Intranasal 
immunisation with a DNA vaccine, which is constructed with the cytomegalovirus 
(CMV) promotor linked to env gp160 and rev genes, has been shown to induce the 
production of mucosal IgA in faeces and vaginal washings in mice. Similarly, oral 
immunisation with HIV env-encoded plasmid DNA encapsulated in microparticles 
induced HIV env-specific immune response in mice which elicited a significant level of 
protection against mucosal challenge with the vPE16 recombinant vaccinia virus 
(expressing the full-length HIV-1 IIIB gp160) (Kaneko et al., 2000). This result is 
consistent with the observation based on intrarectal immunisation with HIV env-specific 
peptide and cholera toxin (Belyakov et al., 1998a, 1998b). These data indicate that oral 
vaccination may represent a very effective approach in providing protection against 
HIV-1 infection acquired via mucosal surfaces. 
Considerable progress has also been made recently in primate models for development 
of mucosal vaccines against HIV. It has been demonstrated that when rhesus macaques 
were sequentially vaginally, rectally and orally immunised with hybrid particles that 
carry the SIV gag protein p27 (SIVp27:Ty-VLP) prototype vaccine linked to the cholera 
toxin B (CTB) epitope followed by a oral boost, specific sIgA and IgG antibodies were 
detected in the urine, urethra washings, seminal fluid and vaginal secretions (Lehner et 
al., 1992). Use of recombinant adenovirus containing SIV envelope gene by oral and 
intranasal immunisation successfully elicited anti-SIV humoral, cellular and mucosal 
immune response in rhesus macaques (Buge et al., 1997). A study significantly extends 
these observations, by taking advantage of the lymphatic drainage from the rectum 
(Lehner et al., 1996). The iliac lymph nodes which drain the genitorectal mucosa were 
selected as the target of vaccine injection for the first time. It was found that cells 
secreting IgA antibody to p27, CD8-suppressor factor and the chemokines RANTES and 
MEP-1p significantly increased in the iliac lymph nodes and total protection was found 
in four out of seven macaques after rectal SIV challenge. These results have raised the 
possibility that application of HIV antigens to mucosal surfaces may be a fruitful 
approach of vaccination against AIDS. 
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Clinical trials of HIV-1 vaccines are being carried out in human volunteers (Kovacs et 
al., 1993; Walker et al., 1994; Kahn et al., 1994; Mascola et al., 1996; Keefer et al., 
1997; Nitayaphan et al., 2000; Boyer et al., 2000; Fazal et al., 2000; Nilsson et al., 
2001) aimed at determining the humoral, cellular as well as mucosal immune responses 
to the vaccine product and the safety of the candidate HIV vaccines (Funkhouser et al., 
1993; Perry et al., 1993; AIDS Vaccine Evaluation Group, 2001). Intramuscular 
immunisation with two recombinant gpl60 candidate vaccines failed to induce 
detectable sIgA in the saliva and nasal washing samples although IgG was detected in 
nasal washing and sera. It has been suggested that vaccines inoculated via the parenteral 
route are unlikely to induce protective mucosal immunity. This is due to the different 
origin of precursor B and T cell which populate the systemic and mucosal immune 
compartment, a fact which should been considered when a mucosal vaccine is 
developed. It is generally accepted that formulation with novel adjuvants or antigen 
delivery systems could be the most likely to induce HIV-specific mucosal immunity 
(Mestecky et al., 1994; McCormack et al., 2000). 
Recombinant envelope protein-based subunit vaccines have been extensively tested in 
phase 1111 human clinical trials (Klein, 2001, Mascola and Nabel, 2001). Human trials of 
a recombinant subunit gp120 antigen (derived from HIV-IS strain) have shown to be 
well tolerated, and antibodies with neutralising activity against HIV-1 can be generated 
and boosted, in immunised seronegative volunteers (Kahn et al. 1994; Mascola et al., 
1996; Keefer et al., 1997; Nitayaphan et al., 2000). A bivalent subunit vaccines 
comprising recombinant gpl20 proteins from HTV-1MN and a primary HIV-1 isolate are 
currently being tested in phase Ill trial since 1998 (in North America) and 1999 (in 
Thailand). Efficacy results of these phase III trials are expected to become available 2-3 
years later (Migasena et al., 2000; Mulligan et al., 1999). 
Formulation HIV-1 subunit vaccines with a combination of adjuvants to induce potent 
immune responses in immunised subjects was also investigated. HIV-1 seronegative 
volunteers received 200 .tg recombinant monomeric HIV-1 rgpl20w6ID derived from a 
dual co-receptor tropism isolate HLV-1ACH320 in 50 .tg 3D-MPL (3-deacylated 
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monophosphoryl lipid A) and 50 jtg QS-21, a novel adjuvant QS-21 derived from the 
soapbark tree Quilaja saponaria, together with a novel oil and water emulsion (SB62) at 
0, 4 and 28 weeks, induced antibody titres as high as those seen in HTV-1 infection, 
albeit the quality of the antibodies remained different in that there was no evidence of 
primary isolate neutralisation. Cellular immunity was also enhanced in immunised 
subjects in terms of lymphoproliferative responses, but HIV-1 specific CD8 CTL was 
not demonstrated (McCormack et al., 2000). Recently, a phase II study of two HIV-1 
gp120 vaccines induced neutralising antibodies and envelope-specific 
lymphoproliferation in populations at risk for acquiring FIIV-1 infection (McElrath et 
al., 2000). Studies showed that envelope subunit vaccines induced neutralising 
antibodies that were generally type-specific and failed to neutralise primary HIV-1 
isolates (Graham et al., 1996, McCormack et al., 2000; Nitayaphan et al., 2000). 
Furthermore, phase 1111 clinical trials have shown that envelope subunit vaccine rarely 
induce a CD8 CTL response (Graham et al., 1996; Locher et al., 1999; McCormack et 
al., 2000; Nitayaphan et al., 2000), but lymphoproliferative responses to intact HIV-1 
glycoproteins have been readily detected (McCormack et al., 2000; Schooley et al., 
2000; McElrath et al., 2000). Of note, some participants in Phase I/IT trials who were 
immunised with HIV-1 gp120 vaccine had significant neutralising antibodies against 
vaccine isolates but still became infected during or following immunisation (Berman et 
al., 1997; Connor et al., 1998, Locher et al., 1999). This feature remains a major 
obstacle of HIV vaccine development. 
Live recombinant vaccinia and attenuated canarypox vectors (ALVAC) based HIIV-1 
vaccines evaluated in human clinical phase I/Il trials have demonstrated safety profiles 
(Graham et al., 1993; Pialoux et al., 1995; Clements-Mann et al., 1998; Belshe et al., 
2001). An ALVAC based FIIV-1 vaccine encoding multiple 1-IV-1 gp120, p55 and 
protease (vCP205) has been initially assessed in a phase H trial. 435 volunteers 
including people at both higher and lower risk for FITV infection received vCP205 
with/without gp120 boosting. More (94%) subjects given vCP205 plus gp120 than those 
(56%) who received vCP205 alone developed neutralising antibody to HIV-1MN. CD8 
CTL were detected in 33% of volunteers given vCP205, with or without gp120 (Belshe 
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et al., 2001). These data suggested that weak neutralising antibody responses induced by 
live recombinant viral vector, as has been demonstrated (Graham et al., 1992), can be 
heightened by boosting with recombinant envelope protein. In a recent study, a 
vaccination regimen consisting of a ALVAC based vector expressing 1-TV-1 Env, Gag, 
and Pol, in combination with a recombinant gpl20 subunit protein resulted in 
neutralising antibodies in 91% of vaccinees and CD8 CTL responses in 62% of 
subjects. Moreover, boosting with HIV-1 rgp120 did not increase the CTL responses to 
HIV-i envelope proteins, but did enhance the magnitude and frequency of neutralising 
antibodies to HIV-1MN (AIDS Vaccine Evaluation Group 2001). Similar results were 
also demonstrated in other clinical trials including priming with HTV-1 gp160-vacinia 
and boosting with HTV-i rgpl20 (Corey et al., 1998); priming with ALVAC based 
vector expressing fly-i gp120, gp4l, gag and protease followed by boosting with 
rgpi20 in HIV-1 seronegative volunteers (Evans et al., 1999), and priming with 
ALVAC-HIV-1 gpi60 and boosting with rgp120 in HIV-1-uninfected adults (Clements-
Mann et al., 1998). More frequent and longer-lived (6 months after the last 
immunisation) HIV-1 CD8 CTLs and/or neutralising antibodies were induced by 
priming with live recombinant viral vector, followed by boosting with recombinant 
HIV-1 envelope proteins than immunising with live recombinant vector or recombinant 
HIV-1 envelope protein alone (Ferrari et al., 1997; Verrier et al., 2000). Therefore, 
inducing protective humoral and cellular immune responses by HIV-1 vaccines might be 
achieved by formulating live recombinant viral vector based HIV-1 vaccines consisting 
of multiple HIV-1 genes with rgp 120 booster regimen. 
DNA vaccines encoding HIV-1 proteins have been tested in Phase I trials to evaluate the 
safety and immunogenicity as HIV-1 vaccine candidates in HIV-1 uninfected healthy 
volunteers. An REV-1 env/rev DNA vaccine was administered intramuscularly to HIV-1 
seronegative persons at a dose of 100 or 300 tg at 0, 4, 8, and 24 weeks. Subjects who 
received the 300 j.tg dose exhibited antigen-specific T cell proliferative responses and 
antigen-specific production of both INF-y and 3-chemokines. This study supports the 
idea that REV-i DNA vaccines can stimulate immune responses in naive volunteers 
(Boyer et al., 2000). Notably, a phase I trial of the first DNA vaccine specifically 
designed to combat the dade A HIV-1 virus, which is the most prevalent strain in many 
parts of Africa, was officially launched in Oxford in 2000 and later in Kenya in 2001. 
The trial was conducted in low risk healthy volunteers and is to evaluate the safety and 
immunogenicity of the DNA vaccine. The results are expected to be ready in about two 
years (Fazal et al., 2000). 
1.5.2 Edible vaccine development 
By using recombinant DNA technology, a subunit vaccine is made by isolating genes 
from human pathogens (viruses and bacteria) and transferring the DNA into a transgenic 
(containing the transferred gene) host, which produces a protein (subunit of pathogen) 
that contains the antigenic fingerprint of the disease-causing agent but does not itself 
cause disease. These subunit vaccines are purified from the transgenic hosts and injected 
as vaccines to induced immunity against a specific disease. 
Transgenic plants comprise a new production system that does not require vaccine 
purification or injection and provides the possibility that a fresh or pureed fruit such as 
banana or tomato could replace the needle as a means of vaccinating children and adults 
against deadly diseases. The vaccine-producing transgenic plant is created by placing the 
gene encoding the antigenic subunit under the control of plant-specific DNA regulatory 
sequences, which is then induced to integrate into the nuclear chromosome of the plant 
cell. Then, the antigen protein is produced and accumulated to a significant level in 
transgenic plants (Figure 1.13). 
In 1992, Mason et al. first reported that the gene-encoding HBsAg of hepatitis virus B 
was successfully expressed in transgenic tobacco and that the HBsAg produced in 
transgenic plants is antigenically and physically similar to the HBsAg particles derived 
from human serum and recombinant yeast, which are currently used as vaccines. This 
findings led to the hypothesis that transgenic plants may offer a new way of generating 
vaccines, thereby allowing a very inexpensive means of oral immunisation simply 
through consumption of the edible vaccine. This concept is supported by the subsequent 
demonstration that the HBsAg expressed by transgenic tobacco was in a form that was 
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Figure 1.13 Schematic protocol for production of candidate vaccines in plants 
(Modified from Richter et al., 1996). 
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able to stimulate a B-and T-cell immune response in immunised mice (Mason et al., 
1995). In 1996, the capsid protein of Norwalk virus, which causes epidemic acute 
gastroenteritis in humans, was expressed in genetically engineered tobacco and potato 
plants. When mice were either fed with the transgenic tubers which expressed 
recombinant Norwalk virus-like particles (rNV), or given extracts of tobacco leaf 
expressing rNV by gavage, serum IgG and secretory IgA specific for rNV were detected, 
indicating the potential usefulness of this subunit antigen as edible vaccine (Mason et 
al., 1996). In addition to virus, bacterial components have also been reported to have 
been successfully expressed in transgenic plants (Haq et al., 1995). 
To investigate the possibility of transgenic plant derived oral vaccine which could be 
developed to combat enterotoxic Echerichia coil (E. coli) and cholera, which cause 
severe diarrhea and sometimes death, transgenic tobacco and potato plants expressing 
the binding subunit of E. coli heat-labile enterotoxin (LT-B), which is a highly active 
oral immunogen, were produced (Haq et al., 1995). Although the levels of expression in 
these plants were low, the proteins were immunogenic in mice fed with the raw potato 
tubers. Mice fed the plant derived antigen had higher levels of anti-LT-B serum IgG 
(humoral immune responses) and faecal IgA (mucosal immune responses) when 
compared with mice gavaged with authentic bacterial LT-B. Furthermore, the antibodies 
produced against the tobacco-derived LT-B were able to neutralise LT activity, 
indicating the potential protective value of the immune response. Recently, the LT-B 
produced in transgenic potatoes was found to be in an appropriate form for 
immunogenicity even after cooking (Arakawa et al., 1998). This advance may have the 
potential benefit for human beings as humans do not normally consume raw potatoes. 
These data support the concept that a food source containing a foreign antigen can result 
in oral immunisation (Haq et al., 1995; Mason et al., 1998). May et al. (1995) developed 
an Agrobacterium-mediated plant transformation system for the generation of transgenic 
banana system, which gives us encouragement that banana could be served as edible 
food vaccine to protect humans from infectious disease. 
Based upon animal trials, the US food and drug administration approved human clinical 
67 
testing of raw potatoes containing LT-B in 1997. The results showed that edible 
vaccines are feasible for humans. Volunteers who consumed raw potatoes developed 
LT-B-specific IgA; the amplitude of the responses was comparable to a challenge with 
106  virulent enterotoxigenic E. coli (an amount sufficient to induce severe diarrhea) 
(Tacket et al., 1998). A companion paper reports that secretory antibodies produced in 
transgenic plants to passively immunise human volunteers prevent enterotoxigenic E. 
coli infection (Ma et al., 1998). 
Transgenic plants as a vaccine production and delivery system to protect animals from 
infectious diseases has also been explored. A study showed that protection against a 
viral disease by immunisation with a transgenic plant expressed antigen was achieved 
(Carrillo et al., 1998). The structural protein VP1 of foot-and-mouth disease virus 
(FMDV), which has frequently been shown to contain critical epitopes, has been 
expressed in different vectors and shown to induce virus-neutralising antibodies and 
protection in experimental and natural host. The transformed plants (Arabidopsis 
thaliana) expressing VP1 were produced (Carrillo et al., 1998). Mice immunised with 
leaf plant extracts elicited specific antibody response to synthetic peptides, FMDV VP1 
and intact FMDV particles. Additionally, all of the immunised mice were protected 
against the challenge with virulent FMDV. Recently, the major structural protein VP60 
of rabbit hemorrhagic disease virus (RHDV) has been successfully expressed in 
transgenic potato plants (Castanon et al., 1999). The rabbits immunised with leaf 
extracts showed high level of anti-VP60 antibody titres and were fully protected against 
the hemorrhagic disease. Very recently the specific immune response to porcine 
transmissible gastroenteritis virus (TGEV) was achieved in pigs by immunisation with 
recombinant TGEV spike protein expressed in transgenic tobacco plants (Tuboly et al., 
2000). 
There is likely to be immunological concerns about oral tolerance. In theory, too much 
orally administrated proteins delivered over an extended period might produce immune 
tolerance. But whether oral tolerance would develop if the amount of edible vaccine 
used was appropriate remains unclear. Because orally administrated proteins 
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theoretically need to overcome the oral unresponsiveness of the alimentary tract, which 
is the mucosal immune system's selective ability to not react immunologically against 
antigens of food and intestinal microorganisms even though it responds vigorously to 
pathogens (Cruse and Lewis, 2000). So far all the studies on edible vaccine have been 
reported to induce immune response against the immunising antigen in animals (Haq et 
al., 1995; Thanvala et al., 1995; Arakawa et al., 1998; Carrillo et al., 1998; Ma et al., 
1998; Mason et al., 1995; 1998; Tracket et al., 1998; Castanon et al., 1999; Tuboly et 
al., 2000). 
Taken together, the concept of edible vaccine is only a few years old but progress has 
been fast. Research on edible plant vaccines has moved from theory to proof-of-
principle. Plant based oral vaccines may offer a new approach to vaccination strategies, 
in particular, in cases where a local immune response is crucial in the prevention of 
infections. The transgenic edible plant vaccines have shown to be a potential new 
generation of novel, encouraging and prospective vaccine production and delivery 
systems with its distinguishing characteristics including inexpensive and local 
production, unnecessary preparation or purification and easy transportation and storage. 
1.6 Aims and work presented in this thesis 
Since antibodies to HIV-1 in urine from HIV-1 seropositive or exposed seronegative 
subjects can reflect the mucosal immune response in the genital tract as well as the 
systematic immune response to HIV-1, my work in this thesis was aimed to firstly 
compare the specificity of anti-HIV antibodies of different isotypes present in paired 
urine and serum of HIV-1 seropositive and HEPS individuals, investigate the possibility 
of local antibody in urine samples from highly exposed, FHV-1 seronegative individuals 
and its role in mediating mucosal protection against HIV-1, and evaluate the theory that 
exposed seronegative individuals may develop a local anti-HIV antibody response, 
detectable in urine. Secondly it was to develop a novel method for the generation of Env 
protein of HIV-1 in transgenic plants to investigate the feasibility for creation of 
inexpensive and safe IIIV "edible vaccine". 
In order to investigate the local antibodies to HIV-1 in both HIV-1 seropositive and 
exposed HIV-1 seronegative individuals, the IgG, IgA and sIgA antibodies to different 
HIV-1 viral proteins in 3 paired urine and serum samples, and the corresponding 2 swab 
wash samples from HIV-1 seropositive individuals in Edinburgh and Uganda, and in 9 
paired urine and serum samples from exposed HTV-1 seronegative individuals from 
Uganda was studied by WB. The antibody pattern in paired urine and serum or the 
corresponding swab wash samples from MV-1 seropositive individuals, and in paired 
urine and serum samples from exposed HLV-1 seronegative individuals were, 
respectively, compared and the local immune response to HIV-1 in both MV-1 
seropositive and exposed HIV-1 seronegative individuals were analysed. 
To investigate the feasibility of expressing FHV-1 gpl60 protein in transgenic plants, 
both plant leaf and tuber expression vectors containing HIV-1 gp160 gene were 
constructed. To achieve this vector construction, the full-length of HIV-1 gpl60 was 
amplified from DNA template by PCR and cloned into plant plasmids pIBT210.1 
containing the plant leaf specific promoter 35S and pIBT240. 1 containing the plant tuber 
specific promoter patatin, respectively. DNA fragments containing the required HIV-1 
gpl60 gene and the plant leaf specific promoter 35S or the plant tuber specific promoter 
patatin were then cut from the recombinant plasmids pIBT210.1 or pIBT240.1 with the 
appropriate enzymes and cloned into plant binary vector pGPTV-KAN. To obtain the 
transgenic plants, the desired recombinant plant expression vectors were transformed to 
Agrobacterium tumefaciens strain LBA4404 and the HIV-1 gpl60 gene then transferred 
to potato and tobacco as well as to NT-1 plant cells by Agrobacterium-mediated plant 
transformation system. The transformants were cultured and selected on selection 
medium containing the appropriate amount of kanamycin. The transgenic tobacco 
plantlets, potato microtubers and NT-1 transformants were generated following the 
appropriate plant tissue culture and transformant selecting procedure. The integration of 
HIV-1 gpl60 gene in the transgenic tobacco genome was tested by PCR. The 
transcription of MV-1 gpl60 gene in transgenic tobacco plantlets was analysed by RT-
PCR. Expressions of HIV-1 gplóO protein in transgenic tabaco plantlet leaves, potato 
microtubers and NT-1 cell transformants were investigated by gpl60/120 ELISA. 
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All chemicals were supplied by SIGMA Chemicals Co., England unless otherwise 
stated. 
2.1.2 Specimens 
Paired serum and urine samples from HIV-1 seropositive and seronegative individuals in 
Edinburgh and Uganda were collected and aliquoted. These samples containing 0.1% 
(w/v) sodium azide were then stored at —70 °C until used. Prior to HIV-1 antibody 
analysis by Western blot, all samples used were inactivated at 56 °C for' 1 hour. The urine 
samples were then centrifuged at 500 x g for 15 minutes at room temperature. The urine 
supernatants were concentrated 100-fold using a Minicon B15 (Amicon) or later 200-
fold with Miniplus' concentrator (Amicon) for use in subsequent Western blots. 
Vaginal swabs from HIV-1 seropositive women in Edinburgh were placed in 10 ml of 
PBS containing 0.1% sodium azide after swabbing the vaginas of the patients. The 
samples were aliquoted after collecting and stored at —70 °C until used. 
2.2 METHODS 
2.2.1 Preparation of total HIV viral proteins 
2.2.1.1 Cells for propagation of HIV 
Both H9 and C8166 cells are non-adherent cells. 
2.2.1.1a H9 cell line 
H9 cells, which is human cutaneous T-cell lymphoma (Mann et al., 1989) clone derived 
from HUT78 cell line (human cutaneous T-cell lymphoma from peripheral blood of a 
patient with Sezary Syndrome) (Gazdar et al., 1980), are less susceptible to syncytium 
formation than C88166 cells (see 2.2.1.1b), but good for virus replication. This cell line 
was obtained from AIDS Reagent Project (kindly donated by Dr A Doyle), and cultures 
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were grown in RPMI (Hyclone) supplemented with 2 mM L-glutamine, 100 u/mI 
penicillin and 10 .tg/ml streptomycin and 10 % fetal calf serum (FCS) (this medium will 
be referred to as RSA from now on) in 25 or 75 cm  sterile tissue culture flasks (Costar, 
High Wycombe, UK) at 37 °C with 5 % CO2 until approximately 5 x 105 cells/ml, and 
then were split in 1: 10 for maintenance. 
2.2.1.1b C8166 cell line 
C8166 cells which is human T-lymphoblastoid cell line, carries a defective HTLV-1 
genome. C8166 cells are very susceptible to syncytia formation and used as indicators of 
virus fusion and replication (Salahuddin et al., 1983; Lee et al., 1984). This cell line was 
obtained from AIDS Reagent Project (kindly donated by Dr P Clapham and Dr G 
Farrar). The C8166 cell line was cultured in RPMI (Hyclone) supplemented with 2 mM 
L-glutamine, 100 u/mI penicillin and 10 tg/ml streptomycin and 10 % fetal calf serum 
(RSA) in 25 or 75 cm  sterile tissue culture flasks (Costar, High Wycombe, UK) at 37 °C 
with 5 % CO2 and subcultured every 3-4 days for maintenance. 
2.2.1.2 Production of virus stocks 
1-HV-1 IIIB is a sync yti um-i nducing (SI) strain and was obtained from the AIDS Reagent 
Project (kindly donated by Dr. R. Gallo and Dr. M. Popovic). The virus was passaged in 
the H9 culture maintained in RSA medium. 3 ml of H9 cells at a concentration of 7.5 x 
106  cells/ml were infected by adding imI of HIV supernatant (TCID 50 4.25 x 106) 
cultured in 6 ml of RSA medium and incubated at 37 °C with 5 % CO2 for 4-5 days. lml 
of infected cells were then cocultivated with C8166 cells at a concentration of 2.5 x 106 
cells/ml for overnight. The well-established infection was indicated by induction of 
numerous syncytia. Four volumes of uninfected H9 cells at a concentration of 5 x 105 
cells/ml were then added to one volume of the infected H9 cells, the mixture was 
cultured for 3-4 days. After titration, the virus containing supernatants were stored at - 
70°C until used. 
2.2.1.3 Titration of virus 
C8166 cells were prepared at 4 x 10 5 cells per ml in RSA medium. 133 .tl of RSA 
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medium was added to the first six wells of a 96 well U-bottomed microplate (only 
central 60 wells of the plate used) and 150 p,l to the rest, 67 jal of virus containing 
supernatants was added to the first six wells (1:3 dilution). 50 i.tl of this was transferred 
to then next round of wells and the processes repeated, until the final row where 50 p1 
was discarded. 50 p1 of C8166 cell suspension was added (2 x 10 4 cells per well) making 
1:4 dilution of the viral stock solution in row 1, 1:16 in row 2, etc. The plate was then 
incubated at 37°C, 5%CO2 for 4 days. On day 4, 100 p1 medium was removed and 
replaced with fresh RSA medium. On day 8, infected wells were assessed for the 
presence of syncytia. TCID 50/ml was calculated by Reed and Meunch's method 
(Dulbecco, 1988). 
2.2.1.4 Preparation of viral lysates from culture supernatants 
1-HV-1IIIB infected H9 culture fluids as described above were centrifuged at 1500rpm 
for 10 minutes. The supernatants were filtered through a 0.45pm membrane microfilter 
(Sartorius) and inactivated at 56 °C for 3 hours. They were then concentrated by passage 
through a 20% sucrose cushion in a SH-80 rotor (Dupont) at 20,000 rpm for 2.5 hours. 
The pellet was resuspended in lysis buffer (50 mM Tris-HCI, pH 7.2, 150 mM NaCl, 1% 
Triton X 100, 1% Sodium deoxycholate, 0.1% sodium dodecyl sulphate) in a volume 
that was equal to 1 in 200 original volume, and then aliquoted and stored at -70 °C until 
use. The antigen preparation was assessed by SDS-PAGE. 
2.2.1.5 Preparation of HIV-1 IIIB lysates from infected cells 
28 ml of the harvested HIV-1 TuB infected H9 cell culture fluids were centrifuged at 
1500rpm for 10 minutes. The pellet was washed twice with sterile PBS (Oxoid Limited, 
England) and then resuspended in lysing buffer (50 mM Tris; 5 niM EDTA; 150 MM 
NaCl and 0.5% (w/v) CHAPS which was added after the other reagents have dissolved) 
at a concentration of 1 x 108  cells/mi. To this was then added 1/10 volume of above 
lysing buffer and the mixture vortexed for 30 seconds. It was then placed on ice for 25 
minutes prior to centrifugation at 1500rpm for 5 minutes at 4 °C. The supernatant was 
collected, aliquoted and stored at —70 °C for future use. 
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2.2.2 Immunoassays 
2.2.2.1 Western blot 
2.2.2.1a Sodium-dodecyl sulphate-polyacrylamide gel electrophoresis of proteins 
(SDS-PAGE) 
The Hoefer Mighty Small SE 250/280 minigel apparatus (Hoefer Scientific Instruments, 
California, USA) and the Gradient Former model #GM-040 (C.B.S. Scientific Co., 
California, USA) were used. The HIV-1 0 virus preparations or recombinant proteins 
(AIDS Reagent Project, MIRC) were separated by SDS polyacrylamide gel 
electrophoresis using a Tris-glycine buffer (50 mM Tris and 384 mM glycine) 
containing 0.1%SDS. The resolving gels consisted of 5%-20% linear gradient 
acrylamide gel made from stock solution (30% acrylamide/1.034% bis acrylamide, 
ScotLab) in 375 mM Tris-HCI buffer (pH 8.7) containing 0.1% SDS. 25 .tl of 10% 
ammonium persulfate and 2.6 tl of TEMIED (N,N,N',N'-tetramethylethylenediamine) 
were added to each of 8 ml of 5% light gradient gel solution and 20% heavy gradient gel 
solution. The filling flow from the gradient maker to gel sandwich was adjusted to 2 ml 
per minute. 1 ml of Methanol was applied to the top of the gel gently, and the gel 
allowed to polymerise at room temperature for 1 hour. Then the resolving gel was 
overlaid with 3% acrylamide (stacking gel) in 125 mM Tris-HC1 buffer (pH 6.8) 
containing 0.1% SDS. Prior to loading, samples were mixed with an equal volume of 2 
X sample buffer (125 mM Tris-HCI; 20% (v/v) glycerol; 4% SDS; 2% (v/v) 2-
mercaptoethanol and 0.001% bromophenol blue) and boiled for 3 mm. 20 j.l of the 
mixture was loaded onto a well of an analytical gel. Gels were run at 20 mA of constant 
current until the bromophenol blue tracking dye entered the resolving gel and then 
increased the current to 30 mA until the bromophenol blue tracking dye reached the 
bottom of the resolving gel (1 hour). The gel was used for the subsequent 
immunoblotting or staining with Coomassie Blue. 
2.2.2.1b Western blot 
Separated proteins were transferred from the gel to pre-wetted nitrocellulose membranes 
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(Sartorius) at 0.8mA/cm 2  for 1 hr using a semi-dry electroblotter (Ancos, Denmark) in 
transfer buffer (48 mM Tris, 39 mM glycine and 20% methanol). After transfer, the 
nitrocellulose membranes were blocked using 10% dried skimmed milk (J Sainsbury 
plc, Stanford, UK) in PBS with constant agitation at room temperature for 2 hours 
before incubation with either primary antibodies or the samples (see section 2.1.2 for 
details), diluted in antibody dilution buffer (PBS with 0.5% Tween 20 and 1% dried 
milk), for 3 hours at room temperature or overnight at 4 °C with constant agitation, were 
diluted with PBS/T. Unbound primary antibody was removed by washing in PBST (PBS 
containing 0.05% Tween 20) three times. Blots were then incubated for 2 hrs with sheep 
anti-human IgG (SAPU) or sheep anti-human IgA (SAPU), which was prediluted 1 in 
300 with antibody dilution buffer, at room temperature with agitation. The blots were 
again washed three times with PBST prior to incubation with horseradish peroxidase 
(HRP) conjugated donkey anti-sheep IgG, diluted 1:300 with antibody dilution buffer, at 
room temperature for 2 hours under agitation. After washing, the peroxidase activity was 
detected colorimetrically by the addition of a fresh solution of 3,3-diamonobenzidine 
(DAB) tetrahydrochloride (10 mg (1 tablet) was dissolved in 15 ml of PBS, pH7.6; 12 tl 
of 30% hydrogen peroxide was added to the DAB solution prior to use). After 
incubation at room temperature for 15 to 30 minutes, the reaction was stopped by 
washing the strips 2 times with distilled water. 
2.2.2.1c HIV-1 western blot kit 
The samples of serum, urine and vaginal swab (see section 2.1.2 for details) were diluted 
1:50 by adding 40 il samples or control to the 2.0 ml sample buffer (PBS containing 
0.03% Tween-20) containing 3% powered milk supplied. The presence of antibodies to 
HIV-1 proteins was then detected using HIV-1 Western Blot Kit (Epitope, Inc., 
Beaverton, Oregon). The assay was performed by following the manufacturer's 
instructions. 
2.2.2.2 HIV-1 gp1601120 ELISA (Enzyme linked immunosorbant assay) 
This assay is modified from the method basically developed by Moore and Jarrett 
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(1988). 
2.2.2.2a Coating of plates 
Inimunosorbant removawell strips (Dynatech laboraatories, Inc., Chantilly, VA, USA) 
were fitted into the corresponding M1croELISA strip holder (Dynatech laboraatories, 
Inc., Chantilly, VA, USA). These strips were coated with sheep polyclonal antibody 
(Ab) to HIV-1 gpl20 (D7324, AAlto BioReagents Ltd, Dublin, Ireland) at a 
concentration of 4 j.tg/ml in coating buffer (100 mM NaHCO3, pH 9.6) by incubation 
overnight at room temperature. The wells were washed 4 x 200 .U/well with wash buffer 
(0.05% Tween20 in lx TBS (50 mM Tns-HC1, pH7.6; 145 mM NaCl)), blocked for 1 
hour at 37°C with 100 .tl 2% BSA (Bovine serum albumin) in 1 X TBS, and then 
washed again with wash buffer. The plates were then sealed into plastic bags with silica 
gel sachets (BDH laboratory supplies, Poole, England, UK) as desiccant and kept at - 
20°C until use. 
2.2.2.2b ELISA 
The coated strips were removed from the —20 °C freezer and equilibrated to room 
temperature. Samples were diluted two fold with 0.1% Empigen (Calbiochem) in 
IxTBS. To obtain a standard curve, recombinant gpl60 (AIDS Reagent Project, MRC, 
UK) was diluted to 25, 12.5, 6.25, 3.125 and 0 ng/ml with 0.1% Empigen (Calbiochem) 
in 1 X TBS. 100l.tl of the samples and different dilutions of recombinant gpl60 were 
added to the duplicate wells and the plates were incubated for 3 hours at 37°C. Unbound 
proteins were removed by washing 4 times with 200 tl wash buffer per well. 
lOOpi of anti gpl20 monoclonal antibody (AIDS Reagent Project, MRC, UK) which had 
been diluted to a concentration of 1 j.tg/ml with wash buffer containing 1% BSA, was 
added to the wells (except blank wells) and incubated for 1 hour at 37°C. The wells were 
washed 4 x 200 .tl/well as above. 
100.tl of biotinylated F (ab') 2 Goat anti-human IgG (Zymed, San Francisco) diluted 
1:1000 with wash buffer containing 1% BSA was added and incubated for 1 hour at 
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37°C. The plates were washed as before. 
100 p.1/well of extravidin alkaline phosphatase (EA-AP, 1:1000 in wash buffer 
containing 1% BSA) was added to the wells (except blank wells) and incubated for 1 
hour at 37°C. Unbounded EA-AP was removed by washing 4 x 200 p.1/well with the 
wash buffer. The bound EA-AP was detected with SIGMA FAST p-Nitrophenyl 
phosphate (pNPP) substrate system (one pNPP tablet and one Tris Buffer tablet were 
dissolved in 5 ml distilled water) using 100 p.1/well of substrate solution for all wells 
including the blank. The plates were kept in the dark for 15-30 minutes. The reactions 
were stopped with 50 p.1 of 0.4 M NaOH and the optical density (OD) determined at 
405nm using a Labsystems Multiskan Bichromatic Reader. The machine was zeroed 
with blank wells (two empty wells per plate). Concentration of samples was estimated 
by reference to a standard curve (see section 5.3.4.1). 
2.2.3 General molecular biology methodology 
2.2.3.1 Polymerase chain reaction 
Plasmids (see Chapter 4) containing the whole env160 sequence or DNA extracts from 
transgenic plants leaves were used as template for amplification of HIV-1 specific env 
DNA fragments. The PCR reaction conditions were as follows: 4 ng of plasmids or 5p.l 
of DNA extracts and 0.25 p.M of each primer were used per reaction. PCR mixture 
consisted of 50 mM Tns HCI (pH 9.1), 16 mM ammonium sulphate, 3.5 mm M902, 
and 150 p.g/ml nuclease-free BSA, 3.3 p.M dNTPs and 2 units (for extending DNA 
strands less than 1Kb (kilobase pairs)) or 5 units (for extending a strand by 2.6Kb) of 
Taq DNA polymerase (purchased from either Sigma Chemicals Co., England or Helena 
BioSciences, Sunderland, UK). All the reaction mixtures were made up to 20 p.1 with 
DEPC (Diethyl procarbamine) treated distilled water (dH20) and overlaid with paraffin 
oil to prevent evaporation. They were then subjected to thirty cycles consisting of 94 °C 
for 45 seconds, 55 °C for 45 seconds, 72 °C for 3 minutes, followed by a single cycle of 
72°C for 10 minutes, on either a GENEE Thermal Cycler (Techne) or PCR Express 
(Hybaid). 10 p.1 samples of each PCR reaction were analysed on a 1% TAE agarose gel 
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electrophoresis (see section 2.2.3.2). 
2.2.3.2 Agarose gel electrophoresis of DNA 
1% agarose (Flowgen, Staffordshire, UK) in 1 X TAE (40mM Trisacetate, 1mM EDTA 
(Ethylenediamine tetraacetic acid), pH8.5) was melted by microwave for 4 minutes. 
After cooling to 60°C, ethidium bromide (EB) was added at a final concentration of 0.3 
.tg/ml. The gel then was poured into gel cast and allowed to set. Electrophoresis running 
buffer (1 X TAE) was added to the tank to just cover the gel. Then DNA samples (PCR 
product and plasmid DNA) were loaded, and the gel was run at 100 volts for about 1 
hour until DNA fragments were well resolved. 1 Kb DNA ladder (GIBCOBRL) or 
Lambda/Hind!!! DNA marker (Promega) 1Kb DNA ladder (Gibco) was run alongside 
the samples as DNA molecular weight marker. DNA bands in the gels were visualized 
on a ultra-violet (UV) transilluminator, and photographed using a Polaroid CU-5 land 
camera and black and white Polariod 667 film or Eagle EyeThl  system (Stratagene). 
2.2.3.3 Digestion of DNA with restriction endonucleases 
Restriction endonuclease cleavage was accomplished simply by incubating the 
enzyme(s) (including EcoRI, Hindlil, NcoI, Sad, Sall, Smal and XbaI) with the DNA in 
appropriate reaction conditions supplied by the manufacture (see Chapter 4 for details). 
Generally, 20 .tl digestion mixture consisted of 2 xl of 10 X digestion buffer supplied 
with each enzyme (Promega or NewEngland Biolabs), 0.2 p.1 of 100 X BSA, 1 p.g DNA 
samples, 10 units of each enzymes (0.5-1 p.1), and dH 20 was added to make up to 20 p.1. 
The reaction mixture was incubated at 37°C (for EcoRI, Hindlil, NcoI, Sac!, Sal! and 
XbaI) or 25°C (for Sma!) in a water bath for 2 hours. When the double digestion 
(cleaving a DNA substrate with two restriction endonucleases simultaneously) was 
performed, the digestion buffer that resulted in at least 75% activity for both enzymes 
was used. When the two combination enzymes required different optimal digestion 
temperature, such as Smal and Sac!, the double digestion was performed sequentially. 
Restriction enzymes were inactivated by heating at 65 °C for 15 minutes and the 
digestion reaction was either used for subsequent agarose gel electrophoresis, phenol 
extraction or kept at -20 °C until use. 
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2.2.3.4 Purification of PCR products 
PCR products were purified using QlAquick PCR purification kit (QlAgene, Germany), 
according the manufacturer's manual. In brief, 5 volumes of buffer PB (supplied by 
manufacturer) was added to the PCR reaction and mixed. Then mixture was applied to 
the QlAquick column and centrifuged for 1 minute at 13,000rpm. After washing with 
0.75m1 washing buffer PE (supplied by manufacturer), the DNA was eluted with 30 tl 
DEPC treated dH20 and kept at -20 °C until use. 
2.2.3.5 Phenol extraction and ethanol precipitation of DNA 
An equal volume of 25:24:1 (v/v/v) phenol/chloroform/isoamyl alcohol was added to the 
DNA solution and mixed by vortexing vigorously for 30 sec. After microcentrifuging for 
5 minutes at room temperature, the upper (aqueous) layer was transferred to a new tube 
taking care to avoid any material at the interface. If a white precipitate was present at the 
interface, the DNA solution was repeatedly extracted with phenol/chloroform/isoamyl 
alcohol a second time. 0.1 volume of 3M sodium acetate (pH5.2) and then 2-2.5 volume 
of ice-cold 100% ethanol were added and mixed by vortexing. To precipitate the DNA, 
the tube was placed at -20 °C overnight or at -70°C for 30 minutes or on dry ice for 15-20 
minutes and pelleted by microcentrifuging for 30 minutes at 4 °C. The pellet was washed 
twice with lml 70% ethanol and dried in a Speedvac evaporator or on a 65°C heat block 
for 5-15 minutes depending the size of the pellet. The DNA pellet was dissolved in 10-
20 pi of DEPC treated dH20. 
2.2.3.6 Recovery of DNA from agarose 
DNA was separated on a 1 % (wlv) low melting point agarose (Flowgen) or routine 1% 
agarose gel made up in 1 X TAE buffer. DNA in the gel was visualized by UV 
illumination and the DNA fragment of the predicted size was cut out of the gel. DNA 
was then extracted and purified by using the Geneclean II kit (BlO 101 Inc., Stratech 
Sci., England) following the manufacturer's instruction (see section 2.2.3.6a). Later 
samples were extracted and purified by using Prep-A-Gene DNA purification Systems 
(BlO-RAD) (see section 2.2.3.6b). 
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2.2.3.6a Geneclean 
3 volumes of 6M sodium iodide (NaT) were added to the gel slice containing DNA and 
the gel was melted in a 55°C water bath. 5 j.tg of Glassmilk suspension (silica) was 
added and mixed by inverting the tube several times. The mixture was then placed on ice 
for 15 minutes, mixing every 2 minutes. The GlassmilkfDNA complex was pelleted by 
microcentnfuging for 5 seconds at 13000 rpm. The pellet was washed three times with 
500.tl NEW WASH (NaCl, Tris, EDTA and ethanol). The DNA was then eluted from 
the Glassmilk by incubating the suspension at 55°C for 5 minutes in 8 .tl of DEPC 
treated dH20 and microcentrifuging for 30 seconds. The elution was repeated once more 
and the two supernatants were pooled and centrifuged for 5 minutes at 13000rpm to 
remove any traces of matrix. The DNA concentration in the supernatant was estimated 
by running 1.0 pA of sample on 1% agarose gel alongside Lambda/Hindu DNA marker 
(see section 2.2.3.7). 
2.2.3.6b Prep-A Gene DNA purification 
The desired DNA band containing 1 pg of DNA required was excised from an agarose 
gel. The volume of the gel slice was estimated by weighing and converting to milliliters 
(ml). Conversion of grams (g) to ml was accomplished by assuming 1 g of a gel slice is 
equal to 1 ml. 3 volumes of binding buffer (6 M sodium perchlorate; 50 mM Tris (pH 
8.0); 10 mM EDTA (pH 8.0)) was added to the gel slice and heated at 50 °C on a water 
bath for 5 minutes to dissolve the agarose. To this was added 5 .tl of Prep-A-Gene 
matrix and mixed by inverting the tube several times. The mixture was then incubated 
for 15 minutes at room temperature, mixing every 5 minutes. The DNA/matrix complex 
was pelleted by centrifuging at 13,000rpm for 30 seconds. The pellet was rinsed with 
200 pA of binding buffer (6 M sodium perchlorate; 50 mM Tris (pH 8.0); 10 mM EDTA 
(pH 8.0)) and centrifuged for 30 seconds at 13,000 rpm. The pellet was then washed 
twice with 200 pA of wash buffer (400 mM NaCl; 20 mM Tris (pH 7.5); 2 mM EDTA 
(pH 7.5) and 50% ethanol (v/v)). After the second wash, all traces of liquid were 
carefully removed by using an automatic with a fine pipette tip. The bound DNA was 
eluted by incubating the DNA/matrix complex at 50 °C for 5 minutes in 10 .tl of dH20. 
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Following centrifugation at 13,000rpm for 2 minutes, the supernatant containing DNA 
was collected and re-centrifuged for 5 minutes at 13000 rpm to remove any traces of 
matrix. 1 .tl of the supernatant was used for checking DNA concentration by running on 
1% agarose gel alongside LambdafHindlll DNA marker (see section 2.2.3.7). 
2.2.3.7 Measurement of DNA and RNA concentration 
Concentration and purity of DNA and RNA was determined by measuring the 
absorbance at 260nm and 280nm in a spectrophotometer (CE 594, Jencons (Scientific) 
Ltd, UK). An absorbance of 1 unit at 260nm is equivalent to 50 .tg of double stranded 
DNA per ml or 40 pg of single stranded DNA or RNA per ml. Purity of the DNA or 
RNA was determined by calculating the ratio between the absorbance values at 260nm 
and 280nm, where pure DNA or RNA has a ratio of 1.5-2.0. Thus the concentration of 
DNA or RNA was obtained by using the following formula. 
Concentration of DNA (pg/ml) = Absorbance at 260nm x dilution factor x 50 
Concentration of RNA (.tgIml) = Absorbance at 260nm x dilution factor x 40 
For small amount of DNA, estimates were taken by visualizing the intensity of the 
fluorescence under UV illumination compared to LambdalHindlll DNA marker of the 
known concentration. 
2.2.3.8 Cloning PCR products into pCR-Script m Amp SK(+) cloning vector 
To insert the PCR products (the whole IIIV-1 env gene) into a vehicle for subsequent 
cloning into plant plasmids pIBT210.1 nd pIBT240.1 (see Chapter 4 for details), PCR-
ScriptSK(+) cloning vector (see Figure 4.1) (Stratagene, Cambridge, UK) was 
employed to clone the PCR product containing HIV-1 env gene and was used according 
to manufacturer's instruction. In brief, ligation reactions were set up at molar ratios of 
approximately 40-100:1 (PCR product: cloning vector) and the reaction mixture 
consisted of 10 ng of pCR-Script SK(+) cloning vector, 0.5 p.1 of 10 MM ATP, 5 units 
of Srf I restriction enzyme, 4 p.1 of PCR product and 4 units of T4 DNA ligase in 1 X 
pCR-Script reaction buffer supplied. Ligation reactions were incubated for 2 hours at 
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room temperature and heated to 65°C for 2 minutes. After cooling on ice for 5 minutes, 
2 p.1 of ligation mixture was used to transform 40 p.1 Epicurian Coli XL 1-Blue MRF' 
KAN supercompetent cells (Stratagene) in a ice-chilled 5 ml Falcon 2054 polypropylene 
tube (Falcon) containing 25 mM -mercaptoethanol. The transformation reaction was 
incubated on ice for 45 minutes and heat pulsed on a 42°C heat block for 45 seconds. 
After cooling on ice for 2 minutes, 0.3 ml prewarmed Soc medium (see Appendix I) 
was added to the transformation reaction. The tube was then incubated at 37 °C for 1 
hour with shaking at 225-250 rpm. 50 p.1 and 100 p.1 of the transformation reaction was 
spread onto separate LB agar plate containing ampicillin (20 p.g/ml), 20 p.1 of 0.2 M 
IPTG (isopropyl-43-D-thio-galatopyranoside) and 20 p.1 of 10% (w/v) X-gal (5-Bromo-4-
chloro-3-indoyl--D-galactopyranoside). The plates were incubated at 37 °C for 14-16 
hours. Next day, the white colonies which indicated possible successful the insertion 
(see section 4.3.2) were chosen for examination. 
2.2.3.9 Ligation of DNA fragments into plasmids 
The ligation of restriction endonucleases digested DNAIPCR fragments into the specific 
plasmid required were performed following the manufacturer's instructions by using 
either rapid DNA ligation kit (Boehringer Mannheim) or T4 DNA ligase and buffer 
purchased from New England Biolab (UK). 
The ligation molar ratio (ratio) of insert DNA to cloning vector DNA (vector) was 
generally 3:1. 100 ng purified digested vector was used for each ligation reaction and the 
amount of purified digested insert DNA in nanograms (ng) was optimized by using the 
following equation: 
no. of bps of insert DNA x ng of. vector 
no. of bps of vector 	x ratio 
Therefore, for ligation of HIV-1 env gene consisting of 2596 base pairs (bps) into bOng 
cloning vector pIBT240.1 consisting of 5554 bps, and the molar ratio of insert DNA to 
cloning vector was 3:1, the amount of purified HIV-1 env gene fragment should be 
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calculated as following 
')cQt Y inn 
5554 	x3=140.2ng 
2.2.3.9a Rapid DNA ligation 
The vector DNA and insert DNA were combined in one tube containing 2 i.tl of 5 x 
DNA dilution buffer and sufficient DEPC treated dH20 to make the final volume of 
reaction mixture to 10 pi reaction mixture. 10 .tl of 2 X T4 DNA ligation buffer 
(supplied with the kit) and 5 units T4 DNA ligase were added to the tube and mixed 
thoroughly by flicking the tube with fingers for several times. Then the reaction mixture 
was incubated for 15-30 minutes at room temperature. 2 l.tl of each ligation reaction was 
used directly for the transformation of DH5a competent cells (see section 2.2.3.10). 
2.2.3.9b Overnight ligation 
In this method, insert DNA and cloning vector were combined in one tube. To 1 tl of 10 
X ligase buffer (500 mM Tris-HCI, pH7.5; 100 MM MgCl2; 100 mM dithiothreitol 
(D'TT), 10 mM rATP, 250 j.tg/ml bovine serum album (BSA)), 0.5 pi of T4 DNA ligase 
(400 ulj.tl) (New England Biolabs) and 8.5 i.tl of DEPC treated dH20 or dH20 were 
added and mixed well by gently flicking the tube with fingers several times. The 
reaction mixture was then incubated at 16 °C overnight. 2 pi of each ligation reaction 
was used directly for the transformation of DH5a competent cells (see section 2.2.3.10). 
2.2.3.10 Transformation of competent cells 
Transformation of MAX efficiency DH5UTM competent cells (GIBCO BRL) was 
performed by adding the 1-2 ng plasmid or 2-5 tI ligation mixture to the 40 l.tl cells in a 
ice-chilled Falcon 2054 polypropylene tube (Falcon) and incubated on ice for 45 
minutes followed by heat shock on 42°C heat block for 45 seconds. The cells/DNA was 
placed on ice for 2 minutes, and 300pi 42 °C prewarmed SOC medium (see Appendix I) 
was added. Then cells were incubated at 37 °C for 1 hour under shaking at 225 rpm. 50-
100 .tl cells were spread on each LB/agar plates (see Appendix I) containing either 100 
86 
xg/ml ampicillin or 50 .tg/ml kanamycin depending on the specific selection marker of 
the plasmid. The plates were incubated for 16 hours at 37 °C, after which those 
containing colonies were removed and stored at 4 °C for up to one month. 
2.2.3.11 PCR screening of recombinant plasmids 
This methodology was kindly supplied by Dr. Hugh Mason (Boyce Thompson Institute 
for plant research, Cornell University, USA). 
Single colonies of presumed transformants were picked up with a sterile plastic pipette 
tip and dispersed in 50 pi sterile dH 20. 18-20 j.il of this bacterial suspension was then 
used in a 25 jtI PCR reaction for 25 cycles using the PCR program and conditions 
described in 2.2.3.1. 15 .tl of each reaction was run on 1% agarose gel to examine 
products. The remainder of the recombinants bacterial suspensions identified as 
recombinants was added to 3 ml of LB containing 100 .tg/ml ampicillin or 50 tg/ml 
kanamycin and cultured overnight. 
2.2.3.12 Minipreparation of plasmid DNA 
2.2.3.12a Alkaline lysis miniprep. 
Transformants grown on selective agarose plates were inoculated into 3 ml LB/amp and 
grown up overnight at 37°C with shaking. 2.5 ml of overnight culture was pelleted by 
centrifuging at 6000 rpm for 2 min and re-suspended in 100 p1 of Soln I (50 mM Tris-
HC1 pH7.5; 10 mM EDTA; 10% Glucose; 1 pg of RNase per sample) and placed at 
room temperature for 5 mm. 200 p1 of SoIn H (0.2 M NaOH; 1% SDS) was added, 
mixed gently, and placed on ice 5 mm (inverted every 2 mm). To this 150 tl Soln III 
(3M KAOc, pH 4.9) was added, mixed gently by inverting tube several times and placed 
on ice for 5 min prior to the mixture being centrifuged at room temperature for 5 min at 
13000 rpm. The supernatant was recovered into a fresh eppendorf tube taking care to 
avoid any floating or pelleted material. imI of cold 100% ethanol was added and mixed 
by inverting the tube for 5 times. After incubation at room temperature for 2 minutes, 
plasmid DNA was pelleted by centrifuging at 12000rpm for 10 min at room temperature. 
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The pellet was washed once with 70% cold ethanol, centrifuged for 5 min at 13000 rpm, 
dried at 65°C and then resuspended in 30-40 p1 dH 20 according to the pellet size. The 
plasmid DNA was stored at -20°C. 
2.2.3.12b Isopropanol miniprep 
This methodology was kindly supplied by Dr. Hugh Mason (Boyce Thompson Institute 
for Plant Research, Cornell University, USA). 
Transformants grown on selective agarose plates were inoculated into 3 ml LB/amp and 
grown up overnight at 37°C with shaking. Next day, 2.5m1 of overnight culture was 
centrifuged at 6000 rpm for 30sec and the pellets was re-suspended in 50 iJ  water. 300 
p1 TENS (0.1N NaOH, 0.5% SDS in TE), mixed gently several times, and placed at 
room temperature for 5 mm. 200 p1 of ammonium acetate was added, mixed gently and 
placed on ice for 5 minutes, prior to the mixture being centrifuged at 4 °C for 3-5 min at 
13000 rpm. The supernatant was recovered into a fresh eppendorf tube taking care to 
avoid any floating or pelleted material. 0.6 volume of isopranpanol was added and 
mixed. After incubation at room temperature for 5-10minutes, plasmid DNA was 
pelletted by centrifuging at 13000rpm for 10 min at room temperature. The pellet was 
washed once with 70% cold ethanol, air-dried and then resuspended in 30-40 p1 dH20. 
The plasmid DNA was stored at -20°C. 
2.2.3.13 Midipreparation of plasmid DNA 
3 ml of overnight culture prepared as previously described as 2.2.3.12a was inoculated 
into 100 ml of LB/amp or LBIkan (see Appendix I) and incubated at 37 °C for 16 hours 
with shaking. Next day, This culture was centrifuged at 4000 rpm for 20 minutes and the 
resulting cell pellet was completely re-suspended in 3 ml of Cell Resuspension Solution 
(50 mM Tris-HCL, pH7.5; 10 niM EDTA; 100 ug/mi RNase A). 3 ml of Cell Lysis 
Solution (0.2 M NaOH; 1% SDS) was added and mixed by inverting the tube several 
times until the cell suspension became clear. 3 ml of Neutralisation Solution (1.32 M 
potassium acetate, pH4.8) was then added and mixed by inverting the tube several times. 
The lysate was centrifuged at 4000 rpm for 30 minutes at 4 °C. The supernatant was 
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carefully collected to a new centrifuge tube, avoiding the white precipitate. 10 ml of the 
resuspended resin (Promega) was added and the resin/DNA mix was then transferred to 
a Wizard Midicolumn per preparation. A vacuum was applyed to pull the resin/DNA 
mix into the Midicolumn. The column was washed twice with 15 ml of Wash Solution 
(200 mM NaCl; 20 mM Tris-HCL, pH 7.5; 5 mM EDTA (concentration prior to ethanol 
addition) 55% final concentration of ethanol). After the second wash, the resin was dried 
by continuing to draw a vacuum for 30 seconds after the solution had been pulled 
through the column. The Midicolumn was separated from the reservoir and transfered to 
a 1.5 ml microcentrifuge tube, and than centrifuged at 13000 rpm for 2 minutes to 
remove any residual Column Wash Solution. After the Midicolumn had been transferred 
to a new microcentrifuge tube, 300 .tl of preheated (65-70 °C) DEPC treated dH20 was 
added to the Midicolumn and incubated for 1 minute. The Midcolumn was spinned at 
13000 rpm for 2 minutes. The eluted DNA was then centrifuged at 13000 rpm for 5 
minutes to remove resin fines which could be observed as small translucent particles in 
the DNA solution. The supernatant containing plasmid DNA was carefully transferred to 
a new tube. After measuring the DNA concentration on spectrophotometer (see section 
2.2.3.7), the DNA solution was aliquoted and stored at -20°C until use. 
2.2.3.14 Storage of bacterial stocks 
2 ml overnight culture was grown up in LB with 100 tg/ml ampicillin or 50 .tg/ml 
kanamycin. The bacteria were spun down for 2 minutes at 500-1000 rpm. The 
supernatant was removed and the pellets were resuspended in 1 ml LB containing 20% 
glycerol and transferred to Eppendorf tube. Then the tube was snap frozen on dry ice 
and kept at -70°C. 
2.2.3.15 Nested reverse transcription (RT)-PCR 
Nested PCR is a more sensitive form of PCR involving two rounds of amplifications 
with two sets of primers: an outer pair for the first round, with a second pair nested 
within the out pair, for the second round. This double action increases the sensitivity and 
specificity and allows the amplification from low level of target DNA. 
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2.2.3.15a eDNA synthesis 
6.5 .t1 RNA extracts (see section 2.2.4.5) from transgenic tobacco leaves was added to 
the tube containing 2tl 5 X RT buffer (250 mM Tris-HC1; 200 mM KC1; 25 MM MgCl2 ; 
(Promega) and 1 tI (1 unit) of RNase-free DNase (RQ1; Promega). The mixture was 
incubated for 30 minutes at 37 °C. Then, the RQ1 was inactived in the mixture by 
incubating at 65°C for 15 minutes. 5 .tl of RQ1 treated RNA solution was added to a 
tube containing 1.5tl (0.75 pg) of oligo (dT) 1 5 primer (Promega) and the tube was 
incubated at 65°C for 10 minutes to denature secondary structure of niRNA. The tube 
was then immediately cooled on ice. 14.5 p1 premix consisting of 3 p1 of 5 X RT buffer; 
4 x 2 p1 of each of 10 mM dATP, 10 mM dGTP, 10 mM dCTP, and 10 mM dTTP; 2 p1 
of 100 mM DTF and 1.5 .tl (75 units,) of ExpandTm reverse transcriptase (Boehringer 
Mannheim) was added to the tube containing RNA and oligo (dT) 1 5 primer (Promega). 
This reaction was incubated for 1 hr at 42°C. Subsequently, the reaction mixture was 
either used directly for PCR or stored at —20 °C until use. 
2.2.3.15b Primary PCR 
4 p1 of cDNA reaction as template; 0.2 p1 of HIV-1 gp4l primer 254 and 0.2 p1(0.2 pg) 
of oligo (dT) 1 5 as outer pair of primers and 30 cycles of PCR program was performed 
(see section 2.2.3.1). 
2.5 p1 of RQ1 treated RNA was incubated with 0.5 p1(0.25 pg) DNase-free RNase 
(Boehringer Mannheim) at 37 °C for 30 minutes and then incubated at 65 °C for 15 
minutes. The mixture was put on ice and used as control PCR template. 
2.2.3.15c Secondary PCR 
3 p1 of primary PCR product was used as PCR template and I-IIV gp4l primer 518 and 
256 (see section 2.2.3.18) which nested within the outer pair primers used in the primary 
PCR was used as inner pair of primers, and 30 cycles of PCR program was performed 
(see section 2.2.3.1). 
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2.2.3.16 Protein assay 
The total protein concentration in the extracts of transgenic plant leaf, microtuber and 
plant NT-1 cells was assayed by using protein assay kit II (Bio-Rad) following the 
manufacturer's microassay instruction with some modifications. Briefly, 20 ml of dH20 
was added to the lyophilised BSA (supplied) to yield a concentration of approximately 
1.4 mg/ml. BSA solution was diluted with 1 X TBS to produce concentrations of 0.5 
mg/ml; 0.25 mg/ml; 0.125 mg/ml; 0.0625 mg/ml; 0.03125 mg/ml; 0.015625 mg/ml; 
0.0078 125 mg/ml and 0 mg/ml (blank) as protein standards. Protein samples were 
diluted 1:40 with 1 X TBS. 40 jil of each of protein samples and standard dilutions were 
added into duplicate wells of a 96 microtiter plate. 160 tl of a 1:4 dilution of dye reagent 
concentrate was added to each well of the plate and mixed well using a multi-channel 
pipette. The plate was incubated at room temperature for iS minutes to 30 minutes and 
the optical density (OD) determined at 595nm using a Labsystems Multiskan 
Bichromatic Reader. 0D595 value was plotted versus concentration of standards and the 
unknowns were read from the standard curve. 
2.2.3.17 Sequencing of HIV-1 env gene 
Sequencing of the HIV-1 env gene insert was performed by using ABI PRISM 
TM  dye 
terminator cycle sequencing ready reaction kit (for Applied Biosystems 373 DNA 
sequencer) (Perkin Elmer, UK) or ABI PRISM Tm BigDyeTm terminator cycle 
sequencing ready reaction kit (for ABI PRISM Tm 310 genetic analyser) (PE Applied 
Biosystem, USA) with ampliTaq ® DNA polymerase. 
2.2.3.17a Sequencing PCR 
For each reaction, the following reagents were added: 6.0 .tl of terminator ready reaction 
mix; 1 .tg plasmid DNA and 0.2 gl primer (5 pmol-10 pmol). Appropriate amount of 
DEPC treated dH 20 or dH20 was added to make the volume up to 20 .tl and mixed 
reactions overlayed with 20 j.tl of mineral oil. The tubes were then placed on the thermal 
cycler. The following program performed for 25 cycles: 94 °C for 30 sec; 55 °C for 30 
sec; 60°C for 3 minutes. PCR products were then used for ethanollNaAc precipitation 
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prior to sequencing. 
2.2.3.17b EthanollNaAc precipitation of sequencing PCR products 
For each sequencing reaction, 2.0 pi of 3M sodium acetate (NaAc), pH4.6 or 3.0 tl of 
2M NaAc, pH4.6 and 50 jil of chilled 95% ethanol (EtOH) was added to 1.5-ml 
microcentrifuge tube. 20 i.tl contents of the sequencing PCR reaction was transferred to 
the tube of NaAcIEtOH mixture and mixed thoroughly. The tube was incubated at room 
temperature for 15 minutes and covered with aluminium foil to avoid the light. After 
spinning for 30 minutes at 13,000 rpm, the pellet was rinsed with 250 tl of chilled 70% 
EtOH and dried at 90 °C for 2 minutes. Then, the tubes were placed on ice until loading. 
2.2.3.17c Electrophoresis on the ABI PRISM 310 Genetic Analyser 
For analysing the sequence on the ABI PRISM 310 Genetic Analyser (Perkin-Elmer), 
POP-6 polymer was set as run module; BD Set-any primer was set as dye set/primer file 
and Taq terminator matrix was set as matrix file. 
Before loading, each sample pellet was re-suspended in 20 .tl of template suppression 
reagent (TSR, supplied by the manufacturer). After heating at 95°C for 2 minutes to 
denature, the tube was briefly spun and placed on ice for a while. The tubes were placed 
on the sample tray in the order the same as sample sheet. The sample tray was put back 
into the analyser and the sequencing was initiated simply by click "run" icon on the 
menu. As the run completed (one hour per sample), the data was collected and printed 
out. 
2.2.3.17d Electrophoresis on the Applied Biosystems 373A DNA sequencer 
Polyacrylamide sequencing gel 
The gel plates were cleaned thoroughly with Alconox (Alcono, USA), rinsed with hot 
water and dH20, and then air dried before assembling. 6% sequencing gel (240mm in 
length and 0.4mm in thickness) was made by dissolving 30g of Urea in 9 ml of 40% 
(wlv) acylamide/bis (19:1) solution (Bio-Rad), 0.5 g of Amberlite' MB-150 resin 
(Supelco, Bellefonte, USA) and 20 ml of dH20 for 1 hour. The gel solution was then 
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filtered and degassed through a 0.2 pm cellulose acetate filter which was prewetted with 
6m1 of 10 X TBE (890 mM Tris-borate; 20 mM EDTA, pH 8.0). 300 p.1 of freshly 
prepared 10% (wlv) ammonium persulphate and 33 p1 of TEMED (N,N,N',N'-
Tetramethylethylenediamine, 1131, Eastman Kodak Company, UK) were added to the 6% 
acrylamide/ureaJTBE gel solution. The gel was poured and allowed to set for 2 hours. 
Electrophoresis on ABI 373 DNA sequencer 
The sample sheet was set up on the Macintosh (MAC), and on the ABI machine, filter 
set A was chosen for Taq sequencing. Then the gel plate was scanned before the 24 
sharks-tooth comb was inserted and the gel equipment was assembled. 1.5 litre of 10 X 
TBE was made with dH20 to fill up the upper and lower buffer tanks. The wells were 
rinsed with lx TBE buffer to remove excess urea. 
The purified and dried sequencing PCR products were resuspended in 4 p1 of FE (5 
volume of deionized formamide to 1 volume of 25 mM EDTA (pH8.0) containing 50 
mg/ml blue dextran) by pipetting up and down for Ssec. The tubes were heated at 90 °C 
for 2 minutes exactly and put them on ice immediately. The wells of sequencing gel 
were rinsed with lx TBE buffer again to remove excess Urea, and then the odd wells 
were loaded with samples. The gel was run for 5 minutes and the even samples were 
loaded into the wells. The machine was left to run at 2500volts, 40mA at 40 °C for 12 
hours. 
Data analysis 
The sequencing data was collected from the MAC and preliminarily edited within TED 
(part of the Staden computer package) using Seqprocess (written by Dr. C. Wade, Centre 
for HIV Research, University of Edinburgh). The sequences were then assembled using 
Xbap software (Staden computer package) and Seqedit script (written by Dr. C. Wade, 
Centre for 1-HV Research, University of Edinburgh). Subsequently, sequences were 




2.2.3.18a HIV-1 gp 120 V1/V2 primers 
402 sense 	: 5'-GATCAAAGCCTAAAGCCATG-3' 	(+6121*) 
403 antisense 	5'-CAATAATGTATGGGAAATT'G-3' 	(6419*) 
2.2.3.18b HIV-1 gp120 V31V4 primers 
306 sense 	5'-TGGCAGTCTAGCAGAAGAAG-3' 	(+6570*) 
634 anti sense 	5' -ATTCTGCATGGGAGTGTG-3' 	 (7026*) 
2.2.3.18c HIV-1 gp4i primers 
254 sense 	: 5'-GGAAAACTCATVFGCACCAC-3' 	(+7582*) 
518 sense 	5'-GTAATAAATCTCTAGAACAGATCTGG-3' (+7628*) 
256 antisense 	: 5'-TCAAGCGGTGGTAGCTGAAG-3' 	(8079*) 
2.2.3.18d Plant TEV/vsp primers 
TEV/vsp primers were kindly supplied by Dr Hugh Mason (Boyce Tompson institute for 
plant research, Cornell University, USA). 
TEV sense 	: 5'-GCATFCTACTFCTA11TGCAGC-3' 	(+2252**) 
Vsp antisense 	: 5'-GTGCATATCAGCATACC-3' 	 (2408**) 
*position of primer on HIV-HXB2 sequence. 
**position of primer on plant plasmid pIBT240. 1 sequence. 
2.2.3.18e N16OF/S16OR primers 
This pair of primers was designed by Y Li to introduce NcoI site and Sacl site at the 5' and 
3'of 1-IIV- 1 env gene respectively. 
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N160F 	sense 	: 5'-ATACTCCATGGAATGAGAGTGAAGGAG-3' 
S160R 	antisense 	: 5'-ATCTAGAGCTCTCTTATAGCAAAATC-3' 
2.2.4 Plant molecular biology methodology 
All the plant molecular biology and plant tissue culture methodology, plant explants and 
NT-1 cell line used in this thesis were kindly supplied by Dr. Hugh Mason (Boyce 
Tompson Institute for Plant Research, Cornell University, USA) and his co-workers. 
2.2.4.1 Electroporation transformation of Agrobacterium tumefaciens 
The Gene Pulser' (Bio-Rad) was set to 2.5KV. 1 p.1 of plasmid DNA was added to 50 
p.1 of Agrobacterum tumefaciens strain LBA4404 and mixed gently in an ice-cold 
electroporation cuvette. The outside of the cuvette was cleaned by wiping with 
Kimwipes and placed into the sample chamber of the machine Electroporation was 
performed by applying the pulse for 5 milliseconds (msc). The cuvette was removed and 
lml of ice-cold YENB medium (see Appendix I) was added to the cuvette immediately. 
The mixture was transferred to a sterile culture tube and incubated at 30 °C for 1 hour 
with shaking at 250 rpm. The transformation culture was plated on LBIkan agar plates 
(see Appendix I) and incubated at 30 °C for 48-72 hours. 
2.2.4.2 Plant transformation and regeneration 
To produce transgenic plants, the target gene was introduced into plants by 
Agrobacterum tumefaciens mediated plant transformation. The plant leaves from 
plantlets were cut with surgical blade into small strips (approximate 5 x 8 mm). The cut 
leaf strips were inoculated with Agrobacterum tumefaciens strain LBA4404 transformed 
with the recombinant pGPTV-KAN vector containing HIV-1 env 160 gene, and during 
the subsequent coculture on regeneration medium for 2-3 days, the bacteria bind to the 
plant cells around the wounded edge of the explant and the gene transfer process occurs. 
After the transformation had occurred, the explants were transferred to regeneration/ 
selection medium containing 500 p.g/ml carbenicillin to kill the bacteria and 50 p.g/ml or 
300 .tg/ml kanamycin to inhibit untransfomed plant cells. During the next 3 weeks, the 
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transformed cells grew into calli and differentiated into shoots via organogenesis. After 
3-6 weeks, the shoots were excised from the explants and induced root on rooting 
medium containing 500 p.g/ml carbenicillin and 50 j.tg/ml or 100 .Lg/ml (see the 
following sections and Appendix I for details). 
Due to the low efficiency of plant transformation and foreign protein expression, 
transformation of plant tissue was performed 2-4 times per Agrobacterium tumefaciens 
culture at 1-2 week intervals. All the plant cultures were grown in medium plates or 
Magenta boxes sealed with Micropore tape (General Medical Corp.) under the mixture 
of cool and warm white fluorescent lights (GE 40 Watt bulbs) on racks at 26 °C for16 
hour day length, and subsequently at 22 °C for 8 hour night time conditions. 
2.2.4.2a Tobacco ("sumsun") transformation and regeneration 
Inoculation 
A. tumefaciens strain LBA4404 transformed with the recombinant plant expression 
vector pGPTV-KAN-210.1S-envl60 containing HIV-1 envl60 gene (see section 4.3.7.1 
for details) was used for tobacco transformation. 3m1 of A. tumefaciens culture was 
grown in YENB with 50uglml kanamycin at 30 °C with shaking at 250 rpm for 48 hours. 
0.5 ml of the culture was taken to measure OD at 600 nm using spectrophotometer (DU-
64, Beckman). The optimum 0D600 reading should be 0.6-0.7 (approximately 6 x 108 
cells/ml). If 0D600 was over 1.0, the culture was diluted until the 0D600 reading was 
below 0.5 and cultured for another hour. The 0D600 reading was checked periodically. 
The overnight culture was centrifuged at 3,500 rpm for 30 minutes. The pellet was 
resuspended in 20m1 MSO medium (see Appendix I). 
Healthy, unblemished leaves were harvested from young tobacco (Nicotiana tobaccum 
strain "sumsun") plants and cut into 3-5 millimeter strips on the sterile paper towel under 
sterile conditions in a laminar flow cabinet to produce a wounded edge. The cut leaf 
strips were then inoculated by immersion in 50 ml of the A. tumefacienslMSO solution 
for less than 2 minutes with gently shaking. Each leaf strip was gently blotted dry on 
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sterile paper towels and placed upside down on MS 104 medium plate (see Appendix I). 
Approximately 30-40 leaf strips were placed on each petri dish and 3-4 petri dishes used 
for each transformation. 
Shooting 
After incubation for 2 days under the above conditions, the inoculated explants were 
transferred to MS selection media (see Appendix I) and incubated for 2 weeks under the 
above conditions. The explants were then removed and placed upside down on fresh MS 
selection medium plates (see Appendix I). This process was repeated every 2 weeks 
until shoots appeared, generally, this would take 4-6 weeks. 
Rooting 
From the callus of an explant, when shoots from a callus were approximately 1-2 cm tall 
and had at least 1 node they were cut cleanly and placed upright in MS rooting medium 
(see Appendix I) in a Magenta box (5 plants per box) to root. Care was taken to take 
only one shoot from each explant to ensure no sibs were propagated. When more than 3 
leaflets were observed on the plantlet (generally this would take 3-6 weeks), the leaflets 
were collected for analysis of DNA, RNA and protein expression (see Chapter 5). 
2.2.4.2b Potato "FL1607" transformation and regeneration 
Preculture explants 
Potato cultivar, Solanum tuberosum L. cv. "FL1607" plantlets were maintained by serial 
propagation on CM media in Magenta boxes. Leaves from young plants were cut into 3-
5 millimeter strips on the sterile paper to produce a wounded edge and precultured 
upside down in petri plates containing solid LC1 media (see Appendix I) for 3-4 days 
until callus formation was observed around the wounded edges. Approximately 30-40 
leaf strips were cultured on each petri dish and 6-7 plates set up per transformation. 
Inoculation 
2 x 3m1 of A. tumefaciens strain LBA4404 culture was grown for 48 hours in YM 
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medium (GIBCOIBLR) with 50 tg/ml kanamycin at 30°C with shaking at 250 rpm. 0.5 
ml of the culture was taken to measure OD at 600 nm using a spectrophotometer (DU-
64, Beckman). The optimum 0D600 reading should be 0.6-0.7 (approximately 6 x 10 8 
cells/ml). If the 0D600 reading was below 0.5, the culture was grown for another hour. 
The OD600 readings were checked periodically. The overnight culture was centrifuged at 
3,500 rpm for 30 minutes and the pellet was resuspended in 100 ml MSO medium (see 
Appendix I). 
Co-cultivation of leaf strips was performed by adding approximately 150 precultured 
leaf strips (described as above) to 50 ml of above suspension of A. tumefaciens. This 
mixture was incubated at room temperature for ten minutes with occasional inversion. 
After blotting on sterile paper towels to remove excess bacteria, the leaf strips were 
placed upside down on fresh LC1 plates and incubated under the above conditions until 
a ring of bacteria could be observed around the wounded edges, This usually took 3-4 
days. The strips were transferred to fresh plates containing LC1 media supplemented 
with 500 pg/ml carbenicillin and 50 j.tg/ml kanamycin (LC1 c/k) every week until green 
callus formed on the cut edges of the leaf strips indicating that they were ready for 
regeneration. This would take approximately 2-3 weeks. 
Shooting 
Shoots were regenerated by transferring callus formed from leaf strips to fresh petri 
plates containing solid LC2 c/k (see Appendix I) media every week until shoots were at 
least 2 cm and included at least one node, This would generally take 3-6 weeks. 
Rooting 
Shoots were removed from the leaf strips after the second axillary bud had formed and 
were placed in Magenta boxes containing CM media with 50 pg/ml kanamycin to 
induce roots. The leaf strips were then transferred to a new LC2 c/k plates. 
Microtuber induction 
When the rooted plantlets were about 5-6 cm high, a process which would take 3-6 
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weeks, the stem which included one node, was cut from the plantlet and placed upright 
on a petri dish containing Tuberization medium (see Appendix I) and incubated at 18 °C 
in the dark until the microtuber was formed and grown up to 3-6 mm in diameter, a 
process which generally took 4-6 months. The microtubers were then harvested for 
analysis (see Chapter 6) 
2.2.4.3 NT-1 cell Transformation 
2.2.4.3a NT-1 cell 
NT (Nicotiana tabaccum)-i cells were cultured in NT-1 media (see Appendix I) and 
incubated at 26°C in the dark with shaking. The cell cultures were then subcultured 
(1:40) and fed with fresh medium every week. Before transformation with 
Agrobacterium tumefaciens strain LBA4404, the NT-1 cell suspension was split 1:1 with 
NT-1 medium and cultured for 3 days under the above condition. i pA of 20 MM 
Acetosyringone (3' ,5 ' -Dimethoxy-4' -hydroxy-acetophenone, Aldrich Chem. Co.) 
freshly made in 100% ethanol was added to per ml of cells before inoculation. 
2.2.4.3b Inoculation 
3 ml of the Agrobacterium tumefaciens strain LBA4404 culture was grown up in 
YENB/kan at 30°C with shaking at 250 rpm for 48 hours. 
Acetosyringone treated NT-1 cells were pipetted up and down about 20 times to induce 
small lesions in the cells and increase the efficiency of the transformation. 0 jAl, 50 p1, 75 
p1, 100 p1 and 200 p1 of bacteria culture were added to separate petri dishes containing 4 
ml of NT-1 cells, and mixed thoroughly. The plates were wrapped with parafilm and 
incubated for 3 days at 26 °C in the dark. 
2.2.4.3c Generation of NT-1 transformants 
10 ml of NT-1 medium containing 500 tg/mI carbenicillin (NTC) was added to each of 
above inoculated NT-1 cell plates. The cells were then pipetted into 50 ml conical tubes 
containing 35 ml of NTC medium (see Appendix I). The tubes were centrifuged at 
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1,000rpm for 5 minutes at room temperature. The pellets were resuspended in 50 ml 
NTC medium and spun a second time. The cells were then resuspended in 
approximately 4 ml of NTC medium and plated out on NTKC (see Appendix I) at 2.0 
ml per plate. The plates were left open in the hood for 10-15 minutes until there was no 
longer excessive surface fluid on the plates prior to being sealed with paraflim. The 
plates were then incubated at 26 °C in dark for 3-4 weeks to allow the transformants to 
appear. The transformants were then transferred to fresh NTKC plates. After incubation 
for 4-5 weeks under the above condition, colonies were collected for protein expression 
analysis (see Chapter 6). 
2.2.4.4 Leaf DNA preparation 
Two leaflets of transgenic plants were collected in a 1.5 ml tube and immediately placed 
in liquid nitrogen for 5 minutes, the tube was then removed and 500 .tl extraction buffer 
(200 mM Tris-HCI pH7.5; 250 mM NaCl; 25 mM EDTA; and 0.5% SDS) was added. 
The sample was ground with pellet pestle (VWR Scientific Products, PA, USA) and 
vortexed briefly before incubation at room temperature for at least one hour. The ground 
sample was centrifuged at 13,000 rpm for 5 mm, and the supernatant was transferred to a 
new tube containing an equal volume of isopropanol. After mixing, the tube was 
incubated at room temperature for 10 minutes. The DNA/isopropanol mixture was then 
centrifuged at 13,000 rpm for 5 minutes, and the pellet washed once with 1 ml of 75% 
ethanol. After air drying for 5-10 minutes, the pellet was dissolved in 40 tl of dH20 and 
stored at —20° C until use. 
2.2.4.5 Leaf RNA preparation 
Two leaflets of transgenic tobacco were placed in a 1.5 ml microcentnfuge tube and 
frozen immediately in liquid nitrogen. The frozen leaflets were then placed on ice and 
ground to a fine powder using a precooled pestle (VWR Scientific Products, PA, USA). 
700 p.1 (2 ml/g) of RNA extraction buffer (0.2 M sodium acetate, pH5.0; 0.1% SDS; and 
0.01 M EDTA) was then added and mixed while the samples were kept on the ice. An 
equal volume of TE (TrisIEDTA) equilibrated phenol (pH8.0) (Sigma) was added and 
mixed vigorously for 3-5 minutes. The sample was centrifuged at 3,000 rpm for 10 
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minutes at 4°C. The aqueous phase was extracted with an equal volume of 
phenol: chloroform (1:1), and mixed and centrifuged as above. The aqueous phase was 
then extracted with an equal volume of chloroform and centrifuged as before. 1/3 
volume of 10 M L1C1 was added to a final concentration of 2.5 M and the RNA was 
precipitated at 4 °C overnight. The precipitate was collected by centrifuging at 13,000 
rpm for 30 minutes at 4°C, and washed once with 1 ml of 2.5 M LiCl and twice with 1 
ml of 70% ethanol. Subsequently, the pellet was dried under vacuum and kept at —70 °C. 
The RNA pellet was resuspended in 50 p1 of DEPC treated dH20 on ice before use. 
2.2.4.6 Leaf protein extraction 
Two leaflets of transgenic tobacco plantlets were placed in 1.5 ml microfuge tubes and 
immediately frozen on dry ice. 200-400 p1 extraction buffer (25 mM NaPi, pH6.6; 100 
mM NaCl; 1 mM EDTA; 0.1% Triton X-100; 10 pg/ml leupeptin; 50 mM Sodium 
ascorbate (this was always added freshly, as it is unstable and will cause a dark orange 
color with time)) was added and the leaf sample was homogenised with a pestle (VWR 
Scientific Products, PA, USA) until the leaf material was finely divided. The extracts 
were then microcentrifuged at 13,000rpm for 5 minutes at 4 °C. The supernatant was 
removed and aliquoted for ELISA or total protein assay, or stored at —70 °C. 
2.2.4.7 Potato microtuber protein extraction 
The transgenic potato microtubers were homogenised with 400 p1 of iced cold extraction 
buffer (25 mlvi NaPi, pH6.6; 100 mlvi NaCl; 1 mM EDTA; 1%Triton X-100; 10 pg/ml 
leupeptin; 50 mM Sodium ascorbate (added freshly as previous section) using pestle 
(VWR Scientific Products, PA, USA) or glass homogeniser (JENCONS, England, UK). 
The homogenate was then centrifuged at 13,000 rpm for 5 minutes at 4 °C. The 
supernatant was removed and aliquoted for ELISA or total protein assay, or stored at - 
70°C. 
2.2.4.8 NT-1 cells protein extraction 
NT (Nicotiana tabaccum)-1 cell transformants were collected from NTKC plates and 
weighed. NT-1 cell transformants were homogenised in 2 mug of iced cold extraction 
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buffer (25 mM NaPi, pH6.6; 100 mM NaCl; 1 mM EDTA; 1%Tnton X-100; 10 .tg/m1 
leupeptin; 50 mlvi Sodium ascorbate (added freshly as previous section) using a glass 
homogeniser (JENCONS, England, UK). The homogenate was centrifuged at 13,000 
rpm at 4°C for 5 minutes. The supernatant was aliquoted for ELISA, or total protein 
assays or stored at —70 °C. 
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Susceptibility to HIV-1 varies between individuals and some individuals are able to 
resist to infection despite multiple and repeated exposure to HIV (Rowland-Jones & 
McMichael 1995a; Shearer et al., 1996). This condition is likely to depend on the 
features of both the host and the virus (Shearer et al., 1996). 
There is increasing evidence that an unconventional immune response, which is HIV-1 
specific but detected in HIV-1 uninfected individuals, at both the cellular and humoral 
levels might be associated with HEPS status (Shearer et al., 1996; Burastero et al., 1996; 
Mazzoli et al., 1997). HIV-1 specific cell-mediated immunity has been detected in a 
high proportion of HEPS individuals (Rowland-Jones et al., 1995b, 1998, 2001). Paxton 
et al. (1996) found that the anti-HIV-1 activity of CD8 lymphocytes in HEPS is greater 
than that of CD8 lymphocytes from nonexposed controls and that their purified CD4 
lymphocytes were relatively resistant to HIV-1 infection in vitro. Studies based on 
rhesus macaques and chimpanzees and their resistance to low doses of HIV or SIV given 
intrarectally or intravaginally indicated that there may be local cellular mucosal immune 
response capable of protecting against challenges (Haynes et al., 1996). This leads to the 
hypothesis that a compartmentalised immune response to HIV is possible in humans. 
HIV-1 specific IgA was detected in the genital tract of 16 out of 21(76%) FHV-1 EUs, 5 
out of 19 (26%) infected women, and 3 out of 28 (11%) lower risk women (P<0.0001) 
(Kau] et al., 1999), indicating a role for mucosal 1-IV-1 specific response in FHV-1 
resistance. Mucosal IgA, especially sIgA which is produced locally on mucosal surface 
(see section 1.3 for details), is present at mucous membrane surfaces, which are the main 
entry sites for most pathogenic organisms. Therefore the presence of these antibodies in 
the genital tract could offer a potent first-line defence against heterosexual transmission 
of HIV, and may contribute to HIV resistance in HEPS population. 
In addition, in a proportion of HEPS, the resistance to infection has a genetic basis. This 
is suggested by the observation that a mutant form of the HIV coreceptor, CCR5, on the 
surface of monocyte/macrophages is present in a subset of such individuals (Liu et 
al., 1996). CCR5 has been identified as a major coreceptor for M-tropic HIV-1 entry (see 
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section 1.1.6.2) Population analyses have shown that individuals homozygous for the 
32-bp deletion in the gene encoding CCR5 are rarely present in HIV infected population, 
indicating that mutant CCR5 confers resistance to HIV-1 infection in vivo as well as in 
vitro (Samson et al., 1996; Dean et al., 1996). 
The majority of worldwide HIV-1 infections are the result of unprotected heterosexual 
contact (d'Cruz-Grote, 1996). The initial host-virus interaction in these populations will 
therefore occur at the level of the genital mucosa where the first defensive barrier 
consists of mucosal immunity, particularly IgA. It has been demonstrated that alteration 
of the normal genital mucosal barrier alters susceptibility to HIV-1 infection (Simonsen 
et al., 1988). HIV infects susceptible cells such as Langerhans cells, macrophages and T 
cells in the genito-urinary tract (Miller et al., 1996), stimulating a local mucosal immune 
response (Bélec et al., 1989a; Cao et al., 1990). In the most infected individuals, MV-1 
specific cytotoxic T cells (Musey et al., 1997) as well as IgG and IgA (Artenstein et al., 
1997) are present in genital tract. Data concerning the contribution of mucosal immunity 
to protection against HIV-1 infection in HEPS population are limited. Therefore, an 
investigation of subtypes of antibodies, especially sIgA, to HTV-1 in genital secretions 
from seropositive and exposed seronegatives would be significant in understanding of 
mucosal immunity to HIV-1 and the mechanism of limiting HIV-1 transmission. A 
recent study has shown that HIV-1 specific IgA was detected in the genital secretions of 
HIV-1 resistant Kenyan sex workers. This strongly suggests that local mucosal 
immunity may have an important role in HIV-1 resistance (Kau] et al., 1999). The, aim 
of this study was to evaluate the theory that HEPS individuals may develop a local anti-
HIV antibody response. 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
3.2.1.1 HIV-1 seropositive samples 
All paired urine and serum and/or vaginal swab samples from HIV-1 seropositive 
individuals were collected by Dr David Yirrell (Centre for HIV Research, Edinburgh 
106 
University, Edinburgh, UK) and are from Uganda or Edinburgh (Table 3.1B). 
All 3 HIV-1 seropositive serum samples (S1590, V3255 and D5206) for optimising 
Western blot experiments were kindly given by Dr David Yirrell (Centre for HIV 
Research, Edinburgh University, Edinburgh, UK) and are all from Scotland. 
3.2.1.2 HEPS subjects and samples 
One of the projects undertaken by the Medical Research Council Programme on AIDS 
in Uganda has been to study sexual mixing patterns between high HIV-1 prevalence 
(40% in general adult population (Nunn et al., 1996)) trading town, surrounding rural 
areas and fishing villages on Lake Victoria (Pickering et al., 1997a). HIV-1 high risk 
143 men and 81 women were involved in a longitudinal study lasted for more than 18 
months. All female individuals were known for selling sex and all men for high rates of 
partner change (Pickering et at., 1996; 1997b; 1997c). The men recorded an average of 
3.1 sexual contacts a week, and the woman 5 sexual contacts a week (Pickering et al., 
1997a). 
9 of the above HIV-1 high risk individuals studied, including 2 females and 7 males who 
had reported HIV-1 seropositive regular partners, were selected for this study. An 
reported average unprotected sexual contacts among these subjects was 29 times over a 
period of 6 months (Pickering, H., personal communication). HIV-1 status was 
determined serologically using 2 EIA systems, Recombigen HIV-1 EIA (Cambridge 
Biotech Corporation, MA, USA) and Wellcozyme HIV-1 Recombinant (Wellcome 
Diagnostics, Dartford, England). All these 9 subjects remained HTV-1 seronegative, 
despite high exposure to HIV-1 as described above, and were thus defined as HEPS 
individuals. 
All paired urine and serum samples from 9 HIV-1 HEPS individuals were collected by 
Dr David Yirrell (Centre for HIV Research, Edinburgh University, Edinburgh, UK). The 
details of subjects and samples are summarised in Table 3.1A. Control serum and urine 
samples were kindly donated by uninfected low risk individuals. 
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It has been reported that cell-debris in urine might cause false-positive I-IIV-1 antibodies 
in immuno assay (Kostolansky F and Friedman-Kien A.E, 1993). To avoid this false-
positive reaction, urine samples were centrifuged and the concentrated supernatants (see 
section 2.1.2) were applied to Western blotting assay in this study. 
3.2.2 Methods 
3.2.2.1 Virus culture 
HIV-1 TuB was passaged in the H9 cell culture as described in section 2.2.1.2. After 
titration as described in 2.2.1.3, the virus stock, with TCID 50 from 105 to 106,  was kept at 
-70°C until used. 
3.2.2.2 EIA test 
All serum samples used were tested with Wellcozyme HIV 1+2 EIA Kit (Murex 
Diagnostics Limited, Dartford, England) immediately after collection and were later re-
tested by the same method at the Hepatitis and FIIV Reference Lab of Medical School, 
Edinburgh University following the manufacturer's instructions. 
3.2.2.3 Western Blot 
Both commercial and "in house" Western blotting strips were used to detect antibodies 
to HIV as described in 2.2.2.1. 
For detection of sIgA, after incubation with serum, urine or swab samples, the 
nitrocellulose strips were incubated with the secondary antibody (mouse monoclonal 
anti-human secretory component (SC), pre-diluted 1:500 with antibody dilution buffer or 
sample buffer (supplied with the HIV-1 Western blot kit)) for 2 hours at room 
temperature under agitation. The strips were then washed and incubated with sheep anti 
mouse IgG (SAPU) (diluted 1:200 with antibody dilution buffer or sample buffer 
(supplied with the HIV-1 Western blot kit)) for 1.5 hours at room temperature with 
constant agitation. Then the HRP conjugated donkey anti sheep IgG was added and the 
peroxidase activity was detected colorimetncally by the addition of a fresh solution of 
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Table 3.1 Details of subjects and samples studied 
A:HIEPS subjects 
ID* Sex Age# Country of Samp1es Date Sero 
Origin 
008C F 38 Uganda B 70395 - 
U 70395 ND 
085W F 39 Uganda B 111095 - 
U 111095 ND 
003B M 25 Uganda B 70395 - 
U 70395 ND 
006B M 19 Uganda B 130795 - 
U 260495 ND 
044B M 19 Uganda B 130795 - 
U 150395 ND 
lOOM M 18 Uganda B 60695 - 
U 60695 ND 
117M M 33 Uganda B 041095 - 
U 041095 ND 
130M M 24 Uganda B 111095 - 
U 111095 ND 
138M M not known Uganda B 181095 - 
U 181095 ND 
B: 1-TV-1 seropositive subjects 
ff* Sex Age Country of Samples Date Sero 
Origin 
078W F not known Uganda B 41095 + 
U 41095 ND 
134M M not known Uganda B 111095 + 
U 111095 ND 
C3221 F not known Edinburgh B 90694 + 
U 90694 ND 
S 90694 ND 
14581 F not known Edinburgh B 90295 + 
U 90295 ND 
5 90295 ND 
Identification number of subjects studied. 
tB=Serum; U=Urine; S=Swab. 
Date of sampling. "Age at sampling 




3.2.2.4 Dot immunobinding assay (DIA) 
5 til of different dilutions of recombinant HIV-1 gpl20 (AIDS Reagent Project, MRC, 
UK) were dotted onto a strip of nitrocellulose (Sartorius, UK) and air dried at room 
temperature for 10 minutes. After incubation with mouse mAb to FHV-1 gpl20 (AIDS 
Reagent Project, MIRC, UK). The strips were washed as described in 2.2.3.1 and 
incubated with either HRP-conjugated sheep anti-mouse IgG (SAPU, Scotland) or sheep 
anti-mouse IgG (SAPU, Scotland) followed by HRP-conjugated donkey anti-sheep IgG 
(SAPU, Scotland). After washing, the peroxidase activity was detected colorimetrically 
by the addition of a fresh solution of 3,3 -di amonobenzi dine (DAB) tetrahydrochioride 
(10 mg (1 tablet) was dissolved in 15 ml of PBS, pH7.6; 12 p1 of 30% hydrogen 
peroxide was added to the DAB solution prior to use). After incubation at room 
temperature for 15 to 30 minutes, the reaction was stopped by washing the strips 2 times 
with distilled water. 
3.3 RESULTS 
3.3.1 Optimisation of western blot 
Western blot allows the detection of antibody directed to individual structural proteins or 
recombinant polypeptides of HIV and it therefore is widely used to analyse the antibody 
response to viral infection. In order to analyse the antibody recognition pattern in urine, 
serum and swab samples collected from MV-1 seropositive and HEPS individuals (see 
section 3.2.1.), Western blot was initially optimised as follows. 
3.3.1.1 Polyacrylamide gel electrophoresis 
Viral proteins were separated by SDS polyacrylamide gel electrophoresis with a Tris 
glycine buffer (50 mM Tris, 384 mM glycine) containing 0.1% SDS (Laemmli 1970). In 
order to separate wider size range of viral proteins, a 5-20% linear gradient 
polyacrylamide gel (30% acrylamide +1.08% bis acrylamide) in 375mM Tris, pH 8.7 
containing 0.1% SDS was used. Samples, mixed with an equal volume of sample buffer, 
were boiled for 3mm. 20p1 of the mixture was loaded onto a well. Gels were run at 180v 
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for 1 hour and then stained by Coomassie Blue (in 20% methanol, 5% acetic acid) 
staining for 15 min at room temperature. Gels were destained in several changes of 20% 
methanol and 5% acetic acid. The result presented in Table 3.2 showed that gradient gel 
appeared to be effective in separating HTV-1 proteins. 
3.3.1.2 Amplification system 
In a further experiment, two amplification systems were compared using DIA to 
optimise the sensitivity of Western blot for detection of antibodies to individual HIV-1 
viral proteins. After the nitrocellulose strip bearing viral recombinant HIV-1 gp120 was 
incubated with mouse mAb to HIV-1 gp120, the specific antibody was detected by 
incubation with either HRP-conjugated sheep anti-mouse IgG (SAPU, Scotland) 
(primary amplification) or being incubated with sheep anti-mouse IgG (SAPU, Scotland) 
followed by HRP-conjugated donkey anti-sheep IgG (SAPU, Scotland) (secondary 
amplification). The results presented in Table 3.3 demonstrated that the secondary 
amplification proved to be more sensitive than the primary amplification system. 
Therefore, the secondary amplification system was chosen for use throughout the 
project. 
3.3.1.3 Antigens preparation 
To obtain the whole range of individual viral proteins, HIV-1 IIIB was passaged in the 
H9 culture and then the viral antigens were purified from HTV-1 culture supernatant and 
infected cells (119) as described in 2.2.2. The reactivity of the antigens obtained with 
HIV-1 seropositive serum (see section 3.2.1.1) was evaluated by Western blot. The 
results are summarised in Table 3.4. Both antigens made from culture supernatant and 
from infected cells were reacted with HIV-1 positive serum (see section 3.2.1.1). 
Antigens made from culture supernatants, were filtered through a 0.45 gm membrane 
microfilter (Sartorius) and then concentrated by passage through a .20% sucrose cushion 
(see section 2.2.1.4). Only two reaction bands corresponding to p65 and p55 appeared 
when the antigens were 2.5-fold concentrated. Reaction bands corresponding to p65, 
p55, p5!, gp4l, p31, and p24 appeared when the antigens were 10- and 80-fold 
concentrated, respectively, in the absence of bands corresponds to gp160, gp120 and 
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p17. However when antigens were 200-fold concentrated after purification by passaging 
through a 20 % sucrose cushion (see section 2.2.2.3) the specific bands associated with 
gp160, gp120, p65, p55, gp4l, p24 and p17 were clearly observed. The antigens made 
from MV-1 II113 infected cells yielded a full range of viral polypeptides of HIV-1 
including gp160, gp120, gp4l, p65, p55, p24 and p17 but showed a strong unacceptably 
high background (data not shown). Therefore, the viral lysate from an 1-HV-1 11IB 
culture supernatant was chosen to use as viral antigens for Western blotting assay. 
3.3.2 HEPS state confirmation 
Serum samples from HEPS population and serum controls were retested by HIV EIA to 
confirm HEPS state before performing Western blotting analysis. No ITV-1 specific 
antibodies were detected in the serum from either HEPS individuals or controls sera 
(Table 3.1). 
3.3.3 Analysis of antibody recognition patterns in HIV-1 seropositive and HEPS 
individuals 
3.3.3.1 Antibody response to HIV-1 antigens in HIV-1 seropositive individuals 
To analyse the pattern of immune response to HIV, three paired urine and serum, and two corresponding 
vaginal swab samples were collected from HIV-1 seropositive individuals. The antibodies against 
individual viral polypeptides of HIV proteins were determined using Western blot assay. 
The specific IgG and IgA to HIV-1 were analysed in paired sera, and urine (n=3) from 
HIV-1 positive individuals (Table 3.1). The results showed that multiple bands were 
detected in all the samples. Of three serum samples (n=3), specific IgG reactive bands to 
HIV-1 viral proteins gp160, gp120, p55, p51, gp4l, p24 and p17 were detected in all 
samples with specific IgG reactivity bands to gp65 and p31 in two out of three tested 
samples. For IgA reaction, all serum samples (n=3) showed specific bands 
corresponding to viral protein p51 in the absence of reactivity to gp160; two of three 
serum samples showed IgA reactivity to gp120, p55, p31, p24  and p17, and IgA 
reactivity to either p65 or gp4l was detected in only one of three serum samples (Figure 
3.1, Table 3.5 and 3.6). No bands were detected in the serum control samples. 
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Table 3.2 Detection of HIV- 1 
proteins following SDS-PAGE (5-20%) 
HIV-1 proteins 	5-20% gradient SDS-PAGE 






p 17 + 
= positive 
Table 3.3. Comparison of amplification system by DIA 
Amplification system 	 Dilution of recombinant HIV gp120 
1/5 	1/25 	1/125 	1/625 
Primary amplification* 	++++ 	++++ 	+ 	 -. 
Secondary amplification** ++++ 	++++ 	 ++ 
* HRP conjugated sheep anti-mouse IgG as secondary antibody. 
** Sheep anti-mouse IgG as secondary antibody. 
$ + = positive; the numbers of plus signs indicates strength of reaction. 
U - = negative 
Table 3.4 Qualitative comparison of viral proteins present in 
culture supernatants (spts) and cell lysates of HIV-1 IIIB-infected H9 cells 
Concentration of HIIV-1 fIB culture spts 
Viral proteins 0 	2.5 	10 	80 	200 	Cell lysate 
160 - 	- 	- - + + 
120 - - - - + + 
65 - 	+ 	+ + + + 
55 - + + + + + 
51 - 	- 	+ + + + 
41 - - + + + + 
31 - 	- 	+ + + + 
24 - - + + + + 
17 - 	- 	- - + + 
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In corresponding urine samples (n=3) multiple HIV specific bands were also 
observed. All three urine samples had the specific IgG reactive bands 
corresponding to lily-i viral protein gp4l, p31 and p24. Of three urine samples, 
two had IgG reactive bands to gpi60, gpl20, p55, pSi and p17, and one had IgG 
reactive bands to p65 (Table 3.5). For IgA reaction, specific IgA bands 
corresponding to viral proteins gp4l and p24 were detected in all of 3 urine 
samples but no reactive bands to gp 160, p65  and p17 were observed. Both urine 
samples from patients C3321 and 14581 had IgA reactive bands to p55 and pSi 
(Table 3.6), and IgA reactive bands to gp120 and p31 were only detected in urine 
samples from patient 14581 (Figure 3.1, Table 3.5 and 3.6). 
In addition to the result in serum and urine samples, specific IgG and IgA to HIV 
were also analysed in two corresponding vaginal swab samples from HIV-1 
seropositive individuals C3321 and 14581 (Table 3.1). As shown in Figure 3.1, 
Table 3.5 and 3.6, both vaginal swab samples had the specific IgG bands 
corresponding to MV-1 viral proteins gp120, p55, pSi, gp41, p31 and p24 in the 
absence of bands corresponding to gp160 and p65. Specific IgG band 
corresponding to p17 was detected in only one of two samples tested. For IgA 
reaction, two bands corresponding to viral proteins gp4l and p24 were detected in 
both vaginal swab samples, and bands corresponding to viral gp120, pSi and p31 
was detected in one of two samples, respectively. 
The mucosal immune response to HIV in these samples was investigated by 
measuring sIgA, because sIgA serves an important effector function in mucosal 
immunity (see section 1.3.2). The results showed that specific sIgA to MV-1 p24 
were detected in all of three urine samples, two out of three serum samples and 
one out of two vaginal swab samples (Figure 3.1, Table 3.5 and 3.6). Specific 
sIgA to HIV-1 gpl60, p65 and gp4l was only detected in urine sample from 
patient 134M but not C3321 and 14581, and sIgA to p31 was only detected in 
urine sample from patient 14581 but not the others. 
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For patient C3321, specific sIgA to HIV-1 p24 were found in all of urine, serum 
and vaginal swab samples collected. In contrast, specific sIgA reactive bands to 
HIV-1 p31 and p24 were detected only in urine sample but not in the 
corresponding serum and vaginal swab samples from patient 14581. For patient 
134M, specific sIgA antibody to HIV-1 viral gp 160, p65, p55, pSi, gp4l, p31, 
p24, and p17 were detected in the serum but only specific antibodies to HIV-1 
gp160, p65, gp4l and p24 were detected in the corresponding urine samples. 
3.3.3.2 Antibodies to HIV-1 antigens in paired serum and urine samples from 
HIV-1 HEPS individuals 
To investigate the systemic and mucosal humoral immune responses in HEPS 
individuals, anti-HIV-1 IgG, IgA and sIgA antibodies were analysed in paired 
serum and urine samples collected from 9 of HIV-1 HEPS individuals (Table 
3.1) using Western blot assay. Healthy control (low risk) samples were used as 
negative control. 
The multiple HIV specific bands were detected, as shown in Figure 3.2, 3.3, 
Table 3.7 and 3.8. Of 9 serum samples from REPS individuals, 4, 4 and 5 
showed IgG reactive bands to HIV-1 gplóO, gp120 and pSi, respectively. One 
and one showed IgA reactive bands to HIV-1 gpl20 and pSi, respectively. A 
similar pattern of IgG reactivity in urine samples from REPS was found. Of 9 
concentrated urine samples (see section 2.1.2), IgG reactive bands corresponding 
to 1-HV-1 gp160, gp120 and p51 were detected in two samples from individuals 
lOOM and 008C; and IgA reactive bands corresponding to HIV-1 pSi viral 
protein was detected in two samples from 085W and 130M. 
In exploring the mucosal immunity, only one single sIgA band corresponding to 
HIV-1 pSi was detected in one serum sample but not in the corresponding urine 
sample. However, specific IgG antibodies to HJV-1 gp160, gpi20 and pSi were 
only detected in urine but not serum sample from individual 008C. Moreover, 
specific IgA antibody to HIV-1 p51 was detected only in urine not in the 
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corresponding serum sample from 130M. Surprisingly, of 4 control urine 
samples, one showed IgA reactive band corresponding to HIV-1 p5!. No bands 
were present in the control serum samples (Figure 3.2, 3.3; Table 3.8). 
3.4 DISCUSSION 
3.4.1 Optimisation of western blot 
There are a variety of methods for HIV antibody detection, currently including 
ETA and Western blot. In this project, Western blot was used to analyse the 
antibody pattern to individual antigens of HIV-1 in paired urine and serum or 
corresponding vaginal swab samples from both HIV-1 infected and HEPS 
individuals. 
The quantity of antigens is critical to produce western blotting of great 
specificity. To obtain good discrimination between viral proteins, viral antigens 
were made from the virus culture supernatant and infected H9 cells. The result 
showed that HIV gpl60, gp120, p65, p55, p51, gp4l, p3!, p24  and p17 were 
released from both supernatant lysate and infected cell lysate. However, it is clear 
that supernatant lysate was superior to cell lysate because the cell lysates 
produced more non-specific bands and dark background caused by nonviral 
proteins derived from the host cells (data not shown). These nonviral protein 
bands made interpretation of results difficult by producing nonspecific reactions. 
The supernatant lysate was thus chosen as a source of viral antigens and 
thereafter applied to the SDS-PAGE and blotting in this study. 
To obtain the greater sensitivity of Western blot, two amplification systems were 
investigated using DIA. HRP-conjugated secondary antibody and I-IRP-
conjugated third antibody were used as detection systems in primary 
amplification system and secondary amplification system, respectively. The 
results showed that the sensitivity of DIA employing the secondary amplification 
system could be increased more than 5 fold over that of DIA employing the 
primary amplification system. This is due to one more antibody involvement 
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Figure 3.1 Analysis of different classes of anti-HIV antibodies in serum, urine and 
vaginal swab from HIV-seropositive individuals by Western blot 
Western blot was performed as described in Chapter 2. 
Serum, urine and vaginal swab samples from two HIV-lseropositive individuals 
Serum and urine samples from one HIV-lseropositive individual 
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Figure 3.2 Analysis of different classes of anti-HIV antibodies in the paired serum and 
urine from five HEPS individuals by Western blot 
Western blot was performed as described in Chapter 2. 
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Table 3.5 Presence of IgG, IgA and sIgA antibodies to HIV-1 antigens in 3 paired serum 
and urine, 2 corresponding vaginal swab samples from HIV-1 seropositive individuals 
HIV-1 Number of samples 
Antigens - 
Serum Urine Vaginal swab 
IgG IgA sIgA IgG IgA sIgA IgG IgA sIgA 
gp160 3 0 1 2 0 1 0 0 0 
gp120 3 2 0 2 1 0 2 1 0 
p65 2 1 1 1 0 1 0 0 0 
p55 3 2 1 2 2 0 2 0 0 
p5! 3 3 1 2 2 0 2 1 0 
gp4l 3 1 1 3 3 1 2 2 0 
p3! 2 2 1 3 1 1 2 1 0 
p24 3 2 2 3 3 3 2 2 1 
p17 3 2 1 2 0 0 1 0 0 
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Figure 3.3 Analysis of the paired serum and urine from four HEPS individuals by 
Western blot. 
Western blot was performed as described in Chapter 2. 
N: Healthy (low risk) control. 
Low positive control. 
High positive control. 
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Table 3.6 Antibody patterns in HIV-1 seropositive individuals 
Viral C3321 14581 134M 
antigen Serum Urine Swab* Serum Urine Swab Serum Urine 
IgG igA sigA IgG IgA sigA IgG IgA sigA IgG IgA sigA IgG IgA sigA !gG IgA sigA IgG IgA sIgA lgG IgA sigA 
gpl60 + 	———————— + 	- 	- + 	----- +-+ +-+ 
gpl20 ++- +-- ++ ++ - ++-+ +-- - 	-- 
p65 + 	———————— +++ +- 	+ 
p55 ++ -+ +- ++ ++ 	- +- +- 	+ +- 	- 
p51 ++ -+ ++ ++ ++-+ +++ +- 	- 
gp4l +- ++ ++ ++ ++ 	- ++ +- 	+ +++ 
p31 +- + ++ -+ ++++ +++ +- 	- 
p24 + - + +++ +++ ++ ++ +++ +++ +++ 
p17 ++ +- +- ++ + 	----- +- 	+ - 	- 	- 
Vaginal swab samples 
Table 3.7 The presence of IgG, IgA and sIgA antibodies to HTV-1 in paired serum 
and urine samples from 9 HEPS individuals and 2 serum, 4 urine controls 
MV-1 Number of samples 
Antigens 
HEPS Control 
Serum Urine Serum Urine 
IgG IgA sIgA IgG IgA sigA IgG IgA sIgA IgG IgA sIgA 
gp160 4 0 0 2 0 0 0 0 0 0 0 0 
gpl2O 4 1 0 2 0 0 0 0 0 0 0 0 
p65 0 0 0 0 0 0 0 0 0 0 0 0 
p55 0 0 0 0 0 0 0 0 0 0 0 0 
p51 5 1 1 2 2 0 0 0 0 0 1 0 
gp4l 0 0 0 0 0 0 0 0 0 0 0 0 
p31 0 0 0 0 0 0 0 0 0 0 0 0 
p24 0 0 0 0 0 0 0 0 0 0 0 0 
p17 0 0 0 0 0 0 0 0 0 0 0 0 
Table 3.8 Antibody patterns in HEPS individuals 
	
Viral 	138M 	 085W 	 130M 	 lOOM 
proteins Serum 	Urine 	Serum 	Urine 	Serum 	Urine 	Serum 	Urine 
IgG IgA sigA IgG IgA sigA IgG IgA sigA !gG IgA sigA IgG IgA sigA IgG IgA sigA IgG IgA sigA lgG IgA sigA 
gpl60 	+- - 	-- - 	+- - 	-- - 	+- - 	-- - 	+- - + - - 
gpl20 +- - -- - +- - -- - ++- -- - +- - + - - 
p65 
p55 





008C 	 117M 	 006B 	 003B 	 044B 
Serum 	Urine 	Serum 	Urine 	Serum 	Urine 	Serum Urine 	Serum 	Urine 
IgG IgA sigA IgG IgA sigA IgG IgA sigA IgG IgA IgA IgG IgA sigA IgG IgA sigA IgG IgA sigA IgG IgA sigA IgG igA sigA IgG IgA sigA 
- 	+ -------------------------- 
- + --------------------------- 
- 	+ --------------------+- +-- - 
amplifying a weak reactive signal which could not be detected by primary amplification 
system. 
3.4.2 Antibody response to HIV-1 in seropositive individuals 
As initial exposure to HIV occurs most frequently at the genital mucosa, it emphasises 
the need to understand the nature of HIV-specific mucosal immune response, especially 
those that could lead to protection against HIV infection. To address this, the mucosal 
antibody responses to HIV in both ITV-1 seropositive and HEPS individuals were 
investigated. The results showed that HIV-specific IgG, IgA and sIgA antibodies can be 
present in urine and vaginal swab samples of HIV-1 infected individuals, although the 
antibody pattern to individual viral polypeptides of REV-i varied with sample tested by 
Western blot assay. 
SIgA is locally produced in mucosal epithelial cells and then transported into external 
secretions selectively (Rudzik et al., 1975; Mestecky et al., 1987; Brandtzaeg 1989) 
(see section 1.3.2.2). In this study, sIgA bands corresponding to viral gpl60, p65, gp4l, 
p3l and p24 were shown in urine samples and sIgA to p24 in vaginal swab sample from 
MV-1 seropositive individuals (Table 3.5 and 3.6). These findings demonstrated that a 
mucosal immune response was induced by HIV infection. These results also supported 
previous reports that local antibody was produced in male and female genital tracts as a 
result of HIV infection and could therefore play an efficient role in neutralising HTV 
virus and limiting the virus transmission on normal mucosa (Bélec et al., 1989a; 1994a; 
1995a; Kutteh et al., 1994; Archibald et al., 1987; O'shea et al., 1990; Wolff et al., 
1992; Hocini et al., 1997). 
Interestingly, specific sIgA antibodies to HIV-1 viral gp 160, p65, p55, pSi, gp4l, p31, 
p24, and p17 were also detected in the serum sample from patient 134M and sIgA 
against p24 in C3321 (Table 3.6). In contrast to IgG, human IgA displays a unique 
heterogeneity in its molecular forms. There are known to be two subclasses of IgA, 
IgA, and IgA2. Serum IgA is predominantly monomeric IgA,. The IgA in external 
124 
secretions, called sIgA consists of a dimer or tetramer with a relative increase in the 
proportion of IgA2 which are produced locally on mucosal surface (See section 1.3 for 
details). The reason for the presence of sIgA in serum in the present study is unknown. 
It is possible that the presence of specific sIgA antibodies in serum in this study could 
be the result of a backflow of sIgA locally synthesised in genital mucosa by an 
unknown pathway. It has been reported that the increased level of polymeric IgA in 
serum during lactation can be the result of a backflow of IgA produced in the mammary 
glands (Halsey et at., 1982). 
IgA antibody is the predominant immunoglobulin on the mucosal surface (Mestecky et 
at., 1987). However, it may not be true for HIV infection. The results of this study 
showed that IgG is the predominant isotype in urine and vaginal swab samples where 
IgG antibodies against gpl60/120, p55, p65/51, p41, p3!, p24 and p17 were present. As 
the HIV specific IgG antibody pattern in paired urine and vaginal swabs samples were 
not similar to that in the corresponding serum samples, it is unlikely that the source of 
these HIV-1-specific IgG antibodies are through serum transudation as suggested by 
some reports (Wolf et at., 1992; Black et al., 1997). It has been demonstrated that IgG 
could be produced locally (Morgan et at., 1980; Heinen et al., 2000). Therefore it is 
assumed that the predominant IgG antibody to HIV- 1 present in urine and vaginal swab 
samples in the present study was locally produced. This finding is similar to the 
previous reports that IgG antibodies to HIV-1 appeared to be largely synthesised in situ 
within the genital tract of both genders (Bélec et al., 1995b; Hocini et al., 1997) and 
IgG excretion was increased in HIV-1 infected women, whereas the IgA secretion 
tended to decrease, suggesting a possible enhanced local IgG synthesis (Bélec et al., 
1995c; Lu et al., 1993). This hypothesis was also supported by the observations in 
animal models that nonclassical mucosal antibodies of the IgG isotype were found to be 
the predominant antibody in the saliva, rectal swabs, vaginal washes, semen and 
urethral washes in HIV-1 infected chimpanzees (Israel and Marx, 1995), and specific 
SW IgG antibodies were found to be predominant immunoglobulin in vaginal swab 
samples of chronically infected rhesus macaques (Miller et al., 1992a). It has also been 
125 
reported that the genital secretory immune response of rhesus macaques following 
intravaginal exposure to antigens consists primarily of IgG (Yang and Schumancher, 
1979). Thus it is possible that IgG is the predominant antibody response on the mucosal 
surface in human subjects in response to HIV infection. 
3.4.3 Antibody response to HIV-1 antigens in HIV-1 HEPS individuals 
The natural immune protection mechanisms preventing HEPS population becoming 
infected are still unclear. But it has been suggested that mucosal immunity may play an 
important role in protecting from HIV infection (see section 1.1.2.4). To address this, 
the humoral immune responses in paired serum and urine samples of 9 HEPS 
individuals were investigated. Their seronegative status was demonstrated by 
immunoassay (ETA) after collecting the paired serum and urine samples, and 
furthermore confirmed before performing Western blot in this study. Systemic and 
mucosal immunity in these HEPS individuals were investigated by profiling the specific 
IgG, IgA and sIgA antibodies to viral proteins of HIV-1 in paired serum and urine 
samples. 
In exploring HIV-1 specific sIgA in HEPS individuals, it was observed that no HIV 
specific sIgA bands were common to all 9 urine samples. However, specific IgG 
antibodies to 1-HV-1 gp160, gp120 and p5l were detected in urine but not the 
corresponding serum sample from individual 008C. Similarly, specific IgA antibody to 
HIV-1 p5l was detected only in urine not in the corresponding serum sample from 
individual 130M (Table 3.8). These results suggest that mucosal immunity was present 
in some HEPS individuals. The role of local anti-virus antibodies is unknown. It is 
generally believed that Langerhans cells located in the mucosal epithelium are the 
mucosal target cells for HIV-1 and thus attract HIV-1 infection following sexual 
exposure (Pope, 1999; Chou et al., 2000). The presence of anti-HIV-1 local antibodies 
in the genital tract may act as an effector mechanism to prevent HIV-1 infection, and 
therefore, play an important role in protecting HEPS individuals against sexual 
transmission of HIV-1. 
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There were more bands recognised by IgG antibody than IgA, suggested that IgG is the 
predominant isotype in genitourinary tracts in these subjects. These findings are similar 
to the antibody production pattern in immunised animal model that a higher level of 
vaginal IgG than that of vaginal IgA was induced in mice when inoculated vaginally 
with a DNA vaccine, suggesting that IgG producing B cells within the vaginal mucosa 
may be preferentially stimulated by HIV-1 envelope antigen (Wang et al., 1997). A 
similar result was also observed in a macaque model in which the iliac lymph node was 
immunised with a subunit SW envelope and core vaccine (Lehner et al., 1996). 
Together with increasing IgA antibody-secreting cells to p27, IgG antibody-secreting 
cells to p27 and gp129 were also increased in the iliac lymph nodes of the immunised 
and protected macaques. However, this observation is not the same as previous studies 
on FIEPS population where HIV specific IgA but not IgG was present in urine and 
vaginal wash samples from HIV-exposed seronegative individuals and HIV-1 resistant 
sex workers (Mazzoli et al., 1997; Kaul et al., 1999). The reason for this discrepancy 
remains unclear but may be related to the sample used and the background of individual 
studied. It should be considered that both HIV-1 specific IgG and IgA may be produced 
locally and associated with protection from HIV infection in HEPS population. 
Interestingly, a weak sIgA band to HIV-1 viral p51 was detected in one of 9 serum 
samples (Table 3.7). It is clear that sIgA is secreted at mucosal sites (Rudzik et al., 
1975; Brandtzaeg et al., 1989). Therefore, this HIV-1 specific sIgA antibody found in 
serum sample can be considered to be synthesised locally in genital mucosa and 
transported back to serum from the mucosal production site by an unknown mechanism. 
Furthermore, this finding also demonstrated that mucosal immunity was induced in this 
HEPS individual. The reason for absence of sIgA in the urine sample is unclear but 
might related to the low concentration of secretory antibody present in urine samples. 
Surprisingly, 1-HV-1 specific IgA band to viral p5l was found in one urine control 
sample from a low risk uninfected individual. This might be due to non-specific cross 
reactive antibodies. The reason for producing this non-specific band is unclear. It was 
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reported that the presence of non-specific cross-reactive antibodies in HIV-1 WB was 
possibly due to recent immunisation; autoantibodies (i.e. antinuclear antibodies and 
rheumatoid factor); lymphoma or liver disease (Ranki et al., 1988; Kleinman et al., 
1988; Dock et al., 1988; 1991; Diagnostic test for HIV, 1997). There also appear to be 
healthy persons with antibodies that cross-react with specific HIV-1 peptides or 
recombinant antigens (Busch et al., 1991; Blomberg et al., 1990). These antibodies may 
have arisen because of molecular mimicry by chance or by functional selection or 
immunisation following activation and noninfectious exposure (Blomberg et al., 1990). 
Specific IgG antibodies to MV-1 viral antigens gpl60, gp120 and p51 were found in 
four serum samples from HEPS subjects, unexpectedly (Figure 3.2 and Table 3.8). 
These results may be interpreted as indeterminate according to CDC (US Centre for 
Disease Control, Atlanta, GA) Western blot criteria which require reactivity to at least 
two of the following antigens: gpl60/120, gp4l and p24 for a positive classification. 
This positive criterion is currently followed by most institutions. However, it is 
dissimilar to most indeterminate Western blot results which show only weak reaction to 
the gag proteins (mostly p17, p24 and/or p55) (Constantine, 1998). There is evidence 
that an indeterminate Western blot result is not predictive of early infection. Some 
individuals may have the identical profile for long periods of time (years) but never 
seroconvert (Constantine, 1998). Jamjoom et al. (1997) reported that two hundred and 
fourteen Western blot-indeterminate samples were followed up by retesting the 
subsequent samples from the same patients with Western blot over a 3-12 month period. 
The results showed that 66.4% samples gave negative results and 30% samples 
remained indeterminate. Thus the gpl60, gpl20 and p51 bands, even when they appear 
as indeterminate results, may indicate a humoral immune response induced by exposure 
to HIV and might play a role in protecting HEPS individuals from infection with HIV. 
However, these indeterminate results need to be repeated over years and other tests 
should be involved, so that the above suggestion could be further investigated. 
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3.4.4 Conclusion 
The systemic and mucosal humoral immunity in HIV-1 infected and HEPS individuals 
was profiled using Western blot in this study. The results demonstrated that a mucosal 
immune response was induced by HIV-1 infection and HIV-1 specific IgG is the 
predominant isotype present in genitourinary tract of HIV-1 infected individuals, which 
may play an efficient role in neutralising HLV virus and limiting the virus transmission 
on normal mucosa. 
Mucosal humoral immunity was demonstrated in some HEPS individuals. Also, HIV-1 
specific IgG antibodies were the predominant isotype present in genitourinary tract of 
HEPS individuals. These results suggested that anti-HIV-1 specific mucosal immune 
response may be associated with a natural protection mechanism in REPS populations 
and provide insight into development of a HIV-1 mucosal vaccine. 
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Construction Of Plant Expression 
Vectors Containing HIV-1 gp160 Genes 
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4.1 INTRODUCTION 
The HIV env gene encodes a single-chain precursor gpl60 which is subsequently 
cleaved to external surface envelope glycoprotein (gp120) and transmembrane 
glycoproteins (gp4l). As described in Chapter 1, the IIIV gpl60 plays a pivotal role in 
the early events of virus attachment and entry into the target cell. The gpl20 molecule 
mediates the attachment of the virus to the cell-surface CD4 receptor and is involved in 
recognition and binding to the target cell receptors (Sattentau et al., 1993). Therefore, 
HIV-specific neutralising antibodies found in the sera of infected individuals are 
predominantly directed against this glycoprotein (Matthews et al., 1986), and antibodies 
to HIV gp160 were detected in genital secretions, urine samples, tears, milk, nasal 
washing, intestinal fluid, cervical fluid and saliva (Bélec et al., 1989a; O'shea et al., 
1990; Sun 1990; Thongcharoen et al., 1992; Wolff et al., 1992; Constantine et al., 1994; 
Janoff et al., 1994; Mestecky et al., 1994), suggesting that gp160 is an antigenic target 
during immune responses to HIV infection. The presence of neutralising antibodies 
might inhibit the transmission of HIV infection in vivo. Based on these studies, HIV gp 
160 was selected as an immunogenic antigen for a HIV vaccine. 
Considerable progress has been made in the development of vaccines against HTV. In 
animal models, it has been shown that oral and intranasal immunisation with FHV 
gp160 induced high levels of IgA, 1gM and IgG in serum, and secretory IgA at the 
mucosal surfaces (Thibodeau et al., 1992; Muster et al., 1995; VanCott et al., 1998; 
Staats et al., 1996), indicating that mucosal immunisation could induce a mucosal 
immune response (Lehner et al., 1992; Mestecky et al., 1994; Morrow et al., 1994; 
Bond et al., 1995; Bukawa et al., 1995; Wu et al., 1997; Kaneko et al., 2000). 
Neutralisation tests showed that HIV specific IgA was capable of neutralising HIV-1 
IIIB, HIV-1 SF2 and HIV-1 MN (Bukawa et al., 1995). This result suggests that Env 
protein delivered orally in combination with cholera toxin adjuvant can effectively 
induce HIV-specific immune response in mucosal tissues and may thus provide 
protection against 1EV-1 transmission to mucosal surfaces. 
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Transgenic plants comprise a new vaccine production system that does not require 
purification or injection and provide the possibility that a fresh or pureed fruit such as 
banana and tomato could replace the needle as a means of vaccinating children and 
adults against deadly diseases. Progress in the development of transgenic plants can be 
attributed to the exploitation of the Agrobacterium transformation mechanism and has 
resulted in the design of modified, non-tumouri genic Agrobacterium Ti plasmids for the 
engineering of transgenic plants. Agrobacterium tumefaciens is the causal agent of plant 
crown gall disease and can genetically transform wounded plant cells, and thus provides 
an ideal vector systems for the generation of transgenic plants. The abnormality of the 
plant growth is due to a relatively small discrete portion of large tumour-inducing (Ti) 
plasmids which are transferred to plant cells. Integration to the plant genome and 
expression of this transferred DNA (T-DNA) results in the crown gall phenotype (Binns 
and Thomashow, 1988; Klee et al., 1989; Depicker et al., 1991). Two regions were 
found critical for gene transfer in Ti plasmids. The first region is known as the virulence 
(vir) region containing genes which are essential for gene transfer, but are not 
themselves generally transferred to the plant genome. The second important region is 
the T-DNA. The Agrobacterium/pl ant interaction is coordinated by a biochemical 
communication process between susceptible plant cells and the infecting bacteria that is 
mediated by the gene products from the vir region on the Ti plasmid. Sensing of the 
plant cell-derived signal molecules by the bacteria leads to the excision of the T-DNA 
from the Ti plasmid, followed by subsequent transfer and integration in the infected 
plant cell genome (Zambryski, 1992). Exploitation of Agrobacterium transformation 
mechanism resulted in the design of modified, non-tumourigenic Agrobacterium Ti 
plasmids for the engineering of transgenic plants. Basically, two types of non-oncogenic 
Agrobacterium vectors are presently in use. Vectors which recombine via DNA 
homology into a resident Ti plasmid are often referred to as integrative or intermediate 
vectors (Fraley et al., 1983). The finding that the T-DNA could be separated from the 
vir genes onto two separate replicons in Agrobacterium led to the development of the 
second type of vector which do not need to recombine into the resident Ti plasmid and 
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are referred to as binary or autonomous vectors (An et al., 1985; Klee et al., 1985). 
Binary vectors are now the most commonly used vector system for creating and 
regenerating transgenic plants. These vectors contain a number of unique restriction 
endonuclease sites which can be used for inserting the foreign genes of interest and 
plant selectable marker(s) between the T-DNA borders and a cloning vehicle capable of 
replicating in E. co/i and Agrobacterium. The recombinant plasmids containing the 
foreign gene of interest are transformed into E. co/i, and subsequently mobilised into an 
Agrobacterium strain harbouring a Ti plasmid (either wild-type, or a "disarmed" Ti 
plasmid in which the T-DNA was deleted). They are replicated in Agrobacterium 
usually with a copy number of 5-10 relative to the Ti plasmid and bacterial 
chromosome. The vir genes resident within Agrobacterium can process and mobilise the 
T-DNA from the bacterium to a plant cell (Ooms et al., 1982; Hood et al., 1986). 
As discussed in Chapter 1, the transgenic plant edible vaccines have shown to be a 
potential new generation of novel, encouraging and prospective vaccine production and 
delivery systems with its distinguishing characteristics including inexpensive 
production, unnecessary preparation or purification and easy transportation and storage. 
Plant based oral vaccines may offer a new approach to vaccination strategies, in 
particular, in cases where a local immune response is crucial in the prevention of 
infections. So far viral antigens from hepatitis virus B (HbsAg) (Mason et al., 1992; 
1995), norwalk virus (Mason et al., 1996), foot-and-mouth disease virus (Carrillo et al., 
1998), hemorrhagic disease virus (RHDV) (Castanon et al., 1999), and porcine 
transmissible gastroenteritis virus (TGEV) (Tuboly et al., 2000) have been successfully 
expressed in transgenic plants. Immunisation with recombinant viral proteins expressed 
in transgenic plants induces a protective immune response in animals. The aim of this 
work was to clone the whole of the region encoding HIV-1 gp 160 and construct a 
recombinant transgenic plant expression vector containing this gene. Plants expressing 
these recombinant proteins would than be used for studies on the immunoreactivity. 
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
4.2.1.1 pCR-Script Amp SK(+) cloning vector 
The pCR-Script Amp SK(+) cloning vector (Stratagene Ltd., Cambridge) is a 2961 
base pair (bp) plasmid, derived from the pBluescript ® II SK(+) phagmid. The pCR-
Script' Amp SK(+) cloning vector contains an ampicillin-resistance gene, a lac 
promoter for gene expression and the SK multiple cloning site (MCS), which is 
modified to include the novel rare-cleavage restriction-enzyme Srf I target sequence 5'-
GCCCIGGGC-3' (Figure 4.1). 
4.2.1.2 HIV-1 plasmid pRNBXX 
The HIV-1 plasmid PRNBXX was made by Dr Sarah Ashelford (Centre for HIV 
research, Edinburgh University). This 6073 bp plasmid contains the HIV-1 env 160 
sequence, an ampicillin-resistance gene and the target sequences of restriction-
endonucleases Not I, BstE I, XhoI and XbaI (Figure 4.2). 
4.2.1.3 Plant plasmids 
Plants plasmids pIBT210.1, pIBT240.1, pIBT110 and pIBT140 were a kind gift from 
Dr Hugh Mason (Boyce Thompson Institute for Plant Research, USA). 
pIBT210.1 (4051 bp) contains the cauliflower mosaic virus 35S promoter (5' CaMV 
35S), which is plant leaf specific. pIBT240.1 (5554 bp) uses a potato tuber-specific 
expression promoter, patatin. Both pIBT2 10.1 and pIBT240.1 have a tobacco etch virus 
5' untranslated region (TEV 5' UTR) which mediates enhancement of translation 
initiation, a polyadenylation signal of a soybean vegetative storage protein gene 
(3'vspB) which is needed to mediate niRNA 3' end processing, an ampici llin-resi stance 
gene and multiple cloning sites which include NcoI, Smal, BamI-II, KpnI and Sad 
(Figure 4.3 and Figure 4.4). 
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Both p1BT1 10 and pIBT 140 are T-DNA binary vectors and contain the left and right T-
DNA borders (LB, RB) which denote the limits of the DNA that is integrated into the 
plant genomic DNA via Agrobacterium tumefaciens-mediated transformation. They 
also contains the neomycin phosphotransferase (nptll) for selection of plant 
transformants using kanamycin, a viral (TEV) 5'-UTR for translation enhancement, the 
3' end from soybean (3'vspB) and multiple cloning sites which include Smal, Ban - HI, 
KpnI and Sad. pIBT11O (13150 bp) contains a CaMV 35S promoter that is plant leaf 
specific (Figure 4.5), while plasmid pIBT140 (14652 bp) uses a potato tuber-specific 
expression promoter patatin (Figure 4.6). 
4.2.1.4 Plant expression vector pGPTV-KAN 
Plant plasmid pGPTV-KAN (glucuronidase plant transformation vector) was kindly 
given by Dr Elke Kemper (Max-Planck-Institut für Züchtungsforschung, Carl von Linné 
Weg 10, D-5000 Köln 30, Germany). This plasmid is a 13387 bp plant binary T-DNA 
vector derived from the plant binary vector pBIN19 which is the most widely used 
binary vector for Agrobacterium-mediated plant transformation (Bevan 1984). The 13-
glucuronidase (uidA) reporter gene it contains can be used for promoter studies, or may 
be exchanged for any other gene of interest as desired. The plant selectable marker gene 
nptll, which confers kanamycin resistance to plants, is driven by the nopaline synthase 
(nos) promoter and located near the T-DNA left border so that the selectable marker and 
uidA reporter genes are divergently organized for efficient expression (Becker et al., 
1992). The plasmid contains unique cloning sites EcoRI, Smal, XbaI, Sail and HindIll 
(Figure 4.7). 
4.2.2 Methods 
The general molecular biology methods were performed as described in 2.2.3. 
4.2.2.1 Pfu PCR 
Plasmid pRNBXX containing the whole envl60 sequence was used as template for 
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Figure 4.11 Circular map of the pCR-Script Amp SK(+) cloning vector 
The pCR-Script Amp SK(+) cloning vector is a 2961 bp plasmid designed to insert 
blunt-ended PCR products at SrfI site. CoIIE1 origin: Plasmid origin of replication. 
LacZ gene: allowing blue-white screening of recombinants. MCS: Multiple cloning 
site. Ampicillin: ampicillin-resistance gene (Amp') for antibiotic selection of the 
cloning vector (adapted from instruction manual of pCR-Script Amp SK(+) cloning 
kit, Stratagene Ltd., UK) 
Figure 4.2 Diagrammatic representation of plasmid pRNBXX 
Plasmid pRNBXX is a 6073 bp plasmid containing the whole env160 sequence (481- 
3054) of HXB2. 
Figure 4.3 Diagrammatic representation of plant plasmid pIBT210. 1 
pIBT2I0.1 (4051 bp) contains the cauliflower mosaic virus 35S promoter (35S 5) 
which is plant leaf specific, a tobacco etch virus 5' untranslated region (TEV), a 
polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB) and the 
multiple cloning sites including NcoI, BamHlI, Smal, KpnI and Sad. 
Figure 4.4 Diagrammatic representation of plant plasmid pIBT240. 1 
pIBT240. 1 (5554 bp) contains a potato tuber-specific expression promoter patatin, a 
tobacco etch virus 5' untranslated region (TEV), a polyadenylation signal of a soybean 
vegetative storage protein gene (3'vspB) and multiple cloning sites including NcoI, 
BamHT, Smal, KpnI and Sac!. 
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Figure 4.5 Diagrammatic representation of plant binary vector pIBT1 10 
Plasmid pIBT1 10 is a 3150 bp plant binary vector. This plasmid contains an expression 
cassette for neomycin phosphotransferase (nptll) located near the right border of T -
DNA for selection of plant transformants using kanamicin, cauliflower mosaic virus 
35S promoter (35S 5'), a tobacco etch virus 5' untranslated region (TEV), a 
polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB) and 
multiple cloning sites including Smal, KpnI and Sad. RB and LB indicate the right and 
left transferred DNA (T-DNA) borders. 
Figure 4.6 Diagrammatic representation of plant binary vector pIBT 140 
Plasmid pIBT140 is a 14652 bp plant binary vector. This plasmid contains a expression 
cassette for neomycin phosphotransferase (nptll), located near the right border of T-
DNA for selection of plant transformants using kanamicin, the plant tuber-specific 
promoter patatin, a tobacco etch virus 5' untranslated region (TEV), a polyadenylation 
signal of a soybean vegetative storage protein gene (3 'vspB) and the multiple cloning 
sites including Smal, KpnI and Sad. RB and LB indicate the right and left transferred 
DNA (T-DNA) borders. 
Figure 4.7 Diagrammatic representation of plant binary vector pGPTV-KAN 
pGPTV-KAN (glucuronidase plant transformation vector) is a 13387 bp plant binary T-
DNA vector. The -glucuronidase (uidA) reporter gene can be exchanged by any other 
gene of interest as desired. The plant selectable marker gene neomycin 
phosphotransferase (nptl1) is located near the T-DNA left border so that the selectable 
marker and uidA reporter genes are divergently organized for efficient expression. The 
plasmid contains unique cloning sites EcoRI, Smal, XbaI, Sall and Hindlil. RB and LB 
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amplification of HIV-1 specific env DNA fragments. The PCR reaction conditions were 
as follows: 4 ng of plasmid template and 100 ng of each of N160F/S160R primers (see 
section 2.2.4.19e) were used per reaction. PCR mixture consisted of 200 MM Tris-HCI 
(pH 8.0), 60 mM ammonium sulphate, 20 mM M902, 100 mM KC1, 1% Triton ® X-100 
and 100 .tg/ml nuclease-free BSA, 200 tLM each dNTP (0.8 mM total) and 2 units of 
cloned Pfu DNA polymerase (Stratagene Ltd., Cambridge, UK). A control reaction was 
set up which lacked any DNA template. All reaction mixtures, including the control, 
were made up to 40 ld with DEPC (Diethyl procarbamine) treated distilled water 
(dH20) and overlaid with one drop (or-20 p1) of paraffin oil to prevent evaporation. 
This reaction mixture was initially denatured at 94 °C for 45 seconds before 2 units of 
Pfu DNA polymerase was added, followed by thirty cycles of 94 °C for 45 seconds, 
55°C for 45 seconds, 72°C for 6 minutes, and one extension cycle of 72 °C for 10 
minutes, on GENEE Thermal Cycler or PCR Express (Hybaid). 8 p1 samples of each 
PCR reaction were analysed on a 1% TAB agarose gel byelectrophoresis (see section 
2.2.3.2). 
4.2.2.2 Ligation of DNA fragments in gel slices 
After digestion with the appropriate restriction endonucleases, the treated DNA was 
subject to electrophoresis in 0.6% (in 1 X TAE buffer) low melting temperature agarose 
gel (Flowgen, Staffordshire, UK) (see section 2.2.3.2). The desired bands containing 
DNA were then cut out in the smallest possible volume with a clean razor blade, and the 
gel slice was placed in a microcentrifuge tube and incubated at the 65 °C for 10 minutes 
to melt the gel. The gel slices containing appropriate DNAs for ligation were combined 
and the mixture was placed at 37 °C for 2 minutes. For each ligation reaction, 1/10 of the 
total volume of 10 X ligation buffer (500 mM Tris-HCI, pH7.5; 70 MM MgCl2; 10mM 
DTI'), 10mM rATP (pH7.5) and T4 DNA ligase (4uJ.tl, Stratagene Ltd., Cambridge) 
were added into the tube separately. After mixing immediately by flicking, the tube 
containing ligation reaction was incubated at 12 °C-16°C for 48 hours. When the ligation 
reaction was completed, the tube was incubated at 37 °C for 10 minutes to remelt the 
resolidified gel slices. Then the ligated products were then used to transform into DH5ct 
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competent cells, as described in 2.2.3.10. 
4.2.2.3 Deletion of NcoI site using mung bean nuclease 
1 g of recombinant plant plasmids pIBT210.1-envl6O ( pIBT210.1NS) or pIBT240.1-
env160 (pIBT240.1SS) were digested with 0.5 p1 (5 Units) restriction endonuclease 
NcoI (New England Biolabs, UK). 2 p1 of 10 X NEBuffer 4 (500 mM potassium 
acetate, 20 mM Tris-acetate, 10 mM magnesium acetate, 1 mM dithiothreitol (pH 7.9)) 
was added and the reaction made up to 20 p1 with dH20 before the reaction mixture was 
incubated at 37°C for 2 hours. 
To this was then added 10 p1 of 10 X mung bean nuclease buffer (500 mM sodium 
acetate (pH5.0), 30 mM NaCl and 1 mM ZnSO4) and 0.5 p1 of mung bean nuclease 
(IvIBN) (New England Biolabs) and the mixture made up to 100 p1 with dH 20. After 
mixing well, it was incubated at room temperature for 15 minutes. This was then 
concentrated to 20 p1 in the speed vacuum microcentrifuge at 13000 rpm for 10 minutes 
at 4°C and loaded on 1% agarose gel, using undigested plasmid in several lanes away as 
a control. The DNA was electrophoresised at 40-50 mA for 2-3 hours until the digested 
DNA fragment was well resolved from any undigested plasmid by comparison with 
undigested plasmid. Finally the digested DNA band was cut out with a clean razor blade 
under UV light and purified using Prep-A-Gene DNA purification Kit (BlO-RAD) as 
described in 2.2.3.6b. 
About 1/10 (1-2 p1) of this purified digested DNA fragment was used to blunt end ligate 
in 1 X ligase buffer (50 mM Tris-HCI (pH 7.5), 10 mlvi MgCl 2, 10 mM dithiothreitol, 1 
mM ATP, 25 pg/mI BSA) containing 0.5 p1(200 Units) of T4 DNA ligase (New 
England Biolabs, UK) in a total of volume of 10 p1. After incubating at 16 °C for 
overnight, 2-4 p1 of the ligation mixture was used to transform 100 p1 of DH5ct 
competent cells as described in 2.2.4.10 and 2.2.4.1. The colonies were screened by 
digestion with NcoI restriction endonuclease. 
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4.3 RESULTS 
4.3.1 Generation of HIV-1 envI60 DNA bearing restriction enzyme site at ends 
PCR primer N160FIIS 160R (see section 2.2.3.18e) was designed to introduce a NcoI site 
and a Sacl site at the 5' and 3'of FIIV-1 env gene respectively. Plasmid pRNBXX 
containing the whole sequence of HIV-1 env16O sequence was used as PCR template 
employing either Taq or Pfu DNA polymerase. 
A series of reactions were set up to try to obtain optimal production because of 
additional bases on primer N160FcoJJS 160R. Different concentrations of template (2 
ng, 4 ng, 6 ng, 10 ng and 20 ng), primers (100 ng, 200 ng, 500 ng and 1 .tg) and dNTPs 
(0.4 mM, 0.8 mM and 1 mM) in total 40 .tl reaction were analysed. For the PCR 
reaction condition, different denaturing temperatures (94 °C, 95°C and 970C), different 
annealing temperatures (50°C, 55°C, 60°C and 65°C) and different PCR cycle number 
(25, 30 and 35) were also tested. In addition, different total reaction volumes (20 .tl, 40 
tl, 50 .tl and 100 p.1) were examined. The experiments showed that the ideal conditions 
for amplification with this paired primers were DNA template at a concentration of 4 
ng; primer concentratioii at 100 ng and the total dNTPs concentration at 0.8 MM in total 
volume of 40 p.1 PCR reaction mixture, and 30 cycles of amplification under 94 °C for 
denature and 55°C for annealing. The results for generation of HIV gpl60 DNA bearing 
enzyme sites at both ends were shown in Figure 4.8. A fragment of 2596 bp was 
successfully amplified with primer N160FcoJJS160R when either Taq or Pfu PCR was 
used. The result also showed that Pfu PCR amplification gave a cleaner and sharper 
2596 bp band than Taq PCR amplification. 
4.3.2 Cloning of env160 PCR products into pCR-Script Amp SK (+) vector 
In order to sequence the PCR products and facilitate the subsequent cloning of the 
env160 gene into plant plasmids, the env160 Pfu PCR products were purified and blunt 
end ligated into pCR-Script Amp SK (+) cloning vector following the manufacturer's 
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Figure 4.8 Amplification of l-IIV-1 envJ60 by PCR with designed NI60FcoIISI6OR 
pn mers 
Amplification of HIV-1 envlóO gene with designed primer set N16OF/S16OR resulted 
in a 2596 bp product when either Taq or Pfu PCR was used. 8 tl of the PCR reaction 
was subjected to electrophoresis on 1% agarose gel stained with ethidium bromide. 
Lane 1: LamdaJHindlll DNA marker 
Lane 2 & 3: PCR products with Pfu DNA polymerase 
Lane 4: PCR product with Taq DNA polymerase 
Lane 5: Negative PCR control without DNA template 
Lane 6: pGEM DNA marker 
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instructions (Stratagene Ltd., Cambridge). Ligation was carried out with different molar 
ratios of vector to insert DNA fragment (1:40, 1:60, 1:80 and 1:100). Different amounts 
of ligation reaction mixture (2, 4, 6 and 8 .tl) were used to transform into XL-1 Blue 
MRF' Kan supercompetent cells (Stratagene Ltd., Cambridge), using 1 tl of insert DNA 
and cloning vector as a control. The products of each transformation mixture were 
plated out onto three LB/amp plates precoated with 20 .tl of 10% (w/v) 5-Bromo-4-
chloro-3-indoyl-f3-D-galactopyranoside (X-gal) for color selection. The colonies were 
screened for blue/white phenotype, white colonies representing possible transformed 
cells containing recombinant plasmids. The results showed that 1:40 and 1:60 molar 
ratio of vector to insert DNA ligation were not successful, while 1:80 and 1:100 molar 
ratio of vector to insert DNA gave efficient ligation and 4 .tl of ligation reaction mixture 
gave the most efficient transformation. 
DNA was prepared by miniprep procedure from 86 of 96 white colonies and screened 
by Taq PCR with primer set of N160F/S160R. The results showed that 37 out of 86 
plasmid DNA minipreps gave the right size (2596 bp) PCR product (Figure 4.9). 22 
PCR positive plasmid DNA minipreps were double digested with NcoI and Sad or/and 
XbaI and Sacl to check the size and the directionality of the insert. The predicted main 
restriction fragment sizes are 2935 bp and 2580 bp when cut with SacI and NcoI with 
both cloning orientation; and 4799 bp and 716 bp with cloning direction of NcoI at the 
upstream of Sacl site, or 2935 bp, 1906 bp and 716 bp with cloning direction of Sacl at 
the upstream of NcoI site when cut with XbaI and Sad. As shown in Figure 4.10a and 
b, 21 colonies analysed gave the predicted sized fragments 4799 bp and 716 bp when 
double digested with XbaI and Sad, demonstrating that envl60 had been successfully 
cloned into pCR-Script SK(+) cloning vector in the orientation of NcoI site at the 
upstream of Sacl site (Figure 4.11). These recombinant plasmids containing HIV-1 
envl60 (5557 bp) were designated as pBSNS for subsequent cloning FIIV-1 envl60 into 
plant plasmids pIBT210.1 and pIBT240.1. 
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Figure 4.9 i'aq PCR screenin of recombinant plasmids pBSNS containing insert 
I envl6O 
Plasmid DNA minipreps were screened by PCR using designed primer set 
N16OF/SI6OR. 8 j.tl of the PCR reaction was subjected to electrophoresis on 1% agarose 
gel. Positive recombinant plasmid (designated as pBSNS) resulted in a 2596 bp PCR 
product. 
Lane 1: LambdalHindlll DNA marker 
Lane 2: Positive control plasmid pRNBXX 
Lane 3-20: DNA minipreps from white colonies 
Lane 21: Negative control without DNA template 
Lane 22: pGEM DNA marker 
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Figure 4.10 Restriction fragment analysis of recombinant plasmid pBSNS 
Plasmid DNA minipreps extracted from PCR positive colonies were digested with 
restriction enzymes and were subjected to electrophoresis alongside undigested plasmid 
in order to confirm the size and the directionality of the insert and check the completion 
of the digestion. The predicted main restriction fragment sizes of double digestion with 
Sacl and NcoI are 2935 bp and 2580 bp; and with XbaI and Sacl are 4799 bp and 716 
bp. 
Double digestions with both XbaJJSacI and NcoIISacI 
Lane 1: LamdalHindlll DNA marker 
Lanes 2, 5 and 11: Undigested plasmid preparation 
Lanes 3, 6 and 13: Digestion with XbaI/SacI 
Lanes 4, 7 and 12: Digestion with NcoJJSacI 
Lane 8-10: empty (no samples loaded) 
Lane 14: Inserted DNA control (2596 bp) 
Lane 15: 1Kb DNA ladder 
Double digestion with XbaL/SacI 
Lane 1: LamdalHindlll DNA marker 
Lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18: Undigested plasmid preparation 
Lanes 3, 5, 7, 9, 11, 13, 15, 17 and 19: Digestion with XbaIISacI 
Lane 20: 1Kb DNA ladder 
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4.3.3.Cloning of HIV-1 env160 into plant plasmid pIBT210.1 
pIBT210.1 (see section 4.2.1.3 ) was chosen for the generation of a recombinant 
plasmid containing CaMV promoter 35S, translation enhancement TEV, HIV-1 env160 
and a polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB). The 
plasmid pIBI210.1 contains a multiple cloning site with NcoI, Smal and Sad 
restriction endonuclease sites to facilitate the cloning of foreign DNA. The required 
portion of env160 was generated by Pfu PCR incorporating NcoI and SacI restriction 
enzyme sites at the 5' and 3' ends, respectively, to enable directional cloning of env160. 
Typically 5 X 40 tl of Pfu PCR reactions were set up and the PCR products were 
pooled before being purified using QlAquick PCR purification kit (QlAgene, Germany) 
as described in 2.2.4.4. 5 p.g of pIBT2 10.1 and purified PCR product were both cut with 
NcoI and Sacl using 1 X NEBuffer 1 (10 mM Bis Tris Propane-HC1, 10 MM MgCl 2, 1 
mM DTT (pH7.0 at 25 0C)) (New England Biolabs, UK) following the manufacturer's 
instructions. Restriction enzyme digestion was carried out for 4 hours at 37 °C. The 
digested pIBT210.1 fragment was phenol: chloroform extracted and was ethanol 
precipitated as described in 2.3.3.5. The DNA was then resuspended in 10 .il of DEPC 
treated dH20. The digested and purified PCR sample was loaded on 1% low melting 
gel. The correctly sized bands (2596 bp) were excised, extracted from the low melting 
gel using Geneclean H kit (BlO 101 Inc., Stratech Sci.) as described in 2.2.3.6a and 
resuspended in 6 .tl of DEPC treated dH20. 0.5 .tl of each sample was run on 1% 
agarose gel to estimate the amount of DNA in the sample by comparing band intensities 
with those of known amounts of DNA markers. Ligation was set up in molar ratio of 
1:10 of vector to insert DNA. 3 p.1 and 6 p.1 of ligation reaction and 1 pi of vector and 
insert DNA control were transformed into Epicurian Coli DH5a competent cells 
respectively and colonies grown on agar plates for 16 hours at 37 °C. The result showed 
that ligation was successful and 3 p.1 of ligation reaction mixture gave the most efficient 
transformation. 20 colonies were selected and grown in 3 ml of LB/amp for 16 hours at 
37°C for minipreparation. The plasmid DNA minipreps were screened by Taq PCR with 
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N160F/S160R primer set and resulted in 15 PCR positive (2596 bp as PCR product) 
(Figure 4.12). 5 out of 15 PCR positive plasmid minipreps were further cut with XbaI 
which site only located in the insert DNA, NcoL/SacI and NcollHindffl, respectively. 
The recombinant plasmid would give sized fragments 6606 bp from digestion with 
XbaI, 4026 bp and 2580 bp from double digestion with NcoI and Sacl and 3843 bp, 
1927 bp and 836 bp from double digestion with NcoI and HindIll. The 5 colonies 
analysed gave these predicted sized fragments (Figure 4.13a and b), demonstrating that 
HIV-1 env160 had been successfully cloned into pIBT210.1 in the correct orientation 
(Figure 4.14). The recombinant plasmid containing HIV-1 env160, which is 6606 bp in 
size, was designated as pIBT210.1NS and used for subsequent cloning of env16O into 
plant expression vector pGPTV-KAN. 
4.3.4 Cloning of HIV-1 env160 into plant plasmid pIBT240.1 
A description of plant plasmid pIBT240. 1 is given in the 4.2.1.3 and was chosen for the 
generation of a recombinant plasmid containing potato tuber-specific promoter patatm, 
translation enhancement TEV, HIV-1 env160 and a polyadenylation signal of a soybean 
vegetative storage protein gene (3'vspB ). The plasmid pIBT240.1 contains a multiple 
cloning site with NcoI, Smal and Sacl restriction endonuclease sites which similar to 
pIBT210.1 to facilitate the cloning of foreign DNA. The required portion of env160 was 
generated by Pfu PCR or pBSNS incorporating NcoI and Sacl restriction enzyme sites 
at the 5' and 3' ends, respectively, to enable directional cloning of env160. 
Initial attempts at inserting env160 into pIBT240. 1 employed the directional cloning 
approach with DNA fragment produced from pBSNS or Pfu PCR products. Typically 5 
x 40 j.tl of Pfu PCR reactions were set up and the PCR products were pooled and 
purified using QlAquick PCR purification kit (QlAgene, Germany) as described in 
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Figure 4.12 Tuq PCR screening of recombinant plasmids pIBT2I0.INS containing 
insert HIV-1 envlOO 
Plasmid DNA minipreps were screened by PCR using designed primer set 
NI6OF/S16OR. 8 il of the PCR reaction was subjected to electrophoresis on 1% agarose 
gel. Positive recombinant plasmid (designated as pIBT2I0.INS) resulted in a 2596 bp 
PCR product. 
Lane 1: LamdafHindlll DNA marker 
Lane 2: Positive control plasmid pRNBXX 
Lane 3-12: Plasmid DNA minipreps from 10 colonies 
Lane 13: Negative control without DNA template 
Lane 14: pGEM DNA marker 
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Figure 4.13 Restriction fragment analysis of recombinant plasmid pIBT210.1NS 
Plasmid DNA extracted from PCR positive colonies were digested with restriction 
enzymes and were subjected to electrophoresis alongside undigested plasmid in order to 
confirm the DNA band size and completion of digestion. The predicted restriction 
fragment size with XbaI was 6606 bp; with NcoI and Sacl 4026 bp and 2580 bp, and 
with NcoI and HindIll 3843 bp, 1927 bp and 836 bp. 
Digestions with XbaI and NcoJJSacI 
Lane 1: Lamdafllindlll DNA marker 
Lane 2: Insert DNA control (2596 bp) 
Lanes 3, 6, 9 and 12: Undigested plasmid DNA 
Lanes 4, 7, 10 and 13: Digestion with XbaI 
Lane 5, 8,11 and 14: Double digestion with NcoI and Sad 
Double digestion with NcoI and Hindlil 
Lane 1: Lamdalllindlll DNA marker 
Lanes 2 and 4: Undigested plasmid DNA 
Lanes 3 and 5: Double digestion with NcoI and Hindill 
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2.2.3.4. 5 .tg of pIBT240.1, pBSNS and purified PCR product were all cut with NcoI 
and SacI using 1 X NEBuffer 1 (10 mM Bis Tris Propane-HC1, 10 MM M902, 1  MM 
DTT (pH7.0 at 25°C)) (New England Biolabs, UK) following the manufacturer's 
instructions. Restriction enzyme digestion was carried out for 4 hours at 37 °C. The 
digested pIBT240. 1 and pBSNS fragments were phenol:chloroform extracted and 
ethanol precipitated described in 2.2.3.5. The DNA was then resuspended in 10 .tl of 
DEPC treated dH20. Digested and purified PCR product or pBSNS DNA samples were 
loaded on 1% low melting gel and the correctly sized bands (2584 bp fragment 
produced from digestion of purified PCR product and pBSNS) were excised and 
extracted from the agarose using Geneclean H kit (BlO 101 Inc., Stratech Sci.) as 
described in 2.2.3.6a before being resuspended in 6-10 .tl of DEPC treated dH20. 0.5 .tl 
of each sample was run on 1% agarose gel to estimate the amount of DNA in the 
sample by comparing band intensities with those of known amounts of DNA markers. 
Ligation of PCR or pBSNS fragment with pIBT240. 1 fragment was set up in molar 
ratios of 1:3, 1:4, 1:5, 1:8 and 1:10 of vector to insert DNA, respectively. 3, 5 and 7 .tl 
of each ligation reaction were transformed into both E. coli DH5a cells respectively and 
colonies grown on LB/amp plates for 16 hours at 37 °C. This approach was repeated 
three times without successful ligation between env160 and pIBT240. 1. 
A second approach was taken to attempt to clone env160 into pIBT240.1 involving both 
blunt and sticky end ligation. 5 tg of pIBT240.1 was initially cut with restriction 
endonuclease Smal to produce blunt ends in 1 X NEBuffer 4 (20 mM Tris-acetate, 10 
mM magnesium acetate, 50 mM potassium acetate, 1 mM Dli' (pH7.9 at 25 0C)) (New 
England Biolabs, UK) at 25°C for 2 hours, then digested with Sacl using the same 
buffer as Smal at 37 °C for 2 hours, while purified PCR product was digested only with 
Sac! at 37 °C for 3 hours. Digested DNA samples were loaded and extracted from 
agarose gel as above. Ligation was set up in molar ratio of 1:8 of vector to insert DNA. 
24 colonies were selected and grown in 3 ml of LB/amp for 16 hours at 37 °C. 5 tl of 
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plasmid DNA minipreps were loaded on 1% agarose gel alongside of plasmid 
pIBT240.1 for size comparison (Figure 4.15). 12 plasmid DNA minipreps from 
possible positive colonies were subjected to PCR using N160F/S160R primer set for 
further checking. 9 out of 12 screened recombinant plasmid DNAs gave the right size 
PCR product (2596 bp). 3 out of 9 PCR positive plasmid DNAs were analysed by 
restriction enzyme digestion to determine the presence of envl60. The predicted 
restriction fragments would be 8132 bp when digested with a single enzyme either NcoI 
or Sad, and 5535 bp and 2580 bp when double digested with NcoI and Sad. All 3 
plasmid DNA analysed gave the predicted sized fragments (Figure 4.16). One of these 
was subsequently sequenced. These results showed that the recombinant plasmid was 
8129 bp in size and gave the correctly predicted restriction fragments when digested 
with a single enzyme either NcoI or Sad (Figure 4.17). This recombinant plasmid was 
designated as pIBT240.1SS using for subsequent cloning of envl60 into plant 
expression vector pGPTV-KAN. 
4.3.5 Construction of plant expression vector pIBT110-envl60 
pIBT110 is a 13150 bp T-DNA binary vector (as described in 4.2.1.3) and contains a 
CaMV 35S promoter that is plant leaf specific (Figure 4.5). Thus, pIBT1 10 was 
initially chosen as a vector to generate a recombinant plasmid containing HIV-1 envl60 
to establish HTV-1 env160 transgenic plant leaf expression system. pIBT1 10 contains 
the multiple cloning sites Smal and Sacl which can be used for inserting envl60 gene. 
HIV-1 envl60 gene for insertion was generated by Pfu PCR as described in 4.3.1 
containing Sacl restriction enzyme site at the 3' ends. The amplified envl60 gene was 
then ligated into pIBT1 10 using both blunt and sticky end ligations. Pfu PCR products 
were digested with Sacl and pIBT110 was cut with Smal and then with Sacl as 
described above. Ligation was then set up in molar ratio of 1:5 of vector to insert DNA. 
3 .tl of ligation reaction was transformed into DH5ct competent cells as described in 
2.2.4.10. and colonies grown on agar plates containing 50 j.tg/ml kanamycin for 16 
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Figure 4.15 Plasmid DNA size screening of possible recombinant pIBT240. 1 
5 j.il of plasmid DNA minipreps was subject to electrophoresis on 1% agarose gel 
alongside pIBT240. 1 to compare the plasmid sizes. The possible recombinant plasmids 
containing HIV-1 envl60 would be 8129 bp in size resulting in a higher position on 
agarose gel than that of pIBT 240.1(5554 bp in size) after electrophoresis. 
Lane 1: LambdaIHindIII DNA marker 
Lane 2 & 14: Plasmid pIBT240.1 
Lane 3-13: Plasmid DNAs from different colonies 
Figure 4.16 Restriction fragment analysis of recombinant plasmid pIBT240.1SS 
Plasmid DNA extracted from PCR positive colonies was digested with restriction 
enzymes and was subjected to electrophoresis alongside undigested plasmid in order to 
confirm the DNA band size and completion of digestion. The predicted restriction 
fragment size with NcoI or Sacl was 8129 bp; and with NcoI and Sacl mainly 5535 bp 
and 2580 bp. 
Lane 1: LambdaIHindffl DNA marker 
Lane 2: Undigested plasmid pIBT240. 1SS 
Lane 3: Digestion with NcoI 
Lane 4: Digestion with Sad 
Lane 5: Double digestion with NcoI and Sad 
Lane 6: 1 Kb DNA ladder 
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Figure 4.11 Diagrammatic representation of recombinant plasmid pBSNS containing 
envl6O 
Diagram of recombinant plasmid pBSNS (5557 bp) constructed by inserting blunt-
ended env160 PCR products at SrfI site. ColE! origin: Plasmid origin of replication. 
LacZ gene: allowing blue-white screening of recombinants. 
Figure 4.14 Diagrammatic representation of recombinant plant plasmid pIBT2 10.1 NS 
containing env160 
Diagram of recombinant plant plasmid pIBT210.INS (6606 bp) constructed by 
inserting envlOO into plant plasmid pJBT2 10.1 at NcoI and Sacl sites to generate the 
Agrobacteriuni transform vector containing a cauliflower mosaic virus 35S promoter 
(35S) which is plant leaves specific, a tobacco etch virus 5' untranslated region (TEV), 
envl60, a polyadenylation signal of a soybean vegetative storage protein gene (3'vspB). 
Figure 4.17 Diagrammatic representation of recombinant plant plasmid pIBT240.1SS 
containing env160 
Diagram of recombinant plant plasmid pIBT240.1SS (8129 bp) constructed by inserting 
env160 into plant plasmid pIBT240. 1 at Smal and Sacl sites to generate the 
Agrobacterium transform vector containing a plant tuber-specific expression promoter 
patatin, a tobacco etch virus 5' untranslated region (TEV), env160, a polyadenylation 
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Hirsilli 4281) XbaI 4217 
hours at 37°C. 10 colonies were picked up with a sterile plastic pipette tip and dispersed 
in 50 tl of DEPC treated dH20. 18 tl of each bacterial suspension was subject to a 25 
l Taq PCR reaction with hot start using N160FcoL/SI60R primer set. The PCR 
program (as described in 2.2.3.1) was run for 30 cycles with last extension cycle of 10 
minutes at 72°C. 15 tl of each PCR reaction was loaded on 1 % agarose gel to check 
the product. The results showed that all 10 colonies gave the right size band (2596 bp) 
with 6 giving strong positive (Figure 4.18a). All 10 positive colonies were further 
separately cultured in 3 ml of LB/amp for 16 hours at 37 °C for plasmid DNA minipreps 
and then were subject to Taq PCR for further check. The results showed that 9 out of 10 
plasmid DNA minipreps gave the same pattern as seen for colony bacterial suspension 
with one exception which gave multiple bands on plasmid DNA PCR but a low 
intensity band of correct size on colony suspension PCR (Figure 4.18b). This 
demonstrated that PCR screening bacterial suspension is a reliable method for screening 
colonies. 3 plasmid DNA samples which were colony suspension and plasmid DNA 
PCR positive were analysed by restriction enzyme to determine the presence of env 160. 
The correct recombinant plasmids containing env160 would give DNA fragments 15728 
bp; 13845 bp and 1883 bp; 12423 bp and 3305 bp when cut with single enzyme Sad, 
XbaI and EcoRI respectively; and 12423 bp, 2738 bp and 567 bp when double digested 
with EcoRl and Sad. All 3 plasmid DNA samples analysed gave the correctly sized 
fragments (Figure 4.19). One of them was subsequently subjected to PCR using plant 
primer set TEV and vsp (see section 2.2.3.18d) and showed the correct sized band 
(2723 bp) (Figure 4.21b) and was designated as pIBT1 10-env160 (Figure 4.20). 
4.3.6 Construction of plant expression vector pLBT140-envl60 
Plasmid pIIBT140 is a 14652 bp T-DNA binary vector (see section 4.2.1.3 for details). 
This plasmid contains the plant tuber-specific promoter patatin and thus was initially 
chosen as a vector to produce a recombinant plasmid containing HIV-1 env160 which 
can transform Agrobacterium to establish HIV-1 envI60 transgenic plant 
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Figure 4.18 Taq PCR screening recombinant plasmid pIBT1 10 containing env160 
Colony bacterial suspensions or plasmid minipreps were screened by PCR using 
designed primer set N160F/S160R. 8 jii of the PCR reaction was subjected to 
electrophoresis on 1% agarose gel. Positive recombinant plasmid colonies or minipreps 
resulted in a 2596 bp PCR product. 
Colony bacterial suspension PCR 
10 bacterial colony suspensions gave the right sized band (2596 bp) with 6 strong 
positive colonies (colony 3, 4, 5, 6, 7 and 10) which showed high intensity bands and 4 
weak positive colonies (colony 1, 2, 8 and 9) which showed lower intensity band. 
Lane 1: LamdafHindlll DNA marker 
Lane 2: Positive control plasmid pRNBXX 
Lane 3-12: Colony 1-10 bacterial suspensions 
Lane 13: Negative control without DNA template 
Lane 14: pGEM DNA marker 
Plasmid DNA PCR 
9 out of 10 plasmid minipreps from the corresponding 10 colonies gave the same 
pattern as that of colony bacterial suspension PCR (Figure 4.18a). All 9 samples gave 
the right sized band (2596 bp) with 6 giving strong positive samples from colony 3, 4, 
5, 6, 7 and 10, which showed high intensity bands; and 3 weak positive samples from 
colony 1, 2 and 9, which showed lower intensity bands. Colony 8 (lane 10) gives 
multiple bands. 
Lane 1: LamdalHindlll DNA marker 
Lane 2: Positive control plasmid pRNBXX 
Lane 3-12: Plasmid DNA miniperps 1-10 from the corresponding colony 1-10. 
Lane 13: Negative control without DNA template 
Lane 14: pGEM DNA marker 
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Figure 4.19 Restriction fragment analysis of recombinant plasmid pIBTIIO-envl6O 
Plasmid DNA with both colony bacterial suspension and plasmid DNA PCR was 
digested with restriction enzymes and were subjected to electrophoresis alongside 
undigested plasmid in order to examine the DNA band sizes and completion of 
digestion. The predicted restriction fragment sizes with Sacl are 15728 bp; with XbaI 
13845 bp and 1883 bp; with EcoRl 12423 bp and 3305 bp and with EcoRI and Sad 
12423 bp. 2738 bp and 567 bp. 
Lane 1: LamdalHindlll DNA marker 
Lane 2: Digestion with Sac! 
Lane 3: Digestion with XbaI 
Lane 4: Digestion with EcoRI 
Lane 5: Double digestion with EcoRI and Sad 
Lane 6: Undigested plasmid 
Lane 7: 1 K DNA ladder 
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tuber expression system. Similar to pIBT1 10, pIBT140 contains the multiple cloning 
sites Smal and Sacl which can be used for inserting env160 PCR product. Cloning HIV-
1 env16O into pIBT 140 employed the same strategy as inserting env160 into pIBT1 10. 
Inserting env160 generated by Pfu PCR was digested with Sacl and ligated to 
predigested pIBT140 with Smal and SacI to generate the recombinant plasmid 
pIBT140-env16O as described above with a few modifications. 
Ligation was set up in molar ratio of 1:6 of vector to insert DNA. Both 3 and 6 p1 of 
ligation reaction were transformed into DH5a competent cells. Colonies were grown on 
agar plates containing 50 .tg/ml kanamycin for 16 hours at 37 °C and 28 colonies were 
picked and dispersed in 50 p.1 of DEPC treated dH20. 18 p.1 of each bacterial suspension 
was subjected to a 25 p1 Taq PCR reaction with hot start using N150F/S160R primer 
set. The results showed that 20 out of 28 colony bacterial suspensions gave the right 
sized band (2596 bp) with 9 strong positive which showed higher intensity bands than 
11 weak positive. 20 plasmid DNA minipreps from the 20 corresponding PCR positive 
colonies were prepared following the standard alkaline lysis protocol (described in 
2.2.3.12a) and subjected to Taq PCR as further check. The results showed that while 11 
plasmid DNA preparations from the corresponding 11 weak positive colonies failed to 
show any bands, 9 plasmid DNA preparations from the corresponding 9 PCR strong 
positive colonies were again PCR positive (Figure 4.21a). 3 of these were subjected to 
Taq PCR using plant primer set TEV/vsp to check the presence of inserting DNA. 
Primer TEV is located 69 bp upstream of NcoI site, and vsp 55 bp downstream of Sad 
site in plant binary vector (see section 2.2.3.18d). Thus the correct recombinant 
plasmids would give a 2723 bp PCR products using TEV/vsp primer set while pIBT1 10 
and pIBT140 would give 145 bp as control. The result showed that all 3 plasmids 
produced the right sized bands (Figure 4.21b). These 3 plasmid DNAs were 
subsequently analysed by restriction enzyme digest to determine the presence and 
orientation of env 160. The correct recombinant plasmids containing env16O would give 
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Figure 4.21 Taq PCR screening recombinant plasmid pIBI 110 containing envl60 
3 Plasmid DNA minipreps from the corresponding PCR strong positive colonies were 
further checked by PCR using primer sets N16OF/S16OR and TEV/vsp. 8 p.1 of the PCR 
reaction was subjected to electrophoresis on 1% agarose gel. All plasmid DNAs tested 
gave the right size 2596 bp PCR products with primer set N160F/S160R and 2723 bp 
fragments with primer set TEV/vsp (positive control pIBT 140 and pIBT1 10 gave 145 
bp bands and the recombinant plasmid pIBT1 10-envl60 gave the same size band (2723 
bp) as pIIBT-140-envl60). 
PCR using primer set N16OF/S16OR 
Lane 1: Lamdalllindlll DNA marker 
Lane 2: Positive control plasmid pRNBXX 
Lane 3-5: 3 plasmid DNAs 
Lane 6: Negative control without DNA template 
Lane 7: pGEM DNA marker 
PCR using plant primer set TEV/vsp 
Lane 1: LamdaJHindllI DNA marker 
Lane 2: plasmid pIBT140 
Lane 3-5: 3 Plasmid DNAs 
Lane 6: plasmid pIBT1 10 
Lane 7: pIBT11O-envl6O 
Lane 8: Negative control without DNA template 
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Figure 4.22 Restriction fragment analysis of recombinant plasmid pIBT 1 10-envl60 
3 plasmid DNAs from both colony bacterial suspension and plasmid miniprep PCR 
positive colonies were digested with restriction enzymes and were subjected to 
electrophoresis alongside undigested plasmid in order to examine the DNA band size 
and completion of digestion. The predicted restriction fragment sizes with Sacl are 
17230 bp; with EcoRl 13925 bp and 3305 bp; and with Sacl and Sall 12311 bp and 
4919bp. 
Lane 1: 1Kb DNA ladder 
Lane 2-4: Undigestion plasmid DNA 
Lane 5-7: Digestion with Sad 
Lane 8-10: Double digestion with Sacl and Sail 
Lane 11-13: Digestion with EcoRI 
Lane 14: Lamdalllindlll DNA marker 
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Figure 4.20 Diagrammatic representation of recombinant plant vector pIBT1 loss 
containing env160 
Diagram of recombinant plant vector pIBT1 lOSS (15728 bp) constructed by inserting 
env160 into plant T-DNA vector pIBT1 10 at Smal and Sacl sites in order to introduce 
env160 into Agrobacterium and then generate transgenic envl60 leave expression 
system. This recombinant plasmid contains the selection marker gene neomycin 
phosphotransferase (nptll) which is located near the right border of T-DNA, the 
cauliflower mosaic virus 35S promoter (35S'), a tobacco etch virus 5' untranslated 
region (TEV) and a polyadenylation signal of a soybean vegetative storage protein gene 
(3 'vspB). RB and LB indicate the right and left transferred DNA (T-DNA) borders. 
Figure 4.23 Diagrammatic representation of recombinant plant vector pIBT14OSS 
containing env160 
Diagram of recombinant plant vector pIBT14055 (17230 bp) constructed by inserting 
env160 into plant T-DNA vector pIBT140 at Smal and Sacl sites in order to introduce 
env160 into Agrobacterium and then generate transgenic envl60 tuber expression 
system. This recombinant plasmid contains the selection marker gene neomycin 
phosphotransferase (nptll) which is located near the right border of T-DNA, plant tuber 
specific promoter patatin, a tobacco etch virus 5' untranslated region (TEV) and a 
polyadenylation signal of a soybean vegetative storage protein gene (3'vspB). RB and 
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fragments 17230 bp; 13925 bp and 3305 bp when cut with single enzyme Sacl and 
EcoRI, respectively; and 12311 bp and 4919 bp when double digested with Sail and 
Sad. All 3 plasmid DNA samples analysed gave the correctly sized restriction 
fragments (Figure 4.22) and were designated as pIBT 140-envl60 (Figure 4.23). 
4.3.7 Construction of plant expression vector pGPTV-KAN-210.1S-envl60 and 
pGPTV-KAN-240.1S-envl 60 
Plant plasmid pGPTV-KAN (glucuronidase plant transformation vector) is a 13387 bp 
plant binary vector. As described in 4.2.1.4, plasmid pGPTV-KAN has a novel trait in 
that the 3-glucuronidase (uidA) reporter gene located near the right border and the plant 
selectable marker gene nptll, which confer kanamycin resistance to plants and located 
near the T-DNA left border, are divergently organised for efficient expression. The 
plasmid contains unique cloning sites Smal, XbaI, Sail and Hindill upstream of the 
uidA gene and EcoRI downstream of the promoter for uidA (Pnos) to allow the 
exchange by any other gene of interest as desired (Figure 4.7). 
4.3.7.1 Construction of plant expression vector pGPTV-KAN-210.1NS-envl60 
To construct a plant expression vector for efficient expression of envl60 in plant leaves, 
recombinant plasmid pIBT210. iNS containing CaMV promoter 35S, translation 
enhancement TEV, HIV-1 envl60 and a polyadenylation signal of a soybean vegetative 
storage protein gene (3'vspB) was chosen to generate a recombinant plant binary vector 
pGPTV-KAN-2 10.1 NS-envl6O. 
The required portion of 35S promoter, 5' TEV, envl60 and vsp3' gene produced from 
plasmid pIBT210.1NS were designed to insert into pGPTV-KAN at EcoRI and Hindill 
sites. Considering that there is one HindlIl site inside the envl60 gene, the generation of 
pGPTV-KAN-210.1NS-envl60 initially involved cloning the insert DNA fragments 
into pGPTV-KAN at Smal and EcoRI sites. Typically, 5 .tg of pIBT210.1NS was 
digested with PstI in 1 X NEBuffer 3 (100 mM NaCl, 50 mM Tris-HC1, 10 MM M902, 
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1 mM DTF (pH 7.9 at 25°C)) at 37°C for 2 hours and then 15 units of T4 DNA 
polymerase, 50 p.g/ml of BSA and 100 urn of each dNTP were added. This was 
incubated at 12 °C for 30 minutes to remove 3' overhangs and thus generate a blunt end. 
The digested plasmid was extracted with phenol:choloroform and ethanol precipitated 
as described in 2.2.3.5. It was then resuspended in 10 p1 of DEPC treated dH 20 and 
digested with EcoRI in 1 X NEBuffer EcoRl (100 mM Tris-HCI, 10 mm MgCl2, 50 
mM NaCl, 0.025% Triton X-100 (pH 7.5 at 25 0C)) for 2 hours. 5 p.g of pGPTV-KAN 
was digested with Smal in 1 X NEBuffer EcoRI for 2 hours at 25 °C and then cut with 
EcoRI for 2 hours at 37 °C. All digested DNA fragments were loaded on 0.6% low 
melting gels to isolate the required band (3965 bp from pINT210.1NS and 11126 bp 
from pGPTV-KAN). Then the required DNA fragments were extracted from the 
agarose gel using Geneclean II kit as described in 2.2.4.6. The ligation was set up at 
both 1:3 and 1:5 molar ratio of vector to insert DNA. Then 3-5 p.1 of ligation reaction 
was transformed into DH5a competent cells. This experiment was repeated for 3 times 
without successful ligation. 
The second attempt involved 3 fragments ligation, that is, both 35S promoter and TEV 
gene fragment produced by digestion of p1BT210.1 at HindIll and NcoI sites, and 
env16O and vsp3' fragment produced from digestion of pIBT210.1NS at NcoI and 
EcoRI, were cloned into pGPTV-KAN at EcoRI and Hindill sites in one ligation 
reaction. Initially, the cloning was attempted by gel slice ligation, thus the step of 
extraction digestion fragments from agarose gel was removed to keep the intact sticky 
end and increase the efficiency of ligation reaction. Generally, 2 p.g of pIBT210.1 was 
digested with NcoI and HindIll in 1 X NEBuffer2 (10 mM Tris-HC1, 10 mM MgCl, 50 
mM NaCI, 1 mM Dill' (pH 7.9 at 25 °C)) for 3 hours at 37 °C. 2 p.g of pIBT210.1NS was 
digested with NcoI and EcoRI in 1 X NEBuffer EcoRl (100 mM Tris-HCI, 10 MM 
M902, 50 mM NaCI, 0.025% Triton X-100 (pH 7.5 at 25 °C)) for 3 hours, and 2 p.g of 
pGPTV-KAN was digested with EcoRI and HindIll in 1 X NEBuffer EcoRl (100 mM 
163 
Tns-HC1, 10 MM MgCl2, 50 mM NaCl, 0.025% Triton X-100 (pH 7.5 at 25 °C)) for 3 
hours. All digested samples were loaded on 0.7% low melting gels and run for 3 hours 
until the required bands were well separated on the gel. Then the required bands were 
excised from the agarose gel in as smaller slices as possible The gel slices containing 
DNA were melted at 65°C for 10 minutes and the melting mixture containing 
appropriate DNAs were mixed and the ligation were set up as described in 4.2.2.2. The 
ligation mixture was incubated for 48 hours at 12-16 °C. When the ligation reaction was 
completed, the tube was incubated at 37 °C for 10 minutes to remelt the resolidified gel 
slices and diluted at 1:30, to avoid gel resolidifying when performing the 
transformation. 10 t I of diluted ligated product was transformed into MAX efficiency 
DH5a competent cells (GIBCO BRL) as described in 2.2.3.10. Clones were grown on 
agar plates containing 50 .tg/ml of kanamycin. This experiment was repeated three 
times without successful ligation. 
Subsequently the 3 fragment ligation was performed with purified DNA sections. The 
digestion procedures of pIBT210.1 with Hindill and NcoI; pIBT210.1NS with NcoI and 
EcoRI and pGPTV-KAN with EcoRI and Hindill were performed as above. All 
digested DNA fragments were loaded on 0.7% low melting or routine agarose gel and 
run for 4-5 hours to isolate the required bands (836 bp from pIBT210.1; 3141 bp from 
pINT210.1NS and 11126 bp from pGPTV-KAN). Then the required DNA bands from 
pIBT210.1, pIBT210.1NS and pGPTV-KAN were cut using sharp and clean blades. 
The DNA fragments produced from both pIBT210.1 and pIBT210. iNS were extracted 
from the agarose gel using Geneclean II kit as described in 2.2.3.6a, while the pGPTV-
KAN vector was extracted and purified using Prep-A Gene DNA purification kit (BlO-
RAD) following as described in 2.2.3.6b. The ligation was set up at 1:15-1:20 molar 
ratio of pGPTV-KAN fragment to insert DNA from pIBT2 10.1 and 1:4-1:5 molar ratio 
of pGPTV-KAN vector to insert DNA from p1BT210.1NS and performed at 12-16 °C 
for 24 or 48 hours, respectively. 3-5 .tl of ligation reaction was transformed into DH5ct 
competent cells. This experiment was repeated for 3 times without successful ligation. 
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Subsequently, to reduce shearing DNA fragments when extracting from agarose gel, all 
the digested DNA fragments were extracted and purified using Prep-A Gene DNA 
purification kit as described in 2.2.3.6b. The DNAs were resuspended in 10 .tl of dH20. 
To increase the ligation efficiency, the ligation reaction of the same molar ration as 
before was incubated at 16 °C for 72 hours. 5 .tl of ligation reaction was transformed 
into DH5ct competent cells by heat shock protocol as described in 2.2.3.10, while 1 tl 
of ligation reaction was transformed into DH5a competent cells by electroporation as 
described in 2.2.4.1. After incubating on agar plates containing 50 jtg/ml of kanamycin 
at 37°C for 16 hours, electroporation transformed DH5a cells produced more than 100 
colonies. Although heat shock transformed cells produced only about 50 colonies they 
were generally larger that those from electroporation transformed colonies. 6 colonies 
from heat shock transformed and 5 colonies from electroporation transformed colonies 
were picked and subjected to PCR screening with N160F and S160R primers. 9 out of 
11 colonies showed the right sized band (2596 bp), 5 from heat shock transformed 
colonies and 4 from electroporation transformed colonies. 4 out of 9 PCR positive 
colony bacterial suspensions were further cultured in 3 ml of LB containing kanamycin 
for 16 hours at 37 °C to prepare plasmid DNA. 4 plasmid DNA minipreps were further 
confirmed by PCR using plant primer set TEV and vsp and digested with EcoRI and 
Hindill restriction enzyme. The results showed that all DNA samples analysed gave the 
predicted PCR products (2704 bp) (Figure 4.24) and restriction fragments 11126 bp, 
2763 bp and 1214 bp when cut with EcoRI and Hindill which demonstrated that the 
35S promoter, TEV, env160 and vsp 3' genes were successfully cloned into pGPTV-
KAN. 2 colonies containing the recombinant plasmids were further cultured in 2 x 6 ml 
and then 200 ml of LB containing 50 j.tg/ml of kanamycin for midiprep stock of plasmid 
DNAs. The plasmid DNA midipreps were cut with EcoRI and Hindifi and gave the 
correctly sized restriction fragments as above (Figure 4.25). This recombinant plasmid 
containing the insert DNA fragments were used for transformation of Agrobacterium 
and named as pGPTV-KAN-210.1NS-envl6O (Figure 4.26). 
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Figure 4.24 Taq PCR examination of recombinant plasmids pGPTV-KAN-210.1NS-
env]60 and pGPTV-KAN-240. 1NS-envl6O 
Plasmid DNAs were examined by PCR using plant primer set TEV and vsp. 8 l.tl of the 
PCR reaction was subjected to electrophoresis on 1% agarose gel. All the plasmid DNA 
tested (4 from pGPTV-KAN-210. 1NS-envl6O and 4 from pGPTV-KAN-240. iNS-
envl6O) showed the correct 2704 bp PCR products. Control plasmid pIIBT240. 1 gave a 
143 bp band. 
Lane 1: Lambda/Hin dill DNA marker 
Lane 2: Positive control plasmid pIBT240.1 
Lane 3-6: Recombinant plasmid pGPTV-KAN-2 10.1 NS-envl 60 minipreps 
Lane 7-10: Recombinant plasmid pGPTV-KAN-240. 1 NS-envl6O minipreps 
Lane 11: Negative control without DNA template 
Lane 12: pGEM DNA marker 
Figure 4.25 Restriction fragment analysis of recombinant plasmids pGPTV-KAN-
210.1 NS-envl6O and pGPTV-KAN-240. 1 NS-envl6O 
Plasmid DNA midipreps were digested with restriction enzymes and were subjected to 
electrophoresis to examine the DNA band sizes. All DNA samples analysed gave the 
predicted restriction fragment sizes with pGPTV-KAN-210.1NS-env16O 11126 bp, 
2763 bp and 1214 bp, and pGPTV-KAN-240.1NS-env16O 11126 bp, 4266 bp and 1214 
bp when cut with EcoRI and HindlU. 
Lane 1: 1Kb DNA ladder 
Lane 2-3: Recombinant plasmid pGPTV-KAN-210.1NS-envl60 DNA digested with 
EcoRI and Hindlil 
Lane 4-5: Recombinant plasmid pGPTV-KAN-240.1NS-envl60 DNA digested with 
EcoRI and HindUl 
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4.3.7.2 Construction of plant expression vector pGPTV-KAN-240.1NS-envl60 
To efficiently express HTV-1 env160 in plant tuber system, a plant expression vector 
containing tuber-specific promoter a patatin, translation enhancement TEV, HIV-1 
env160 and a polyadenylation signal of a soybean vegetative storage protein gene 
(3'vspB ) was designed to construct plant expression vector pGPTV-KAN-240.1NS-
envi 60. 
The initial  attempt at cloning patatin, TEV, env160 and 3 'vspB was by inserting the 
required genes produced from pIBT240.1SS into pGPTV-KAN at EcoRI and Sail sites. 
At first, the cloning was attempted by gel slice ligation to keep the intact sticky end and 
facilitate the ligation efficiency. 2 .tg of pIBT240.1SS and 1 pg of pGPTV-KAN was 
digested with EcoRI and Sall in 1 X NEBuffer EcoRl (100 niM Tns-HC1, 50 mM NaCl, 
10 MM MgCl2, 0.025% Triton X-100 (pH 7.5 at 250C)) for 3 hours at 37 °C, separately. 
Both digested pIBT240. 1SS and pGPTV-KAN fragments were loaded on 0.7% low 
melting gel and run for 3-4 hours until the required bands (5476 bp from pIBT240. 1SS 
and 11144 from pGPTV-KAN) were well resolved on the gel. The required bands were 
cut from the agarose gel and melted at 65°C for 10 minutes. The melting mixture 
containing appropriate DNAs were mixed and the ligation were set up as described in 
4.2.2.2 and carried out for 48 hours at 12-16 °C. When the ligation reaction was 
completed, the tube was incubated at 37 °C for 10 minutes to remelt the resolid gel slices 
and diluted at 1:30 to avoid resolidifying the gel during performing transformation. 10 
pi of diluted ligated product were transformed into MAX efficiency DH5a competent 
cells (GIBCO BRL) as described in 2.2.3.10. Clones were grown on agar plates 
containing 50jig/ml of kanamycin. This experiment was repeated 3 times without 
successful ligation. 
Then the cloning was attempted using purified fragments ligation. 5 tg of pIBT240.1SS 
and pGPTV-KAN was digested and loaded on a 0.7% low melting gel as before. The 
required DNA fragments were extracted from agarose gel using Geneclean H kit or 
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Prep-A Gene DNA purification kit (BlO-RAD) following the manufacturer's 
instructions. The ligation was set up at molar ratios of 1:3, 1:4, and 1:5. 3 and 5 .tl of 
each ligation reaction was transformed into DH5a competent cells and colonies were 
grown on agar plates as above. This experiment was repeated for 3 times but failed to 
ligate the desired DNA fragments. 
The second approach of cloning the desired genes into pGPTV-KAN involved a 3 
fragment ligation, that is, both patatin promoter and TEV fragments produced by 
digestion of pIBT240.1 at Hindlil and NcoI sites, and env160 and vsp3' fragment 
produced from digestion of pIBT210. INS at NcoI and EcoRI, were cloned into pGPTV-
KAN at EcoRI and HindH1 sites in one ligation reaction. Briefly, 2 pg of pIBT240.1 
was digested with NcoI and Hindill in 1 X NEBuffer2 (10 mM Tris-HCI, 10 mM 
MgCl, 50 mM NaCl, 1 mM DTF (pH 7.9 at 250C)) for 3 hours at 37 °C. 2 j.tg of 
pIBT210.1NS was digested with NcoI and EcoRI in 1 X NEBuffer EcoRl (100 mM 
Tris-HC1, 10 MM MgC1 2 , 50 mM NaCl, 0.025% Triton X-100 (pH 7.5 at 25°C)) for 3 
hours, and 2 tg of pGPTV-KAN was digested with EcoRI and Hindill in 1 X NEBuffer 
EcoRl (100 mM Tris-HCI, 10 MM MgC12, 50 mM NaCl, 0.025% Triton X-100 (pH 7.5 
at 25°C)) for 3-4 hours. All digested samples were loaded on 0.7% low melting gel and 
run for 3-4 hours until the required bands were well resolved on the gel. The required 
bands (2339 bp from pIBT240.1; 3141 bp from p1BT210.1NS and 11126 bp from 
pGPTV-KAN) were cut and extracted from the agarose gel using Prep-A Gene DNA 
purification kit (BlO-RAD) as described in 2.2.3.6b. The DNAs were resuspended in 10 
tl of dH20. The ligation was set up at 1:5 and 1:6 molar ratio of pGPTV-KAN 
fragment to insert DNA from pIBT210.1 and 1:4-1:5 molar ratio of pGPTV-KAN 
vector to insert DNA from pIBT210.1NS. All reactions were performed at 12-16 °C for 
72 hours. 5 tl of each ligation reaction was transformed into DH5a competent cells by 
heat shock protocol as described in 2.2.3.10, while 1 j.tl of each ligation reaction was 
also transformed into DH5a competent cells by electroporation as described in 2.2.4.1. 
After incubating on agar plates containing 50 tg/ml of kanamycin at 37 °C for 16 hours, 
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electroporation transformed DH5a cells produced more than 100 colonies while heat 
shock transformed cells produced only about 40 colonies but with more bigger colonies 
than that of electroporation transformed ones. 4 colonies from each method transformed 
colonies were picked and subjected to PCR screening using primer set N160F and 
S160R. 7 out of 8 colonies showed the right sized band (2596 bp) with 4 from heat 
shock transformed and 3 from electroporation transformed colonies. 4 out of 7 PCR 
positive colony bacterial suspensions were further cultured in 3 ml of LB containing 
kanamycin for 16 hours at 37 °C to prepare plasmid DNA. 4 plasmid DNA minipreps 
were further confirmed by PCR using plant primer set TEV and vsp and digested with 
EcoRI and Hindu!. The results showed that all DNA samples analysed gave the right 
sized PCR products (2704 bp) (Figure 4.24) and restriction fragments 11126 bp, 4266 
bp and 1214 bp when cut with EcoRI and Hindill This demonstrated that the patatin 
promoter, TEV, env160 and 3'vspB genes had been successfully cloned into pGPTV -
KAN. 2 colonies containing the recombinant plasmids were further cultured in 2 x 6 ml 
and then 200 ml of LB containing 50 j.tg/ml of kanamycin for midiprep stock of plasmid 
DNAs. The plasmid DNA midipreps were examined with restriction digestion with 
EcoRI and Hindlil and produced the right restriction fragments as above (Figure 4.25). 
This recombinant plasmid containing the insert DNA fragments was used for 
transformation of Agrobacterium and named as pGPTV-KAN-240.1NS-env16O (Figure 
4.27). 
4.3.7.3 Deletion of NcoI site in pIBT210.1NS and pIBT240.1SS 
The NcoI restriction site located upstream of the env160 gene in the constructed 
expression vectors pGPTV-KAN-2 10.1 NS-envl6O and pGPTV-KAN-240. 1 NS-envl 60 
contains three adjacent nucleotides ATG which could be used as start codon by plant 
translation system and result in breaking the reading frame of envl60. It is therefore 
decided to delete this site using mung bean nuclease (MBN), which is capable of 
degrading single-stranded extensions from the ends of DNA. 
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Figure 4.26 Diagrammatic representation of recombinant plant vector pGPTV-KAN-
210.1NS-envl60 
Diagram of recombinant plant vector pGPTV-KAN-210.1NS-env16O (15103 bp) 
constructed by inserting DNA fragment containing the cauliflower mosaic virus 35S 
promoter (35S), env160, a tobacco etch virus 5' untranslated region (TEV) and a 
polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB) produced 
from pIBT210.1 and pIBT210.1NS into plant binary vector pGPTV-KAN 
(glucuronidase plant transformation vector) at EcoRI and Hindill sites to introduce 
env160 into Agrobacterium and then generate transgenic env160 leave expression 
system. This recombinant plasmid contains the plant selection gene neomycin 
phosphotransferase (nptll) which is located near the left border of T-DNA. RB and LB 
indicate the right and left transferred DNA (T-DNA) borders. 
Figure 4.27 Diagrammatic representation of recombinant plant vector pGPTV-KAN -
240. 1NS-envl6O 
Diagram of recombinant plant vector pGPTV-KAN-240.1NS-envl6O (16606 bp) 
constructed by inserting DNA fragment containing the plant tuber specific promoter 
patatin, envl60, a tobacco etch virus 5' untranslated region (TEV) and a 
polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB) produced 
from pIBT240.1 and pIBT210.1NS into plant binary vector pGPTV-KAN 
(glucuronidase plant transformation vector) at EcoRI and Hindill sites to introduce 
envl60 into Agrobacterium and then generate transgenic env160 tuber expression 
system. This recombinant plasmid contains the plant selection gene neomycin 
phosphotransferase (nptlf) which is located near the left border of T-DNA. RB and LB 
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The deletion of NcoI sites resulted in discharging of 4 nucleotides for pIBT210. INS and 
18 nucleotides for pIBT240. 1SS (Figure 4.28a and b). The NcoI deleted recombinant 
plasmids pIBT210.1NS and pIBT240.1SS were designated as pIBT210.1S and 
pIBT240.1S, respectively. The predicted size of pIBT210.1S and pIBT240.1S would be 
6602 bp and 8111 bp. 
Deletion of NcoI site was performed as described in 4.2.2.3. Briefly, 1 .tg of 
recombinant plant plasmids pIBT210. iNS and pIBT240.1SS were digested with 0.5 .tl 
(5 Units) of NcoI in 1 X NEBuffer 4 (50 mlvi potassium acetate, 20mM Tris-acetate, 10 
mM magnesium acetate, 1 mM DYF (pH 7.9 at 250C)) (New England Biolabs, UK) at 
37°C for 2 hours, followed by blunt-ending with 5 units mung bean nuclease (MBN) 
(New England Biolabs) at room temperature for 15 minutes. The reaction mixtures were 
loaded on 1% agarose gel with undigested plasmid as a control and run for 2-3 hours 
until the digested DNA fragments was well resolved from any undigested plasmids. 
Then the digested and blunt-ending DNA band was cut out and purified with Prep-A-
Gene DNA purification Kit (BlO-RAD) as described in 2.2.3.6b. 2 jji of each of DNA 
resuspension was used to blunt end ligate in 1 X ligase buffer (50 mM Tris-HC1 (pH 
7.5), 10 MM MgC1 2, 10 mM dithiothreitol, 1 mM ATP, 25 pg/ml BSA) using 0.5 tl 
(200 Units) of T4 DNA ligase at 16°C for overnight. 2-4 j.tl of each of the ligation 
mixtures were transformed into DH5a competent cells by both heat shock and 
electroporation methods as described in 2.2.3.10 and 2.2.3.1, and the colonies grown on 
agar plates containing 100 pg/ml ampilcilin. 7 and 5 plasmid DNA minipreps from 
pIBT210.1S and pIBT240.1S colonies respectively were screened by digestion with 
NcoI restriction endonuclease and confirmed by digestion with HindlU. NcoI deleted 
recombinant plasmids would give no digestion pattern when cut with NcoI enzyme. 
pIBT210.1S would be expected to give 2759 bp and 3843 bp and pIBT240.1S 4262 bp 
and 3849 bp when cut with HindlU. 4 out of 7 NcoI deleted pIBT210.1NS and 4 out of 
5 NcoI deleted pIBT240.1SS plasmid DNA minipreps gave the predicted digestion 
pattern (Figure 4.29a, b and c). The sequences of pIBT210.1S and pIBT240.1S plasmid 
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Figure 4.28 Deletion of NcoI sites on recombinant plasmids pIBT210.1NS and 
pIBT240. 1SS 
Deletion of NcoI was achieved by mung bean nuclease (MEN) which removes 5' 
extensions produced by digestion with NcoI restriction enzyme. Then the blunt ended 
lineansed plasmid DNAs were circularised using T4 DNA ligase. There are one and 
two NcoI sites on recombinant plasmid pIBT210. iNS and pIIBT240.1SS, respectively, 
thus deletion of NcoI sites resulted in the loss of 4 nucleotides for pIBT210.1NS and 18 
nucleotides for pIBT240.1SS. The bold nucleotides indicate the target sequence of 
restriction endonuclease NcoI. 
a. Deletion of NcoI site on recombinant plasmid pIBT210. INS 
p1BT210. iNS 
5 '---ATAGCCATGGAATGA---3' 
3'---TATCGGTACC YFACT ---5' 
cut with NcoI 
5 '---ATAGC 	CATGGAATGA --- 3' 
3'---TATCGGTAC 	CTF ACT---5' 
add MEN (5' extensions were removed and 4 nucleotides were discharged) 
5'---ATAGC 	 GAATGA --- 3' 
3' --- TATCG CT TACT---5' 
add T4 DNA ligase 
5 '---ATAGCGAATGA---3' 
3'---TATCGC TFACT ---5' 
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Figure 4.28 (continued) 
b. Deletion of NcoI sites on recombinant plasmid pIBT240.1SS 
pIBT240.1SS 
5 ---GCCATGGATCCCCC TCCATGGA --- 3' 
3 '---CGGTACCTAGGGGGAGGTACCT---5' 
cut with NcoI 
5'---GC 	CATGGATCC CCCTC 	CATGGA --- 3' 
3 '---CGGTAC 	CTAGGGGGAGGTAC 	CT---5' 
add MBN (5' extensions were removed and 18 nucleotides were lost) 
5'---GC 	 GA---3' 
3'---CG CT ---5' 
add T4 DNA ligase 
5 '---GCGA---3' 
3'---CGCT --- 5' 
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Figure 4.29 Restriction digestion to demonstrate deletion of NcoI sites on 
pIBT210.1NS and pIBT240.1SS 
Plasmid DNA minipreps from p1BT210.1S and pIBT240.1S colonies were digested 
with NcoI and then loaded on a 1% agarose gel alongside with undigested plasmid 
DNAs to examine the deletion of NcoI sites. The correct recombinant plasmids with no 
NcoI sites would gave no digestion pattern, which is the same as the corresponding 
undigested plasmid DNA. 4 of 7 NcoI deleted pIBT210.1NS colonies (colony 2, 4, 6 
and 7) (a) and 4 out of 5 NcoI deleted pIBT240.1SS colonies (colony 2, 3, 4 and 5) (b) 
gave the correct pattern. 
Plasmid DNA minipreps from NcoI deleted pIBT21O.INS colonies 
Lane 1: Lambda/Hin dill DNA marker 
Lane 2, 4, 6, 8, 10 & 14: Undigested plasmid DNAs from the colony 1-5 and 7. 
Lane 3, 5, 7, 9, 11, 12 and 13: Plasmid DNAs from the corresponding colony 1-7 
digested with NcoI. 
Plasmid DNA minipreps from NcoI deleted pIBT240. 1SS colonies 
Lane 1: LambdalHindlll DNA marker 
Lane 2, 4, 6, 8 and 10: Undigested plasmid DNAs from the colony 1-5. 
Lane 3, 5, 7, 9 and 11: Plasmid DNAs from the corresponding colony 1-5 digested with 
NcoI. 
Restriction digestion of pIBT210.1S and pIBT240.1S with Hindili 
The NcoI deleted recombinant plasmids pIBT210.1S and pIBT240.1S were analysed by 
digestion with restriction enzyme Hindill. All DNA samples analysed (4 of each 
pIBT210.1S and p1BT240.1S) gave the correctly sized fragments, which are 3843 bp 
and 2759 bp for pIBT210.1S and 4262 bp and 3849 bp for pIBT240.1S. 
Lane 1: LambdalHindIll DNA marker; Lane 18: 1Kb DNA ladder 
Lane 2,4,6 & 8: Undigested plasmid DNAs of pIBT210.1S 
Lane 3,5,7 & 9: Plasmid DNAs of pIIBT210.IS digested with Hindili 
Lane 10, 12, 14 & 16: Undigested plasmidDNAs of pIBT240.1S 
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were ascertained on an ABI PRISM 310 Genetic Analyser (Perkin-Elmer) as described 
at 2.2.3.17c using primer TEV to verify the deletion of NcoI sites. The results 
demonstrated that NcoI site in both pJBT210.1S and pIBT240.1S had been deleted and 
the MEN blunted ends had been successfully ligated as desired (Figure 4.43 and 
Figure 4.44). These two colonies were chosen for subsequent cloning the required 
genes into plant binary vector pGPTV-KAN. 
4.3.7.4 Construction of plant expression vector pGPTV-KAN-210.1S-env160 
To construct the desired plant expression vector for efficient expression of env160 in 
plant leaf system, NcoI site deleted recombinant plasmid pIBT2 10.1S containing CaMV 
promoter 35S, translation enhancement TEV, HIV-1 env160 and a polyadenylation 
signal of a soybean vegetative storage protein gene (3 'vspB) was chosen to generate a 
recombinant plant binary vector pGPTV-KAN-2 10.1 S-envl 60. 
The required portion of 35S promoter, 5' TEV, env160 and vsp3' gene produced from 
plasmid pIBT210.1S were designed to be inserted into pGPTV-KAN at EcoRI and 
HindlIl sites. Considering that there is one Hindlil site inside the env160 gene, partial 
digestion of pIBT210.1S with Hindill restriction enzyme was employed. Typically, 1 
pg of pI1BT210.1S was cut with 20 units (1 jii) EcoRI and different concentrations of 
HindlIl (10, 5, 2.5, 1.25, 1, 0.75, 0.5 and 0.25 units) in a total volume of 40 .tl of 1 X 
NEBuffer EcoRl (100 mM Tris-HC1, 10 MM MgCl 2, 50 mM NaCl, 0.025% Triton X-
100 (pH 7.5 at 25 °C)). After incubating at 37 °C for 2 hours, all digestion reaction 
mixtures were loaded on 1% agarose gel and run for 3-4 hours until required bands 
were well resolved. The result showed that all 10, 5 and 2.5 units of HindlU resulted in 
complete digestion (2759 bp, 2629 bp and 1214 bp), while 1.25, 1, 0.75 and 0.5 units of 
Hindifi resulted in partially digestion (3973 bp and 2629 bp or 5388 bp and 1214 bp), 
and 0.25 unit of Hindlil led to no digestion. (6602 bp) (Figure 4.30a and b). All the 
required bands (3973 bp) produced by partial digestion in different lanes were cut and 
mixed and extracted from the agarose gel using Prep-A Gene DNA purification kit as 
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Figure 4.30 partial digestion of recombinant plasmid pIBT210.1S with restriction 
endonuclease Hindlil 
1 .tg of plasmid pIBT210.1S was cut with 15 units and different concentration of 10, 5, 
2.5, 1.25, 1, 0.75, 0.5 and 0.25 units of HindIll in a total of 40 .tl of 1 X NEBuffer 
EcoRl (100 mM Tris-HC1, 50 mM NaCl, 10 MM  MgC12, 0.025% Triton X-100 (pH 7.5 
at 25°C)). 10, 5 and 2.5 units; 1.25, 1, 0.75 and 0.5 units; and 0.25 units of Hindlil 
resulted in completely digestion; partial digestion and undigestion of analysed 
pIBT21O.S, respectively. 2759 bp, 2629 bp and 1214 bp; 3973 bp and 2629 or 5388 bp 
and 1214 bp; and 6602 bp restriction fragments were generated by complete digestion; 
partial digestion and without any digestion, respectively. 
Digestion of pIBT210.1S with EcoRI and different concentration of 10, 5, 2.5 and 
1.25 units of HindHI 
Lane 1: LambdalHindlll DNA marker 
Lane 2: Digestion of pIBT210.1S with EcoRI and 10 units of Hindlil 
Lane 3: Digestion of pIBT210.1S with EcoRI and 5 units of HindIll 
Lane 4: Digestion of pIBT210.1S with EcoRI and 2.5 units of Hindlil 
Lane 5: Digestion of p1IBT210.IS with EcoRI and 1.25 units of Hindill 
Digestion of pIBT210.1S with EcoRI and different concentration of 2.5, 1, 0.75, 0.5 
and 0.25 units of HindIll 
Lane 1: Digestion of pIBT210.1S with EcoRI and 2.5 units of Hindlil 
Lane 2: Digestion of pIBT210.1S with EcoRI and 1 unit of HindIH 
Lane 3: Digestion of pIBT210.1S with EcoRI and 0.75 units of Hindill 
Lane 4: Digestion of pIBT210.1S with EcoRI and 0.5 units of Hindlil 
Lane 5: Digestion of pIBT210.1S with EcoRI and 0.25 units of Hindill 
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described in 2.2.3.6b. The DNA pellet was resuspended in 10 tl of dH 20 and used for 
ligation with pGPTV-KAN vector digested with EcoRI and Hindifi. 1 .tg of pGPTV-
KAN was cut with EcoRl and Hind][11 as before and the required fragment (11126 bp) 
purified using Prep-A Gene DNA purification kit. The ligation reaction was set up at 
molar ratio of 1:3 of vector to insert DNA fragment and 5 and 10 .tl of ligation reaction 
was transformed into DH5a competent cells. Colonies were grown on agar plates 
containing 50 .tg/ml kanamycin. This experiment was repeated 3 times until the ligation 
was successful. Colonies were screened by PCR, as above, using plant primer set TEV 
and vsp. 20 out of 24 colonies showed the right sized PCR products (2700 bp) including 
15 strong and 5 weak positive colonies (Figure 4.31). 6 plasmid DNA minipreps were 
prepared from 6 out of 15 strong PCR positive colonies and analysed by restriction 
digestion to examine the presence of the required inserted DNA. The correctly 
recombinant plasmids would give 11126 bp, 2759 bp and 1214 bp when cut with EcoRI 
and Hindill. All samples analysed gave the correct sized fragments (Figure 4.32) and 
one of them was further cultured for midiprep stock. This recombined plasmid was 
designated as pGPTV-KAN-210.1S-env16O (Figure 4.33) and used for subsequent 
Agrobacterium transformation and transgenic plant generation. 
4.3.7.5 Construction of plant expression vector pGPTV-KAN-240.1S-env160 
To construct the desired plant expression vector for efficient expression of env16O in 
plant tuber system, NcoI site deleted recombinant plasmid pIBT240.1S containing plant 
tuber-specific promoter patatin, translation enhancement TEV, HIV-1 env160 and a 
polyadenylation signal of a soybean vegetative storage protein gene (3'vspB ) was 
chosen to generate a recombinant plant binary vector pGF1TV-KAN-240.1S-env16O. 
The attempt to clone the required portion of patatin promoter, 5' TEV, env16O and 
3'vspB genes into pGPTV-KAN involved partial digestion of pIBT240. IS with EcoRI 
and HindHI because there is one HindRI site inside the env16O gene. Briefly, 1 .tg of 
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Figure 4.31 Taq PCR screening recombinant plasmid pGPTV-KAN containing CaMV 
35S promoter and env160 
Bacterial cell suspensions were subjected to PCR using plant primer set TEV and vsp. 8 
pi of the PCR reaction was loaded on 1% agarose gel and run for 1 hour at 80 mA. The 
correctly recombined plasmid colonies resulted in a 2700 bp PCR product. Strong 
positive results were obtained for colonies 2-8, 12, 13, 15, 17 and 18 and weak positive 
results for colonies 14 and 16. 
Lane 1: Positive control plasmid pI1BT210.1S 
Lane 2-19: Colony 1-19 bacterial suspensions 
Lane 20: Negative control (without DNA template) 
Lane 21: pGEM DNA marker 
Figure 4.32 Restriction fragment analysis of recombinant plasmid pGPTV-KAN 
210.1S-envl6O 
Six plasmid DNAs prepared from strong PCR positive colonies were cut with restriction 
enzymes and were subjected to electrophoresis alongside undigested plasmid in order to 
examine the DNA band sizes and extent of digestion. The predicted restriction fragment 
sizes were 11126 bp, 2759 bp and 1214 bp when cut with EcoRI and HindIll. All 
samples analysed gave the correct sized restriction fragments. 
Lane 1: 1 Kb DNA ladder 
Lane 2, 4, 6, 8, 10 and 12: Undigested plasmid DNAs 
Lane 3, 5, 7, 9, 11 and 13: Double digestion with EcoRI and Hindifi 
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pIBT240.1S was cut with 20 units (1 j.tl) EcoRI and different concentrations of Hindu 
(10, 5, 2.5, 1.25, 0.5 and 0.25 units) in a total volume of 40 jxl of 1 X NEBuffer EcoRI 
(100 mM Tris-HCI, 10 MM MgCl 2, 50 mM NaCl, 0.025% Triton X-100 (pH 7.5 at 
25°C)) at 37°C for 2 hours. All digestion reactions were run on a 1% agarose gel. 10, 5 
and 2.5 units of HindHI resulted in completely digestion (4262 bp, 2635 bp and 1214 
bp), while 1.25 and 1 units of Hindlil resulted in partial digestion (5476 bp and 2635 bp 
or 6897 bp and 1214 bp); and 0.5 and 0.25 unit of Hindlil resulted in no digestion (8111 
bp). The required bands (5476 bp) were cut and extracted from the agarose gel using 
Prep-A Gene DNA purification kit. The DNA pellet was resuspended in 10 p1 of dH20 
and used for ligation with EcoRI and Hindill digested pGPTV-KAN vector. 1 .tg of 
pGPTV-KAN was cut with EcoRI and Hindill as before and the required fragment 
(11126 bp) was also purified using Prep-A Gene DNA purification kit. The ligation 
reaction was set up at molar ratio of 1:3 of vector to insert DNA fragment. Then 5 or 1 
il of ligation reaction was transformed into DH5a competent cells by heat shock or 
electroporation method, and colonies were grown on agar plates containing 50 tg/ml 
kanamycin. 49 and more than 100 colonies were grown from heat shock and 
electroporation transformed cells, respectively. 4 colonies from each method of 
transformation were screened by PCR using plant primer set TEV and vsp. All 8 
colonies gave the right size PCR products (2700 bp) (Figure 4.34). 4 plasmid DNA 
minipreps were prepared from 4 out of 8 PCR positive colonies and analysed by 
restriction digestion to examine the presence of the required insert DNA. The correctly 
recombinant plasmids would give 11126 bp, 4262 bp and 1214 bp when cut with EcoRI 
and Hindlil. All samples analysed gave the correct sized fragments (Figure 4.35) and 
one of them was further cultured for midiprep stock and designated as pGPTV-KAN-
240.1S-envl60 (Figure 4.36) for subsequent Agrobaterium transformation. 
4.3.8 Sequencing of cloned env160 in recombinant plasmids 
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Figure 4.34 Taq PCR screening recombinant plasmid pGPTV-KAN containing patatin 
promoter and envl60 gene 
8 bacterial cell suspensions were subjected to PCR using plant primer set TEV and vsp. 
8 .tl of the PCR reaction was loaded on 1% agarose gel and run for 1 hours at 80 mA 
electric current. All samples tested gave the right sized PCR products (2700 bp). 
Lane 1: LambdafHindHl DNA marker 
Lane 2: Positive control plasmid pIBT240.1S 
Lane 3-10: Colony 1-8 bacterial suspensions 
Figure 4.35 Restriction fragment analysis of recombinant plasmid pGPTV-KAN -
240.1 S-envl6O 
4 plasmid DNA minipreps prepared from PCR positive colonies were cut with EcoRI 
and Hindlil. All the digests were loaded on 0.7% agarose gel alongside undigested 
plasmid to examine the DNA band sizes and completion of digestion. The predicted 
restriction fragment sizes were 11126 bp, 4262 bp and 1214 bp and all 4 samples 
analysed gave the correct sized restriction fragments. 
Lane 1, 3, 5 and 7: Undigested plasmid 
Lane 2, 4, 6 and 8: Plasmid DNAs double digested with EcoRI and Hindlil 
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Figure 4.33 Diagrammatic representation of recombinant plant vector pGPTV-KAN-
210. 1S-envl6O 
Diagram of recombinant plant vector pGPTV-KAN-210. 1NS-envl6O ( 15099 bp) 
constructed by inserting a DNA fragment containing the cauliflower mosaic virus 35S 
promoter (35S), envl60, a tobacco etch virus 5' untranslated region (TEV) and a 
polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB) produced 
by partial digestion of recombinant plasmid pIBT210.1S into plant binary vector 
pGPTV-KAN (glucuronidase plant transformation vector) at EcoRI and BndHI sites to 
introduce env160 into Agrobacterium and then generate transgenic env160 leaf 
expression system. This recombinant plasmid contains the plant selection gene 
neomycin phosphotransferase (nptll) which is located near the left border of T-DNA. 
RB and LB indicate the right and left transferred DNA (T-DNA) borders. 
Figure 4.36 Diagrammatic representation of recombinant plant vector pGPTV-KAN-
240.1 S-envl6O 
Diagram of recombinant plant vector pGPTV-KAN-240.1S-envl6O (16602 bp) 
constructed by inserting a DNA fragment containing the plant tuber specific promoter 
patatin, envl60, a tobacco etch virus 5' untranslated region (TEV) and a 
polyadenylation signal of a soybean vegetative storage protein gene (3 'vspB) produced 
by partial digestion of recombinant plasmid pIBT240.1S into plant binary vector 
pGPTV-KAN (glucuronidase plant transformation vector) at EcoRI and HindIll sites to 
introduce envl60 into Agrobacterium and then generate transgenic env160 tuber 
expression system. This recombinant plasmid contains the plant selection gene 
neomycin phosphotransferase (nptll) which is located near the left border of T-DNA, 
RB and LB indicate the right and left transferred DNA (T-DNA) borders. 
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The cloned HIV-1 env160 genes in different recombinant plasmids including pBSNS, 
pIBT21O.1NS, pliBT240.1SS, pIBT1 loss and pIBT14OSS were produced by Pfu PCR 
amplification using pRNBXX containing the whole env160 sequence of HXB2 as DNA 
template. The primer set N160F and S160R was designed to amplify the env160 gene in 
Pfu PCR reaction and introduced restriction enzymes NcoI and Sacl sites at 5' and 3' 
ends respectively to facilitate the construction of plant recombinant expression vector 
containing HIV-1 env160. As PCR amplification may introduce base changes and a 
single PCR reaction may also, by chance, amplify one variant preferentially from 
another, the inserting env160 genes of each above recombinant plasmids were partially 
sequenced using ABI 373 DNA sequencer as described in 2.2.3.17. Different primers 
were used when sequencing the insert env160 and junction regions, primers TEV and 
N160F for the upstream junction and the 5' end regions; primer 306 and 634 for V3 and 
V4 regions and S160R and vsp for the 3' end and downstream junction regions (for 
details of primers see section 2.2.3.18). Approximately 1125 bp out of 2571 bp of 
env160 in each of recombinant plasmids and the junction regions were sequenced. The 
results showed sequences obtained from different recombinant plasmids using the same 
set of primer were all the same and sequences obtained using primer 634 were 
completely overlapped with that obtained using primer 306; sequences obtained using 
primers N160F and S160R were partially overlapped with that using primers TEV and 
vsp, respectively. All portions of sequences were checked against the published 
sequences of HXB2. No major deletions or mutations were observed in the analysed 
env160 or junction sequences (Figure 4.37, 38, 39, 40, 41 and 42). The amino acid 
sequences were read and compared to that of HXB2 Env 160 polypeptide sequence. No 
deletions or mutations were found in all sequence analysed. Therefore these clones were 
used for further expression work. 
4.4 DISCUSSION AND CONCLUSION 




I --------- I --------- I --------- I ---------I --------- 
1 	11 	21 	31 	41 
50 TGGGATGTTGATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACCGTCT 
50 tGlyMetLetMetIleCysSerAlaThrGltLYSLetTrPValThrValT 
I---------I-- ------- I ------ --- I --------- 
51 	61 	71 	81 	91 
100 ATTATGGGGTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCA 
100 yrTyrGlyValProValTrpLysGltAlaThrThrThrLetPheCySAla 
I---------I---------I-------- - I --------- - --------- 
101 	111 	121 	131 	141 
150 TCAGATGCTAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACA 
150 SerAspAlaLysAlaTyrAspThrGltValHiSASflValTrpAlaThrHi 
I---------I --------- I --------- I --------- I --------- 
151 	161 	171 	181 	191 
200 TGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATG 
200 sAlaCysValProThrAspProAsnPrOGlflGltValValLetValASflV 
I ------ --- I ---------------- --- I --------- - --------- 
201 	211 	221 	231 	241 
250 TGACAGAAAATTTTAACATGTGGAAAAATGACATGGTAGAACAGATGCAT 
250 alThrGltAsnPheAsnMetTrpLysAsnAspMetVa]-GltGlflNetHiS 
I --------- - --------- I -------- - I ---------I --------- 




Figure 4.37 Sequence of cloned envl60 in recombinant plasmids using primer N160F 
The cloned HIV-1 envl60 genes in different recombinant plant plasmids including 
pBSNS, p1BT210.1NS, pIBT240.ISS, pIBT11OSS and pIBT140SS were sequenced 
using ABI 373 DNA sequencer and both nucleotide and polypeptide sequences obtained 
were checked and compared with that of published HXB2 sequences. All sequences 
obtained from different recombinant plasmids using primer N160F were the same as 
that of HXB2 at position of 5800-6115. 
183 
0 AAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCC 
0 GlyGlyGltArgAspArgAspArgSer I leArgLetValAsnGlySer 
I --------- - --------- I ---------I ---------I --------- 
43 	53 	63 	73 	83 
50 TTGGCACTTATCTGGGACGATCTGCGGAGCCTGTGCCTCTTCAGCTACCA 
48 LetAlaLetlleTrpAspAspLetArgserLetcysLetpheserTyrHi 
I---------I ---------I ---------I --------- 
93 	103 	113 	123 	133 
100 CCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGTGGAACTTCTGG 
98 sArgLetArgAspLetLetLetllevalThrArgllevalGltLetLetG 
I---------I ---------I ---------I ---------I --------- 
143 	153 	163 	173 	183 
150 GACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAGTAT 
148 lyArgArgGlyTrpGltAlaLetLysTyrTrpTrpAsnLetLetGlnTyr 
I---------I ---------I ---------I ---------I --------- 
193 	203 	213 	223 	233 
200 TGGAGTCAGGAACTAAAGAATAGTGCTGTTAGCTTGCTCAATGCCACAGC 
198 TrpSerGlnGltLetLysAsnSerAlavalSerLetLetAsnAlaThrAl 
I---------I ---------I ---------I --------- 
243 	253 	263 	273 	283 
250 CATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAAGTAGTACGGAG 
248 aIleAlavalAlaGltGlyThrAspArgvalIleGltvalvalGlnGlyA 
I---------I ---------I ---------I ---------I --------- 
293 	303 	313 	323 	333 
300 CTTGTAGAGCTATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAA 
298 laCysArgAlaIleArgHisIleProArgArgIleP2rgGlnGlyLetGlt 
I---------I ---------I ---------I ---------I --------- 




Figure 4.38 Sequence of cloned env160 in recombinant plasmids using primer S 160R 
The cloned HIV-1 env160 genes in different recombinant plant plasmids including 
pBSNS, pIBT210.1NS, pIBT240.1SS, pIBT11OSS and pIBT140SS were sequenced 
using ABI 373 DNA sequencer and both nucleotide and polypeptide sequences obtained 
were checked and compared with that of published HXB2 sequences. All sequences 
obtained from different recombinant plasmids as above using primer S160R were the 
same as that of HXB2 at position of 7991-8341. 
184 
0 TAATTAGATCTGTCAATTTCACGGACAATGCTAAAACCATAATAGTAcAG 
0 IleArgSerValAsnPheThrAspAsnAlaLysThrl le I leValGin 
- I --- I ---- I------ 
15 	25 	35 	45 	55 
50 CTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAG 
48 LetAsnThrSerVa1G1tI1eAsnCysThrArgproA3nsnsnThrAr 
I---------I --------- I ---------I --------- 




115 	125 	135 	145 	155 
150 GAAAAATAGGAAATATGAGACAAGCACATTGTAACATTAGTAGAGCAAAA  
148 lyLys IleGlyAsrlMetArgGlnAlaRisCysAsnhleserArgAlaLys 
I --------- - --------- I -- 	- I --------- 
165 	175 	185 195 	205 
200 TGGAATAACACTTTAACAGATAGCTAGCAAATTAAGAGACATTTGG 
198 TrpAsrlAsnThrLetLysGlnhleAlaSerLysLetArgGltGlnpheGl 
I---------I - I --------- I ------------------- 
215 	225 	235 	245 	255 
250 AAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA 
248 yAsnAsnLysThrllellePheLysGlnSerSerGlyGlyAspproGltl 
I------------------I -------- - I --------- 
265 	275 	285 	295 	305 
300 TTGTCGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGT?TTCA 
298 leValThrHisSerPheAsnCysGlyGlyGltphepheTyrcysAsnser 
-- I -------  -- I --------- I --------- I --------- 
315 	325 	335 	345 	355 
350 ACACAACTGTTTAATAGTACTTGGTTTAATAGTACTTGGAGTACTGAA 
348 ThrGlnLetPheAsnSerThrTrpPheAsnSerThrTr -pSerThrGlt 
-- - --------- I --------- - --------- I --------- 
365 	375 	385 	395 	405 
Figure 4.39 Sequence of cloned env160 in recombinant plasmids using primer 306 
The cloned HIV-1 envl60 genes in different recombinant plasrnids including pBSNS, 
pIIBT2I0.INS, pJIBT240.ISS, pIBTI lOSS and pIBT140SS were sequenced using ABI 
373 DNA sequencer and both nucleotide and polypeptide sequences obtained were 
checked and compared with that of published HXB2 sequences. All sequences obtained 
from different recombinant plasmids as above using primer 306 were completely the 




0 	 LysPheSerProPheThrAs 
I --------- I --------- I --------- I --------- I --------- 
29 	39 	49 	59 	69 
50 CGATAGCCATGGAATGAGAGTGAAGGAGAAATATCAGCACTTGTGGAGAT 
20 nAspSerHisGlyMetArgValLysGltLysTyrGlflHiSLetTrpArgT 
I --------- - --------- I --------- I ------- -- I --------- 
79 	89 	99 	109 	119 
100 GGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTGATGATCTGTAGT 
70 rpG1yTrpArgTrpG1yThrMetLetLetG1yMetLetMetI]eCYSSer 
I --------- I --------- I --------- I --------- I --------- 
129 	139 	149 	159 	169 
150 GCTACAGAAAAATTGTGGGTCACCGTCTATTATGGGGTACCTGTGTGGAA 
120 AlaThrGltLysLetTrpValThrValTyrTyrGlyValPrOValTrPLy 
I---------I --------- I --------- I --------- I --------- 
179 	189 	199 	209 	219 
200 GGAAGCAACCACCACTCTATTTTGTGCATCCGATGCTAAAGCATATGATA 
170 sGltAlaThrThrThrLetPheCysAlaSerAspAlaLySAlaTyrASpT 
$ --------- I --- ------ I ---------I -- ------- I --------- 
229 	239 	249 	259 	269 
250 CAGAGGTACATAATGTTTGGGCCACACATGCCTGTGTACCCAC 
220 hrGltValHisAsnValTrpAlaThrHisAlaCysValPro 
I --------- I --------- - --------- I --- ------ I --------- 
279 	289 	299 	309 	319 
Figure 4.40 Sequence of cloned env160 in recombinant plasmid pIIBT210.INS using 
primer TEV 
The HIV-1 envl60 gene was inserted into plant plasmid pIBT210.1 at NcoI and Sad 
sites and generated recombinant plant plasmid pIBT210.1NS. The inserting junction 
and 5' end of cloned envl60 region in pIBT210.1NS was sequenced using ABI 373 
DNA sequencer and the result was compared with that of pIBT2 10. 1, primer NcoI and 
5' region of HXB2. The sequence obtained aligns with that of pIBT210.1 at positon 
780-836, oligonucleotides CATGGA which were introduced by the designed primer 
N160F and HXB2 at position 5785 (start codon of envl60 gene in HXB2 genome)-
6014. The NcoI site introduced by designed primer N160F is underlined. 
186 
0 ATTTCTTTTAAAGCAAAAGCAATTTTCTGAAAATTTTCACCATTTACGAA  
I --------- - --------- I ---------I ---------I--------- 
43 	53 	63 	73 	83 
50 CGATAGCCATGGATCCCCCTCCATGGAATGAGAGTGAAGGAGAJ&TATCA 
0 	ProTrplleProLetHisGlyMetArgvalLysGltLysTyrGl 
I---------I ---------I --------- I ---------I--------- 
93 	103 	113 	123 	133 
100 GCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGT 
44 nllisLetTrpArgTrpGlyTrpArgTrpGlyThrMetLetLetGlyMetL 
I --------- I---------I --------- - --------- I --------- 
143 	153 	163 	173 	183 
150 TGATGATCTGTAGTGCTACAGAAJ.AJ.TTGTGGGTCACCGTCTATTATGGG 
94 etMetlleCysSerAlaThrGltLysLetTrpvalmrvalTyr'ryrGly 
I---------I ---------I ---------I ---------I --------- 
193 	203 	213 	223 	233 
200 GTACCTGTGTGGAAGGAAGCAACCACCACTCTATTTTGTGCATCCGATGC 
144 ValProValTrpLysGltAlaThrThrThrLetphecysAlaserAspAl 
I---------I ---------I ---------I---------I --------- 
243 	253 	263 	273 	283 
250 TAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACACATGCCTGTG 
194 aLysAlaTyrAspThrGltValHisAsnvalTrpAlaThrHisAlacysv 
I---------I --------- - --------- I ---------I --------- 




Figure 4.41 Sequence of cloned envl60 in recombinant plasmid pIBT240.1SS using 
primer TEV 
The HIV-1 envl60 gene was inserted into plant plasmid pIBT240.1 at Smal and Sad 
sites and generated recombinant plant plasmid p1BT240. 1 SS. The inserting junction and 
5' end of cloned envl60 region in pIBT240.1NS was sequenced using ABI 373 DNA 
sequencer and the result was compared with that of pIBT240.1, primer N160F and 5' 
region of HXB2. The sequence obtained aligns with that of pIBT240. 1 at position 2283-
2350, oligonucleotides CTCCATGGA which was introduced by designed primer 
N160F and HXB2 at position 5785 (start codon of envl60 gene in HXB2 genome)-6014 
without any deletion or mutation contained. The NcoI site introduced by designed 
primer N160F is underlined. 
187 
0 TCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATT 
0 PheSerTyrHisArgLetArgAspLetLetLet I leValThrArgI le 
I --------- I --------- I ---------I ----- ---- I --------- 
1 	 11 	21 	31 	41 
50 GTGGAACTTCTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAA 
48 ValGltLetLetGlyArgArgGlyTrpGltAlaLetLySTyrTrpTrpAs 
I -------- - I --------- I --------- I ---------I --------- 
51 	61 	71 	81 	91 
100 TCTCCTACAGTATTGGAGTCAGGAACTAAAGAATAGTGCTGTTAGCTTGC 
98 nLetLetGlnTyrTrpSerGlnGltLetLysAsnSerAlaValSerLetL 
I --------- I --------- - --------- I -- ------- I --------- 
101 	111 	121 	131 	141 
150 TCAATGCCACAGCCATAGCAGTAGCTGAGGGGACAGATAGGGTTATAGAA 
148 etAsnAlaThrAlaIleAlaValAlaGltGlyThrAspArgValIleGlt 
I---------I ---------I ---------I ---------I --------- 
151 	161 	171 	181 	191 
200 GTAGTACAAGGAGCTTGTAGAGCTATTCGCCACATACCTAGAAGAATAAG 
198 ValValGlnGlyAlaCysArgAlaIleArgHisIleProArgArgIleAr 
I --------- I ---------I---------I ------ ---I--------- 
201 	211 	221 	231 	241 
250 ACAGGGCTTGGAAAGGATTTTGCTATAAGAGAGCTCTCTCAACAATCTAG 
248 gGlnGlyLetGltArglleLetLetTer 
I --------- - --------- I ---------I ---------I --------- 
251 	261 	271 	281 	291 
300 CTAGAGTTTGCTCCTAT 
301 	311 
Figure 4.42 Sequence of cloned envl60 in recombinant plasmids using primer vsp 
The cloned HIV-1 envl60 genes in different recombinant plasmids including 
pIBT210.1NS, pIBT240.1SS, pI1BT11OSS and pIBTI4OSS were sequenced using an 
ABI 373 DNA sequencer and both nucleotide and polypeptide sequences obtained were 
checked and compared with that of published HXB2 sequences. All sequences obtained 
from different recombinant plasmids using primer vsp were the same as that of HXB2 at 
position of 8078-8355, oligonucleotides GAGAGCT which were introduced by primer 
S160F at pIBT210.1 position 860-891 which is the same as pIBT240.1 at position 2363-
2394. The Sacl site introduced by designed primer S 160R is underlined. 
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Figure 4.43 Sequence of NcoI site deleted plasmid pIBT210.1S using primer TEV 
Deletion of restriction endonuclease NcoI site on recombinant plasmid pIBT210.1S was 
verified by sequencing on ABI PRISM 310 Genetic Analyser using primer TEV. The 
sequence obtained was checked and compared with that of pIBT210.1, primer N160R 
and HXB2 and aligns with p[BT210.1 at position 772-836, two junction nucleotides GA 
which introduced by primer NcoI and HXB2 at position of 5785 (the start codon of 
envl60 in HXB2 genome)-6146. The arrow indicates the location of restriction enzyme 
NcoI target sequence prior to deletion. 
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Figure 4.44 Sequence of NcoI site deleted plasmid pIBT240.1S using primer TEV 
Deletion of restriction endonuclease NcoI site on recombinant plasmid pIBT240.1S was 
verified by sequencing on ABI PRISM 310 Genetic Analyser using primer TEV. The 
sequence obtained was checked and compared with that of pIBT240. 1, primer N1 60R 
and HXB2 and aligns with pIBT240.1 at position 2275-2339, two junction nucleotides 
GA which were introduced by primer N160R at HXB2 position of 5785 (the start codon 
of env160 in HXB2 genome)-6137. The arrow indicates the location of two sites of 
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Figure 4.45 Representative diagram showing generation of plant expression vectors 
containing plant leaf specific promoter CaMV 35S or plant tuber specific promoter 
patatin, HIV-1 env160 gene, a translation enhancer element TEV and a transcription 











NT-i cell transformation 
vectors containing plant leaf specific promoter CaMV 35S or plant tuber specific 
promoter patatin, HIV-1 envl60 gene, a translation enhancer element TEV and a 
transcription processing mediating sequence 3'vspB were constructed. The construction 
procedure was concluded as shown in schematic diagram (Figure 4.45). 
4.4.1 PCR amplification and cloning of HIV-1 env160 
In order to clone into plant vector, HIV-1 env160 was initially amplified by PCR using 
plasmid pRNBXX (see section 4.2.1.2) as DNA template. Sequences from the 5' and 3' 
ends of env160 in pRNBXX were chosen for the complementary sense and antisense 
PCR primer pair, respectively. Restriction enzyme target sequences were attempted to 
introduce at 5' and 3' ends of env160 to make the cloning easier. Primer set N160F and 
S 160R (detail see section 2.2.4.19e) was designed to introduce NcoI and SacI at 5' and 
3' ends of envl60, respectively. The whole sequence of HIV-1 (2596 bp) was 
successfully amplified using primer set pNF and pSR. As Taq polymerase has no 
editing function there is always a possibility that PCR amplification will introduce base 
changes. It is reported that the estimates for the error rate introduced by Taq vary from 
1 in 300 to 1 in 9000 for the single base pair substitutions and 1 in 41000 for frameshift 
mutations (Meyerhans et al., 1989; Perrin and Gilliand, 1990; Tindall and Kunkel, 
1988). Pfu DNA polymerase, a proofreading DNA polymerase isolated from 
Pyrococcus furiosus, is devoid of terminal deoxynucleotidyltransferase (TdT) activity 
which is characterized by the addition of nontemplate-directed nucleotide(s) at the 3' 
end of PCR-generated fragments and generates blunt-ended PCR products exclusively. 
Therefore, Pfu DNA polymerase was the choice for use in cloned env16O PCR 
amplification to increase the specificity and fidelity of PCR products. In exploring the 
optimal condition of PCR amplification, the results show that template and primer 
concentrations of 4-6 ng and 100 ng respectively in a total volume of 40 .tl PCR 
reaction mixture appeared to be most effective amplification. For the PCR reaction 
conditions, most product was found when the denaturing temperature was 94 °C; the 
annealing temperature was 55 °C and 30 PCR cycles (Figure 4.8). 
192 
In order to sequence the PCR products and facilitate the subsequent cloning of the 
env16 gene into plant plasmids, the env160 Pfu PCR fragment was firstly cloned into a 
cloning plasmid. As Pfu DNA polymerase possesses the ability to remove extended 
bases by its 3'-35' exonuclease activity to generate the inserts ensures the high-fidelity, 
blunt-ended PCR products and thus Pfu PCR amplified env160 products works ideally 
with the pCR-Script Amp SK (+) cloning vector. The results showed that 1:80-1:100 
ligation molar ratio of vector to insert DNA gave the efficient ligation and 4 pJ of 
ligation reaction mixture gave the most efficient transformation. 37 out of 86 colonies 
(43%) gave the right size (2596 bp) products when subjected to PCR screening (Figure 
4.9) and 21 out 22 PCR positive colonies gave the predicted sized fragments when 
double digested with XbaI and Sad, demonstrated that env16O had been successfully 
cloned into pCR-Script SK(+) cloning vector. Furthermore, all 21 colonies containing 
recombinant plasmid showed the same cloning orientation with NcoI site upstream of 
Sacl site (Figure 4.11). The transformation protocol allows one hour of growth of 
competent cells in LB to express the ampicillin resistant phenotype prior to plating for 
single colonies on selective agar but this period is likely to be insufficient to allow more 
than one cell division and therefore the 21 colonies are unlikely to have been the result 
of a single ligation or transformation event. Several factors such as the insert sequence, 
heat pulse length of transformation, the sensitivity and preference of the competent cells 
might involved into the orientation of insert DNA of recombinant plasmids, however, 
no clear explanation could be put forward. 
4.4.2 Construction of recombinant plant binary vector containing HIV-1 env160 
Progress in the development of transgenic plants can be attributed to the exploitation of 
Agrobacterium transformation mechanism resulted in the design of modified, non-
tumourigenic Agrobacterium Ti plasmids for the engineering of transgenic plants. 
Binary vectors, which were developed came after the discovery that the transferred 
DNA (T-DNA) region remain functional when separated from the resident Ti plasmid 
onto two separate replicons in Agrobacterium (de Framond et al., 1983; Hoekema et al., 
1983), are now the most commonly used vector system for creating and regenerate 
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transgenic plants. These vectors contain a number of unique restriction endonuclease 
sites which can be used for inserting the foreign genes of interest and plant selectable 
marker(s) between the T-DNA borders and a cloning vehicle capable of replicating in E. 
coli and Agrobacterium. 
Three plant binary vectors pGPTV-KAN, pIBT1 10 and pJBT140 were used in 
constructing the plant vector containing HIV-1 envl60 for expression of HIV-1 Env160 
in transgenic plants. All of them contain the left and right T-DNA borders (LB, RB) 
which denote the limits of the DNA that is integrated into the plant genomic DNA via 
Agrobacterium tumefaciens-mediated transformation and the neomycin 
phosphotransferase (nptll) for selection of plant transformants using kanamycin. 
However, the plant select marker gene (nptll) was located near right border in pGPTV-
KAN but left border in both pIBT1 10 and pIBT140. It was reported that T-DNA is 
transferred from right border to left border to plant cells by Agrobacterium mediated 
transformation (Zambryski, 1992). Therefore, the identification of drug-resistant, plant 
transformants containing complete T-DNA insertions is facilitated by using plant vector 
containing selectable marker gene, nptll located close to the left T-DNA border. The 
position of nptII located near the right border of T-DNA increases the likelihood of 
obtaining plants carrying the selectable marker gene, but not the gene of interest, which 
results in obtaining the kanamycin-resistant plant cells harbouring truncated T-DNA 
insertions. Thus, pGPTV-KAN was the optimal plant vector used for constructs 
containing HIV-1 env160. As the interested plant leaf and tuber promoter CaMV 35S 
and patatin are not constructed in pGPTV-KAN but in pliBTi 10 and pLBT140 
respectively, cloning of liv-1 env160 into pGPTV-KAN to generate the constructs 
used for Agrobacterium transformation and subsequent production of transgenic plants 
had to be achieved in two stages. Furthermore, as the transformation of Agrobacterium 
and plant cells or plantlets had to be performed in the USA and the time was limited, 
cloning of HIV-1 env160 into pIBT1 10 and pIBT 140 was also attempted as a back-up 
constructs in case the cloning of env160 into pGPTV-KAN might not be achieved. 
194 
4.4.2.1 Cloning of envl60 into plant vector pIBT110 and pIBT140 
To make constructs containing envl60 and 35S or patatin promoters using plant vector 
pIBT1 10 and pIBT140, the required env160 portions produced by Pfu PCR were 
inserted into pIBT1 10 and pIIBT 140 at Smal and Sacl sites and successfully generated 
the desired recombinant plasmids pIBT1 10-envl6O and pIBT140-envl60 (see section 
4.3.5 and 4.3.6). The colonies containing the recombinant plasmids were screened using 
bacterial suspension PCR using primer set N160F/S160R or lately TEV and vsp. For 
screening of pIBT1 10-env colonies, 10 out of 10 colonies gave the right sized PCR 
products (2596 bp) with 6 strong positive and 4 weak positive. The results of 
subsequent plasmid minipreps PCR confirmation demonstrated that all 6 colonies with 
strong bacterial suspensions PCR positive remain plasmid DNA PCR positive but 3 out 
of 4 weak positive remain positive showed plasmid DNA PCR positive (Figure 4.18a 
and b). For screening of pIBT140-envl60 colonies, 20 out of 28 colony bacterial 
suspensions gave the right sized band (2596 bp) with 9 strong positive and 11 weak 
positive. 20 plasmid DNA minipreps from 20 corresponding PCR positive colonies 
were subjected to Taq PCR for a further check. The results showed that 11 plasmid 
DNA preparations from the corresponding 11 weak positive colonies failed to show any 
band, while 9 plasmid DNA preparations from the corresponding 9 PCR strong positive 
colonies remained PCR positive (Figure 4.21a). Colony screening PCR is a faster, 
effective and painless screening method compared to the traditional plasmid miniprep 
screening although some false positive colonies could be introduced. However, the false 
positive could be avoided by only considering the strong positive colonies which 
showed the strong intensity predicted size band as the colonies containing recombinant 
plasmids. 
4.4.2.2 Cloning of env160 into plant vector pGPTV-KAN 
As mentioned above, cloning of HIV-1 envl60 into pGPTV-KAN to generate the 
constructs used for Agrobacterium transformation and subsequent production of 
transgenic plants had to be achieved in two stages. HIV-1 env160 produced by Pfu PCR 
amplification or digestion of recombinant plasmid pBSNS with NcoI and Sacl was 
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attempted to be initially cloned into plant plasmid pIBT210.1 and pIBT240.1 to 
generate the initial stage recombinant plasmids containing CaMV promoter 35S, 
translation enhancement gene TEV, env160 and a polyadenylation signal of a soybean 
vegetative storage protein gene (3 'vspB); and plant tuber-specific promoter patatin, 
env160, TEV and 3 'vspB genes. Then the required portion containing env160, 35S or 
patatin promoter TEV and 3 'vspB genes was produced from the above initial stage 
recombinant plasmids and cloned into pGPTV-KAN at EcoRI and Hindifi sites. 
HTV-1 env160 gene produced by Pfu PCR reaction were successfully cloned into 
pIBT210.1 at NcoIand Sacl sites and generated the recombinant plasmid pIBT210. INS 
containing CaMV promoter 35S, env160, TEV and 3'vspB genes and p1BT240.1SS 
containing plant tuber promoter patatin, envl60, TEV and 3 'vspB genes. The insert 
env160 fragments produced by either Pfu PCR reaction or digestion of pBSNS with 
NcoI and SacI could not be successfully cloned into pIBT240. 1 vector at NcoI and Sad 
sites, even by varying the ligation molar ratio (1:3, 1:4, 1:5, 1:8 and 1:10) of vector to 
insert. This unsuccessful ligation might have occurred because the sticky ends of the 
insert or the vector DNA fragments produced after restriction enzyme digestion were 
broken due to shearing on more than one silica particle when extracted from the low 
melting gel using Genecleanil kit. Then the alternative approach was used by cloning of 
Pfu env160 PCR products into pIBT240. 1 at Smal and Sacl sites involving one blunt 
end ligation and the recombinant plasmid pIBT240.1SS containing plant tuber promoter 
patatin, env160, TEV and 3'vspB genes was successfully generated. 
When performing plant transformation using the above recombinant pGPTV-KAN 
plasmids containing env16O and 35S or patatin promotor, the NcoI site located at the 
upstream of env160 gene in the constructed contains three adjacent nucleotides ATG 
which may be, by chance, used as start codon by plant translation system and result in 
breaking the reading frame of env160. To ensure the efficiency of expression of env160 
in transgenic plants, NcoI site at the upstream of env16O in recombinant plant vectors 
was deleted. As there are other three NcoI sites in the constructed plant vectors pGPTV- 
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KAN-210.1NS-envl60 and pGFT'V-KAN-240.1NS-envl60 (Figure 4.26 and Figure 
4.27), the deletion work had to move back to the first stage recombinant plasmids 
pIBT210.1NS and pIBT240.1SS. The deletion of NcoI site was performed using mung 
bean nuclease (MBN), which is capable of removing 3' and 5' extensions from the ends 
of DNA fragments. NcoI sites were successfully deleted when incubating the NcoI 
digested plasmid DNA with MEN at room temperature for 15 minutes. These results 
were verified by sequencing two NcoI deleted recombinant plasmids pINT210.1S and 
pIBT240.1S (Figure 4.28a and b). The deletion of NcoI resulted in discharging of 4 
nucleotides for pIBT21O.1NS and 18 nucleotides for pIBT24O.1S (Figure 4.28a and b). 
The NcoI site deleted recombinant plasmids p1BT210.1NNS and pI1BT240.1S were 
designated as pIBT210.1S and pIBT240.1S respectively and used for generating desired 
plant constructs containing 35S or patatin, env160, TEV and 3 'vspB genes to transform 
Agrobacterium and plant cells. The portions of required DNA fragments produced from 
both pIBT210.1S and pIBT240.1S were designed for cloning into optimal plant binary 
vector pGPTV-KAN at EcoRI and Hindill sites. As there is one Hindill restriction site 
located inside env160, partial digestions of pIBT210.1S and pIBT240.1S with EcoRI 
and Hindlil were employed to generate the required DNA fragments containing envl60 
(3973 bp for pIBT2I0.1S and 5476 bp for pIBT240.1). The digestion patterns varied 
between each experiment even with the same reaction conditions. The reason for this 
discordance is not clear. Perhaps the efficiency and activity of restriction enzyme 
slightly varied or the incubation time was slightly different. The required sized DNA 
fragments produced by partial digestion of pIBT210.1S or pIBT240.1S with Hindlil 
and EcoRI were successfully ligated with EcoRI and Hindlil cut pGPTV-KAN vector. 
4.4.3 Sequencing of cloned envl60 in recombinant plasmids 
As the cloned HIV-1 envl60 genes were produced by Pfu PCR amplification using 
pRNBXX containing the whole env160 sequence of HX132 as DNA template, the base 
changes may be introduced. Furthermore, a single PCR reaction may also by chance 
amplify one variant preferentially from another. The inserting envl60 genes of 
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recombinant plasmids including pBSNS, pIBT210.1NS, pIBT240.1SS, pIBT11OSS and 
pI13T140SS were partially sequenced as described in 2.2.4.18 using 3 primer sets 
TEV/vsp, N160F/S160R and 634/306. Primer sets TEV/vsp and N160F/S160R were 
used for sequencing 5' and 3' end of envl60 and adjacent junction regions, respectively; 
primer set 306/634 were used for sequencing V3-V4 region of env160. Approximately 
1125 bp out of 2571 bp of envl60 in each of recombinant plasmids were analysed. The 
results were checked against the published sequences of HXB2 and pIBT210.1 or 
pIBT240. 1 and the amino acid sequences were read and compared to that of HXB2 
envl60 polypeptide sequence. No deletions or mutations were observed in both 
analysed env160 or junction regions DNA and amino acid sequences (Figure 4.37, 38, 
39, 40, 41 and 42) when using the above 3 primer sets TEV/vsp, N160F/S160R and 
634/306. Therefore these desired recombinant plant vectors containing HIV-1 envl60 
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5.1 INTRODUCTION 
Plant cells exhibit a variety of traits that distinguish them from animal cells, such as the 
presence of a large central vacuole and a cell wall. However, perhaps the most 
significant factor that distinguishes plant cells from animal cells is that many varieties 
of full-grown adult plants can regenerate from individual plant cells and that an adult 
plant can be said to have been cloned from a single cell of a parent plant (White, 1954). 
Plants that can be cloned with relative ease include tomatoes, potatoes, carrots, 
pertunias, and cabbage, to name only a few. The ability to grow a whole plant from a 
single cell means that researchers can engage in the genetic manipulation of the cell, let 
the cell develop into a mature plant, and examine the genetic manipulation effects 
within a relatively short period of time. Based on this significant characteristic of plant 
cells, together with the refinement of gene cloning, tissue culture and plant 
transformation, a springboard was produced from which unprecedented applications 
could evolve. One such application is edible vaccines which should be cheaper and 
simpler to be produced, be more heat stable than vaccines made in the conventional 
way, and more applicable to use in the low-funded health care systems of developing 
countries. 
Agrobacterium-mediated transformation is most commonly used for the production of 
edible vaccines. Agrobacterium is a plant pathogen that during the process of infection 
transfers a segment of its DNA (T-DNA) to its host plant cells. By taking advantage of 
this process, a gene of interest, inserted into a plant expression cassette, can be 
transferred into plant genomes through a process similar to conjugation. During tissue 
culture, transformed plant cells are positively selected on medium containing the 
appropriate antibiotics and regenerated into transgenic plants. In nature, Agrobacterium 
tumefaciens infects only dicotyledons or "dicots", plants which have two embryonic 
leaves, including such plants as tobacco, potatoes and soybeans (Peters, 1993). 
Considerable progress has been made in development of edible vaccines since the 
expression of a vaccinogen in tobacco plants was firstly reported in 1990 (Curtiss and 
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Cardineau). Norwalk virus capsid protein expressed in transgenic tobacco was able to 
induce both serum IgG and secretory IgA specific for rNV in mice dosed by gavage 
(Mason et al., 1996). Respiratory syncytial virus (RSV) fusion (F) protein expressed in 
transgenic tomato plants has been shown to induce the development of both serum and 
mucosal RSV-F specific antibodies in mice orally dosed by ripe transgenic tomato fruits 
(Sandhu et al., 2000). Hepatitis B surface antigen (HbsAg) was successfully expressed 
in transformed tobacco plants (Mason et al., 1992) and have been demonstrated to be 
immunogenic when administered parenterally to mice (Thanavala et al., 1995). 
Recently HbsAg was successfully expressed in edible (potato) plants (Richter et al., 
2000). Kong et al. (2001) have demonstrated that edible plant-based rHBsAg is an oral 
immunogen in mice. In this study, transgenic potato plants were grown to maturity in 
soil and harvested to collect tubers, which contained on average 8.35 .tg of HBsAg per 
gram of fresh tuber. Mice were then fed with peeled potato pieces once per week for 3 
consecutive weeks. Each mouse received 5 g of tuber (containing an average of 42 g of 
HBsAg per dose) per feed. Anti-HB5Ag antibodies were detected in mice fed with 
HBsAg-transgenic potatoes. Furthermore, the strong secondary response seen after 
boosting with rHBsAg represents a true memory response, generated as a result of the 
mice being fed HBsAg transgenic potatoes. These results demonstrated that plant-
derived HBsAg, delivered as food, is orally immunogenic in mice and can elicit a 
primary antibody response. These support the concept that a food source containing a 
foreign antigen given by mucosal routes can induce the development of immune 
response to a pathogen. Thus the feasibility of using transgenic plants as an expression 
and delivery system for an edible vaccine against human diseases is verified. The 
transgenic plant edible vaccines may represent a potential new generation of novel 
vaccine production and delivery systems with distinct characteristics including 
inexpensive production, unnecessary preparation or purification and easy transportation 
and storage. 
The use of transgenic plants as vaccine production and delivery systems to protect 
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animals from a number of infectious diseases has also been explored. The structural 
protein VP! of foot-and-mouth disease virus (FMDV) (Carrillo et al., 1998), The major 
structural protein VP60 of rabbit hemorrhagic disease virus (RHDV) has been 
successfully produced in transgenic potato plants (Castanon et al., 1999). Recently, 
transgenic potato plants were created for expression of the N-terminal domain of the 
glycoprotein S (N-gS) from transmissible gastroenteritis coronavirus (TGEV), which 
carries the major antigenic sites of the protein. Mice were fed with potato tubers 
expressing TGEV N-gS (0.02-0.07% of total soluble tuber protein) three times per week 
with 2g of transgenic potato tuber for a two months period. Antibodies specific for N-
gS protein were developed in mice orally fed with potato tubers expressing N-gS 
proteins (Gómez et al., 2000). These studies showed that the protection of animals 
against a viral disease by feeding with a transgenic plant expressed antigens was 
possible, and thus using a food plant to produce and deliver an edible vaccine is 
feasible. 
Studies on the development of mucosal vaccines against HTV-1 have been shown to 
induce both mucosal and systemic immune responses to HIV (Lehner et al., 1992; 
Thibodeau et al., 1992; Mestecky et al., 1994; Morrow et al., 1994; Bond et al., 1995; 
Muster et al., 1995; VanCott et al., 1998; Staats et al., 1996), which raised the 
possibility that application of HIV antigens on mucosal surfaces may be a fruitful 
approach to vaccination against AIDS. To investigate the feasibility of production of 
I-IIV edible vaccines, the recombinant expression vectors (see Chapter 4) were 
introduced into transgenic tobacco by the Agrobacterium-mediated plant transformation 
system. The transformation efficiency of the fly-1 gpl60 gene to the transgenic 
tobacco plantlets was tested by PCR. Expression of HJV-1 gpl60 gene by the transgenic 
tobacco was demonstrated at mRNA level with RT-PCR. The specificity and expression 
level of HIV-1 gpl60 proteins were analysed by ELISA. 
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
5.2.1.1 Plant materials 
Nicotiana tabacum "sumsun" was maintained as an axenic plant culture in hormone-free 
MS medium. Leaves of about 1-2 cm in length were used for transformation. 
5.2.1.2 Agrobacterium 
Agrobacterium tumefaciens strain LBA4404 harbouring Ti plasmid pAL4404 
(Hoekema et al., 1983) was kept at -70°C until use. 
5.2.2 Methods 
5.2.2.1 Production of transgenic tobacco plantlets 
Recombinant plant binary vector pGPTV-KAN-210.1S-env16O (see section 4.3.7.4) 
containing the 1-HV-1 gp160 expression cassettes were used for tobacco (Nicotiana 
tabacum) "sumsun" plant transformations using Agrobacterium-mediated methods 
according to Horsch et at. (1988) with modifications. Briefly, the vector was transferred 
to Agrobacterium tumefaciens strain LBA4404 by electroporation (see section 2.2.3.1). 
Tobacco was transformed by cocultivating leaf discs (Horsch et al., 1988) with 
Agrobacterium strain LBA4404 transformed with transfer vector pGPTV-KAN-210.1S-
env160. The explants were transferred to regeneration medium containing 500 .tg/ml 
carbenicillin to kill the bacteria and 300 .tg/m1 of kanamycin to inhibit untransformed 
plant cells. After generating on transformed callus, shoots were rooted in selecting 
medium containing 500 .tg/ml carbenicillin and 100 .tg/ml of kanamycin (details see 
section 2.2.4.2a). After 3-6 weeks, leaves from transgenic tobacco plantlets were used 
for analysing gpl60 protein expression. 
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5.2.2.2 PCR analysis of HIV-1 envl60 gene in transgenic tobacco plantlets 
Transgenic tobacco piantlet leaf DNA extracts were prepared as described in 2.2.4.4, 
and the HIV-1 gpl60 gene in leaf genomes was detected by PCR (protocol see section 
2.2.3.1) using 3 sets of paired primers 402/403, 306/634 and 518/256 (see section 
2.2.3.18). Plasmid pGPTV-KAN-210.1S-envl60 which had been used to transform 
tobacco plant was used as positive control and untransformed tobacco leaf DNA 
extracts were used as negative control. Each sample was tested 2-3 times. 
5.2.2.3 Transcription analysing of HIV-1 envl60 in transgenic tobacco plantlets 
Total RNA from leaves of tobacco plantlets transformed with recombinant binary 
vector pGPTV-KAN-210.1S-envl60 was isolated as described previously in 2.2.4.5. 
RT-PCR was performed (as described in 2.2.3.15) to analyse the transcription of HIV-1 
gp16O gene in transgenic tobacco plantlets leaf genome. RNA extracted from the serum 
of an HIV-1 seropositive patient (kindly given by Dr David Yirrell, Centre for HIV 
research, Edinburgh University) was used for positive control and RNA from 
untransformed wild type tobacco "sumsun" as negative control. 
5.2.2.4 Analysis of the expression of HIV-1 gp160 in transgenic tobacco plantlets 
Proteins from transgenic tobacco plantlet leaves were extracted by grinding with liquid 
nitrogen in Eppendorf tubes, extracted in extraction buffer (see section 2.2.4.6), 
followed by homogenising with a pestle. After centrifuging at 13,000 rpm for 5 minutes 
at 4°C, the supernatants were collected and aliquoted. The total protein concentration 
was measured using protein assay kit II (Bio-Rad) as described in 2.2.3.16. The 
expression of gpl60 was assayed with HIV-1 gpl60/120 ELISA (see section 2.2.2.2). 
Untransformed wild type tobacco "sumsun" plantlet leaves were used as a negative 
control. Each sample was tested in duplicate. The final concentration of protein was 
taken as the mean of the readings obtained in 2-3 independent assays. The HIV-1 gpl60 
protein expression level (ng/mg total soluble protein) in each of transformants was 
calculated as follows: 
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(protein concentration in transformant - background concentration in control) x 2 
total protein concentration of transformant 
Percentage of the total soluble leaf protein in each of transformants was calculated as 
follows: 
expression level of gpl6O protein (ng/mg total protein) x 106  x 100% 
5.3 RESULTS 
5.3.1 Generation of transgenic tobacco plantlets 
The recombinant binary vector pGPTV-KAN-210. 1S-envl6O (see chapter 4) 
containing HIV-1 gp160 gene was transferred to Agrobacterium tumefaciens strain 
LBA4404 by electroporation. After incubation at 30 °C for 48 hours, the transformants 
were picked up and verified by both PCR using plant primer set TEV and vsp and 
restriction digestion to examine the presence of required inserted HIV-1 gp16O gene. 
The colonies that showed the right sized PCR products (2700 bp) and restriction 
fragments (11126 bp, 2759 bp and 1214 bp when cut with EcoRI and Hindifi) (Figure 
5.1 and Figure 5.2) were used to transform tobacco (Nicotiana tabacum "sumsun") by 
the Agrobacterium-mediated method (Horsch et al. 1988). Approximately 250 shoots. 
were generated from transformed calli selected on medium containing 500 .tg/ml 
carbenicillin and 300 jig/ml of kanamycin. 205 shoots were cut from the calli and 
rooted in rooting medium containing 500 .tg/ml carbenicillin and 100 pg/ml of 
kanamycin. Approximately 100 plantlets were rooted and selected. The transgenic 
plantlets resistant to the selective medium did not show any morphological difference 
compared to non-transgenic tobacco plantlets (Figure 5.3a, b, c, d). 
5.3.2 PCR analysis of kanamycin-resistant tobacco plantlets 
Total genomic DNA from leaf tissues of regenerated kanamycin-resistant plantlets was 
used for PCR analysis to verify the integration of HIV-1 envl60 genes in the host 
genome. 3 paired primers 402/403, 306/634 and 256/518 (see section 2.2.3.18) 
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Figure 5.1 Taq PCR screening Agrobacterium transformants transformed with 
recombinant plasmid pGPTV-KAN-210.1S-envl6O containing CaMV 35S promoter 
and envl6O 
Agrobacterium transformants DNA minipreps were subjected to PCR using plant 
primer set TEV and Vsp (see section 2.2.3.18d). 8 .tl of the PCR reaction was loaded on 
1% agarose gel and run for 1 hour at 80 mA electric current. The correctly transformed 
colonies resulted in a 2700 bp PCR product. 
Lane 1: 1Kb DNA ladder 
Lane 2: Positive control plasmid GPTV-KAN-210.1S-envl6O 
Lane 3-7: Agrobacterium transformants 1-5 DNA minipreps 
Lane 8: Negative control without DNA template 
Figure 5.2 Restriction fragment analysis of Agrobacterium transformants transformed 
with recombinant plasmid pGPTV-KAN-210.1S-envl60 containing CaMV 35S 
promoter and envl60 
5 Agrobacterium transformants DNA minipreps were cut with restriction enzymes and 
were subjected to electrophoresis alongside undigested plasmid. The predicted 
restriction fragment sizes are 11126 bp, 2759 bp and 1214 bp when cut with EcoRI and 
Hindu. All samples analysed gave the correct sized restriction fragments. 
Lane 1: 1 Kb DNA ladder 
Lane 2-6: Double digestion with EcoRI and HindlU 
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Fig.5.1 
















Figure 5.3 Development of transgenic tobacco (Nicotiana tabacum "sumsun") plantlets 
Tobacco (Nicotiana tabacum "sumsun") explants are infected with A. tumefaciens strain 
LBA4404 carrying the recombinant expression vector pGPTV-KAN-210.1S-envl6O 
and cultured on selecting medium containing 500 j.tg/ml carbenicillin and 300 pg/mI of 
kanamycin. During the next 4 weeks, the transformed cells grew into calli and 
differentiate into shoots via organogenesis. Between 4 and 6 weeks, the shoots develop 
enough to remove them from the transformed callus to inducing root in selecting 
medium containing 500 pg/mI carbenicillin and 100 pg/ml of kanamycin. After 3-6 
weeks, rooted plantlets would grow enough for analysing gp160 protein expression in 
leaves. 
Calli were formed around the wounded edge of the explant after transformation with 
A. tumefaciens strain LBA4404 carrying the vector pGPTV-KAN-210.1S-env16O. 
Shoots were generated during 4-6 weeks after transformation. 
Plantlets were developed in 3-6 weeks after the shoots were removed from the 
transformed callus and rooted in selecting medium. 




annealing to V1/V2, V31V4 and gp4l regions of 1-HV-1 env160 gene respectively were 
used for PCR reactions and specifically amplified 298bp, 456bp and 45 lbp sized 
fragments of the envl60 gene, respectively. DNA extracts were prepared from 30 
kanamycin -resistant plantlet leaves which were selected randomly to detect the 
presence of the HIV-1 gpl60 gene in the transgenic plantlets. PCR analysis showed the 
presence of all specific V1JV2, V3/V4 and gp4l region products of the expected sizes 
when amplified with 3 paired primers respectively although some nonspecific bands 
also appeared in 29 out of 30 tested transformants. 1 out of 30 samples (No 5) showed 
correctly sized V1/V2 and V31V4 region PCR products produced with paired primers 
402/403 and 306/634 in the absence of gp4l PCR product amplified with primer 518 
and 256. No specific V1/V2, V3/V4 and gp4l region PCR products was detected in 
untransformed tobacco plantlet leaves (Figure 5.4a, b and c and Table 5.2). 
5.3.3 Transcriptional analysis of transformants 
To investigate the transcription of integrated env160 gene in transgenic tobacco 
plantlets, the presence of gene fusion mRNA was analysed. Total cellular RNAs were 
extracted from 17 plantlet leaves positive in all V1IV2, V3/V4 and gp4 1-specific PCR 
reactions and further tested by RT-PCR as described in section 2.2.3.15. HIV-1 gp41 
primer 254 and oligo (dT) 15  were used as outer paired primers in the primary PCR and 
paired HIV-1 gp41 primers 518 and 256 as the inner paired primers used in the 
secondary PCR which resulted a 451bp DNA fragment product. The result showed that 
14 out of 17 transformed plantlets genome conjugated with HIV-1 env160 genes 
showed specific transcription of env160 genes and 3 out of 17 plant showed negative 
reaction in RT-PCR. To rule out the possibility of contaminant DNA sequence in the 
RNA leaf extracts, the leaf RNA preparations were treated with RNase free DNase 
(RQ 1 , Promega) before cDNA synthesis. Furthermore, the purified RNA was treated 
with RNase (Boehringer Mannheim) and subjected to the primary and secondary PCRs. 
No amplified DNA fragments were detectable under these conditions in 14 RT-PCR 
positive leaf RNA extracts from the transgenic plantlets. This demonstrated that cDNA 
was specifically systhesised from mRNA transcripted from integrated envl60 gene and 
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the positive RT-PCR reactions were RNA dependent. No correctly sized PCR product 
was detected in untransformed wild-type tobacco "sumsun" plantlets (Figure 5.5a and 
b). 
5.3.4 HIV-1 gp160 protein expression in transgenic tobacco plantlets 
5.3.4.1 gpl60/120 enzyme-linked immunosorbent assay (ELISA) 
To investigate the 1-TV-1 gp160 protein expression in transgenic tobacco "sumsun" 
plantlets, a specific ELISA was developed to detect the gp160 protein in the leaf protein 
extracts from transgenic plantlets. 
The initial attempt to establish gpl60/120 ELISA involved a sandwich ELISA 
approach. Briefly, ELISA plate or immunosorbant strips were coated with sheep 
polyclonal antibody to HIV-1 gp120 (D7324, Aalto BioReagents Ltd, Ireland) at room 
temperature overnight. The plates were then washed three times with TBST (50 MM 
Tris-HC1, pH7.6; 145 mM NaCl and 0.05% Tween 20) and blocked with 5% milk in 
TBST for 1 hour at 37 °C. Then, doubling dilutions of recombinant gpl60 protein (AIDS 
Reagent Project, MRC, UK) and 2 x diluent of plant leaf extracts to be tested were 
added and incubated for 2 hours at 37 °C. After being washing with TBST, a monoclonal 
antibody to HIV-1 gpl60/gp4l (AIDS Reagent Project, MRC, UK) was added and the 
plate was incubated at 37 °C for 1 hour. After washing three times and incubating with 
horseradish peroxidase conjugated sheep anti-mouse IgG for 1 hour at 37 °C, the plate 
was washed as before once more. The reaction was developed by the addition of TMB 
(3,3',5'5-Tetramethylbenzidine) liquid substrate system and stopped by addition of IN 
H2SO4 10-20 minutes later. The absorbance was read at 450nm. Different coating 
antibody concentration of 2, 4, 6 and 8 .tg/ml; different concentration of monoclonal 
antibody to HIV-1 gpl60/gp4l at 1:25, 1:100, 1:400 and 1:1600; and different 
concentration of horseradish peroxidase conjugated sheep anti-mouse IgG antibody 
at1:500, 1:1000, 1:2000, 1:4000, 1:8000 and 1:1600 were tested in combination. After a 
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Figure 5.4 PCR analysis of DNA extracts from transgenic plantlets 
Total genomic DNA from leaf tissues of transgenic tobacco "sumsun" plantlets were 
extracted as described in 2.2.4.4. The presence of HIV-1 env160 gene in the transgenic 
plantlets were detected by PCR using 3 paired primers 402/403, 306/634 and 518/256 
annealing at V1/V2, V3/V4 and gp4l regions of env160, respectively. PCR reactions 
were performed as described in 2.2.3.1. 12 ,xl of each of PCR reactions was loaded on 
1% TAE agarose gel and run for 1-2 hours at 80 mA. The correctly integrated 
transgenic plantlets leaf DNA extracts resulted in a 298bp, 456bp and 451bp PCR 
product when using paired primers 402/403, 306/634 and 518/256, respectively. 
Plasmid pGPTV-KAN-210.1S-envl60 containing the whole gene of HIV-1 env160 was 
used as a positive control whereas untransformed tobacco "sumsun" plantlet leaf DNA 
as a negative control. No specific V1IV2, V3/V4 and gp4l region PCR products were 
detected in untransformed tobacco plantlet leaf DNA extracts. 
1Kb DNA ladder 
pGEM DNA marker 
P: Plasmid pGPTV-KAN-210.1S-envl60 
Ni: Untransformed tobacco "sumsun" plantlet 
N2: Negative control without DNA template 
Lane 1-30: Transgenic tobacco "sumsun" plantlet 5, 6, 24, 27, 30, 34, 46, 52, 56, 63, 64, 
69, 74, 87, 89, 97, 100, 102, 106, 107, 109, 110, 113, 114, 116, 119, 120, 122, 126 and 
146. 
PCR analysis with V1/V2 primers 402 and 403 
PCR analysis with V3/V4 primers 306 and 634 
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Figure 5.5 HIV-1 envl60 transcription in transformed tobacco "sumsun" plantlets 
analysed by RT-PCR 
17 transformed tobacco plantlets conjugated with envl60 genes were analysed for the 
presence of gene fusion mRNA by RT-PCR as described in 2.2.3.15. Samples were 
treated with or without RNase to assess the RNA specificity of the reaction. The 
positive reaction resulted a 451bp PCR products. 14 out of 17 transgenic plantlets tested 
(24, 30, 46, 63, 74, 87, 97, 100, 106, 107, 116, 119, 120 and 126) showed specific 
transcription of env160 genes in RNase un-treated RNA samples with no amplified 
DNA fragments detectable in the corresponding RNase treated RNA samples and 
untransformed wild type tobacco "sumsun" plantlet leaf RNA extracts. 
The upper picture shows the RNA samples without RNase-treated and the lower picture 
showed the corresponding RNase treated RNA samples. 
a Transgenic plantlet 24, 30, 46, 63, 64, 69, 74, 87 and 97 RT-PCR analysis 
lanel: 1Kb DNA ladder 
lane2: Positive control HIV-1 RNA 
Lane3-11: Transformed tobacco plantlet 24, 30, 46, 63, 64, 69, 74, 87 and 97 
Lane 12: Untransformed tobacco "sumsun" plantlet 
Lane 13: Negative control without DNA template 
Lane 14: pGEM DNA marker 
b. Transgenic plantlet 100, 106, 107, 116, 119, 120, 122 and 126 RT-PCR analysis 
lanel: 1Kb DNA ladder 
lane2: Positive control HIV-1 RNA 
Lane3-10: Transformed tobacco plantlet 100, 106, 107, 116, 119, 120, 122 and126 
Lane l 1: Untransformed tobacco "sumsun" plantlet 
Lane 12: Negative control without DNA template 
Lane 13: pGEM DNA marker 
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number of attempts, this method wat abandoned due to its limited sensitivity and 
specificity (data not shown). 
The subsequent approach involved the application and modification of a gpl60/120 
ELISA system developed by Moore and Jarrett (1988). As described in 2.2.2.2, the 
ELISA plates or strips were coated with sheep polyclonal antibody to HIV-1 gpl20 
(Aalto BioReagents Ltd, Ireland) and blocked with 2% BSA in TBST. After incubating 
with the twofold dilutions of recombinant gp160 protein (D7434; AIDS Reagent 
Project, MRC, UK) which was used as standard and 1:2 diluted leaf protein extracts, 
anti gpl20 monoclonal antibody (AIDS Reagent Project, MIRC, UK) was added to the 
plates. Then the detecting antibodies biotinylated F(ab')2 goat anti-human IgG (Zymed, 
San Francisco) and extravidin alkaline phosphatase were subsequently added to the 
plate. pNPP substrate (Sigma) system was used as indicating system. The optical 
density (OD) was read at 405nm. Combinations of different concentrations of coating 
antibody (2, 4, 6 and 8 .tg/ml) and monoclonal antibody to HIV-1 gp12O (0.5, 1.0, 2.0 
and 4 jtgIml) were investigated. The results showed that when the coating antibody was 
used at a working concentration of 4 j.tg/ml and the secondary antibody monoclonal 
antibody used at a working concentration of 1 jtg/ml with both detecting antibody and 
extravidin alkaline phosphatase (Zymed, San Francisco) at a working concentration of 
1:1000 dilution, the optimal sensitivity and specificity was achieved. The positive 
control, recombinant HIV-1 gpl60 (AIDS Reagent Project, MRC, UK), was used as a 
twofold diluted series to give gpl60 protein levels of 0-25 ng/ml per assay, the 
absorbance at 405nm after color development gave a linear relationship in this range 
(Figure 5.6). This ELISA system was used for subsequently investigation of HTV-1 
gpl60 protein expression in transgenic tobacco "sumsun" plantlets. 
5.3.4.2 HIV-1 gp160 protein expression in transgenic tobacco plantlets 
The presence of HTV-1 gp16O protein in the Agrobacterium tumefaciens strain 
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Figure 5.6 Representative ELISA standard curve 
The gpl60/120 ELISA was performed as described in 2.2.2.2. The positive control 
recombinant HIV-1 gpl60 (AIDS Reagent Project, MRC, UK) was twofold diluted to 
give gpl60 protein levels of 0-25 ng/ml per assay, and the absorbance at 405nm after 
color development gave a linear relationship in this range. 
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transformed tobacco plantlets was investigated using the gp160/120 ELISA as described 
above. The amount of protein in each of the kanamycin-resistant transformants was 
determined by the Bio-Rad protein assay as described in 2.2.3.16. The gp160 expression 
level in the kanamycin-resistant transformants was calculated as described in 5.2.2.4. 
Leaf protein samples were prepared from 96 transgenic tobacco planlets as described in 
2.2.4.6. 84 out of 96 tested leaf protein samples showed the presence of MV-1 gp160 
protein, the expression level ranging from 0.03 to15.88 ng/mg soluble protein (Table 
5.1). Extracts from 12 out of 96 transformants tested and untransformed wild type 
tobacco "sumsun" plantlets showed no detectable levels of gpl6O protein (Figure 5.7). 
The percentage of the total soluble protein corresponding to gp160 protein accumulated 
in the leaves of tobacco transformants was up to 0.0016% of the total soluble leaf 
protein (Figure 5.8). The mean level of gpl6O in transgenic tobacco "sumsun" plantlets 
was 4.12 ng per mg total soluble protein. The mean level of gp160 accumulation in the 
leaves of pGPTV-KAN-210.1S-env160 transformed tobacco planlets was 0.0004% of 
the total soluble leaf protein. 
Among the 84 transgenic tobacco plantlets which were positive in ELISA, the level of 
gp160 protein expression was variable. 46 plantlets showed low levels of gp160 protein 
expression, ranging from 0.01 to 4 ng/mg total soluble protein. 33 plantlets showed 
relative middle levels of gp160 protein expression, ranging from 4 to 12 ng/mg total 
soluble protein. 5 plantlets showed relative high levels of protein expression, ranging 
from 12 to 16 ng/mg total soluble protein (Figure 5.9). 
5.4 DISCUSSION 
Plant based oral vaccines offer a new approach to vaccination strategies. The major 
advantages of such edible vaccines are the low production cost and the ease of 
administration. The concept of vaccine production using transgenic plants was first 
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Figure 5.7 Expression level of gp160 protein in kanamycin-resistant tobacco "sumsun" 
leaf extracts by gpl60/120 ELISA 
The gpl60/120 ELISA was performed as described in 2.2.2.2 and the expression level 
of gp160 in transgenic tobacco "sumsun" plantlets was calculated as described in 
5.2.2.4. The figure shows the mean of the expression level of gpl60 in each 
transformant obtained in two independent assays. An untransformed tobacco plantlet 
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Figure 5.8 Accumulation of gpl60 in transgenic tobacco plantlets leaves 
The figure shows gpl60 expression percentage of soluble leaf protein in transgenic 
tobacco plantlets which was calculated as described in 5.2.2.4. An untransformed 
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Table 5.1 Expression levels of gp160 in transgenic tobacco plantlets 
gp160/total soluble 
protein (ng/mg) 
Percentage of total 
soluble protein (%) 
Transgenic tobacco 
plantlets 
0 0 12 
0.01-1.00 0.000001-0.0001 20 
1.01-2.00 0.0001-0.0002 9 
2.01-3.00 0.0002-0.0003 14 
3.01-4.00 0.0003-0.0004 3 
4.01-5.00 0.0004-0.0005 6 
5.0 1-6.00 0.0005-0.0006 5 
6.01-7.00 0.0006-0.0007 2 
7.01-8.00 0.0007-0.0008 4 
8.01-9.00 0.0008-0.0009 2 
9.01-10.00 0.0009-0.001 6 
10.01-11.00 0.001-0.0011 4 
11.01-12.00 0.0011-0.0012 4 
12.01-13.00 0.0012-0.0013 4 
13.01-14.00 0.0013-0.0014 0 
14.01-15.00 0.0014-0.0015 0 
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Figure 5.9 Distribution of expression level of gpl60 protein in transgenic tobacco 
plan tlets 
The figure shows the distribution of expression level of protein of gpl60 in the 
transgenic tobacco plantlets. 
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Table 5.2 PCR, RT-PCR and ELISA analysis of leaf extracts from 
transgenic tobacco plantlets 
Transgenic 
plantlets 
PCR RT-PCR ELISA 
(gpl6O ng/mg 
 total protein) 
 Primers 
402/403 306/634 518/256 
5  + - ND# 0 
6 + + + ND 0 
24 + + + + 0.133 
27 + + + ND 0 
30 + + + + 4.825 
34 + + + ND 0.390 
46 + + + + 0.030 
52 + + + ND 0.506 
56 + + + ND 0.344 
63 + + + + 0 
64 + + + - 2.824 
69 + + + - 2.688 
74 + + + + 0.200 
87 + + + + 4.451 
89 + + + ND 0.128 
97 + + + + 0 
100 + + + + 0.319 
102 + + + ND 0 
106 + + + + 0 
107 + + + + 5.606 
109 + + + ND 0.152 
110 + + + ND 0 
113 + + + ND 0.776 
114 + + + ND 0 
116 + + + + 0.070 
119 + + + + 4.58 
120 + + + + 9.312 
122 + + + - 7.03 
126 + + + + 4.47 
146 + + + ND 0.149 
Contro l* - - - - 0 
Untransformed plantlet leaves 
Not done 
$ Represent positive reaction 
Represent negative reaction. 
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described by Mason et al. in 1992, and since more authors have described antibody 
response to parentally or orally administration of plant-derived antigens (Haq et al., 
1995; Thanvala et al., 1995; Mason et al., 1995; 1996; 1998; Arakawa et al., 1998; 
Carrillo et al., 1998; Ma et al., 1998; Tracket et al., 1998; Castanon et al., 1999; Tuboly 
et al., 2000). 
Transformation of tobacco by cocultivating leaf discs with the appropriate 
Agrobacterium strain is the paradigm for Agrobacterium-mediated transformation of 
plant tissues and subsequent selection and regeneration of transgenic plants. This system 
possesses the unique advantage of allowing efficient gene transfer, selection and 
regeneration to be coupled together in a simple process. Together with the fact that 
tobacco is naturally susceptible to infection with A. tumefaciens, and also responds 
exceedingly well in culture (Horsch et al., 1988). Tobacco plant is considered as the 
ideal experimental system for the initial establishment of transgenic plant system. 
In this chapter, we have reported the production of a transgenic tobacco plantlet system 
expressing the envelope glycoprotein, gpl60 of 1-TV-1. 
5.4.1 DNA analysis of kanamycin-resistant tobacco plantlets 
The recombinant binary vector pGPTV-KAN-210.1S-env16O (see chapter 4), 
containing CaMV promoter 35S, translation enhancement TEV, HIV-1 env160 and a 
polyadenylation signal of a soybean vegetative storage protein gene 3 'vspB, was used to 
transform Agrobacterium tumefaciens strain LBA4404 harbouring Ti plasmid pAL4404 
(Hoekema et al., 1983). The HIV-1 envl60 gene was then subsequently transferred to 
tobacco (Nicotiana tabacum "sumsun") genome by the Agrobacterium-mediated 
transformation (Horsch et al. (1988). 30 out of 96 rooted kanamycin-resistant tobacco 
plantlets were selected for the detection of the presence of the integrated gp160 gene by 
PCR using primers based the inserted genes (Figure 5.4). The result showed the 
presence of all HIV region products of the expected size, suggesting that the HIV 
env160 genes were efficiently integrated into the plant host genomes, which is similar to 
other studies on animal viruses showing that foot-and-mouth disease virus VP! protein 
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(Carrillo, et al. 1998) and porcine transmissible gastroenteritis virus S gene (Tuboly et 
al., 1999) were efficiently inserted into the plant host genome. 
1 (No 5) out of 30 samples tested showed correctly sized V1/V2 and V3/V4 region PCR 
products produced with paired primers 402/403 and 306/634 but with the absence of 
gp4l PCR product amplified with primer 518 and 256 (Table 5.2). The reason for this 
incomplete gp160 gene amplification by PCR is unclear, but unlikely due to the 
truncated T-DNA insertion as the gp4l region gene is close to the right border of 
recombinant binary vector pGPTV-KAN-210.1S-envl60 and it is reported that the 
transfer of T-DNA to plant cells by Agrobacterium-mediated transformation is thought 
to start at the right border (Zambryski 1992). 
5.4.2 Transcriptional analysis of Transgenic tobacco plantlets 
To investigate the transcription of integrated gpl60 gene in transgenic tobacco plantlets, 
17 transgenic tobacco plantlets positive in all V1/V2, V3/V4 and gp4l specific PCR 
reactions were further analysed by reverse transcription (RT)-PCR to verify the mRNA 
of env160. 14 out of 17 tested plantlets showed specific transcription of env160 gene. No 
amplified DNA fragments were detectable when RNA preparation treated with RNase in 
tested 14 leaf RNA extracts, which demonstrated that cDNA were specifically 
synthesized from mRNA transcribed from integrated env160 gene and assessing that the 
positive RT-PCR reactions are RNA dependant. This result is consistent with other 
studies (G©mez et al., 1998). 
The above results demonstrated the presence and proper processing of mRNA of 9p160 
gene in the leaves of tested transgenic tobacco plantlets, and that there was no inherent 
transcriptional limitation to the expression of gp160 protein in the transgenic tobacco 
plantlet leaves, which is similar to other reports (Mason et al., 1992; 1996). 
5.4.3 HIV-1 gpl60 protein expression in transgenic tobacco plantlets 
The presence of HIV-1 gp160 protein in the transgenic tobacco plantlet leaves was 
investigated by a gpl60/120 ELISA using monoclonal antibody to HIV-1 gpl20. 96 leaf 
222 
protein extracts from kanamycin-resistant tobacco "sumsun" plantlets were analysed for 
the expression of gp160 protein. Because the site of insertion of the transferred DNA 
into the cellular chromosomal DNA is random, different levels of protein expression in 
independent transformants were expected. Results showed that 84 out of 96 tested plants 
were expressing gpl60 protein at levels ranging from 0.03 to 15.88 ng/mg soluble 
protein, and 12 out of them showed no detectable gp160 protein (Table 5.1). The gp160 
protein accumulated in the leaves of tobacco transformants ranged from 0.000003 to 
0.002% of the total soluble leaf protein (Figure 5.8). 
TEV translation enhancer sequence was fused to CaMV 35S leaf promotor to enhance 
envl60 gene translation in transgenic plantlets while constructing the recombinant 
expression vector (see Chapter 4). It has been reported that TEV 5' UTR appeared to 
enhance the translation of foreign gene, such that it can increase the expression level of 
HbsAg or norvalk virus capsid protein (NVCP) in transgenic tobacco grown plant leaves 
up to 0.01% and 0.23%, respectively (Mason et al., 1992; 1996). However, most 
transformants obtained in our research expressed low levels of gp160 protein in tobacco 
plantlet leaves (Table 5.1), which is similar to E. coli LT-B expression level in 
transgenic tobacco plant leaves (Haq et al., 1995). This inconsistency is perhaps due to 
the response of the plant tissue to HIV envl60 being different from that of HBsAg genes 
and NVCP genes, or might be because the tested leaf extracts were from the different 
growth stage of the plantlets and plants which could affect the amount of the foreign 
protein accumulated in tobacco leaves. Further study is needed to clarify this point. 
In comparison to the results obtained from PCR, RT-PCR and ELISA in the 30 
transgenic tobacco plantlets tested (Table 5.2), 5 transformants showed the presence of 
env160 genes but the absence of the expression of gp160 protein. The reason for the 
absence of expression of the integrated foreign genes is unclear, and could be due to the 
site of integration of the T-DNA into the plant nuclear chromosomal DNA which is 
random. Positional effects can have substantial effects on the level of transcription and 
hence translation in independent transformants. 
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It was found that the expression level of foreign protein was correlated to the abundance 
of mRNA detected in each of the transformants (Mason et al. 1992; 1996). Our results, 
however, observed that 3 transformants were both PCR and RT-PCR positive but 
without detectable expression of gp160 protein; and in contrast, 3 transformants were 
negative in RT-PCR reaction but expression of gp160 protein in tobacco plantlet leaves 
occurred (Table 5.2). The reason for this discrepancy is unclear, it is possibly due to the 
short or incomplete translation of the foreign genes or the amount expressed in the 
leaves tested was not detectable using the current method, or might be because gp160 
protein in transgenic tobacco plantlet leaves degraded before harvest as suggested by 
some reports (Fang et al., 1989; Benfey et al., 1990), and also RNA may have been 
degraded during shipping from USA to UK. However the correlation between 
transcription level of foreign gene and expression level of foreign protein in transgenic 
plant should be further investigated. 
5.4.4 Conclusion 
This study demonstrated that HIV-1 env160 gene can be integrated into the plant host 
genome and gp160 protein can be expressed in transgenic tobacco plantlets, which 
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6.1 INTRODUCTION 
As described before (Chapter 5), transgenic plants represent an inexpensive and easily 
delivered system for the production of animal and human vaccines. The use of 
transgenic potato as a potential edible vaccine delivery system was initially described by 
Haq et al. (1995). Transgenic potato plants were made with the use of genes encoding 
the binding subunit of Escherichia coli heat-labile enterotoxin (LT-B). Mice that 
consumed transgenic potato samples developed serum IgG and mucosal IgA that were 
specific for LT-B, whereas mice fed with the control (non-transformed) tubers 
developed no LT-B-specific antibodies in either serum or mucosal samples. It was 
further demonstrated, by Mason et al. (1998), that mice fed with transgenic potatoes 
expressing LT-B had higher levels of serum and mucosal anti-LT-B than those gavaged 
with bacterial LT-B. This verified the feasibility of using transgenic potatoes as 
expression and delivery systems for oral vaccines against human diseases. Subsequently, 
the expression of norwalk virus capsid protein in transgenic potato has been shown to 
induce specific serum antibodies when fed to mice (Mason et al., 1996). Also cholera 
toxin B subunit (CTB) pentamer was synthesised in transgenic potato plants which, 
when fed to mice, induced mucosal and systemic anti-CTB antibodies at levels sufficient 
to generate protective immunity against the biological effects of CTB (Arakawa et al., 
1997). 
Transgenic potatoes have also been shown to be potential vaccine production and 
delivery systems against animal virus diseases. The major structural protein VP60 of 
rabbit hemorrhagic disease virus (RHDV) has been successfully produced in transgenic 
potato plants. Two rabbits inoculated with leaf extracts from such plants showed high 
anti-VP60 antibody titers and were fully protected against the hemorrhagic disease 
(Castanon et al., 1999). Transgenic potato plants were created for expression of the N -
terminal domain of the glycoprotein S (N-gS) from transmissible gastroenteritis 
coronavirus (TGEV), which carries the major antigenic sites of the protein. Mice fed or 
immunised intraperitoneally with potato tuber extracts expressing N-gS developed 
serum antibodies specific for gS protein and serum IgG specific for TGEV, respectively 
(Gómez et al., 2000). 
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The first human clinical trials for a transgenic, plant-derived antigen was approved by 
US food and drug administration and performed in 1997 (Tacket et al., 1998). 
Transgenic potatoes constitutively expressing a synthetic bacterial diarrhea vaccinogen 
(LT-B) were orally delivered to human volunteers in PhaseIJII clinical trials. Serum and 
faecal samples were collected prior to and at multiple time points after ingestion of the 
transgenic potato. The results showed that a significant rise in both IgG anti-LT-B 
antibodies in 10 of 11 test participants and IgA anti-LT-B antibodies in 6 of 11 test 
volunteers. No LT-B specific antibodies were detected in the control participants. 
Furthermore, a 4-fold rise in sIgA was detected in 5 of 10 volunteers who ingested 
transgenic potatoes. These results demonstrated that transgenic potato plants-derived 
recombinant LT-13 was protected against digestion and proved capable of inducing an 
immune response in humans. 
In this chapter, HIV-1 env160 containing in the recombinant expression vector pGPTV-
KAN-210.1S-envl60 (see section 4.3.7.4) was transformed to NT-1 tobacco cell line by 
Agrobacterium-mediated plant transformation system. As an edible vaccine, injection is 
not the aim; feeding is. Therefore, in this chapter, recombinant expression vector 
pGPTV-KAN-240.1S-envl60 containing plant tuber specific promoter patatin and HIV-
1 env160 genes (see section 4.3.7.5) was used to transform potato cultivar "FL1607". 
The expression level of HIV-1 gpl60 protein in transgenic potato and NT-i cell 
transformants was analysed by gpl60/120 ELISA, respectively. 
6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Both plant materials and Agrobacterium strain LBA4404 were kindly given by Dr Hugh 
Mason (Boyce Tompson Institute for Plant Research, Cornell University, USA) and his 
co-workers. 
6.2.1.1 Plant materials 
a. Potato cultivar "FL1607" 
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Potato cultivar (Solanum tube rosum, variety "Frito-Lay (FL) 1607) shoots were 
maintained by serial propagation as an axenic plant culture in hormone-free CM medium 
(see Appendix I) at 25°C, 16 hours days and 22 °C, 8 hour nights. 
b. NT (Nicotiana tabacum)-1 cell line 
NT (Nicotiana tabacum)-! cell line was cultured in 40 ml of NT-i media (see Appendix 
I) and maintained at 26°C in dark with shaking. The cell culture was diluted in 1:40 in 
volume and fed with fresh medium every week. 
6.2.1.2 Agrobacterium 
Agrobacterium tumefaciens strain LBA4404 harbouring Ti plasmid pAL4404 (Hoekema 
et al., 1983) was kept at -70°C until use. 
6.2.2 Methods 
6.2.2.1 Production of transgenic potato microtubers 
Recombinant plant binary vector pGPTV-KAN-240.1S-envl6O (see section 4.3.7.5) 
containing the HIV-1 gpl60 expression cassettes was used for potato "FL1607" plant 
transformations by the Agrobacterium-mediated methods (Wenzler et al., 1989b). 
Briefly, the vector containing fflV-1 envl60 gene was transferred to Agrobacterium 
tumefaciens strain LBA4404 by the electroporation (see section 2.2.4.1). Potato 
"FL1607" leaf strips were transformed by cocultivation with Agrobacterium strain 
LBA4404 carrying expression vector pGPTV-KAN-210.1S-env16O. The explants were 
transferred to regeneration medium containing 500 .tg/ml carbenicillin, to kill excess 
bacteria and 50 j.tg/ml of kanamycin to inhibit growth of untransformed plant cells. 
Shoots were regenerated and rooted in CM selecting medium containing 50 .tg/ml of 
kanamycin. When the rooted plantlets were about 5-6 cm high, the stem including one 
node was cut from the plantlet and placed upright on the petri plates containing 
tuberization media (see Appendix I) and incubated at 18°C in the dark for 4-6 months 
until the microtuber was formed and grown up to 3-6 mm in diameter (see section 
2.2.4.2b). The microtubers were then harvested for analysis of HIV-i gpl60 protein 
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expression. 
6.2.2.2 Production of transgenic NT-1 cells 
Recombinant plant binary vector pGPTV-KAN-210.1S-env16O (see section 4.3.7.4) 
containing the 1-TV-1 gp160 expression cassettes was used for NT (Nicotiana tabacum)-
1 cell transformations by the Agrobacterium-mediated method. Briefly, the vector was 
transferred to Agrobacterium tumefaciens strain LBA4404 by the electroporation 
method as before (see section 2.2.4.1). Acetosyringone (3', 5'-Dimethoxy-4'-hydroxy-
acetophenone, Aldrich Chem. Co.) treated NT-1 cells were mixed with different 
concentrations of 0 j.tl, 50 pA, 75 p.1, 100 p.1 and 200 p.1 of bacterial suspension. After 
washing with NT-i medium containing 500 p.g/ml carbenicillin (to get rid of the excess 
bacteria), the cells were resuspended and plated on selective NT-1 medium containing 
100 p.g/ml carbenicillin to kill the excess bacteria and 300 p.g/ml of kanamycin to 
suppress the growth of untransformed cells. The plates were incubated at 26 °C for 3-4 
weeks to allow the transformants to generate (details see section 2.2.4.3). The colonies, 
which grew large enough (about 50-100 mm in diameter) in 4-5 weeks, were collected 
and weighed before analysis of gp160 protein expression. 
6.2.23 Analysing the expression of HIV-1 gp160 protein in transgenic potato 
microtubers and NT-i transformants 
Proteins from transgenic potato microtubers or NT-i cell transformants were extracted 
in ice cold extraction buffer (see sections 2.2.4.7 and 2.2.4.8), and homogenised with a 
pestle or glass homogeniser. After centrifuging at 13,000rpm for 5 minutes at 4 °C, the 
supernatant was collected and aliquoted. The total protein concentration was measured 
using protein assay kit H (Bio-Rad) as described in 2.2.3.16. The expression of gp160 in 
transgenic potato microtuber and NT-i transformant extracts was assayed using a HIV-1 
gp160/120 ELISA (details see section 2.2.2.2), untransformed wild type potato 
microtuber and NT-i cell protein extracts were used as control samples, respectively. 
Each sample was tested in duplicate and the test repeated twice. Extracts from transgenic 
potato microtubers and NT-i transformants were diluted 1:10 and 1:2, respectively, with 
antigen dilution buffer containing 0.1% Empigen (Calbiochem) before added to the 
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sheep polyclonal antibody to HIV-1 gpl20 (D7324, Aalto BioReagents Ltd, Dublin, 
Ireland) coated ELISA plates (see section 2.2.2.2b). The final concentration of protein 
was taken as the mean of the readings obtained in 2 independent assays. The HIV-1 
gpl60 protein expression level (ng/mg total soluble protein) in each of transformants 
was calculated as follows: 
(protein concentration in transformant - background concentration in control) x dilution factor 
total protein concentration of transformant 
The percentage of HIV-1 gpl60 protein expression in the total soluble potato tuber or 
NT-i cell protein in each of transformants was calculated as follows: 
expression level of gpi60 protein (ng/mg total protein) x 106  x 100% 
Expression of gpi60 protein in per gram NT-i cell transformants (ng/g) was calculated 
as follows: 
(protein concentration in transformant - background concentration in control) x 2 x 2 
(ml/g, extraction buffer/transfonnant) 
6.3 RESULTS 
6.3.1 Generation of transgenic potato microtubers and NT-1 transformants 
6.3.1.1 Generation of transgenic potato microtubers 
Expression vector pGPTV-KAN-240.iS-envl60 containing REV-i env16O ( see section 
4.3.7.5) was used to transform Agrobacterium tumefaciens strain LBA4404 by 
electroporation (see section 2.2.4.1). After incubation at 30 °C for 48 hours, the 
transformants were picked up and verified by both PCR using plant primer set TBV and 
vsp and restriction digestion to confirm the presence of required inserting HIV-1 env160 
gene. The colonies showed the right sized PCR products (2700 bp) and restriction 
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fragments (11126 bp, 4262 bp and 1214 bp when cut with EcoRI and Hindifi) (Figure 
6.1 and Figure 6.2) and were thus used to transform potato leaf strips by co-cultivation 
(Wenzler et al., 1989b). After 3-6 weeks, kanamycin-resistant shoots were regenerated 
from transformed calli selected on LC2 c/k (see Appendix I) (Figure 6.3a) at a 
frequency of 20%. Leaf explants usually gave rise to one to three shoots (Figure 6.3b). 
Approximately 60 shoots were cut from the calli and rooted in CM medium (see 
Appendix I) containing 50 j.tg/ml kanamycin. Approximately 40 plantlets were rooted 
and transferred to tuberization media (see Appendix I) for microtuber regeneration 
(Figure 6.3c). 32 transgenic potato microtubers were regenerated on tuber induction 
medium (Figure 6.30). All kanamycin-resistant rooted potato "FL1607" plantlets 
showed no morphological difference compared to non-transgenic potato "FL1607" 
plantlets. However, some microtubers from the kanamycin-resistant potato "FL1607" 
planlets showed slower microtuber growth rates compared to those from untransformed 
potato "FL1607" plantlets (data not shown). 
6.3.1.2 Generation of transgenic NT-1 cell transformants 
The recombinant binary vector pGPTV-KAN-210.1S-env160 containing HIV-1 gp160 
gene was constructed (see section 4.3.7.4) and transferred to Agrobacterium tumefaciens 
strain LBA4404 by the electroporation method (see section 2.2.4.1). The presence of 
required HIV-1 envl60 gene in Agrobacterium transformants was verified by both PCR 
using paired plant primer set TEV and vsp and restriction digestion. The colonies that 
showed the right sized PCR products (2700 bp) and restriction fragments (11126 bp, 
2759 bp and 1214 bp when cut with EcoRI and Hindlil) (Figure 5.1 and Figure 5.2) 
were used to transform tobacco NT (Nicotiana tabacum)-1 cells by the Agrobacterium-
mediated method (see section 2.2.4.3). Different volumes (0 j.tl, 50 j.tl, 75 p.1, 100 p.1 and 
200 p.!) of bacterial culture were mixed with 4 ml of NT-i cell suspensions, respectively. 
After incubated at 26 °C in dark for 3-4 weeks on selecting medium containing 300 
p.g/ml of kanamycin, kanamycin-resistant transformants began to appear. Only those 
cultures containing 50 pi, 75 p.1, 100 p.1 of Agrobacterium culture inoculated NT-i cells 
generated kanamycin-resistant transformants. There was no apparent difference in 
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Figure 6.1 Taq PCR screening Agrobacterium transformants carrying recombinant 
plasmid pGPTV-KAN-240. 1S-envl6O 
Recombinant binary vector pGPTV-KAN-240.1S-envl6O containing patatin promotor 
and env160 was used to transform Agrobacterium tumefaciens strain LBA4404 by 
electroporation method (see section 2.2.4.1). Transformant DNA minipreps were 
subjected to PCR using plant primer set TEV and vsp. 8 .tl of the PCR reaction was 
loaded on 1% agarose gel and run for 1 hour at 80 mA electric current. The correctly 
transformed colonies resulted in a 2700 bp PCR product. 
Lane 1: 1Kb DNA ladder 
Lane 2: Positive control plasmid GPTV-KAN-240. 1S-envl6O 
Lane 3-5: Agrobacterium transformants 1-3 DNA minipreps 
Lane 8: pGEM DNA marker 
Figure 6.2 Restriction fragment analysis of Agrobacterium transformants carrying 
recombinant plasmid pGPTV-KAN-240. 1 S-envl60 
3 Agrobacterium transformants DNA minipreps were cut with restriction enzymes and 
were subjected to electrophoresis. The predicted restriction fragment sizes are 11126 bp, 
4262 bp and 1214 bp when cut with EcoRI and Hindill. All samples analysed gave the 
correct sized restriction fragments. 
Lane 1-3: Double digestion with EcoRI and Hindifi 
Lane 4: 1 Kb DNA ladder. 
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Figure 6.3 Regeneration of transgenic potato (Solanum tuberosum, variety "Frito-Lay 
(FL) 1607") microtubers 
Potato (Solanum tuberosum, variety "Frito-Lay (FL) 1607) leave strips were infected 
with A. tumefaciens strain LBA4404 carrying the vector pGPTV-KAN-240.1S-envl6O 
and cultured on selecting medium containing 500 j.tg/ml carbenicillin and 50 tg/ml of 
kanamycin. During the next 3 weeks, the transformed cells grew into callus and 
differentiated into shoots via organogenesis. Between 3 and 6 weeks, the shoots 
developed enough to remove them from the transformed callus to induce rooting in 
selecting medium containing 50 tg/ml of kanamycin. After 3-6 weeks, rooted plantlets 
had grown enough for microtuber induction on tuberization media (see Appendix I). 
After 4-6 months culture at 18 °C in dark, microtubers grew large enough for the analysis 
of gpl60 protein expression. 
Calli were formed around the wounded edges of the leaf strips after transformation 
with A. tumefaciens strain LBA4404 carrying the vector pGPTV-KAN-240.1S-envl60 
Shoots were generated during 3-6 weeks after transformation. Leaf explants usually 
gave rise to one to three shoots. 
Plantlets were developed in 3-6 weeks after the shoots were removed from the 
transformed callus and rooting induced on selecting medium 
dl. Transgenic potato "FL1607" microtubers would grew enough in 4-6 months for 
analysis of gpl60 protein expression. 
d2. Untransformed potato "FL] 607" microtubers. 
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Fig.6.3 
transformant formation between these bacterial culture concentrations. NT-i cell 
cultures inoculated with 200 .tl of bacteria showed no or very few kanamycin-resistant 
transformants (data not shown). No kanamycin-resistant colonies were generated from 
untransformed control NT-i culture plates (Figure 6.4a, b, c and d). 
6.3.2 HIV-1 gp160 protein expression in transgenic potato microtubers and NT-1 
cell transformants 
The presence of HIV-1 gp160 protein in transgenic potato microtubers and NT-i cell 
transformants conjugated with HIV-1 gpl60 genes was investigated by the gp160/120 
ELISA (see sections 2.2.2.2 and 5.3.4.1), respectively. The amount of protein in each of 
the kanamycin-resistant transformants was determined by the Bio-Rad protein assay as 
described in 2.2.3.16. The gp160 protein expression level in the kanamycin-resistant 
transformant was calculated as described in 6.2.2.3. 
6.3.2.1 HIV-1 gp160 protein expression in transgenic potato microtubers 
Following Agrobacterium-mediated potato leaf transformation with recombinant binary 
vector pGPTV-KAN-240.1S-envl60 containing tuber-specific patatin promotor and 
HIV-1 env160 genes, 32 transgenic potato "FL1607" microtubers were generated. The 
expression level of gpi60 protein in microtuber extracts was analysed as described in 
6.2.2.3. Results showed that 8 out of 32 tested microtuber extracts showed the 
expression of gp160 protein, ranging up to 14.92 ng/mg total soluble protein. 24 out of 
32 tested microtuber extracts and that from untransformed wild type potato "FL1607" 
microtubers showed no detectable levels of gp160 protein (Figure 6.5). The percentage 
of the total soluble protein corresponding to gp16O protein accumulated in the potato 
microtuber tissues was up to about 0.002% of the total soluble tuber protein (Figure 
6.6). The mean level of gpl60 protein in 8 transgenic potato "FL1607" microtubers was 
7.4 ng per mg of total soluble protein. The mean level of gpl60 protein accumulation in 
8 transgenic potato "FL1607" microtuber tissues was 0.00074% of the total soluble tuber 
protein. 
Among the 8 transgenic potato "FL1607" microtuber extracts which were positive in 
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Figure 6.4 Development of transgenic NT (Nicotiana tabacum)-1 cell transformant 
Tobacco NT (Nicotiana tabacum)-! cells were inoculated with A. tumefaciens strain 
LBA4404 carrying the recombinant expression vector pGPTV-KAN-210. 1S-envl6O and 
cultured on selecting medium containing 100 iWml  carbenicillin and 300 pg/mI of 
kanamycin. During the next 3-4 weeks, the transformed cells grew into colonies and 
these grew enough for analysis of gpl60 protein expression in 4-5 more weeks. No 
kanamycin-resistant colonies appeared in untransformed NT-1 cell culture. 
Kanamycin-resistant colonies appeared in 3-4 weeks after NT-i cells were inoculated 
with A. tumefaciens strain LBA4404 carrying the recombinant expression vector 
pGPTV-KAN-210. 1S-envl60. 
Kanamycin-resistant NT-i cell transformants grew bigger on selecting medium 
containing 300 pg/ml kanamycin. 
Kanamyci n -resistant NT-i cell colony grew up enough for analysing gp160 protein 
expression in transformants in 4-5 weeks since they first appeared. 
d. Untransformed NT-i cell culture. 
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ELISA, the level of gp160 protein expression was variable. 3 samples showed lower 
level of gpl60 protein expression, ranging from 1- 5 ng/mg total soluble protein; 4 
samples showed an relative intermediate level of gp16O protein expression, ranging from 
5 to 10 ng/mg total soluble protein and only 1 sample showed a relatively higher level of 
gp160 protein expression, of about 15 nglmg total soluble protein (Table 6.1). 
Table 6.1 Expression levels of gpi6O in transgenic potato microtubers 
gpl60/total soluble 
protein (ng/mg) 
Percentage of total 
soluble protein (%) 
Transgenic potato 
transformants 
0 0 24 
1.01-5.00 0.0001-0.0005 3 
5.01-10.00 0.0005-0.001 4 
10.01-15.00 0.001-0.0015 1 
6.3.2.2 HIV-1 gp160 protein expression in transgenic NT-i cell transformants 
Recombinant binary vector pGPTV-KAN-210.IS-envl60 was introduced into tobacco 
NT (Nicotiana tabacuin)- 1 cells by Agrobacterium-mediated method (see section 
2.2.4.3). 32 kanamycin-resistant transformants were generated and extracted for analysis 
of the expression of gpl60 protein in NT-i cell transformants. Results showed that 6 out 
of 32 kanamycin-resistant transformant extracts expressed HIV-1 gp16O protein with the 
maximum expression level of 2.76 ng/mg total soluble protein and 0.872 ng/g 
transformed cells (Table 6.2). 26 out of them and extracts from untransformed NT-i 
cells showed no detectable gpl60 protein (Figure 6.7). The percentage of the total 
soluble protein corresponding to gpl60 protein accumulated in the NT-1 cell 
transformants was up to about 0.0003% (Figure 6.8). The mean level of gpi60 
expression in transgenic NT-1 cell transformants was 0.92 ng/mg total soluble protein 
and 0.4 ng/g transformed cells. The mean level of gp16O accumulation in the transgenic 
NT-i cell transformants was about 0.0001% of the total soluble cell protein. 
All of 6 transgenic NT-i cell transformants showed low expression level of gpi60 
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Figure 6.5 Analysis ot gp 160 protein in potato '11,1607' microtuhers from kanamvci ii - 
resistant transformants by gp 160/120 ELISA 
The gp160/120 ELISA was performed as described in 2.2.2.2 and the expression level of 
gpI6O protein in potato "FL1607" microtubers from kanamycin-resistant transformants 
was calculated as described in 6.2.2.3. The figure shows the mean of the expression 
level of gp16O in each microtuber extract obtained in two independent assays. The 
untransformed potato "FL 1607" microtuber extract was used as the negative control 
(sample No 1). 
Figure 6.6 Accumulation of gp160 protein in potato "FL1607" microtubers from 
kanamycin-resistant transformants 
The figure shows gp160 protein expression as a percentage of the total soluble 
microtuber protein. The wild type potato "FL1607" microtuber extracts was used as the 
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Figure 6.7 Analysis of gpi60 protein expression level in kanamycin-resistant NT-i cell 
transformants by gpl60/120 ELISA 
The gpl60/120 ELISA was performed as described in 2.2.2.2 and the expression level of 
gpl60 in NT (Nicotiana tabacum)-i cell transformant was calculated as described in 
6.2.2.3. The figure shows the mean of the expression level of gp160 in each 
transformant obtained in two independent assays. The untransformed NT-1 extracts was 
used as the negative control (sample No 1). 
Figure 6.8 Accumulation of gp160 protein in kanamycin-resistant NT-i cell 
transformants 
The figure shows gpl60 protein expression percentage of the total soluble NT 
(Nicotiana tabacum)-1 cell protein of kanamycin-resistant NT-i cell transformant, 
which was calculated as described in 6.2.2.3. The untransformed NT-1 cell extract was 
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gp 1 6Oltransformant 
(ng/g) 
2 0.14 0 0 0 
3 0.12 0 0 0 
4 0.31 0 0 0 
5 0.24 0 0 0 
6 0.34 0 0 0 
7 0.46 0 0 0 
8 0.55 0 0 0 
9 0.43 0.1013 0.00001 0.032 
10 0.56 0 0 0 
11 0.34 0 0 0 
12 0.64 0 0 0 
13 0.25 0 0 0 
14 0.4 0 0 0 
15 0.92 0 0 0 
16 0.75 0 0 0 
17 0.61 0 0 0 
18 0.66 0 0 0 
19 0.45 0.8571 0.000086 0.12 
20 0.58 0 0 0 
21 0.29 0 0 0 
22 0.5 0 0 0 
23 0.57 0 0 0 
24 0.58 2.7595 0.00028 0.872 
25 0.67 0 0 0 
26 0.56 1.2329 0.00012 0.36 
27 0.49 0 0 0 
28 0.36 0 0 0 
29 0.45 0.4104 0.000041 0.66 
30 0.53 0 0 0 
31 0.58 0 0 0 
32 0.44 0 0 0 
33 0.25 0.1520 0.000015 0.332 
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Table 6.3 Expression levels of gpl60 protein in transgenic 
NT-i cell transformants 
gp 160/total soluble 
protein (ng/mg) 
Percentage of total 
soluble protein (%) 
Transgenic NT-1 
transformants 
0 0 26 
0.01-1.00 0.000001-0.0001 4 
1.01-2.00 0.0001-0.0002 1 
2.01-3.00 0.0002-0.0003 1 
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protein. 4 out of 6 transgenic NT-1 cell transformants showed gpl60 protein expression 
level ranging from 0.01 to 1 ng/mg total soluble protein; 1 out of 6 showed gp160 
protein expression level of 1.23 ng/mg total soluble protein and 1 out of 6 showed 
gp160 protein expression level of 2.76 ng/mg total soluble protein (Table 6.3). 
6.4 DISCUSSION AND CONCLUSION 
Plant-based expression of candidate vaccines provide unique traits that include low 
production cost, easy transportation and storage and will thus be especially applicable to 
developing countries where they are most needed. Vaccine-producing plant species that 
grow in these countries and the plant tissues containing the recombinant antigen that can 
be directly consumed will be the essential factors to achieve this. The feasibility of 
expressing hepatitis B surface antigen in transgenic tobacco plants was initially 
demonstrated by Mason et al. in 1992. The advantage of using a transgenic tobacco 
system as the initial test system, was described before (5.4). However, tobacco tissues 
are rich in toxic alkaloids that prevent direct animal -feeding studies. Other plant 
species such as transgenic lettuce expressing a hepatitis antigen (Ehsani et al., 1997); 
transgenic tomato expressing rabies virus glycoprotein (McGarvey et al., 1995) and 
transgenic potato expressing a bacterial diarrhea antigen (Haq et al., 1995), norwalk 
virus capsid antigen (Mason et al., 1996) and a cholera antigen (Arakawa et al., 1997) 
were subsequently used to show the potential of "edible vaccine" production and 
delivery systems. Encouraged by the success of the above studies, we decided to 
experiment with transgenic potato system and tobacco NT-1 cell line which have 
characteristics of being easily manipulated in the laboratory and the shortest 
transformants regeneration period for expressing HIV-1 gp160 protein. Part of this work 
was carried out in collaboration with Dr Hugh Mason at the Boyce Tompson Institute 
for Plant Research, Cornell University, USA. 
Kanamycin-resistant shoots were regenerated from transformed calli at a frequency of 
20%, which is lower than reported from Castanon et al. (1999) where regenerants 
appeared on selecting medium at a frequency of 55%. This difference is perhaps due to 
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different transforming efficiencies between potato cultispecieces "FL1607" and 
"Desirée", and foreign genes of HIV-1 env160 and rabbit hemorrhagic disease virus 
VP60 gene carried by Agrobacterium tumefaciens strain LBA4404. 
Kanamycin-resistant potato "FL1607" plantlets showed .no morphological difference 
compared to non-transgenic potato "FL1607" plantlets, however, microtubers 
expressing gpl60 protein from the corresponding kanamycin-resistant transformants 
presented reduced growth rates compared to control microtubers from untransformed 
potato "FL1607" plantlets. This result is similar to a report from Mason et al. (1998) 
that plants expressing higher levels of E. coli heat-labile enterotoxin B subunit (LT-B) 
showed stunting of shoot growth and poor tuber yield. It is likely that, similar to LT-B, 
HIV-1 gpl60 protein expression in potato tuber cells might affect tuber growth pattern 
by an unclear mechanism. It is possible that insertion of the transferred DNA into the 
plant cellular chromosomal DNA (which is random), might have negative effects on the 
growth of plant cells. 
The presence of HIV-1 gp160 protein in potato "FL1607" microtubers from kanamycin-
resistant transformants and tobacco NT-i cell transformants was analysed by the 
gpl60/120 ELISA using a monoclonal antibody to HIV-1 gpl20. 32 of each potato 
microtuber lines from kanamycin-resistant "FL1607" plantlets and NT-1 cell 
transformants were obtained, respectively. Because the site of insertion of the 
transferred DNA into the plant cellular chromosomal DNA is random, and position can 
have substantial effects on the level of expression of foreign protein in independent 
transformants, different expression levels of FHV-1 gp160 protein in each of potato 
microtubers and NT-1 transformants tested were expected. 
Different volumes (0 .tl, 50 .tl, 75 j.tl, 100 p.1 and 200 p.1) of bacterial culture were used 
to inoculate with NT-1 cell suspensions. NT-1 cell cultures inoculated with 200 p.1 of 
bacteria showed fewer kanamycin-resistant transformants than those NT-1 cell cultures 
inoculated with other concentration of bacterial cultures. The fewer transformants at a 
243 
higher concentration of bacterial culture inoculation is probably because the higher 
concentration of bacterial culture is toxic to NT-i cells and inhibits the cell growth. 
The results demonstrated the feasibility of expressing the HIV-1 gpl60 protein in 
transgenic potato microtubers and tobacco NT-i cells. Both transgenic potato "FL1607" 
microtubers and tobacco NT-1 cell transformants showed lower expression levels of 
HIV-1 gpi60 protein (up to about 0.0015% and 0.0003% of total soluble protein in 
transgenic potato "FL1607" microtubers and NT-1 cell transformants, respectively.) 
than those obtained for expressing the N-terminal domain of the glycoprotein S (N-gS) 
of transmissible gastroenteritis coronavirus (TEGV) in transgenic potato "desirée" 
tubers which gave a maximum of 0.07% of total tuber protein (Gómez et al., 2000); 
expressing the cholera toxin B subunit (CTB) pentamer in transgenic potato "Bintje" 
(both microtuber and leaf tissues up to 0.3% of total soluble protein) (Arakawa et al., 
1997) and expression for E. coli enterotoxin (LT-B) in transgenic potato "FL1607" 
microtubers which gave a maximum of 0.01% of total soluble protein (Haq et al., 
1995). This inconsistency is perhaps due to the different response of the potato tuber 
tissues to HTV env16O and other foreign genes such as above N-gS, CTB and LT-B 
genes, or might be because the different potato variety and growth stages could affect 
the accumulated amounts of foreign proteins in tested potato tuber tissues. However, the 
mechanism and subcellular localization of HIV-1 gpl60 protein in plant cells need to be 
investigated. Thus an enhanced plant expression sequence could be designed and new 
recombinant binary vectors which could result in higher levels of HIV-1 gpl60 protein 
expression in transgenic plant cells and tissues could be constructed. 
In conclusion, results presented in this chapter have demonstrated the feasibility of 
expressing HIV-1 gp 160 protein in transgenic potato "FL1607" microtubers and 
tobacco NT-1 cell transformants, which indicates the possibility of using transgenic 
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fly-i is mainly transmitted by heterosexual contact (Overbaugh et al., 1999), therefore 
initial exposure to HIV occurs most frequently at the genital mucosa. This emphasises 
the need to understand the nature of HIV-specific mucosal immune responses, an 
approach that could lead to the generation of protection against HIV infection. 
It is clear that human IgA displays a unique heterogeneity in its molecular forms. There 
are known to be two subclasses of IgA; IgA, and IgA 2. Serum IgA is predominantly 
monomeric IgA,. The IgA in external secretions is called secretory IgA (sIgA) and is 
produced locally at mucosal surfaces (see section 1.3.2). In this study, the presence of 
both IgG and IgA antibodies against FHV-i viral antigens gpl60/120, p65, p55, pSi, 
gp4i, p3!, p24 and p17 was demonstrated in sera of HIV infected individuals using 
Western blot assay. Interestingly, the specific sIgA antibodies to HIV-1 viral antigens 
gp160, p65, p55, p5!, gp4l, p3!, p24 and p17 were also detected in one of three serum 
samples. No clear explanation can be put forward for the presence of sIgA in serum, 
although it is possible that it could be the result of transudation of sIgA. This could have 
been locally synthesised in genital mucosa and reached the serum by tissue damage in a 
similar way to the increased level of sIgA detected in serum during lactation which is 
thought to be the result of a backflow of IgA produced in the mammary glands (Halsey 
et al., 1982). 
HIV infects susceptible cells such as Langerhans cells, macrophages, T cells and 
epithelial cells in genito-urinary tract (Miller et al., 1992b), leading to a local mucosal 
immune response (Bélec et al., 1989a; Cao et al., 1990; Kutteh et al., 1994; Bélec et al., 
1995a). This concept is further supported by the finding of sIgA against HIV-1 gp160, 
p65, gp4l, p31 and p24 was present in urine samples and sIgA to p24 in a vaginal swab 
sample from HIV-1 infected individuals in this study. These support the suggestion that 
female and male genital tracts can produce a strong, specific mucosal response to HIV 
(Bélec et al., 1995a) and could therefore play an efficient role in limiting the virus 
infectivity on mucosal surface by neutralizing 1-IV-1. 
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In most pathogen-infected individuals, both specific IgG and IgA are present in genital 
tract (Artenstein et al., 1997). IgA antibody is the predominant immunolgobulin on the 
mucosal surface (Mestecky et al., 1987). However, it is unlikely to be true for HIV 
infection. The results of this study showed that IgG is the predominant isotype in urine 
and vaginal swab samples where IgG antibodies against gpl60/120, p55, p65/51, p41, 
p31, p24 and p17 were present. The HIV specific IgG antibody pattern in paired urine 
and vaginal swabs samples was not similar to that in the corresponding serum samples. 
Thus it is unlikely that the source of these HIV-1-specific IgG antibodies is through 
serum transudation as suggested by some reports (Wolf et al., 1992; Black et al., 1997). 
It has been demonstrated that IgG could be produced locally (Morgan et al., 1980; 
Heinen et al., 2000). Therefore it is assumed that the predominant IgG antibody to HIV -
1 present in urine and vaginal swab samples in the present study was locally produced. 
This finding is similar to the previous reports that IgG antibodies to HIV-1 appeared to 
be largely synthesised in situ within the genital tract of both genders (Bélec et al., 
1995b; Hocini et al., 1997) and IgG excretion was increased in HIV-1 infected women, 
whereas the IgA secretion tended to decrease, suggesting a possible enhanced local IgG 
synthesis (Bélec et al., 1995c; Lu et al., 1993). This hypothesis was also supported by 
the observations in an animal models that nonclassical mucosal antibodies of the IgG 
isotype were found to be the predominant antibody in the saliva, rectal swabs, vaginal 
washes, semen and urethral washes in HIV-1 infected chimpanzees (Israel and Marx, 
1995), and specific Sly IgG antibodies were found to be the predominant 
immunolgobulin in vaginal swab samples of chronically infected rhesus macaques 
(Miller et al., 1992a). Thus it is possible that anti-HIV IgG is the predominant antibody 
response on mucosal surface in humans. The reason for this phenomenon is unclear. It 
has reported that the secretion rates of total IgA, IgA 1 and IgA2 were markedly reduced 
in women with AIDS when compared with those at early stage of HIV infection, 
indicating impairment of IgA class-specific immunoglobulin production in the 
cervical/vaginal mucosa during HIV infection (Bélec et al., 1995a). Similar selective 
reductions in salivary IgA and in intestinal IgA-producing plasma cells have also 
reported (Kotlre et al., 1987; Jackson et al. 1990; Sun et al., 1990; Muller et al., 1991; 
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Janoff et al., 1994). Since CD4 helper T (Th) cells are essential to both induce and 
maintain appropriate IgA responses in mucosa-associated tissue and since HIV-1 
infection causes a loss of mucosal CD4 lymphocytes (McGhee et al., 1989), it is 
conceivable that the number of CD4 lymphocytes and subsequently IgA-bearing 
plasma cells within the cervical/ vaginal mucosa of HIV-1 infected women may be 
reduced. 
There is increasing evidence that susceptibility to HIV-1 in humans is variable and that 
some individuals are able to resist infection despite multiple and repeated exposure to 
HJV (HEPS) (Rowland-Jones & McMichael 1995a; Shearer et al., 1996). This 
condition is likely to depend on the features of both the host and the virus (Shearer et 
al., 1996). In some individuals the resistance to HIV infection has a genetic basis. It has 
been reported that a mutant form of the HIV co-receptor, CCR5, on the surface of 
monocyte/macrophages is present in such individuals (Dean et al., 1996; Liu et al., 
1996; Samson et al., 1996). However, this is not the story for all the HEPS population. 
There are some reports which supported the idea that HEPS may acquire resistance to 
infection through the induction of CD8 class I MHC-restricted CTL and CD4 T-helper 
responses. Several studies have demonstrated the presence of HIV specific T cell 
responses, in the form of T cell proliferation and interleukin 2 (IL-2) production 
induced by HIV peptides. In addition the generation in vitro of HIV specific cytotoxic T 
lymphocytes (CTLs) has been shown in these individuals (Detels et al., 1994; Shearer et 
al., 1996; Paxton 1996) suggesting that the cellular immune responses may contribute to 
protection from FIIV infection in some highly exposed, persistently seronegative 
(HEPS) persons. 
Increasing evidence (see section 1.4.3) now suggests that mucosal immune responses 
may be involved in protection from HIV transmission in some 11BPS individuals 
(Shearer et al., 1996; Burastero et al., 1996). Analysis of immune activity in HIEPS is 
invaluable in order to understand fully the mechanism for protective activity against 
HJV infection. However, data concerning the contribution of mucosal immunity to 
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protection against HIV-1 infection in HEPS population are still limited. 
In exploring the mucosal immunity to HIV-1 in HEPS, it was observed that specific IgG 
antibodies against HI-i gp 160, gp 120 and p51 were detected in a couple of urine but 
not the corresponding serum samples, which indicated that these IgG antibodies were 
locally produced and IgG were the predominant isotype in these specimens. This 
finding is consistent with the antibody production pattern in DNA vaccine vaginally 
immunised mice that higher levels of vaginal IgG were induced than that of vaginal 
IgA, suggesting that IgG producing B cells within the vaginal mucosa may be 
preferentially stimulated by HIV-1 envelope antigen (Wang et al., 1997). A similar 
result was also observed in a macaque model in which targeted iliac lymph nodes were 
immunised with a subunit SW envelope and core vaccine (Lehner et al., 1996). 
Together with IgA antibody-secreting cells to p27, IgG antibody -secreting cells to p27 
and gp120 were also increased in the iliac lymph nodes of the immunised macaques. 
However, this observation is not similar to previous studies on REPS population where 
HIV-specific IgA but not IgG was present in urine and vaginal wash samples from HIV-
exposed seronegative individuals (Mazzoli et al., 1997) and in the genital tract of HIV-1 
resistant sex workers (Kaul et al., 1999). The reason for this discrepancy remains 
unclear. However, it should be considered that both REV-i specific IgG and IgA may be 
produced locally and contribute to the protection from REV infection observed in REPS 
populations. 
In exploring HIV-1 specific sIgA in REPS individuals, there was no anti-HIV sIgA 
present in all urine samples tested, however, a weak sIgA band to HIV viral p51 was 
detected in one of nine serum samples. The reason for absence of sIgA in urine samples 
is unclear but might relate to the low concentration of secretory antibody present in 
urine. It is clear that sIgA is secreted at mucosal sites (Rudzik et al., 1975; Brandtzaeg 
et al., 1989), and therefore, it is possible that this HIV-1 specific sIgA antibody found in 
serum samples could have been produced locally in genital mucosa and transported 
back to serum from the mucosal production site by an unknown mechanism. Further 
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study is required to clarify this point. 
Overall, all these findings are in keeping with the view that mucosal immunity might be 
important in protection against HIV transmission. HIV-specific antibody with 
neutralising activity in secretions on the mucosal surface is critical for the prevention of 
infection in individuals exposed to HIV, although the types of anti-HIV mucosal 
immune responses required are still not fully understood. 
It is well known that sexual transmission of HIV occurs mainly through mucosal 
surface at the genital tracts or rectum. Therefore, elicitation of immune response at 
mucosal surface is crucial in preventing virus transmission by blocking or neutralising 
virus at this site. Most HIV vaccine candidates, however, have been designed to elicit 
circulating antibodies. These vaccines, given by systemic route, may not induce 
mucosal immune responses (Funkhouser et al., 1993; Perry et al., 1993). Therefore, 
mucosal HIV vaccines, administered by mucosal routes (oral, rectal, intranasal and 
intravaginal) to induce both mucosal and systemic immune responses to HIV antigens 
are under development, although at present most are still restricted to animal models. It 
has been demonstrated that oral and intranasal immunisations can effectively induce a 
mucosal immune response upon re-exposure to antigen (Lehner et al., 1992; Thibodeau 
et al., 1992; Morrow et al., 1994; Bond et al., 1995; Mestecky et al., 1994; Muster et 
al., 1995; VanCott et al., 1998), raising the possibility that application of HIV antigens 
to mucosal surfaces may be a fruitful approach to vaccination against AIDS. However, 
these vaccine candidates still depend on costly protein purification, storage and 
transportation. If less expensive vaccines were available, they would be in immediate 
demand worldwide. Recently, it has been demonstrated that transgenic plants represent 
an inexpensive and easily delivered system for the production of animal and human 
vaccines. 
One significant factor that distinguishes plant cells from animal cells is that full-grown 
adult plants can regenerate from individual plant cells and that an adult plant can be said 
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to have been cloned from a single cell of a parent plant (White, 1954; Krikorian and 
Berqua, 1969). This means that the effects of genetic manipulation in plant cells can be 
examined within a relatively short period of time. 
Agrobacterium-mediated transformation (Horsch et al., (1988) is most commonly used 
for generation of transgenic plants expressing foreign gene(s). Agrobacterium (a plant 
pathogen) can transfer a segment of its DNA (T-DNA) into its host plant cells during 
the process of infection. It is known that the transferred DNA (T-DNA) region remain 
functional when separated from the resident Ti plasmid onto two separate replicons in 
Agrobacterium (de Framond et al., 1983; Hoekema et al., 1983). Therefore a gene of 
interest constructed into a plant expression cassette can be transferred into plant 
genomes through a process similar to conjugation. Based on these findings, plant binary 
vectors were constructed and became the most commonly used vector system for 
creating and regenerate transgenic plants. These vectors contain a number of unique 
restriction endonuclease sites which can be used for inserting the foreign genes of 
interest and plant selectable marker(s) between the T-DNA borders and a cloning 
vehicle capable of replicating in E. coli and Agrobacterium. The recombinant plasmids 
containing the foreign gene of interest are transformed into E. coli, and subsequently 
mobilised into an Agrobacterium strain harbouring a Ti plasmid (either wild-type, or a 
"disarmed" Ti plasmid in which the T-DNA is deleted). During tissue culture, 
transformed plant cells are positively selected on medium containing the appropriate 
antibiotics and regenerated into transgenic plants. 
It is clear that the HIV gpl60 plays a pivotal role in the early events of virus attachment 
and entry into the target cell. Neutralising antibodies against HIV found in the sera of 
infected individuals are predominantly directed against this glycoprotein (Matthews et 
al., 1986), and antibodies to HJV gp160 have been detected in genital secretions, urine 
samples, tears, milk, nasal washing, intestinal fluid, cervicular fluid and saliva (Bélec et 
at., 1989a; O'shea et at., 1990; Sun 1990; Thongcharoen et al., 1992; Wolff et at., 1992; 
Constantine et al., 1994; Janoff et al., 1994; Mestecky et al., 1994), suggesting that 
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gp160 is an antigenic target during immune responses to HIV infection. The presence of 
neutralising antibodies might inhibit the transmission of HIV infection in vivo, 
therefore, in this study, tobacco and potato plants were engineered to express a gene for 
lily-i glycoprotein gp160. 
Initially, two different vectors were constructed for either plant leaf or microtuber 
expression systems. A plant binary vector pGPTV-KAN was used in constructing of 
plant vector containing HIV-1 env160. pGPTV-KAN contains the left and right T-DNA 
borders (LB, RB) which denote the limits of the DNA that is integrated into the plant 
genomic DNA via Agrobacterium tumefaciens-mediated transformation. The 
predominant trait of this vector is that the plant selectable marker gene neomycin 
phospho-transferase (nptll) which confers kanamycin-resi stance to the plant was located 
near left border. It is known that T-DNA is transferred from right border to left border 
to plant cells by Agrobacterium mediated transformation (Zambryski, 1992). Therefore, 
the identification of drug-resistant, plant transformants containing complete T-DNA 
insertions is facilitated by using plant vector containing selectable marker gene, nptll 
located close to the left T-DNA border. If nptll is located near the right border of T-
DNA, it increases the likelihood of obtaining plants carrying the selectable marker gene, 
but not necessarily all the genes of interest since kanamycin-resistant plant cells can 
harbour truncated T-DNA insertions. Thus, pGPTV-KAN was the optimal plant vector 
used for constructs containing HIV-1 env160. However, pGPTV-KAN does not contain 
the plant leaf promoter CaMV 35S or tuber promoter patatin. Therefore construction of 
recombinant pGPTV-KAN containing HIV-1 env160 had to be achieved in two stages. 
The cloned gpl60 encoding sequence was initially cloned into plant plasmid pIBT2 10.1 
and pIBT240. 1 to generate the recombinant constructs containing plant leaf specific 
promoter CaMV 35S, and plant tuber-specific promoter patatin, respectively. Then the 
required portion containing env160, 35S or patatin promoter, translation enhancement 
element TEV 5' UTR and mRNA 3' end processing sequence 3'vspB genes was 
subsequently cloned into pGPTV-KAN. 
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Three expression systems were attempted. Tobacco NT-1 cell line was chosen as it 
possesses characteristics of being easily manipulated in the laboratory and the shortest 
transformants regeneration period for expressing HIV-1 gp160 protein. It is well known 
that tobacco transformation by cocultivating leaf discs with the appropriate 
Agrobacterium strain is the paradigm for Agrobacterium-mediated transformation of 
plant tissues and subsequent selection and regeneration of transgenic plants. This 
system has the unique advantage of allowing efficient gene transfer, selection and 
regeneration to be coupled together in a simple process. Furthermore, tobacco is 
naturally susceptible to infection with A. tumefaciens, and also responds exceedingly 
well in culture (Horsch et al., 1988). Therefore the tobacco plant is considered the ideal 
experimental system for the initial establishment of transgenic plant systems. However, 
tobacco tissues are rich in toxic alkaloids that prevent direct feeding to animals as well 
as humans. Once it was established that there was no inherent limitation to the 
expression or aggregation of HIV gpl60 gene in tobacco, other plants were then 
transformed. As an edible vaccine, injection is not the aim; feeding is. That is why the 
potato microtuber expression system was tried. For tobacco "sumsun" and NT-1 cells, 
the recombinant binary vectors pGPTV-KAN-210.1S-envl60 containing HIV-1 env160 
and leaf promoter CaMV 35S genes was used, whereas for potato "FL1607", expression 
vector pGPTV-KAN-240.1S-envl60 containing env160 and tuber promoter patatin 
genes was used. 
The presence of HIV-1 env160 V1/V2, V3/V4 and gp4l regions was detected in the 
selected transformed tobacco plantlets suggesting that HIV env160 had been efficiently 
integrated into the plant host genome. These results are similar to others (Carrillo, et al., 
1998; Tuboly et al., 1999), who reported that most of the transgenic tobacco plants were 
positive for the transgene by PCR. In exploring the presence of the integrated env160 
gene in transgenic plants, it was found that one tested tobacco transformant genome had 
V1/V2 and V3/V4 regions but lacked gp4l region of env160. The reason for this is 
unclear. It is unlikely due to the T-DNA insertion being truncated as the gp4l region of 
env160 is close to the right border of recombinant binary vector pGPTV-KAN-210.1S- 
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env160 and the transfer of T-DNA to plant cells by Agrobacterium-mediated 
transformation is thought to start at the right border (Zambryski, 1992). 
In exploring the transcription and translation of integrated envl60 in transgenic 
plantlets, we have demonstrated the presence and proper processing and translation of 
mRNA of envl60 gene in the leaves of tested transgenic tobacco plantlets. Most of 
tested transgenic plantlets containing env160 gene showed specific transcription of 
env160 gene, and hence detectable expression of HIV-1 gp160 protein. In comparison 
the results of integration, transcription and translation of envl60 in tested tobacco 
transformants, a small portion of transformants showed the presence of env160 genes 
but the absent of the expression of gpl60 protein. The reason for the absence of 
expression of the integrated foreign genes is unclear, and could be due to the site of 
integration of the T-DNA into the plant nuclear chromosomal DNA which is random 
and positional effects can have substantial effects on the level of transcription and hence 
translation in independent transformants. Moreover, three transformants showed both 
integration and transcription of env160 but undetectable expression of gp160 protein 
(Table 5.2). This observation was different from some reports that the expression level 
of foreign protein correlated with the abundance of mRNA detected in each of the 
transformants (Mason et al., 1992; 1996). The reason for this discrepancy is unclear. 
The absence of detectable gpl60 protein in those transformants might be due to the 
short or incomplete translation of mRNA or the amount expressed in the leaves tested 
was not detectable using the current method; or might be because the gpl60 protein in 
transgenic tobacco plantlet leaves degraded before harvest as suggested by other reports 
(Fang et al., 1989; Benfey et al., 1990). 
HIV-1 gpl60 was expressed in transgenic tobacco plantlets, potato microtubers and 
tobacco NT-i cells. The presence of HIV-1 gp16O protein in the plants harboring and 
expressing the foreign genes was investigated by a gp160/120 ELISA using a 
monoclonal antibody to HTV-1 gp120. Because the site of insertion of the transferred 
DNA into the cellular chromosomal DNA is random, protein expression was variable 
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between transformants. The amount of HIV-1 gp160 protein expressed in transgenic 
potatoes was similar to those found in tobacco plantlets. TEV 5' UTR leader sequence 
in the binary vector used for transforming the tobacco plants can enhance the translation 
of foreign gene (Mason et at., 1992; 1996). However, in the present study, a low yield 
of recombinant gp160 in transgenic plants occurred. The selected transgenic tobacco 
plantlets leaves and potato microtubers showed expression levels of HIV gp160 lower 
than those found expressing hepatitis B surface antigen (Mason et al., 1992) or norwalk 
virus capsid protein (NVCP) (Mason et al., 1996). Similar lower yields of recombinant 
protein in transgenic tobacco leaves also occurred to E. coti gene encoding LT-B when 
they were introduced into plant cells (Haq et al., 1995). 
The reason for a low yield of recombinant protein in transgenic plant leaves is unclear. 
It has been reported that the CaMV 35S promoter, while constitutive, is most active in 
rapidly growing tissues but very low in mature tobacco leaves (Benfey et al., 1990; 
Fang et al., 1989). Therefore, the protein of interest may be degraded before harvest. 
This hypothesis may be in part supported by the observation that the expression level of 
foreign protein was not correlated to the presence of mRNA detected in a few 
transformants as described above. To increase expression of HIV gpl60 in tobacco 
leaves, it is necessary to investigate inducible promoter systems with which wasteful 
synthesis-degradation cycles of foreign protein during normal growth and development 
will be avoided. 
It had been reported that the level of expression of gp160 in heterologous systems 
including E. Coli (Crowl et al., 1985a; 1985b), yeast (Barr et al., 1987) mammalian 
cells (Chakrabarti et al., 1986, Dewar et al., 1989) and insect cells (Hu et al., 1987) 
appears to be very low. Examination of the HIV gp160 protein sequence reveals that it 
contains a signal sequence which has an unusually long hydrophobic domain preceded 
by a highly charged region (Douglas et al., 1997). Replacement of the signal sequence 
of HIV-1 Env protein with those of herpes simple virus glycoprotein increase efficiently 
expression of gpl60 in CHO cells and in insect cells (Lasky, 1986; Berman et al., 1988; 
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Culp et al., 1991). These results support the hypothesis that the signal sequence of 
gpl60 may be responsible for the poor expression in plants. Therefore, replacement of 
the signal sequence of HIV-1 gpl60 protein with plant-derived leader sequence and 
signal peptides may be another strategy to increase the expression of HIV gp160 in 
plants. This strategy is further supported by reports that the increase of expression of 
bacterial antigen could be promoted by a plant cell localisation signal polypeptide 
SEKDEL fused to the antigenic protein. The microsomal retention signal SEKDEL 
(Munro et al., 1987) causes compartmentation of the fusion protein, facilitating 
oligomerisation (Hirst et al., 1987). Use of this signal has been shown to be effective in 
producing high level of bacterial antigens in tobacco leaves and potato microtubers 
(Haq et al., 1995; Arakawa et al., 1998). However, there is limited direct evidence 
regarding the role of signal sequence of HIV -1 in biosynthesis of the protein and how it 
might influence expression. Further study is required to clarify this point. 
The expression of HIV gp160 in potatoes may be increased by using a plant-optimised 
coding sequence, which has shown to increase 5 to 40 fold the expression of bacterial 
genes in potatoes (Mason et al., 1998). Taken together, to obtain the high level of 
protein accumulation necessary to make plants efficient vaccine production systems, 
sophisticated gene manipulations are required. However, there is no theoretical 
limitation to the use of plant cells for generation of antigen-encoded DNA sequences 
from human pathogens. 
The work presented in this thesis demonstrates the feasibility of expressing the 
immunogenic HIV gp 160 in plants. I have demonstrated by ELISA that the HIV gp160 
expressed in transgenic plants retained immunoreactivity with mAb to human derived 
HIV gpl20, indicating that the immunodominant epitopes presented in this protein may 
be authentic to native gpl60. However, further study is required to examine properties 
of gp16O produced in plants. The N-glycosylation in higher organisms is conserved but 
differs slightly in details (Faye et al., 1993). The processing of the N-linked glycans 
occurs along the secretory pathway as the glycoprotein moves from the endoplasmic 
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reticulum through the Golgi apparatus to its final destination. Plants however, do not 
introduce sialic acids on its glycoprotein and synthesise N-glycans having carbohydrate 
motifs that are not found in animal cells (Faye et al., 1993). Thus the complex glycans 
of plants are often smaller than those of animals in part due to the difference above, i.e. 
no heterologous system is able to generate mammalian glycan exactly. It has been 
shown that only some of the properties of HIV gp160 depend on its glycosylation. For 
example, the lack of complex-type glycans in HIV gpl20 expressed in insect cells or in 
gpl20 isolated cells treated with trimming inhibitors seems to have no effect on major 
envelope glycoproteins functions like CD4 binding and infectivity (Montefiori et al., 
1988; Morikawa et al., 1990). However, induction of and the sensitivity towards 
neutralising antibodies (Bolmstedt et al., 1992; Benjouad et al., 1994; Sawyer et al., 
1994) or the host cell tropism of the virus (Cheng-Mayer et al., 1990; 1991) may be 
modulated by alterations in glycosylation. It is, therefore, important to analyse in detail 
to what extent glycans of HIV-1 gp160 produced in transgenic plants differ from the 
natural counterpart and how they affect the function of gpl60, in particular, its 
immunogencity. 
Studies on the development of mucosal vaccines against HIV have been shown to 
induce both mucosal and systemic immune response to HIV (Lehner et al., 1992; 
Thibodeau et al., 1992; Mestecky et al., 1994; Morrow et at., 1994; Bond et al., 1995; 
Muster et al., 1995; VanCott et al., 1998; Staats et al., 1996; 1997), which raised the 
possibility that application of HIV antigens on mucosal surfaces may be a fruitful 
approach to vaccination against AIDS. AIDS represents an international health crisis 
that threatens to overwhelm even the best systems of health care delivery. The hardest 
hit regions are developing countries. Therefore, efficient prevention of AIDS epidemic 
in these areas is the paradigm for the goal of controlling this disease worldwide. To 
achieve this goal an efficient vaccine must be developed. However, the key concern of 
the developing world in the areas of vaccine production and supply can be summed up 
as access and affordability. For example, a highly effective and safe vaccine against 
hepatitis B was developed in early 1980s, but its use in developing countries was long 
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prevented by its high cost. Other vaccines of importance to developing countries, such 
as Haemophilus influenzae type b vaccine and an HIV vaccine (hopeful) will not be 
widely used for these countries unless they are affordable. Therefore new, effective, 
safe and cheap candidate vaccines against major infectious diseases will need to be 
developed and evaluated. This is particular true for a vaccine against HIV as well as 
malaria and diarrhoeal diseases. 
The successful expression of HIV-1 gp160 in transgenic plants provides the possibility 
for the generation of a safe and cheap mucosal vaccine candidate against HIV infection. 
However, many issues or technical challenges must still be resolved before plant-based 
production of HIV-1 gp160 for vaccine candidates gains widespread acceptance. Key 
areas include (1) optimisation of protein production levels as described above. (2) Test 
of oral immunogenicity of recombinant antigen gp160 produced in plants. To this end, 
gpl60 produced in plants will be orally administered to animals and induction of 
protective immune response will be investigated. It is known that in addition to the 
delivery or presentation of antigen, the type of adjuvant incorporated in a vaccine is also 
an important determinant of whether a given antigen administered by mucosal route 
may elicit mucosal immune response. Two bacterial products with the greatest potential 
to function as mucosal adjuvants are cholera toxin B subunit (CTB) and the heat-labile 
enterotxin (LT) (Moms et al., 2000; Xu-Amano et al., 1993). (3) Based on the 
achievements from experimental transgenic tobacco and potato system described in this 
thesis, further expression of HTV-1 gp160 protein in edible transgenic plants such as 
tomatoes and bananas, which can be eaten uncooked to prevent antigen denaturation, 
may provide the ideal tool for the development of cheap, safe, effective and convenient 
HIV oral vaccine. 
Plant based oral vaccines offer a new approach to vaccination strategies. The 
demonstration that some antigens of pathogens expressed in transgenic plants are 
immunogenic when administered orally encourage the study of other antigens expressed 
in plants with the goal of developing edible vaccine. Viral antigens from hepatitis virus 
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B (HBsAg) (Mason et al., 1992; 1995), norwalk virus (Mason et al., 1996), foot-and-
mouth disease virus (Carrillo et al., 1998), hemorrhagic disease virus (RHDV) 
(Castanon et al., 1999), and porcine transmissible gastroenteritis virus (TGEV) (Tuboly 
et al., 2000) have been successfully expressed in transgenic plants. Immunisation with 
recombinant viral proteins expressed in transgenic plants induces a protective immune 
response in animals. Clearly research on plant edible vaccines has moved from theory to 
proof-of-principle. The first human clinical trials for a transgenic, plant-derived antigen 
was approved by US food and drug administration and performed in 1997 (Tacket et al., 
1998). Transgenic potatoes constitutively expressing a synthetic bacterial diarrhea 
vaccinogen (LT-B) were orally delivered to human volunteers. All of IgG, IgA and 
sIgA anti-LT-B antibodies were significantly increased in tested participants compared 
to that of those controls. These results demonstrated that transgenic potato plants-
derived recombinant LT-B was protected against digestion and proved capable of 
inducing an immune response in humans. However, challenging questions including 
whether edible vaccine functions at effector sites in the gut; if oral tolerance could be 
developed with food-born antigens, remain to be answered. Although many obstacles 
have yet to be overcome, it is my opinion that they are not roadblocks. The transgenic 
plant edible vaccines will be a potential new generation of novel, encouraging and 
prospective vaccine production and delivery systems with its distinguished 
characteristics including inexpensive production, unnecessary preparation or 
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SOLUTION AND MEDIA 
LB (LB/amp; LB/kan) 
Tyrpton (Difco) 	 log 
Select yeast extract (Difco) 	5 g 
NaCl (Fisher Scientific) 5 g 
Deionized H20 up to 1 litre 
Autoclave 
Coolto 55°C, 
For LB/amp, add ampicillin at 100 pg/ml. 
For LB/kan, abb kanamycin at 50 jig/ml. 
LB aar (LB/amn: LBIkan) DiateS 
Tyrpton (Difco) log 
Select yeast extract (Difco) 5 g 
NaCl (Difco) 5 g 
Bacto-agar (Difco) 15 g 
Deionized H20 up to 1 litre 
Autoclave 
Cool to 55°C, 
For LB/amp agar plates, add ampicillin at 100 pg/ml 
For LBfkan agar plates, add kanamycin at 50 tg/ml. 
Pour into petri dishes (25m1/100mm plate). 
SOB medium (Der litre 
Tyrpton (Difco) 	 20 g 
Yeast extract (Difco) 	 S g 
NaCl (Difco) 	 0.5 g 
Autoclave 
Add 10 ml of 1M MgCl2 and 10 ml of 1M MgSO4 prior to use, 
Filter sterilizing. 
SOC medium (per 100 ml) 
SOB medium 	 99 ml 
2 M glucose 1 ml 
YENB medium (per litre) 
Select yeast extract (Difco) 	7.5 g 
Nutrient broth (Difco) 	 8 g 
B5 vitamin stock 
Myo-inositol 	 100 mg/ml 
Thiamine-HC1 10 mg/ml 
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Nicotinic acid 	 1 mg/ml 
Pyridoxine-HC1 1 mg/ml 
MSO medium (Der litre 
MS salts (Gibco BLR) 	 4.3 g 
B5 vitamin stock 	 1 ml 
Sucrose 	 30g 
IC agar (JRH Bio Science) 	0.8% 
Adjust pH to 5.7. 
MS 104 medium 
MSO 
Benzyladenine (BA) 	 1.0 p.g/ml 
Napthaieneacidic acid (NNA) 	0.1 pg/mI 
Note: Dissolve 50 mg BA in imi IN KOH, then bring to 100 ml with H20 for stock 
solution. 
MS selection medium 
MS 104 
Carbenicillin (AGRI) 	 500 pg/mI 
Kanamycin (AGRI) 300 pg/mI 
MS rooting medium 
MSO with 0.6% Agar 
Carbenicillin (AGRI) 	 500 pg/mi 
Kanamycin (AGRI) 100 pg/mi 
NT-i media and Diate (Der litre 
MS salts (Gibco BLR) 4.3 g 
Sucrose 30 g 
20 x MES (pH 5.7) 50 ml 
B 1 - inositol 10 ml 
Miller's I 3 ml 
2,4 - D (0.5 mg/ml) 4.4 ml 
Adjust pH to 5.7. 
For plates add 8 g/L TC agar (JRH Bio Science), autoclave 25 minutes. 
For NTC add carbeniciliin (250 mg/ml) to make the final concentration of 500 pg/mI. 
For NTKC add carbenicillin to be the final concentration of 100 pg/mi, and kanamycin 
the final concentration of 300 pg/mI. 
20X MES 
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MES 	 lOg 
Adjust pH to 7.5 with 1M KOH 
Deionized H20 up to 1 litre. 
Miller's I 
KH2PO4 	 60 g 
Deionized H20 up to 1 litre. 
B 1 -inositol 
Thiamine (B 1 ) 	 0.1g 
Myo inositol log 
Bring final volume to 1 litre. 
CM medium (Der litre 
MS salts (Gibco BLR) 	 4.3 g 
Vitamins (1000 X) 1 ml 
Sucrose 	 20 g 
Adjust pH to 5.7 
Hazelton agar (JRH Bio Science) 	8 g 
Autoclave 
Pour 60 ml of media per GA-7 Magenta box. 
LC1 medium(per litre 
MS salts (Gibco BLR) 4.3 g 
Vitamines (1000 X) 1 ml 
Sucrose 30 g 
NNA stock solution (1 mg/ml) 0.2 ml 
BAP stock solution (1 mg/ml) 2.24 ml 
GA3 (1 mg/ml) 10 ml 
Adjust pH to 5.7 
Hazelton agar (JRH Bio Science) 8.5 g 
Autoclave 
Pour 30 ml of media per 100 x 20 mm petri plate. 
BAP stock solution 
To 10 mg benzyl amino purine in a 13 ml glass tube, add 0.5 ml IN HCl to 
dissovle. 
LC  c/k medium 
Prepare LC1 as above; 
Cool to 55°C 
Add to each 500 ml portion 
Carbenicillin (100 mg/ml) (AGRI) 2.5 ml 
Kanamycin (25 mg/ml) (AGRI) 	1 ml 
Pour into petri plate as above. 
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LC2 c/k(per litre) 
MS salts (Gibco BLR) 4.3 g 
Vitamines (1000 X) 1 ml 
Sucrose 30g 
BA stock solution (1 mg/ml) 2.24 ml 
GA3 (1 mg/ml) 10 ml 
Adjust pH to 5.7 
Hazelton agar (JRH Bio Science) 8.5 g 
Autoclave 
Cool to 60°C 
Add to each 500 ml portion: 
Carbenicillin (100 mg/ml) (AGRI) 2.5 ml 
Kanamycin (25 mg/ml) (AGRI) 1 ml 
Tubensation media 
MS salts (Gibco BLR) 	 4.3 g 
Sucrose 	 160g 
Kinetin (1mg/mI) 	 10 ml 
Deionized H20 up to 2 litre. Adjust pH to 5.85 
Aliquot 500 ml/1L flask 
Add 4.5 g Hazelton agar (JRH Bio Science) per flask 
Autoclave 
Cool to 55°C 
To each 500 ml media, add 9.5 ml filter sterilized ancymidol. 
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Abbreviations 
ADCC antibody-directed cellular cytotoxicity 
AIDS acquired immunodeficiency syndrome 
bp base pair 
CCR CC chemokine receptor 
CTL Cytotoxic T lymphocytes 
CVF cervicovaginal fluid 
CXCR CXC chemokine receptor 
env envelope 
EUs exposed uninfected individuals 
gp glycoprotein 
HEPS highly exposed, persistently seronegative 
HTV human immunodeficiency virus 




LTNP long term non-progressor 
MEC major histocompatibility complex 
IvlIP macrophage inflammatory protein 
M-tropic macrophage tropic 
nef negative effector function 
NK natural killer cell 
PBMC peripheral blood mononuclear cells 
P1 primary isolate 
pol polymerase 
RANTES reduced upon activation normal T cell expressed and secreted 
rev regulator of expression of virion proteins 
RNA ribonucleic acid 
SDF stromal cell derived factor 
SHIV chimeric SIVIHIV viruses 
SW simian immunodeficiency virus 
tat trans-activator of transcription 
TCLA T cell line adapted 
vif viral infectivity factor 
vpr virion protein R 
vpu virion protein U 
A2 
Contents 
Abbreviations 	 . A2 
1.1 	Introduction............................................................................................................ A4 
1.2 Immune responses against FIIV .............................................................................. A4 
1.2.1 Humoral immune responses................................................................................ A5 
1.2.2 Cell mediated immune responses........................................................................ A8 
1.2.2.1 CD8+ CTL responses to HIV ........................................................................... A8 
1.2.2.2 CD4+ T cell responses to HIV ....................................................................... A13 
1.2.2.3 	ADCC............................................................................................................. A14 
1.2.2.4 Natural killer (NK) cells................................................................................. A15 
1.3 HEPS: role for genetic variation and immunity in resistance to HIV-1 infection A15 
1.3.1 	Genetic 	variation ............................................................................................... A16 
1.3.1.1 Chemokine receptor polymorphisms .............................................................. A 16 
1.3.1.1aCCR5 ............................................................................................................ A16 
1.3.1.1bCCR2b .......................................................................................................... A18 
1.3.1.2FILA ................................................................................................................ A19 
1.3.2 Immunology of REPS ....................................................................................... A20 
1.3.2.1 Humoral immune response............................................................................. A21 
1.3.2.1a IgA in HEPS individuals .............................................................................. A21 
1.3.2.1b Other antibody responses in HEPS individuals............................................ A23 
1.3.2.2 Cellular immune responses ............................................................................ A23 
1.3.2.2a CD4+ T cell responses in REPS individuals................................................ A23 
1.3.2.2b Cli respouses in HEPS individuals............................................................ A24 
1.4 Conclusion............................................................................................................ A29 
1.5 	References............................................................................................................ A29 
A3 
1.1 Introduction 
Primary HIV infection is characterised by a transient viraemia which declines concordant 
with the onset of the specific cytotoxic T-lymphocyte (CTL) response. Seroconversion, 
with the generation of HIV-specific antibodies to Gag, Env and other viral proteins also 
occurs at this time or shortly afterwards (Weiss and Weiss, 2001). The progression time 
from infection with HIV to the development of AIDS may be affected by the 
effectiveness of control of infection by the host immune system (Buchbinder et al., 1999; 
McMichael et al., 2001) as well as host genetic factors such as chemokine receptor 
polymorphism and human leukocyte antigen (HLA) polymorphism (Michael et al., 
1997a), but such factors are ultimately unable to prevent the development of AIDS 
which features greatly diminished numbers of CD4+ T cells (a massive decline from 
normal adult range 1200 cells/mm 3 to <200 cells/mm 3) (Flint et al., 2000; Weiss and 
Weiss, 2001). However, there is substantial variation in susceptibility to HIV infection 
and exposure to HIV does not inevitably lead to infection. Thus some individuals who 
remained HIV seronegative despite being repeatedly exposed to HIV (defined as highly 
exposed, persistently seronegative (REPS) individuals or exposed uninfected individuals 
(EUs)) have been described in different cohorts of at risk individuals including 
homosexual/heterosexual partners of HIV-seropositive individuals and sex workers 
(Rowland-Jones et al., 1995a; Simonsen et al., 1998; Plummer et al., 1999). Thus the 
question raised is how HIV-specific immune response could play a role in protection 
against HIV-1 infection in HEPS individuals while failing to eradicate HIV in most HTV-
1 infected individuals. This paper will focus on the progress in understanding of the 
factors that determine why REPS individuals remain uninfected. 
1.2 Immune responses against HIV 
The immune system in man can be divided into the innate (non-specific) and the 
acquired (specific) immune systems. The innate immune system such as the skin and 
phagocytic cells imposes physical barriers against invading pathogens and is particularly 
important in warding off pathogenic infection presenting at the mucosal cell surface. It 
has become increasingly clear that it may be involved in primary protection against HIV 
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infection. For example, sexually transmitted infections, particularly those which disrupt 
the epithelial barrier and cause genital ulceration, enhance the risk of HIV infection 
(Simonsen et al., 1988; 1998; Grosskurth et al., 1995). If the innate immune system is 
overwhelmed, specific immune responses are then relied on. The specific immune 
responses are divided into humoral and cellular immune responses. They will be 
considered separately here. 
1.2.1 Humoral immune responses 
The humoral immune response, which is characterised by the production of large 
numbers of antibody molecules specific for the invading pathogen, is uniquely adapted 
to the elimination of extracellular pathogens. This process requires the participation of 
macrophages and activated helper T cells and B cells. 
Early research on the immune response to HIV infection focused on the role of the 
humoral immune response because of the strong, early detectable antibody response 
observed in HIV-infected individuals. Antibodies to HIV proteins can appear as early as 
2 weeks and as late as 6 months after infection (Allain et al., 1986; Gaines et al., 1988), 
but generally within 1 to 3 months (Flint et al., 2000). These antibodies are secreted into 
the blood and on the mucosal surface of the body and can be detected in genital and 
other body fluid. It was shown that the viral gpl20 and gpl60 Env proteins were the 
major targets for human antibody responses (Allan et al., 1985; Barin et al., 1985; 
Moore et al., 1994). Antibodies specific for other HIV proteins, including p66, P 55, 
gp4l, p32, p24, and p17, have also been detected (Carlson 1988; Moore et al., 1994). 
Among the various isotypes, IgG i antibodies are believed to play a dominant role at all 
stages of infection, giving rise to ADCC responses and complement-dependent 
cytotoxicity and neutralising responses (Flint et al., 2000). However, a recent in vitro 
study showed that IgG3 from polyclonal anti-ITV antibodies has more potency in 
neutralising 1-1IV-1 compared to that of IgG I and IgG2 (Scharf et al., 2001). This 
difference appears to be due to the unique structure of IgG3 molecule (Cooper et al., 
1994). The long hinge region (located between CHI  and C2 range of heavy chain) of 
IgG3 permits enhanced flexibility of the Fab arms, thus permitting better divalent 
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binding to multivalent epitopes spaced at a certain ranges of distance from each other. 
Whether this advantage occurs in vivo remains unknown. If this phenomenon was 
retained in vivo, strategies which favor IgG3 may provide a new approach for 
improvement of passive immunotherapy with antibodies, and HIV vaccines which 
induce high-titre of IgG3 antibody response could be advantageous. 
In viral infection, the principle role of antibody is neutralisation which prevents cell 
entry. Following primary infection with HIV-1, neutralising antibodies against I-fly-i are 
detectable in the serum within 1-2 months after infection (Koup et al., 1994; Moore et 
al., 1994). A variety of different observations show that early neutralising antibodies 
tend to be of low titer, are not present in all patients after primary infection, and are only 
able to neutralise a limited range of isolates (Moore and Ho 1995; Legrand et al., 1997; 
Moog et al., 1997; Pilgrim et al., 1997; Stamatos et al., 1998). Even following many 
years of HIV infection, most infected subjects mount only weak neutralising responses 
against primary HIV-1 isolates (Sattentau et al., 1996; Burton et al., 1997a). A study of 
17 recently HIV-1-infected patients followed up for 12 months showed that neutralising 
antibodies were not detectable before month 3 (Legrand et al., 1997). Similar results 
have been reported by Moog et al. (1997), who showed that anti-HIV-1 neutralising 
antibodies against the autologous strains were detected about 1 year after 
seroconversion. This slow development of neutralising antibodies during primary 
infection might be one of the reasons the HIV-1 is able to establish persistent infection. 
Similar delays in neutralising antibody responses have been reported for SW infections 
in macaques (Reimann et al., 1994). These observations question whether antibodies that 
arise in response to HIV infection are critical in controlling HIV infection. However, 
recent work showed that HIV-specific antibody, capable of inhibiting autologous and 
heterologous primary strains of HIV-1, in the presence of natural killer (NK) effector 
cells, is detectable in acutely HIV-1 infected-patients when viremia is declining and as 
early as 3 days after the onset of symptoms of acute infection. The magnitude of this 
antibody response was inversely associated with plasma HIV-1 viremia level. 
Furthermore, antibodies from acutely infected patients likely reduced HIV-1 yield in 
vitro both by mediating effector cell lysis of target cells expressing HIV-1 glycoproteins 
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and by augmenting the release of beta-chemokines MIP-ct and RANTES from NK cells 
(Forthal et al., 2001a). Thus HIV-1-specific antibody could be an important contributor 
to the early control of HTV viremia. Baba et al. (2000) demonstrated that passive 
immunotherapy with IgG monoclonal antibodies against the HIV-1 gp120 CD4 binding 
region and the gp4l neutralising epitope, protected rectally SHIV-infected macaques. 
Similar results have been reported by Parren et al. (2001), who demonstrated that the 
neutralising monoclonal antibody (B12) against an epitope overlapping the CD4+ 
binding site of gp120 protects macaques against vaginal challenge with a pathogenic R5 
simian/human immunodeficiency virus (SHIV) when the animals were intravenously 
given 25 mg of B12 per kg of body weight six hours prior to challenge. Neutralising 
antibody against the HIV-1 Env glycoprotein is capable of protecting macaque monkeys 
from chimeric SFHV infection (Shibata et al., 1999). Moreover, HIV-1 serum antibodies 
against monomeric gpl20 from HIV-1 infected individuals can neutralise primary 
isolates of HIV-1 (Stamatos et al., 1998). These studies indicate neutralising antibodies 
may play a role in controlling or preventing HIV-1 infection. 
There are several possible elements to limit the ability of antibodies to neutralise HIV. 
The HIV-1 envelope is initially synthesized as a precursor (gpl60) that is subsequently 
cleaved to yield gpl20 (an extracellular domain) that is noncovalently associated with 
gp4l (a transmembrane protein) (Rao et al., 1995). Several features of the HTV-1 
envelope limit its ability to be neutralised by antibodies. gpl20 is one of the most 
heavily glycosylated proteins identified to date, and these N-linked glycosylation sites 
are believed to limit the ability of antibodies to bind to gpl20 (Luciw, 1996). In addition, 
the HIV-1 envelope exists as an oligomer of three gpl20-gp4l molecules. 
Oligomerisation of the HIV-1 envelope blocks the ability of antibodies that bind to 
epitopes present on monomeric forms of envelope to bind to the oligomeric form. In fact, 
the majority of antibodies present in HIV-infected people recognise monomeric forms of 
envelope including monomeric gpl20 rather than the mature oligomeric protein (Burton 
et al., 1997b). These data suggest that the accessibility of epitopes is important in 
mediating HIV-1 serum neutralisation. 
Another factor critical to understanding neutralising antibodies involves the distinction 
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between T cell line adapted (TCLA) and primary isolates (PIs) of HIV-1. Adaptation to 
growth in T cell lines generally leads to a selection of HIV-1 virus variants which are not 
representative of the original input population (Meyerhans et al., 1989) and are generally 
more easily neutralised than primary virus isolates (Moore et al., 1995). This property 
appears to result from the great accessibility of several epitopes including the V3 loop 
and the CD4 binding site in TCLA HIV-1 strains for antibody neutralisation (Moore et 
al., 1995). As a result of these factors just listed, primary virus isolates are relatively 
resistant to neutralisation by antibodies (Sattentau et al., 1996; Burton et al., 1997a). 
However, York et al. (2001) showed that HIV-1 Env-specific monoclonal antibodies 
against the VP3 loop and the CD4 binding site of gpl60, bind equally well to 
neutralisation-sensitive TCLA Env and neutralisation-resistant PIs Env. This indicates 
that the different neutralisation sensitivity between TCLA and PIs may not be due to the 
differences in the ability of antibodies to bind the respective Env complexes. If the 
antibody binding event is not different for TCLA and P1 virions, then the differential 
outcome of binding (neutralisation or lack thereof) must arise through other factors 
which are unknown. Further research is needed to explore in detail the process and 
mechanisms of virus neutralisation, which will shed light on the development of 
effective HIV vaccines. 
1.2.2 Cell mediated immune responses 
The cell-mediated immunity (CMI) is the principal controlling/eliminating force against 
intracellular pathogens (McMichael et al., 1983; McMichael and Rowland-Jones, 2001). 
CMI is mediated by antigen-specific T lymphocytes and various non-specific cells such 
as NK cells and monocytes/macrophages of the immune system. 
1.2.2.1 CD8+ CTL responses to HIV 
Cytotoxic T lymphocytes (CTL) are major contributors to the antiviral T cell immune 
response. This T cell population carries the CD8+ membrane glycoprotein on the cell 
surface and recognises and lyses virus-infected cells following binding of the T cell 
receptor to a viral peptide presented by a class I HILA molecule on the infected cell. The 
HLA type of an individual thus plays a major role in determining whether an individual 
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will generate a CTL response to a given epitope. Presentation of viral proteins to CD8+ 
CTL requires synthesis of antigen within the cell. 
HIV-specific CTLs were initially described in 1987 and it was remarkable that human 
leukocyte antigen (HLA)-restricted CTLs could be readily detected in freshly separated 
peripheral blood mononuclear cells or in alveolar lymphocytes from ITV-infected 
individuals, without prior in vitro stimulation with antigen (Walker et al., 1987; Flamand 
et al., 1998; McBreen et al., 2001). Subsequent studies demonstrated that HIV-1 specific 
CTLs could be isolated from infected organs, such as spleen (Cheynier et al., 1994), 
lymph nodes (Hadida et al., 1995; Kuroda et al., 1999), and even from the vaginal 
mucosa of Sly-infected macaques (Lohman et al., 1995; Wilson et al., 2000). HIV-
specific CTLs were also found in individuals exposed but not infected by HIV. The latter 
may reflect the ability to control virus early in infection (Langlade-Demoyen et al., 1994; 
Rowland-Jones et al., 1995; 1998a; 2001; Kau] et al., 2001b) and will be discussed in 
section 1.3.2.2b. In vitro studies showed that HTV-specific CD8+ CTL cells are able to 
inhibit FITV-1 replication (Yang et al., 1997) and eradicate HIV-1 (Lu et al., 2001). 
CD8+ CTLs have been demonstrated against most of the HIV gene products, and are 
predominantly directed against the structural proteins Gag, Pol and Env (Borrow et al., 
1994, Betts et al., 1997; Cao et al., 1997; Wilson et al., 1998; Novitsky et al., 2001), but 
also target regulatory proteins such as Nef (Novitsky et al., 2001), Tat and Rev (Addo et 
al., 2001) and the accessory protein Vpr (Altfeld et al., 2001a). The first identified 
peptide epitope was an HLA-B27-restricted 15-mer in gag (Nixon et al., 1988), now 
known to be the decamer KRWIILGLNK (Rowland-Jones and McMichael 1993), and 
subsequently a large number of epitope peptides have been identified and are recorded in 
the Los Alamo HIV Molecular Immunology Database, New Mexico (Korber et al., 
1998). A significant number of CTL epitopes that are located in highly conserved 
regions of the viral genome and are almost identical among HIV-1 clades might be 
responsible for the observed cross-dade CTL recognition (Betts et al., 1997; Cao et al., 
1997; Durali et al., 1998; Novitsky et al., 2001). Work by Durali et al. (1998) 
demonstrated that epitopes conserved between the 1-HV-1 clades A and B appeared 
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especially frequent in Gag p24, Gag p17, integrase, and the central region of Nef. 
However, a series of CTh epitopes including epitopes in Gag 24 that are unique for each 
HIV-1 subtype might be highly dade specific (Rowland-Jones et al., 1998a; Dorrell et 
al., 1999, Cao et al., 2000). Thus identification of immunodominant CTh regions and 
epitopes across the viral genome might help clarify the issue of dade specificity versus 
cross-dade reactivity for HIV-1 vaccine design. 
A striking feature of HIV infection is that HIV-specific CTLs of an infected person can 
be directed toward multiple epitopes in HIV viral proteins. In HIV-infected individuals, 
HIV-specific CTLs responses have been described against six different HLAB*5  101 
restricted epitopes (Tomiyama et al., 1999); six different HLAB*3501  restricted 
peptides (four Pol and two Nef epitopes) (Tomiyama et al., 1997); 11 different HLA-
A*2402 restricted Gag epitopes (Ikeda-Moore et al., 1998) and as many as 13 different 
HLA-A311 1 and HLA-B35/44 restricted Gag, Pol and Nef epitopes (Dalod et al., 1999). 
Similar results have been reported for SW-infected Rhesus macaques. Egan et al. (1999) 
identified CTL responses against as many as five peptides in an SN-infected macaque. It 
has also been observed that CD8+ lymphocytes from the same SN-infected macaque 
could recognise as many as 14 MamuA*01 (a common MHC class I molecule in 
Rhesus macaque) restricted epitopes in SW Gag (Allen et al., 2001). Therefore, the CTh 
repertoire against HIV-1 or SIV may be broad (in the sense of multiple antigens being 
recognised) and multispecific (in the sense of multiple epitopes being recognised within 
the same antigen). However, the range of FIIV CTL epitopes recognised by infected 
individuals may vary since it has also been observed that an entire CTL response was 
directed toward a single epitope in HIV-1 Gag in HIV-infected hemophiliacs over 
several years (Goulder et al., 1997a). 
Studies of CD8+ Cli response at the different stages of disease provide evidence of the 
importance of HIV-1 specific CD8+ Cli in controlling HIV-1 replication and disease 
progression. Borrow and co-workers (1994) reported that the level of HIV-1-specific 
Cli activity in HIV-1 infected patients paralleled the efficiency of control of primary 
viremia. Patients with strong gpl60-specific Cli responses showed rapid reduction of 
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acute plasma viremia and antigenemia, while in contrast, primary viremia and 
antigenemia were poorly controlled in patients in whom virus-specific CTL activity was 
low or undetectable. This observation is consistent with other studies (Ariyoshi et al., 
1992; Koup et al., 1994), which demonstrated that the early decline in plasma viral 
levels shortly after HIV-1 infection coincides with the appearance of HIV-specific CD8+ 
CTLs. In addition, inverse correlations between frequency of peripheral blood HIV-1-
specific CTL and plasma FIIV load have been reported (Ogg et al., 1998). A recent study 
showed that during acute HIV-1 infection, broader HIV-1 specific Cli responses were 
correlated with lower viral load (Aitfeld et al., 2001). The best evidence for the 
protective immune function of the specific Cli derives from the macaque model of SW 
infection. Yasutomi et al. (1993) have detected CTL precursors as early as 4 days after 
SW infection, peaking with viremia at around 2 weeks. Subsequent studies confirmed 
the correlation of SW-specific CD8+ response with viremia control after SW primary 
infection in macaques (Reimann et al., 1994; Chen et al., 1995). Depletion of CD8+ 
cells results in SW replication being uncontrolled during primary infection and high 
virus load in chronically infected rhesus monkeys (Jin et al., 1999). Reappearance of 
SW-specific CD8+ T cells resulted in a decrease in viremia again (Schmitz et al., 1999). 
These data indicate the importance of CD8+ Cli responses that arise in response to 
HIV-1 infection in controlling HIV replication during primary infection, and a role for 
cellular immunity in protection to HIV-1 in vivo. In addition to resolving the viremia of 
acute infection, early generation of HIV-specific CD8+ CTLs may influence the 
subsequent disease course (Borrow et al., 1994; Koup et al., 1994). It was reported that a 
more broadly directed Cli response correlates with slower disease progression 
(Pantaleo et al., 1997). There is an inverse correlation between disease progression and 
HIV-1-specific CTL activity in HIV-1 infected subjects (Musey et al., 1997). Moreover, 
HIV-infected long-term nonprogressors (LTNPs) appear to have been associated with 
strong virus-specific Cli (Klein et al., 1995; Pantaleo et al., 1995). Pontesilli et al. 
(1998) described that LTNPs maintained the established Cli precursor pool, and that 
the frequency of gag-specific Cli precursors was inversely correlated with virus load. 
On the other hand, viral mutation in CTL epitopes can result in viral escape from CTL 
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recognition, which contributes to disease progression (McMichael 1998; Goulder et al., 
1997a). It has been described that CD8+ CTL are capable of exerting significant 
selective pressure on the viral genome during SW infection (Allen et al., 2000; Chen et 
al., 2000) and HIV infection (Borrow et al., 1997), as evidenced by the rapid appearance 
of epitope escape mutations. Allen et al. (2000) demonstrated that SW Tat-specific 
CD8+ T cell responses select for new viral escape variants during the acute phase of 
infection. Sequencing the entire virus immediately after the acute phase showed that 
amino-acid replacements accumulated primarily in Tat CTL epitopes, indicating that 
Tat-specific CTLs may be significantly involved in controlling wild-type virus 
replication. This implies that responses against viral proteins that are expressed early 
during the viral life cycle might be attractive targets for HIV vaccine development. 
In advanced stages of HTV infection, the numbers of CD8+ T cells drop dramatically and 
effector CTLs become low and virtually disappear (Landay et al., 1993; Gamberg et al., 
1999). Differences between the specificity of FIIV-1 specific CD8+ responses has been 
noted during primary and late HIV infection. The work from Goulder et al. (2001) 
showed that in subjects with chronic HIIV-1 infection, the dominant HLAA*0201 
restricted CTL response is directed against the epitope SLYNTVATL ("5L9") in p17 
Gag (residues 77-85), which were not detectable in 11 HLAA*0201-positive subjects 
with acute HIV-1. In contrast, multiple responses to other epitopes were evident in 7 of 
the 11 A*0201positive subjects with acute HIV-1 infection. Furthermore this study 
confirmed that the HLA.A*0201  5L9 response emerged later than. other CTL response 
and after viral set point has been reached. These data showed that the HIV-specific CTL 
responses that are present and even may dominate in MV-1 chronic infection, may differ 
substantially from those constitute the initial antiviral CTL response. 
In addition to cytolytic responses, noncytolytic CD8+ suppressor activity also appears to 
play a role in controlling viral replication in vivo. Noncytolytic CD8+ mediated 
suppression of 1-HV-1 replication was first described by Walker and coworkers (1986), 
who showed that HIV could be recovered from PBMCs of asymptomatic individuals 
only after the CD8+ cells were removed, and that re-introduction of CD8+ cells 
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suppressed virus production in a dose-dependent manner. Mackewicz et al. (1994) 
demonstrated that CD8+ suppressive activity was most marked before seroconversion 
and showed an inverse correlation with plasma viral load in three of seven HIV-1 
infected individuals. The CD8+ suppressive activity was further confirm by the work 
from Blackbourn et al. (1996) who correlated the control of HIV replication in lymph 
nodes to the non-cytolytic anti-HIV activity of CD8+ T cells. A number of different 
factors are believed to mediate this inhibition, including the -chemokines RANTES, 
MIP-la, and MIP-11 (Cocchi et al., 1995; Rubbert et al., 1997), macrophage-derived 
chemokine (Pal et al., 1997) and IL-16 (Baier et al., 1995). 
1.2.2.2 CD4+ T cell responses to HIV 
CD4+ T helper cells play a critical role in regulating production of antibodies, induction 
and maintenance of CTL responses, and activation of macrophages and natural killer 
cells (Walter et al., 1995; Abbas et al., 1996; Ridge et al., 1998; Zajac et al., 1998). 
Rosenberg et al. (1997) found that in HIV-1 infected individuals, who maintain normal 
blood CD4+ T cell counts and appear to control viremia, HIV-1 Gag p24 specific CD4+ 
T cells proliferative responses were observed, resulting in the elaboration of NF-y and 
antiviral f-chemokines. This observation is in agreement with the finding that Gag-
specific CD4+ T cells responses were detected in most HIV-1 infected subjects with 
non-progressive disease (Pitcher et al., 1999). A recent study further demonstrated that 
CD4+ T cells specific for multiple H1V proteins including Gag, Pol, Env and Nef are 
readily detectable in 21 of 23 chronically infected patients (Betts et al., 2001). Similarly, 
SW-specific CD4+ T cell responses are vigorous in macaques infected with attenuated 
SW viruses that are known to be able to induce protective immunity (Gauduin et al., 
1999). It has been shown that rapid suppression of viral replication in acutely SW 
infected animals by anti-retroviral therapy leads to both a relatively robust CD4+ T cell 
response and, in some cases, an enhanced ability to control viral replication after 
subsequent withdrawal of the antiretroviral therapy (Lifson et al., 2000). These studies 
indicate that HIV-specific CD4+ T cell response may be required to contribute to anti-
HIIV host defense. Furthermore, T helper cell responses were found to be associated with 
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}UV-specific CTL responses in HIV-1 infected persons (Kalams et al., 1999a). In a 
model in which SCID mice were engrafted with PBMC from LTNPs, HIV-1-specific 
CD8+T cells were only able to resist subsequent viral challenge when potent gag-
specific CD4+ T cell responses were present (de Quiros et al., 2000). Thus H1IV-specific 
CD4+ T cell responses may be required for maintaining a functional and effective CTL 
responses in HIV infection as has been suggested (McMichael and Rowland-Jones, 
2001), which supports the premise that induction of strong HIV-specific proliferative 
responses may be important for candidate vaccines. 
A key feature of HIV-1 is its ability to infect and cause depletion of CD4+ T cells, 
particularly, activated CD4+ T cells (Veazey et al., 2000). Without potent antiretroviral 
therapy, most mv-i infected persons experience a progressive decline in CD4+ T cells 
and impairment in T helper function (Clerici et al., 1989; Schrier et al., 1989; Valentine 
et al., 1998; Musey et al., 1999; Oxenius et al., 2000). There are several hypotheses 
proposed to explain HIV-mediated depletion of CD4+ cells including accelerated killing 
of mature T cells, altered movement (CD4+ T cells sequestered into lymphoid organs) 
leading to the appearance of CD4+ T cell loss, and impaired production of new T cells 
(reviewed in McCune, 2001). Therefore, it appears that a deficit in these cells is related, 
in part, to the failure of host immune system to completely control mv-i infection. 
1.2.2.3 ADCC 
Virus-specific antibodies may direct the effector cells which bear Fc receptors, such as 
natural killer (NK) cells and monocytes/macrophages, to lyse the infected cell through a 
process known as antibody-directed cellular cytotoxicity (ADCC). Infected cells 
expressing the HIV envelope or CD4 cells pulsed with the gp120 molecule are 
effectively lysed by this process (Lyerly et al., 1987; Ahmad et al., 1994). Antibodies 
capable of triggering ADCC are predominantly of the IgGi class and are directed against 
the envelope proteins (Ljunggren et al., 1988). Antibodies directed against Gag proteins 
are not as effective at inducing ADCC as antibodies directed against Env proteins (Koup 
et al., 1989). 111V-1-specific antibodies capable of inducing ADCC decline as disease 
progresses. This may be related to the level of effector cell function (Tyler et al., 1990). 
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It has been described that a direct correlation of HIV-1 specific ADCC antibody levels 
with viral load was only observed in patients with high CD4+ cell counts (Ahmad et al., 
2001; Forthal et al., 2001b). These studies indicate that ADCC may be involved in 
control of viremia, and CD4+ lymphocytes likely play a role in ADCC functions. 
1.2.2.4 Natural killer (NK) cells 
NK cells represent a discrete lymphocyte subset defined by CD16/56 expression. NK 
cells are spontaneously cytotoxic to tumour and virally infected targets. As such, they 
may play a role in natural resistance to HIV-1-associated disorders and other 
opportunistic infections. NK cells have been shown to be effective in killing HIV-
infected cells (Brenner et al., 1993; UHum et al., 1999; Hultstrom et al., 2000). 
However, peripheral blood NK cell activity is frequently reduced in HIV-1 infected-
patients with HIV-1-induced disease (Brenner et al., 1993), and the impairment of NK 
cell function is observed throughout the course of I-IIV-1 infection (Cai et al., 1990; Hu 
et al., 1995). The causes of NK cell dysfunction in AIDS-related disorders remain 
unknown. An altered expression of important regulatory receptors has been observed on 
NK cells from HIV-infected patients. The inhibitory NK receptor CD94 was up-
regulated (Andre et al., 1999) and the NK activation molecules CD16 and CD56 down-
regulated (Hu et al., 1995). These phenotypical changes as well as the decreased number 
of NK cells in HIV infection (Hu et al., 1995) may contribute to the decreased NK cell 
activity. This reduction in NK cell function may be one of causes of immunodeficiency 
in HIV-1 infection. A recent study of I-ITV-1 exposed but uninfected (HEPS) individuals 
in Vietnam showed the increased NK cell cytotoxicity present in HEPS individuals, 
compared to low-risk donors, indicating that NK cells may, in part, contribute to natural 
protection against HIV-1 (Scott-Algara et al., 2001). 
1.3 HEPS: role for genetic variation and immunity in resistance to HIV-1 infection 
There has been increased interest and intense studies in understanding the mechanisms 
of controlling HIV-1 infection in HEPS individuals. Different immunological features 
and genetic features have been identified to associate with HEPS status at variable 
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frequencies (Devito et al., 2000a; 2000b; Kaul et al., 2000; 2001a; Butera et al., 2001; 
Broliden et al., 2001; Nicastn et al., 2001; Snwanthana et al., 2001). 
1.3.1 Genetic variation 
1.3.1.1 Chemokine receptor polymorphism 
The chemokine receptors belong to a family of G-protein coupled seven transmembrane 
receptors. There are five CC (cysteine-cysteine) chemokine receptors (CCR) CCR-1-5 
and four CXC chemokine receptors, CXCR-1-4 (Baggiolini et al., 1997). It has been 
identified that the ligands for CCR5 are the C-C chemokines RANTES (reduced upon 
activation normal T cell expressed and secreted), MW (macrophage inflammatory 
protein)-la, and MEP- 10 (Cocchi et al., 1995). CCR5 is a major coreceptor for R5 HIV-
1 entry (Alkhatib et al., 1996; Dragic et al., 1996; Berger et al., 1998). The ligand for 
CXCR4 is stromal cell derived factor (SDF)-1 (Bleul et al., 1996; Oberlin et al., 1996). 
CXCR4 is important for X4 HIV-1 entry (Feng et al., 1996; Berger et al., 1998). CCR2 
and CCR3 have also been shown to be minor coreceptors utilised by a few strains of 
virus (Choe et al., 1996; Doranz et al., 1996). CCR3 is involved in vivo in HIV-1 
infection of microglial cells of the central nervous system (He et al., 1997). It has been 
found that CCR2 occurs as two RNA-splicing variants, CCR2a and CCR2b, which differ 
in their COOH-terminal regions and may affect signal transduction, but not ligand 
binding (Folks et al., 1988; Steinberg et al., 1991). CCR2b is naturally utilized by Sly 
isolates in mangabey macaques (Chen et al., 1998). 
1.3.1.1a CCRS 
It has been demonstrated that a 32-bp deletion (A32) in the CCR5 gene leads to a 
premature stop codon and results in encoding a nonfunctional protein. Liu and 
coworkers (1996) reported that a homozygous CCR5i32 defect in CCR5 gene was 
found in two HEPS individuals. The encoded protein is severely truncated and can not 
be detected at the cell surface. Moreover, this defect had no obvious phenotype in the 
affected individuals. Subsequent studies showed that people who are homozygous for the 
deleted allele (A32) are highly resistant to I-fly-i infection in vivo (Dean et al., 1996; 
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Huang et al., 1996; Samson et al., 1996; Michael et al., 1997a), and cells from such 
people are resistant to the infection by HIV-1 M-tropic strains in vitro (Connor et al., 
1996; Liu et al., 1996; Rana et al., 1997). These results indicate that mutant CCR5A32 
confers resistance to HIV-1 infection in vivo as well as in vitro. 
Population analyses have shown the CCR532 mutant allele to occur at a high frequency 
(8-21.7%) in Caucasians and low frequency (0-6.9%) in all other ethnic groups studied 
(Liu et al., 1996; Huang et al., 1996; Samson et al., 1996; Zimmerman et al., 1997; 
Ruchusatsawat et al., 2000). An A32 allele frequency of 9.2-10% (Liu et al., 1996; 
Samson et al., 1996; Martinson et al., 1997) in Europeans and 8-21.7% in Caucasian 
Americans (Huang et al., 1996; Zimmerman et al., 1997) showed the mutation is highly 
prevalent in these populations. A recent study showed that CCR5WT/A32 (heterozygous 
genotype) and CCR532h32 (homozygous genotype) may be associated with protection 
against HIV infection among high-risk HIV seronegative Caucasian homosexual men 
(Marmor et al., 2001), indicating the protective role of heterozygous genotype 
CCR5WT/32 and homozygous genotype CCR5A32/32 in HIV-1 infection among 
Caucasian populations. 
Based on the observation that homozygous A32 provides resistance to HIV-1 infection in 
Caucasian populations, the hypothesis that people who carry one deleted and one normal 
allele (heterozygous) A32 genotype can be partially protected against HIV-1 infection, is 
suggested and demonstrated by a couple of studies (Samson et al., 1996; Hoffman et al., 
1997). It was found heterozygous CCR532 slows the rate of disease progression in 
infected Caucasian homosexuals (Zimmerman et al., 1997). The presence of two 
CCR5wtJi32 heterozygous genotypes among 139 high-risk HIV-seronegative Africans 
(1.44%) was reported and PBMCs from these two heterozygous individuals were also 
found to be less susceptible to FIIV-1 M-tropic isolates infection in vitro (Kokkotou et 
al., 1998). Heterozygotes have been shown to express less CCR5 on the surface of cells 
(Wu et al., 1997), which may result in reduced rate of viral replication and slowed 
progression to disease. 
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Although they are extremely rare, a few reports showed homozygotes for CCR532 are 
present in HIV infected individuals (Balotta et at., 1997; Biti et at., 1997). Furthermore, 
further studies demonstrated that the CCR532 failed to account for most HEPS cases 
studied (Beyrer et al., 1999; Goh et al., 1999; Sriwanthana et al., 2001). Two studies 
reported that only 1 of 37 HIV-1 HEPS individuals had the homozygous CCR5 32-bp 
deletion (32Iz32) (Akridge et al., 1999; Goh et al., 1999). This observation was 
confirmed by another study which demonstrated that none of 17 FIIV-1 exposed 
seronegative women had the CCR5 32/32 genotype associated with HIV-1 resistance 
(Bernard et al., 1999). Studies from other populations including Thai HEPS individuals 
(Beyrer et at., 1999; Sriwanthana et al., 2001) and Nairobi-based Pumwani HEPS sex 
workers cohort (Fowke et at., 1998) also showed no CCR5 polymorphism associated 
with resistance to I-IIV-1 infection. 
1.3.1.1b CCR2b 
A mutation in the CCR2b receptor gene has also been reported. The mutation occurs at 
CCR2b amino acid position 64 which is a valine to isoleucine amino acid substitution 
(641) in the first transmembrane domain (Smith et al., 1997). Unlike the CCR5A32 
allele, which inactivated the major HIV-1 entry coreceptor, CCR2b-641 caused a 
conservative change and has not shown to effect expression and ligand binding 
(Kostrikis et al., 1998). Genetic association analysis of five AIDS cohorts (3003 
patients) enriched with seroincident subjects (whose the date of seroconversion is 
known) revealed that individuals expressing the CCR2 mutation 641 showed a delayed 
progression to AIDS, but that the polymorphism had no influence on the incidence of 
HIV-1 infection (Smith et al., 1997). This observation was confirmed by subsequent 
study (Anzala et at., 1998), but questioned by another study which reported that there is 
no association of CCR2b-641 with delayed AIDS progression (Michael et at., 1997b). It 
appears that these HIV-1 coreceptor mutant alleles CCR5z32 and CCR2b-641 may play 
a partial role in reducing HIV-1 transmission risk and delaying disease progression. 
In addition, a mutation in the 3' untranslated region of the SDF-1 chemokine gene which 
causes a glycine to alanine switch at amino acid position 801 (SDF-1 3'A) has been 
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described. This mutation, in homozygotes, delays the onset of AIDS, furthermore, the 
SDF-1 3'A effect on disease progression was stronger, than either CCR5i32 or CCR2b-
641 (Winkler et al., 1998). Recently, Sriwanthana et al. (2001) reported a higher 
frequency of SDF-1 3'A in REPS women in Thailand, compared to the healthy controls. 
These data suggested the role of SDF-1 3'A in influence HIV-1 transmission or course of 
disease. The mechanism of this SDF-1 3'A function is not clear, but might relate to the 
role of SDF-1 as ligand for CXCR4, which, in turn, might interfere with the interaction 
between the X4 HIV-1 and the CXCR4 coreceptor. 
1.3.1.2 HLA 
Human leucocyte antigen (HLA), the term for human major histocompatibility complex 
(MHC), encompassing class I and class II loci, is highly polymorphic. Class I is encoded 
by the A, B and C genes and class H by the DP, DQ and DR genes. Class I is expressed 
on the surface of nearly all nucleated cells and recognised by T cytotoxic cells. Class II is 
expressed primarily on B cells, dendritic cells and macrophages and is recognised by T 
helper cells. 
Individual differences seen in HIV-1 susceptibility and AIDS, led to investigations of the 
influence of HLA on HIV infection and disease. An early study showed the HLA types 
A25, A32, B18, B27, B51 and B57 were associated with slow progression to AIDS; and 
A23, B37 and B49 were associated with rapid progression to AIDS (Kaslow et al., 
1996). Subsequently, a comprehensive analysis of HLA genes in HIV-1 cohort 
consisting of 200 slow and 75 rapid progressors to AIDS provides further evidence that 
HLA alleles are associated with fast or slow progression. They identified that HLA class 
I genes A29, B22, B35 and C16 are associated with rapid progression, whereas B14, 
B27, B57, C8, C14 are associated with non-progression. Only the lILA class H allele 
DR1 1 was influential (Hendel et al., 1999). Carrington et al. (1999) revealed that HLA 
class I allele B35 and Cw4 were associated with rapid progression to AIDS in 
Caucasians. Moreover, they found the extended survival of between 28% and 40% of 
The FIIV-1 infected Caucasian individuals who were AIDS-free for over ten years could 
be attributed to their being fully heterozygous at HLA class I loci, lacking B35 and Cw4 
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alleles, or both. A study of an HIV-1 infected long term non-progressor (LTNP) cohort 
revealed a association between HLA class I subtype B5701 allele and non-progressive 
infection (Migueles et al., 2000). These data suggest that HLA alleles can affect the 
course of H1V infection and disease. 
Recent studies reported that certain HLA alleles were associated with HIV resistance 
(MacDonald et al., 2000; 2001; Snwanthana et al., 2001). Analysis of a longitudinal 
cohort of REPS Nairobi and Kenya female sex workers demonstrated that decreased 
HIV-1 infection risk was strongly associated with possession of a cluster of closely 
related HLA alleles in the A2/6802 supertype comprising A0202, A0205 A0214 of the 
HLA-A2 subtype and A6802 of the HLA-A28 subtype. In addition, resistance to 1HV-1 
infection was independently associated with HLA DRB 101 (MacDonald et al., 2000). A 
later study further showed that the HLA class I alleles A2/6802 were associated with 
decreased 1 ­1IV-1 infection risk in perinatally exposed infants (MacDonald et al., 2001). 
Studies of REPS Thai female sex workers revealed a high frequency of HLA- All 
(86%) and HLA-1318 (17.6%) in REPS women compared with low risk healthy controls 
(56% for All and 1.1% for B18) (Beyrer et al., 1999; Sriwanthana et al., 2001). These 
date indicate that certain HLA alleles may present HIV-derived antigenic peptides which 
stimulate immune responses, clearing the virus in at least some exposed FIIV-1 
uninfected individuals. 
1.3.2 Immunology of HEPS 
There is increasing evidence that a range of immune responses including cellular 
immune responses (Clerici et al., 1992; Rowland-Jones et al., 1993; 1995a; 1997; 
1998a; 1998b; 1999; 2001; Kaul et al., 2001b; 2001d), and IgA responses to HIV-1 
(Mazzoli et al., 1997; 1999; Kau] et al., 1999; 2001a; Devito et al., 2000a) are generated 
in REPS populations which play an important role in preventing REPS individuals from 
HIV-1 infection. 
13.2.1 Humoral immune response 
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1.3.2.1a IgA in HEPS individuals 
HIV-1 specific IgA mediated mucosal and systemic immunity have been demonstrated in 
HEPS individuals. A study of sixteen Italian couples discordant for FIIV infection, of 
whom one member was HEPS and another HIV-1 seropositive, demonstrated that H1V-1 
specific IgA but not IgG was present in serum, urine and vaginal wash samples from 
HEPS individuals, whereas both IgA and IgG were observed in those samples from their 
HTV-1 infected partners (Mazzoli et al., 1997; 1999). 5 of 15 sera from HIV-1 exposed 
seronegative individuals were shown to be able to neutralise primary HIV-1 isolates and 
in 2 cases such neutralisation was retained by serum-purified IgA (Mazzoli et al., 1999). 
HIV-1 specific IgA was also detected in genital tracts of 16 out of 21(76%) HIV-1 
resistant Kenyan sex workers (Kaul et al., 1999); and in cervicovaginal lavage fluids of 6 
of 13 (46.1%) Thai HIV-1 HEPS women (Beyrer et al., 1999). When IgA was purified 
from plasma, cervicovaginal fluid (CVF) and saliva samples from HIV-1 resistant 
Kenyan female sex workers, the neutralisation activity of purified IgA was detected in 
73% of plasma; 79% of CVF and 73% of saliva samples. The IgA-mediated 
neutralisation activity present in HEPS is HIV-1 specific because recombinant gpl60 
could block the activity and IgA depleted samples failed to neutralise HIV-1. In contrast, 
IgA from plasma, saliva and CVF samples of low risk uninfected HIV-seronegative 
individuals lacked neutralising activity (Devito et al., 2000a). The cross-dade 
neutralising activity of IgA from Kenyan HEPS sex workers was demonstrated by a 
recent study. IgA from both mucosal and systemic sites was able to neutralise primary 
viral isolates from dade B, clades A and D, which predominate in Kenya. Cross-dade 
neutralising activity appeared to be broadest in CVF samples and lowest in saliva 
samples, which indicated that the genital tract has a higher frequency of exposure to 
HIV-1 than the oral route in these HEPS sex workers (Broliden et al., 2001). Recently, 
Trabattoni et al. (2001) reported that HTV-1 specific IgA was detected in semen and 
urethral swabs of all 12 HEPS heterosexual males, but not in healthy controls. 4 of 12 
seminal fluids from these HEPS males showed neutralising activity against two HIV-1 
primary isolates. These results suggest the HIV-1 specific IgA may play an important 
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role in protection of HEPS male and female individuals from FHV-1 infection. 
The epitopes of HIV-1 recognised by HIV-1 specific neutralisation IgA of serum from 
HIV-1 exposed seronegative were analysed and compared to those of HIV-infected 
patients (Pastori et al., 2000). Neutralisation of primary }IIV-1 strains of IgA of HEPS 
individuals was shown to be mediated by the recognition of different epitopes from H1V-
1 infected patients. IgA of HEPS exclusively mapped to epitopes within 1HV-1 gp4l, 
whereas IgA of HIV-1 infected individuals recognize epitopes within both gpl20 and 
gp4l. Furthermore, epitopes on gp4l seen by IgA of HEPS were restricted to aa 581-584 
regions of gp4l, in contrast, those seen by IgA of HIV-infected patients were identified 
within aa 589-618 and aa 642-673 regions of gp4l. These results have important 
implications for the development of HIIV-1 preventive vaccines. 
The ability of HIV-1 specific IgA from HEPS individuals to inhibit HIV-1 epithelial 
transcytosis has been investigated using a transwell system. The apical-basolateral 
transcytosis of primary 1HV-1 isolates across human mucosal epithelium was modelled 
using two chambers separated by a nitrocellulose filter on which a tight monolayer of 
epithelial cells was allowed to grow. The upper chamber represented the apical (luminal) 
side to which HP/-i infected PBMCs were added. The lower chamber represented the 
basolateral (mucosal) side to which antibodies tested were added. The effect on HIV-1 
epithelial transcytosis of IgA, isolated from the genital tract, saliva, and plasma of HEPS 
individuals including a sex worker cohort in Nairobi, Kenya and a discordant couple 
cohort in Italy, were evaluated. The results showed that purified IgA (three of six CVF 
samples, five of ten saliva samples, and three of six plasma samples from HEPS 
individuals) was able to inhibit FI11V-1 transcytosis. In contrast, IgA from low risk, 
healthy control subjects had no inhibitory effect on HIV-1 transcytosis. Moreover, the 
main part of the inhibition of HIV-1 transcytosis by the IgA antibodies was shown to be 
at the intracellular level (Devito et al., 2000b). Recently, Broliden et al. (2001) found 
that IgA purified from saliva, CVF and plasma of Kenya HEPS sex workers could 
inhibit FIJV-1 transcytosis in approximately 50% of samples tested. These results 
indicated that the mucosal IgA present in HEPS individuals could mediate intracellular 
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neutralisation in epithelial cells at the mucosal site in a way that has been reported by 
Bomsel et al. (1998), in which it was demonstrated that the epithelial transcytosis of 
primary FHV-1 isolates could be blocked by anti-H1V-1 dimeric IgA. Because the most 
common way of spreading H1V is sexual transmission (Overbaugh et al., 1999), the 
presence of FHV-1 specific IgA in HEPS individuals in the genital tract could offer a 
potent first-line defense, and IgA in sera may form a second line of defense, against 
HIV-1 infection. Thus these observations may, in part, contribute to HIV-1 resistance in 
HEPS people. 
1.3.2.1b Other antibody responses in HEPS individuals 
It was reported that anti-CD4 autoantibodies were detected in 33-34% HIV-1 exposed 
seroneagtive individuals (Burastero et al., 1996; Lopalco et al., 1999). These antibodies 
could block FIIV-1 driven syncytia formation, and inhibited the ability of CD4 binding to 
specific anti-CD4 monoclonal antibodies, but did not interfere with the CD4-gp120 
interaction (Burastero et al., 1996). A recent study showed that antibodies against HLA 
class I and CD4 were found in 11 of 17 and 9 of 17 HEPS sera (but none of the low risk 
control sera) (Lopalco et al., 2000). The correlations between the HEPS status and either 
anti-HLA antibodies or anti-CD4 antibodies were statistically significant (Lopalco et al., 
2000). These results indicated that in some HEPS individuals, the resistance to HTV-1 
infection, may be associated with autoantibodies which are possibly specific for cellular 
antigens involved in the MV-1 infection process. 
1.3.2.2 Cellular immune responses 
1.3.2.2a CD4+ T cell responses in HEPS individuals 
Specific CD4+ I cell responses to HIV-1 in the absence of anti-HIV IgG antibody 
detection were first described in 5 of 5 repeatedly exposed, but HIV-1 seronegative, 
homosexual men. Peripheral blood mononuclear cells (PBMC) from these subjects 
secreted IL-2 in response to a panel of HIV envelope peptides (Clerici et al., 1992). 
Similar results were reported from other studies. Mazzoli et al. (1997) found that 
following HIV-1 Env-stimulation, PBMCs from 9 of 16 Italian HEPS individuals 
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secreted more IL-2 than those from HIV-1 infected individuals. Kau] et al. (1999) 
reported that systemic T helper lymphocyte responses to HIV-1 envelope peptides were 
detected in 11 out of 20 (55%) HIV-1-resistant Kenyan female sex workers. A similar 
observation was also reported by Fowke et al. (2000) who found that HIV-1 resistant 
Nairobi female sex workers had significantly increased HIV-1 specific T-helper 
responses, as determined by in vitro IL-2 production to HIV-1 envelope peptides and 
soluble gpl20 (compared to low-risk seronegative and HIV-1-infected controls). T-
helper cell responses to HIV-1 envelope peptides were also detected in 38% newborns of 
HIV-infected women by measuring IL-2 production. No HIV-1 infections were acquired 
in those infants in whom T helper cell responses were detected in cord blood at the time 
of delivery or post-natally through breast-feeding (Kuhn et al., 2001). These data support 
the suggestion that HIV-1 specific T helper cell responses contribute to natural resistance 
to HIV-1 infection, possibly by supporting CTL responses in HEPS individuals. 
1.3.2.2b CTL responses in HEPS individuals 
Rowland-Jones et al. (1993) demonstrated HIV-1 specific CTLs in an uninfected child 
born to an I-llV-1 seropositive mother, which provided a suggestive role of CTL in HIV-
1 infection and clearance, although the reactivity was only transient, possibly related to 
the loss of persistent antigenic stimulation. Further reports soon followed of 1HV-1 
specific CTLs in exposed HIV-1 seronegative (HIEPS) individuals. Detels et al. (1994) 
described that higher levels of neutrophils and CD8+ cells were present in repeatedly 
exposed HIV-1 seronegative homosexual men than in HIV-1 seropositive males. 
Rowland-Jones et al. (1995a) demonstrated the presence of HLA class I restricted HIV-
2-specific Cli in 5 of 6 HEPS Gambian female sex workers. HIV-specific Cl'L were 
subsequently found in 6 out of 15 highly exposed and apparently HIV-resistant Kenyan 
sex workers, predominantly towards epitopes highly conserved between B dade and the 
Kenyan A & D clades of HIV-1 (Rowland-Jones et al., 1998a, 1998b). The strong 
implication from these studies is that the presence of HIV-1-specific CTL may, in part, 
contribute to HIV-1 resistance in REPS. The hypothesis was further supported by a 
number of studies within MV-1 discordant partners (of whom, one repeated high-risk 
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sexual activity with an HIV-1-infected partner, but retained V-1 seronegative (HEPS) 
status), which demonstrated HIV-specific CTLs present in 35% (Akridge et al., 1999); 
36% (Goh et al., 1999) and 41.1% (Bernard et al., 1999) of HEPS individuals with the 
absence of inherited CCR5t32 defects. These results indicate that cellular immunity 
rather than inheritance of the i32 CCR5 mutation accounts more often for persistently 
HIV-1 resistant cases. Up to date, HIV-specific CTLs have now been described in a 
number of studies in HEPS cohorts of the sex workers (Rowland-Jones et al., 1995a; 
1998a; Kaul et al., 2000; 2001b, 2001d; Snwanthana et al., 2001); HIV-1 discordant 
couples (Zerhouni 1997; Akridge 1999; Bienzle et al., 2000; Goh et al., 1999; Nicastri et 
al., 2001; Trabattoni et al., 2001); homosexual men (Paxton et al., 1996; Schmechel et 
al., 2001); infants borne to HIV-1 infected mothers (Rowland-Jones et al., 1993; de 
Maria et al., 1994); health care workers with occupational exposures (Pino et al., 1995) 
and recently intravenous drug users who remain HTV seronegative despite exposure to 
HIV through needle sharing with HIV infected partners (Makedonas et al.,2001). 
The presence of local HIV-specific IgA mediated humoral immune responses (see 
section 1.3.2.1a), raised the interest and possibility that local HIV-specific cellular 
immune responses, may be present in HEPS individuals, which has recently been given 
credence by Kau] and his colleagues (2000; 2001d). They have demonstrated that HIV-
specific CD8+ CTL responses were found in 11 of 16 (69%) cervix samples from HIV-
1-resistant REPS and none from low risk individuals using an IFN-y ELISPOT assay. 
Furthermore, lily-i-specific CTL responses in the cervix directed against the same 
epitopes as the systemic CTL responses in 9 of 11 (82%) resistant sex workers. The 
frequencies of HIV-specific CD8+ cells were slightly higher in cervix than in blood in 
HEPS sex workers, whereas in i-flY infected individual cervical CTL response 
frequencies were lower than in blood, which indicated that there was relative enrichment 
of CD8+ CTLs in the genital mucosa in H[V REPS compared with RIV infected 
individuals. These data suggest that mucosal cellular immunity may play an important 
part in resistance to HIV-1 heterosexual transmission in REPS people. The mechanism 
by which these mucosal CTL could function remains unclear. It has been demonstrated 
HIV-1 can cross into the submucosa by transcytosis across a tight epithelial barrier, a 
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process that can be inhibited by HIV-specific IgA (Bomsel et al., 1998; Devito et al., 
2000b), and that such virus can infect CD4+ and CCR5+ T cells and macrophages 
present in this region (Patterson et al., 1998; Yeaman, et al., 1998). Furthermore, the 
cervical submucosa is well supplied with CD8+ T lymphocytes (Olaitan et al., 1996), 
and CD3+ cytolytic activity is present in the genital tract (Olaitan et al., 1996; Patterson 
et al., 1998; Yeaman et al., 1998). These data lead to the hypothesis that HIV-1 specific 
cervical CTLs in the submucosa may target susceptible host cells, which have undergone 
productive infection by HIV-1 after viral transcytosis across the epithelial membrane, 
and thus may play a role in HIV infection and clearance. 
Shearer and Clerici (1996) proposed that the resistance against 1-HV infection in HEPS 
individuals who exhibit HIV specific cellular immune responses may be in part, acquired 
immunity through "natural immunisation". Accidentally-acquired immunity may 
therefore protect from HTV infection. This possibility has been supported by work from 
Zhu and colleagues (1999), who have detected HIV-1 viral sequences from bulk CD4+ 
lymphocytes in a minority of HEPS subjects. However, the phenomenon of H1V-1 
resistance is not absolute. Maintenance of HIV-1 natural immune resistance will require 
ongoing antigenic priming, which has been demonstrated by Kaul and his coworkers 
(2001c; d). They have found that 12 (approximately 10%) of Kenyan HIV-1 resistant sex 
workers, who used to be HIV-1 resistant despite high exposure to HIV-1 (11 of 12 had 
had an estimated 527 unprotected exposure for an average of 6.9 years), eventually 
became HIV-1 seropositive despite preceding FIIV-1 specific CD8+ responses. 
Comparison of immunological and behavioral variables between late seroconverters and 
persistent REPS sex workers controls revealed that seroconversion was correlated with a 
reduction in sex work over the preceding year which resulted in waning of HIV-specific 
CD8+ responses. A break from sex work was associated with a loss of HIV-specific 
CD8+ responses, although restarting sex work led to the return of HIV-1 specific CTL 
responses. Subsequently, it was found there is an association between the duration of 
uninfected HIV exposure and both the frequency and magnitude of HIV epitope-specific 
CTL responses (Kaul et al., 2001b). These findings suggested that ongoing HIV 
exposure may be necessary to maintain an efficient HIV specific CTL response in REPS 
FEW 
individuals, as is seen in antiretroviral therapy treated chronic HIV-1 infection patients 
whose levels of HIV-1 specific Cli responses declined after suppression of viremia 
with potent antiretroviral therapy (Dalod et al., 1998; Kalams et al.,1999b; Ogg et al., 
1999a; Nixon et al., 1999). Similar results were also found in health care workers and 
infants born to 1-HV-1 infected mother, after a single exposure to HIV by needle-stick 
injury or at birth, HIV-specific cytotoxic and helper T lymphocyte responses can be 
detected but fall below the limits of detection within 2-8 months (Rowland-Jones et al., 
1993; Pinto et al., 1995). 
It has been showed that HIV-1 specific CTLs detected in REPS individuals were specific 
for HLA class I restricted epitopes within HIV-1 Env, Gag, Pol, Nef and Rev (Rowland-
Jones 1995a; 1999; Kaul et al., 2001b; d; Schmechel et al., 2001). H1V-specific CTL in 
two groups of African REPS female sex workers shows extensive cross-dade reactivity 
between different viral sequences. In a small group of Gambian HIV resistant women 
exposed to both HIV-1 and HIV-2, studied over 4 years, HLA-B 35 -restricted CTL were 
repeatedly detected and exhibit cross-reactivity between the IIIV-1 and HIV-2 sequences 
of the Cli epitopes (Rowland-Jones et al., 1995a). In Kenyan 1HV-1 resistant female 
sex workers, HI1V-1 specific CTLs were detected directed towards epitopes conserved 
between HIV-1 clades B, A and D (Rowland-Jones et al., 1999). To elucidate the 
mechanism of protective FIIV-1 specific Cli responses in REPS individuals, Kaul et al. 
(2001b; c) have recently compared the specificity of CTL epitopes between 91 REPS 
and 87 HIV-1 infected Kenya sex workers. The results revealed that at certain HLA class 
I restricted HIV-specific CTL responses in HIV-infected women tended to be against 
epitopes rarely or never recognised in REPS individuals, and at these same alleles, 
responses in REPS women tended to recognise epitopes that were subdominant, or 
unrecognised in infected women. Furthermore, these differences in epitope specificity 
were only seen for responses restricted by HLA class I A2, A24, A6802, B14 and B18 
which were shown to be associated with HTV-1 resistance (MacDonald et al., 2001). It 
was also found that later seroconverters in REPS sex workers was associated with an 
epitope specificity switch to those preferentially recognised by HIV-1 infected sex 
workers. These data suggested that there may be functional differences between 
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specificity of CTLs for different epitopes. 
The HIV- 1 specific CTL responses in HEPS population are generally low in magnitude 
and breadth (Herr et al., 1998; Rowland-Jones et al., 1998b; Kaul et al., 2000; 2001b; 
Schmechel et al., 2001; Sriwanthana et al., 2001). It has been shown that the CTL 
responses in HTV infected individuals were approximately tenfold stronger than those in 
REPS individuals (Kaul et al., 2000; 2001b; d). HIV-1 specific CTLs are believed to be 
important in controlling viremia and preventing disease progression in HIV-infected 
individuals (Borrow et al., 1994; Ogg et al., 1998; 1999b), but are ultimately unable to 
prevent the development of AIDS and death (Wodarz and Nowak 1999). Thus the 
question raised is how HIV-specific CTL could play a role in protection against HIV-1 
infection in HEPS individuals while failing to eradicate H1V in HIV-1 seropositive 
individuals. To answer this, based on the described observation in HEPS cohorts as 
above, Rowland-Jones (2001) recently proposed a hypothesis that the quality of T cell 
response, rather than its magnitude, in HEPS individuals may be different from HIV-1 
infected individuals and thus may be an important factor to provide the REPS status. 
Both the quality of CTL responses and the presence of effector T cells in the genital tract 
(encountering virus following sexual exposure) may be of importance. Animal models 
suggested that murine mucosal rather than systemic (splenic) HIV-specific CTL were 
necessary to confer resistance to mucosal viral transmission (Belyakov et al., 1998). A 
study in SN-infected rhesus macaques has shown that class I HLA-restricted SN Env 
specific CTL responses in the jejunal lamina propria was correlated with protection from 
SlY challenge (Murphey-Corb et al., 1999). These studies indicate that HTV-specific 
Cli present in the genital tract are likely to be important in mediating protective 
immunity against sexual transmission of HIV- 1. The specificity of Cli responses were 
directed towards conserved regions of HIV-1 which were likely to be functional 
importance to the virus. As discussed above, resistance to HIV-1 is, in part, related with 
specific class I HLA molecules (MacDonald et al., 2001), these alleles might be 
represented in particularly efficient HIV-specific CTL or present specific protective 
epitopes (Kaul et al., 2001d). It has been described that low levels of perforin and low 
production of INF-y were detected in CD8+ T cells of chronically HJV infected subjects 
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(Appay et al., 2000), which indicated the functional impairment of HIV specific CD8+ 
cells in HIV-1 infected individuals. However, such parameters (function of CD8+ T 
cells) have not been studied in HEPS population, and it is worth to investigate the intact 
function of CD8+ T cells and its association with resistance to HIV infection in HEPS 
individuals. 
In addition, noncytolytic activity of T cells also appears to play a role in resistance to 
FIIV infection in HEPS individuals. The factors responsible for such protection have not 
been clearly identified. Recent work from Butera and colleagues (2001) showed an 
association between production of a novel viral suppressive activity with resistance to 
infection among Thai HIV-1 HEPS female sex workers. Further study showed that this 
activity was the unique product of CD4+ T cell and CD16+ monocyte cocultures. The 
exact mechanism by which of this novel viral suppressive factor could function remains 
unclear. 
1.4 Conclusion 
Identification of the components of protective immunity is crucial for the development 
of effective prophylactic and therapeutic vaccine strategies. Analysis of HIV-specific 
responses in highly exposed but persistently HTV seroneagtive (HEPS) individuals may 
thus provide a unique resource to elucidate the components and correlates of protective 
immunity to HIV. So far considerable progress has been made toward understanding of 
the factors that determine the REPS status. These results suggest that a combination of 
factors, including IgA mediated humoral immune responses, both mucosal and systemic 
cellular immunity and also host genetic factors, may be involved in the resistance to HIV 
infection in HEPS people. These findings are of great importance to help define factors 
related to protective immunity against HIV which is desirable for an effective HIV 
vaccine. More research is necessary to shed further light on the mechanism of the genetic 
and immunological correlates of this condition. 
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Abbreviation 
AIDS acquired immunodeficiency syndrome 
ALVAC Albany vaccine 
BCG Bacille Calmette-Guérin 
bp base pair 
CTB Cholera toxin B subunit 
CU Cytotoxic T lymphocytes 
3D-MPL 3-deacylated monophosphoryl lipid 
DNA deoxyribonucleic acid 
env envelope 
GM-CSF granulocyte macrophage colony stimulating factor 
gp glycoprotein 
HAART highly active antiretroviral therapy 
FIEPS highly exposed, persistently seronegative 
HTV human immunodeficiency virus 
HSV herpes simple virus 
IFA incomplete Freund's adjuvant 
IFN 	- interferon 
Ig immunoglobulin 
IL interleukin 
LTR long terminal repeats 
mAb monoclonal antibody 
IvIF microfluid 
MIP macrophage inflammatory protein 
MTP-PE muramyl tnpeptide-dipalmitoyl phosphatidylethanolamine 
MVA modified vaccinia virus Ankara 
nef negative effector function 
NYVAC New York vaccine 
PND principal neutralising domain 
pOl polymerase 
QS Quilaja saponaria 
RANTES reduced upon activation normal T cell expressed and secreted 
rev regulator of expression of virion proteins 
RT reverse transcriptase 
SCID severe combined immunodeficiency 
SFV Semliki forest virus 
SHIV chimeric SIV/HIV viruses 
SIV simian immunodeficiency virus 
tat trans-activator of transcription 
TNF tumour necrosis factor 
VEE Venezuelan equine encephalitis 
vif viral infectivity fact 
VLP virus-like particle 
vpr virion protein R 
vpu virion protein U 
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1.1 Introduction 
lily was first identified in 1983 and subsequently recognised as an etiologic agent for 
acquired immunodeficiency syndrome (AIDS). In spite of extensive prevention 
programs, the HIV/AIDS epidemic is still spreading worldwide, particularly in 
developing countries. WHO estimates that there are thirty-six million people living with 
HIV/AIDS; 22 million people have died and 15,000 new infections occur each day (Piot 
et al., 2001). While highly active antiretroviral therapy (HAART) has provided 
therapeutic benefit to those who can obtain and tolerate it, at least 95% of all people 
infected with HIV live in regions with limited resources such as sub-Saharan Africa, 
where recently developed antiretroviral treatments are neither affordable nor widely 
available (Schwartlander et al., 2001). Therefore, the development of an effective HIV-1 
vaccine remains the best strategy for controlling the FIIV epidemics. This overview will 
focus on different vaccine approaches that have been tested to date in animal models and 
human clinical trials. 
1.2 The challenge for the development of an effective HIV vaccine 
The extraordinary genetic diversity of HIV-1 is a major problem to overcome in the 
development of an effective vaccine that is universally effective against the various 
clades and viral strains (Coffin, 1995; Wei et al., 1995). HIV-1 rapidly mutates during 
infection, resulting in generation of viruses, which are able to escape immune 
recognition (Borrow et al., 1997; Price et al., 1997). Because a significant proportion of 
HIV-specific neutralising antibodies and cytotoxic T lymphocytes (CTL) responses are 
type specific and capable of neutralising (for neutralising antibodies) or killing (for CTL) 
the strain of virus from which the immunogen derived, but not other divergent strains 
(Goudsmit et al., 1991; Carmichael et al., 1996), this genetic diversity has fostered 
efforts to define and structure immunisation strategies that induce broadly immune 
response or utilise multivalent HIV vaccines. 
Definitive immunological correlates of protection against HIV-1 infection remain 
uncertain, which poses considerable difficulty for the development of an HIV-1 vaccine 
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(Nabel, 2001). Like other lentiviruses, HIV can integrate into the host genome where it 
can remain in a latent form that does not express HIV structural proteins and is thus less 
likely to be recognizable by the immune system (Chun et al., 1997). This capacity of 
HIV-1 to achieve true latency poses another difficulty to HIV-1 vaccine development. 
Finally, transmission of HIV-1 predominately occurs across a mucosal surface (Kresina 
et al., 1999), therefore mucosal immunity may be required to prevent the sexual 
transmission of the virus. However our knowledge of mucosal infections and the 
immune responses responsible for defending against it is quite limited. 
1.3 Protective immunity against HIV-1 
The development of an effective vaccine must be based on an understanding of the 
humoral and cellular immune responses which impact HIV-1 infection and are likely to 
have a critical role in the clinical outcome. Neutralising antibody and CTL are major 
effectors of anti-viral immunity. Definitive immunological correlates of protection 
against HIV remain undefined, but much is known about HIV-specific protective 
immune responses associated with long term survival and maintenance of low viral loads 
(Deacon et al., 1995; Kirchhoff et al., 1995; Pontesilli et al., 1998), and natural 
resistance to HIV (Rowland-Jones et al., 1995; Kaul et al., 2001). It is clear that multiple 
aspects of immune response have potential to contribute to protective immunity (Dittmer 
et al., 1999). 
1.3.1 Cell-mediated immunity 
CTLs are also known as killer T cells, which recognise, bind and kill cells that display 
foreign antigens. Evidence for the protective role of cell-mediated immunity against 
HIV-1 come from a variety of observations. During acute infection the appearance of the 
CD8+ CTL response is temporally related with the control of HIV-1 replication (Borrow 
et al., 1994; Koup et al., 1994) and a strong HFV-specific CD4+ T cell mediated 
response is correlated with viral load (Rosenberg et al., 1999). Studies on individuals 
remaining uninfected despite multiple exposures (termed as HEPS, highly exposed. 
persistently seronegative) have demonstrated HIV-1 specific cellular immune response, 
MR 
including HIV specific CD8+ activity and T-helper responses (Rowland-Jones et al., 
1993; 1995; 1998; Kaul et al., 2000; 2001), suggesting that transient infection may occur 
inducing protective immune response mediated by CTLs. In addition, HIV-specific Cli 
responses are also associated with long-term non-progressors, who have HIV-1 
persistent infection but do not progress to AIDS for greater than 12 years. Some of these 
individuals are infected with HIV isolates which replicate poorly (Deacon et al., 1995; 
Kirchhoff et al., 1995). However, others are infected by HIV isolates with the capability 
of normal replication but have maintained a strong and broad HIV-1 specific immune 
response including HIV-specific CD4+ T cell proliferation (Rosenberg et al., 1997) and 
strong CD8+ CTL activity (Dyer et al., 1999; Pontesilli et al., 1998), which are believed 
to be responsible for their delayed disease progression. 
Probably the best evidence for the importance of CTLs in the control of HIV has come 
from studies in non-human primate models. The CTL response is the best correlate of 
viremia control after simian immunodeficiency virus (SW) primary infection in 
macaques (Reimann et al., 1994). This concept is further supported by recent studies 
showing that depletion of CD8+ cells results in SlY replication being uncontrolled 
during primary infection and high virus load in chronically infected rhesus monkeys (Jin 
et al., 1999; Schmitz et al., 1999). There are now several observations using different 
vaccine strategies suggesting that HIV-specific CTL play a major role in inhibiting HIV 
replication. Early studies using SW vaccines demonstrated that induction of CD8+ Cli 
responses with weak or absent antibody responses correlates with reduction of viral load 
and delayed disease progression (Hirsch et al., 1996). Subsequent studies have shown 
similar patterns (Buge et al., 1997; Allen et al., 2000; Davis et al., 2000; Leno et al., 
2000, Ourmanov et al., 2000; Barouch et al., 2001b). Protection of animals immunised 
with attenuated SlY was associated with the development of CD8+ Cli (Miller et al., 
1997; Johnson and Desrosiers, 1998; Wyand et al., 1999). Taken together, the apparent 
importance of CTLs in controlling HIV replication as discussed above has had a large 
impact on vaccine development, where many recent efforts have centered on eliciting 
cellular immune response (Robinson et al., 1999; Allen 2000; Leung et al., 2000; 
Barouch et al., 2001b; Gorse etal., 2001; Nilsson et al., 2001). 
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1.3.2 Humoral immunity 
Antibodies which are capable of neutralising HIV infectivity are often undetectable or at 
low titre during acute HIV-1 infection (Legrand et al., 1997; Moog et al., 1997). These 
observations suggest that neutralising antibodies that arise in response to FIIV infection 
may not play a major role in limiting viral replication. However, this does not mean that 
neutralising antibodies can not prevent H1V infection or such an immune response can 
not be induced by a vaccine. A variety of different observations support the concept that 
it is important for a successful HIV vaccine to induce neutralising antibodies against the 
virus. 
Passive antibody studies have suggested that HIV/SIV infection may be preventable by 
anti-HIV/SW antibodies (Mascola et al., 1999; Baba et al., 2000; Parren et al., 2001). 
Studies evaluating polyclonal anti-HIV-1 antiserum (Prince et al., 1991); monoclonal 
anti-V3 antibody in HIV-1 infected chimpanzees (Emini et al., 1992); monoclonal 
antibody against an epitope overlapping the CD4+ binding site of gpl20 in S1-UV-
infected macaques (Parren et al., 2001) and polyclonal serum in SW-infected macaques 
(Putkonen et al., 1991) have shown that when sufficient levels of antibodies are present 
prior to challenge that viral infection can be prevented. Passive prophylaxis using a 
human monoclonal antibody (mAb) has protected SCID (severe combined 
immunodeficiency) mice from infection with two primary I-IIV isolates (Gauduin et al, 
1997). Passive transfer of IgG from an SW-infected long term nonprogressor can delay 
disease progression when given to macaques at the time of SW infection (Haigwood et 
al., 1996). Importantly, neutralising antibody against the HIV-1 envelope glycoprotein is 
capable of protecting macaque monkeys from chimeric SWJHTV-i (SHIV-1) infection 
(Shibata et al., 1999). Passive prophylaxis with neutralising antibodies has protected 
rhesus macaques against vaginally transmitted infection (Mascola et al., 1999; Parren et 
al., 2001), indicating the ability of antibody to confer prevention at a mucosal surface, 
which may also be of great importance for a successful FIIV vaccine. In vitro studies 
showed that IgG3 polyclonal anti-HIV has more potency in neutralising HIV-1 compared 
to that of IgG i and IgG2 (Scharf et al., 2001). If this phenomenon exist in vivo, strategies 
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which favour IgG3 may provide a new approach for improving HIV vaccines. More 
recently, it has been demonstrated that HIV-specific antibody from a patient with acute 
HIV infection can inhibit HI_V replication in the presence of natural killer effector cells 
(Forthal et al., 2001). These observations support the concept that induction of 
neutralising antibody responses may be important in vaccine induced protection. 
1.4 Animal models for HIV-1 vaccine evaluation 
Animal models are of great importance for evaluation of different strategies for inducing 
protective immunity against HIV infections. Although transgenic mice and rabbits have 
been engineered which are susceptible to Hi_V infection, non-human-primates represent 
relevant model for head to head comparison of vaccine candidates. For studies 
evaluating I-il_V vaccine, these non-human-primate challenge models can be divided into 
three categories: lily-i chimpanzee model, SIV-macaque model and SHIV-i macaque 
model (Nath et al., 2000). Chimpanzees are susceptible to Hi_V-i infection, which can 
establish a long-term persistent infection. However, infected chimpanzees rarely develop 
disease and are limited in quantity, which is a problem for vaccine testing (Kumar et al., 
2001a). The SIV-macaque model uses an SW virus, which can persistently replicate to 
very high level in macaque. Similar to HIV-infected human beings, infected animals can 
develop an AIDS-like disease. This model could be potentially used for the 
establishment of correlates of protection. Although the Sly and HIV-1 in general have 
substantial nucleotide sequence homology, the envelopes of these viruses are quite 
divergent (Nath et al., 2000) Therefore, the meaningful interpretation of the immune 
response must be assessed carefully. Differences in important envelope epitopes between 
HIV-1 and SW have limited the utility of this SIV-macaque model for evaluating HIV-1 
Env-based vaccine candidates. In efforts to resolve this problem in the SIV-macaque 
model, the chimeric SIVIHIV-i (SHIV-1) virus was constructed by replacing SW env 
with HI_V-i env (Nathanson et al., 1999). Therefore SI-U_V-i has the gag and poi 
structural genes of SW and the env gene of HIV-1. This SF11_V-1 macaque model makes 
it possible to test HIV-i envelope immunogens directly in an animal model. 
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1.5 HIV vaccines strategies 
1.5.1 Subunit vaccine 
Initial efforts to elicit vaccine-induced immune responses to FIIV-1 have focused on the 
viral envelope glycoprotein (Fast et al., 1993). The viral envelope glycoprotein contains 
the CD4 binding site, the region that attaches to human cells and thus has a pivotal role 
in the early events of virus attachment and entry into the target cell. Importantly, 
neutralising antibodies against HIV-1 found in the sera of infected individuals are 
predominantly directed against this glycoprotein (Poignard et al., 1996; Kwong et al., 
1998; Wyatt et al., 1998; Saphire et al., 2001), and antibodies to FIIV gpl60 have been 
detected in genital secretions, urine samples, tears, milk, nasal washing, intestinal fluid, 
cervicular fluid and saliva (O'shea et al., 1990; Sun et al., 1990; Thongcharoen et al., 
1992; Wolff et al., 1992; Constantine et al., 1994; Janoff et al., 1994; Mestecky et al., 
1994). Furthermore, experimental stimulation of neutralising antibodies to HIV was first 
achieved by immunisation of animals with either recombinant or purified natural gp120 
(Lasky et al., 1986; Robey et al., 1986). Moreover, this glycoprotein also contains 
epitopes that elicit cellular immune responses (Kahn et al., 1995; Mooij et al., 1998). 
For these reasons, vaccines based on genetically engineered HIV envelope proteins 
either gpl20 or gp16O have been the best studied to date. 
The efficiency of gpl20 vaccines have been extensively studied in non-human primate 
animals. Early studies in the HIV-1 infected chimpanzee model indicated that rgp 120 
vaccine could protect against challenge with either HTV-1 LAI  or HTV-l sj (Berman et al., 
1990; 1996; Girard et al., 1991; Bruck et al., 1994). More encouraging results have been 
obtained using HIV-1 gpl60s from H1V-1LAI and HIV-1MN and V3-MN peptides in two 
chimpanzees in which immunised animals were protected against intravenous infection 
with a heterologous FITV-1 strain IilV-l s . The neutralising antibody to H[V-1LAI or 
HIV-1MN detected in immunised chimpanzees suggested that humoral immune responses 
had mediated this protection against heterologous H[V-1 infection (Girard et al., 1995). 
In the rhesus macaque model, immunisation with recombinant SW surface glycoprotein 
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has had only limited success in inducing protection against challenge with pathogenic 
SIVmac strains. In one study, immunisation with recombinant envelope protein from 
SIVmac could induce virus-binding but no neutralising antibodies were produced and no 
protection against intravenous challenge of cell-free virus was observed (Giavedoni et 
al., 1993). Subsequent studies further showed that rgp120 from HIV-1 failed to protect 
macaques against infection with SHIV-i virus (Stott et al., 1998). The failure of this 
vaccine to prevent replication of the virus may be associated with the lack of CTL 
response as the monomeric rgp 120 is known to be a poor inducer of Cli responses 
(Corey et al., 1998; Kumar et al., 2000). This inability of inducing Cli responses of 
monomeric gp120 was improved by using oligmeric gpl20 as vaccine immunogen. Luke 
et at. (1996) reported that protection against the autologous pathogenic SIV has been 
achieved in all three rhesus macaques immunised with SW gpl30 (surface protein of 
SIV) oligomers. A similar result was obtained using oligomeric HIV-1 Env protein 
gpl40 which is an oligomeric structure composed of uncleaved gpl20 linked to the 
ectodomain of g41. Strong neutralising antibodies against a homologous virus was 
elicited in rhesus macaques immunised with oligomeric HIV-1 gpl40. After intravenous 
challenge with SHIVHXB2, three of the four vaccinated macaques exhibited no evidence 
of virus replication (Earl et al., 2001), suggesting the possibility that immunisation with 
oligomeric, rather than monomeric, envelope proteins may improve protective efficacy. 
However, these studies uniformly demonstrated that immunisation with recombinant 
viral envelope protein failed to elicit broadly neutralising antibody response against both 
homologous and heterologous HIV-1 strains, and there was a lack of Cli responses in 
immunised animals. This may be attributed to intrinsic properties of the I-HV envelope 
glycoprotein including multimenc complex present on the virion surface, extensive 
glycosylation and marked genetic variability. It has been reported that antigens generated 
in mammalian cells induced higher level of neutralising antibodies against H1V-1 than 
those produced in insect cells (Dolin et al., 1991), baculovirus (Keefer et al., 1994) or 
yeast systems (Keefer et al., 1996), probably due to more natural glycosylation achieved 
in mammalian cells than in non-mammalian cells (Belshe et at., 1994; Graham et al., 
1996). This demonstrated that the degree of glycosylation of the recombinant envelope 
protein of 1TV-1 has a critical effect on its ability to induce neutralising antibodies. The 
use of monomeric gpl60/120 may contribute to the reduction of immunogenicity of 
subunit vaccines. In addition to the poor induction of CTL responses by monomeric 
gpl20 as described above, it has also been reported that antibodies induced against 
monomeric forms of the HIV-1 envelope proteins failed to efficiently neutralise primary 
I-HV-1 isolates because of the failure to generally recognise oligomeric envelope proteins 
present on HTV virions (Sattentau, 1996; Burton et al., 1997). 
In view of the extreme diversity of FIIV-1, it is important to develop vaccination 
strategies that generate and sustain significant level of cross-reactive neutralising 
antibodies and cellular immune responses. Consideration of the unique properties of the 
HIV-1 envelope glycoprotein including multimeric complex present on the virion 
surface, extensive glycosylation and marked genetic variability must be made. It might 
be possible to induce strong and/or broadly neutralising antibody response and cellular 
immune responses by following strategies. (i) A vaccine containing a cocktail of 
envelope protein representing the majority of prevailing HIV-1 isolates. A recent study 
showed that macaques immunised with polyvalent vaccine consisting of gp120 proteins 
from multiple HIV-1 viral isolates (LAI, RF, 89.6, AD8, Bal and DH12) generated 
broader neutralising antibodies against three or more HTV-1 isolates, (albeit this breadth 
of neutralisation was limited almost entirely to the virus strains used for vaccination), 
than that in macaques immunised with monovalent vaccine containing gpl20 of HTV -
1 DHI2 only. These results suggested that mixtures of HTV-1 envelope glycoproteins could 
induce increased breadth of immune responses against multiple HIV-1 strains (Cho et 
al., 2001). (ii) Modification of HTV-1 envelope proteins (such as loop deletion) to 
increase their immunogenicities by increasing the exposure of conserved neutralisation 
epitopes (Cao et al., 1997; Reitter et al., 1998). In a recent study, the modified HIV -
'SF162 envelop protein with partial deletion of the second hypervariable region (V2) was 
more effective than unmodified protein in eliciting potent neutralising antibodies not 
only against the homologous HIV-1, but also against several heterologous primary HIV -
1 isolates in immunised rabbits. But in rhesus macaques, only those immunised with the 
modified immunogen elicited neutralising antibodies against several heterologous 
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primary HTV-1 isolates. These results suggested that specific modifications introduced in 
HTV-1 envelope proteins could elicit potent cross-reactive neutralising antibodies against 
heterologous primary HIV-1 isolates (Barnett et al., 2001). 
Recombinant envelope protein-based subunit vaccines have been extensively tested in 
phase 1/11 human clinical trials (Klein 2001, Mascola and Nabel 2001), and the bivalent 
subunit vaccines comprising recombinant gpl20 proteins from HIV-1MN and a primary 
HTV-1 isolate are currently being tested in phase ifi trial since 1998 (in North America) 
and 1999 (in Thailand). Efficacy results of these phase ifi trials are expected to become 
available 2-3 years later (Mulligan et al., 1999; Migasena et al., 2000). Generally, the 
typical vaccination schedule in phase 1/Il clinical trial has consisted of 0, 1, and 6 month 
injections with different doses of 15-600 j.tg immunogen for each injection, followed by 
a booster injection at 12 to 18 months (Graham et al., 1998). The principal findings 
related to immune responses generated by HIV-1 recombinant subunit vaccine in human 
clinical trials include: (I) HIV-1 envelope protein based vaccine have been generally well 
tolerated and immunogenic in FHV-1 seronegative individuals (Dolin et al., 1991, 
Graham et al., 1996; Keefer et al., 1997; Migasena et al., 2000; Nitayaphan et al., 2000), 
and particularly were also safe and well tolerated in neonates born to HTV-1 infected 
women (Cunningham et al., 2001). (II) Use of adjuvants affect the magnitude of 
antibody responses, although moderate or severe local reaction including pain, erythema 
and swelling, and/or systemic reaction including fever, headache, malaise, myalgia, 
nausea and rash) occurred (Keefer et al., 1996; 1997; McCormack et al., 2000). A novel 
adjuvant QS-21, an amphipathic molecule from the soapbark tree Quilaja saponaria, 
was demonstrated to be able to promote a reduction in antigen (recombinant soluble 
HTV-lMr.4 gp120 protein) dose by up to 100 fold without affecting magnitude of antibody 
generation, suggesting that QS-21 may provide an effective adjuvant to reduce the dose 
of a soluble protein immunogen (Evans et al., 2001). A combination of adjuvants was 
also investigated. 1-UV-1 seronegative volunteers received recombinant 200 tg 
monomeric HIV-1 rgp12Ow61D derived from a dual co-receptor tropism isolate FHV-
1 ACH320 in 50 jig 3D-MPL (3-deacylated monophosphoryl lipid A) and 50 j.tg QS-21 
together with a novel oil and water emulsion, induced antibody titres as high as those 
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seen in HIV infection, albeit the quality of the antibodies remained different in that there 
was no evidence of primary isolate neutralisation. Cellular immunity was also enhanced 
in immunised subjects in terms of lymphoproliferative responses, but FIIV-1 specific 
CD8+ cytotoxicity was not demonstrated (McCormack et al., 2000). Studies reported 
that FIIV-1 rgp 120 formulated with an adjuvant, consisting of an emulsion of polysorbate 
80 and sorbitan trioleate and the oil-in-water emulsion is microfluidised (MF59), can 
induce type-specific and cross-reactive neutralising antibodies against homologous and 
heterologous FIIV-1 strains in immunised HIV-1 seronegative volunteers (Nitayaphan et 
al., 2000). FHV-1 specific lymphoproliferative responses were induced in all 49 
rgp12OIMiF59 vaccinated participants, but CD8+ cytotoxic T lymphocyte activity was 
shown in only one participant (Graham et al., 1996). The use of aluminum hydroxide 
(alum) and incomplete Freund's adjuvant (IFA) as HIV-1 rgp160/120 vaccine adjuvants 
in human clinical trials were also reported (Pialoux et al., 1995; Migasena et al., 2000). 
The effect of addition of an immunomodulator, muramyl tripeptide linked covalently 
with dipalmitoyl phosphatidyl-ethanolamine (MTP-PE) which is a synthetic lipophilic 
derivative of the naturally occuring compound muramyl dipeptide in mycobacterial cell 
wall, to a candidate HIV-1 vaccine Env 2-3 (Chiron Biocine Co.) formulated with MF59, 
was investigated. Results showed that 15 of 30 Env 2-3 in MTP-PEIMF59 vaccinees 
developed severe, although self-limited systemic and/or local reactions, compared to 
adverse effects in 2 of 18 subjects who received Env 2-3 in MF59. No significant 
difference was observed between those two immunised groups in terms of induction of 
neutralising antibodies to FHV-IsF2 and lymphoproliferative responses to the immunogen 
Env 2-3. These results suggested that the addition of MTP-PE significantly increased 
reactogenicity, but had little, if any, effect on immunogenicity (Keefer et al., 1996). (HI) 
Recombinant HIV-1 envelope proteins, formulated in any available adjuvant, rarely 
induce a CD8+ CTL response (Graham et al., 1996; Connor et al., 1998; McCormack et 
al., 2000; Nitayaphan et al., 2000), but lymphoproliferative responses to intact FIIV-1 
glycoproteins have been readily detected in immunised 1-IIV-1 seroneagtive individuals 
(Belshe et al., 1993; Cooney et al., 1993; McCormack et al., 2000; McElrath et al., 
2000; Schooley et al., 2000), including neonates and infants born to FHV-1 infected 
women (Borkowsky et al., 2000). (IV) Neutralising antibodies induced by recombinant 
HIV-1 envelope proteins are generally type-specific which can only neutralise 
homologous HIV-1 strains, but not primary HIV-1 isolates (Graham et al., 1996; 
Mascola 1996, McCormack et al., 2000; McElrath et al., 2000; Nitayaphan et al., 2000), 
with a relatively short half-life (declined about 10-fold in 6 months after the last boost 
(Migasena et al., 2000)). (V) Even though some participants in Phase I/H trials who were 
immunised with HIV envelope protein vaccine had significant neutralising antibodies 
against vaccine isolates have in their sera, they still have become infected during or 
following immunisation (Berman PW et al., 1997; Connor et al., 1998; Graham et al., 
1998; Locher et al., 1999; Migasena et al., 2000), suggesting that immunisation with 
such HTV-1 vaccines is less than 100% effective in preventing or rapidly clearing 
infection. This feature remains a major obstacle of HIV vaccine development. 
In addition to recombinant envelope protein-based vaccines, HIV-1 regulatory proteins 
such as Tat and Rev, RT have also been tested as potential vaccine candidates (Cafaro et 
al., 1999; Osterhaus et al., 1999; Pacheco et al., 2000). The data reported by Cafaro and 
coworkers (1999) showed that monkeys, immunised with a biologically active Tat 
protein, were protected against challenge by SHIV. 
1.5.2 Live recombinant vaccines 
Live recombinant vaccines are recombinant viral vectors expressing SIVIHTV 
immunogens. The viral vectors are either replication defective or live-attenuated viruses. 
Live recombinant vaccines can mimic antigen presentation that occurs during natural 
viral infection, and thereby offer advantages including the potential to present antigens in 
a natural form (i.e., with correct conformation, glycosylation, and oligomerization), and 
the ability to induce CD8+ Cli responses. Potential disadvantages of live recombinant 
vectors include their potential to cause disease in vaccinees, especially in 
immunocompromised hosts, and the possibility that pre-existing immunity against the 
vector could render the vaccine ineffective, as has been demonstrated in a vaccinia based 
vaccine (Cooney et al., 1991). 
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A number of different live viral recombinant vectors have been developed and used for 
the development of HIV vaccines, including poxviruses (Ourmanov et al., 2000; Seth et 
al., 2000a), adenoviruses (Zhong et al., 2000), poliovirus (Crotty et al., 2001), herpes 
simplex virus (HSV) (Murphy et al., 2000), alphaviruses such as venezuelan equine 
encephalitis (\TEE) viruses (Davis et al., 2000) and semliki forest virus (Mossman et al., 
1996; Berglund et al., 1997), rhinoviruses (Smith et al., 1998), rabies virus (McGettigan 
et al., 2001), Sendai virus (Kano et al., 2000) and influenza virus (Palese et al., 1997). 
Among these recombinant viral vectors, the poxvirus family, notably vaccinia and 
canarypox, have been widely used as HIV-1 vaccine candidates. Primate studies showed 
that recombinant vaccinia vectors expressing SW gag proteins can induce SW Gag 
specific Cli responses in vaccinated rhesus monkeys (Shen et al., 1991). And the SW 
Nef specific CTL responses, induced by a recombinant vaccinia virus expressing SW 
Nef, has been shown to significantly reduce viral loads in immunised macaques 
following intravenous challenge with pathogenic SWMAC (Gallimore et al., 1995). 
However, a recombinant vaccinia virus expressing the surface glycoprotein of SWMAC 
was unable to provide effective immunity against intravenous challenge with pathogenic 
virus in immunised rhesus macaques with undetectable neutralising antibodies 
(Giavedoni et al., 1993). 
Due to safety concerns regarding vaccinia virus as a vaccine vector and the fact that 
immunosuppression was a contraindication for vaccination with vaccinia virus, recent 
efforts have focused on the highly attenuated poxviruses NYVAC (New York vaccine), 
ALVAC (Albany vaccine) and MVA (modified vaccinia Ankara). NYVAC is a 
Copenhagen strain of the vaccinia virus with mutations that attenuate its virulence. 
ALVAC is a canarypox recombinant which is unable to complete its replicative cycle but 
is able to synthesize foreign proteins in non-avian species. MVA is a vaccinia virus 
strain that was attenuated by undergoing 570 passages in primary chicken embryo 
fibroblasts, and contains six large genomic deletions that reduce its pathogenicity 
(Blanchard et al., 1998). The limited replicative ability of these virus strains enhances 
safety, albeit at the cost of reduced immunogenicity. 
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Studies with macaques have demonstrated the ability of recombinant FIIV-1-
NYVAC/ALVAC vectors to induce HIV-specific neutralising antibodies and T-cell 
proliferative responses, and the efficiency of HTV-1-NYVAC/ALVAC vaccines in cross 
protecting macaques from intravenous challenge with HIV-2 (Abimiku et al., 1995). 
Similar protection was also demonstrated in rhesus macaques immunised with 
recombinant IIIV-2-ALVACINYVAC (Franchini et al., 1995). However, Girard et al. 
(1995) reported that two chimpanzees immunised with the live recombinant canarypox 
virus expressing gpl60 proteins of HIV-1MN failed to induce protection from intravenous 
inoculation of IUV-ls. Similar results were seen in macaques immunised with 
recombinant HIV-2-ALVACINYVAC vectors and subsequently boosted with either 
recombinant vectors or HIV-1 gpl20. Immunised animals became infected following 
challenge with HIV-2, although either T cell proliferative activity (for HIV-2-ALVAC) 
or neutralising antibodies (for HIV-2-NYVAC) was elicited (Myagkikh et al., 1996), 
suggesting this prime/boost immunity is not sufficient to confer protection in immunised 
animals. Interestingly, Benson et al. (1998) demonstrated that vaccination with NYVAC 
vector expressing SW gag, poi and env genes could induce protection of macaques 
against intrarectal exposure of pathogenic SIV mac251, but did not protect macaques 
following intravenous challenge, although either neutralising antibodies (immunised 
with NYVAC-SIV vector alone) or CTL responses (immunised with both NYVAC-SIV 
vector and NYVAC-IL-12/IL-2 vector) were induced in immunised animals. These data 
indicated that the route of exposure may have an important implication in the evaluation 
of vaccine efficacy in SIV/macaque model. 
Studies with MVA vectors expressing SW Gag-Pol (Seth et al., 2000a) or SW Gag-Pol 
and FIIV-1 Env (Barouch et al., 2001a) defined the role of CTL in control of viremia. In 
these two studies, immunisation with recombinant MVA vectors induced potent Gag-
specific CTL responses. Of note, the magnitude of the vaccine elicited CTL responses 
prior to SW or SHIV challenge was associated with the magnitude of reduction in 
viremia following challenge. 
Both NYVAC- and ALVAC-based FIIV-1 vaccine candidates evaluated in human 
clinical phase IJH trials have demonstrated good safety profiles (Pialoux et al., 1995; 
Clements-Mann et al., 1998; Belshe et al., 2001). An ALVAC based vector (vCP205) 
encoding multiple HIV-1 gp120, p55 and protease has been initially assessed in a phase 
II trial. 435 volunteers including people at both higher and lower risk for HIV infection 
received vCP205 with/without gp120 boosting. More (94%) subjects given vCP205 plus 
gp120 compared with 56% of those who received vCP205 alone, developed neutralising 
antibody to HIV-1MN. CD8+ CTL cells were detected in 33% of volunteers given 
vCP205, with or without gpl20 (Belshe et al., 2001). These data suggested that weak 
neutralising antibody responses induced by live recombinant vectors, as has been 
demonstrated (Graham et al., 1992), can be heightened by boosting with recombinant 
envelope proteins. Elicitation of both potent humoral and cellular immunity are desirable 
characteristics of an HIV vaccine regimen. Therefore, various vaccinia-based vaccines 
are being assessed in prime-boost approaches to extend the potency and breadth of the 
immune response and to induce the protective humoral and cellular immunities. In a 
more recent study, a combination vaccine regimen consisting of a canarypox vector 
containing Env, Gag, and Pol, in combination with a recombinant gp120 subunit protein 
resulted in neutralising antibodies in 91%, and CD8+ CTh responses in 62% of 
vaccinees. Boosting with HIV-1 rgpl20 did not increase the CTh responses to HIV-1 
envelope proteins, but did enhance the magnitude and frequency of neutralising 
antibodies to HIV-1MN (AIDS Vaccine Evaluation Group, 2001). Similar results were 
also demonstrated in other clinical trials including priming with HIV-1 gp160-vaccinia 
followed by boosting with rgpl60 in vaccinia-nalve adults (Graham et al., 1993); 
priming with HIV-1 gpl60-vacinia and boosting with HIV-1 rgpl20 (Corey et al., 1998); 
priming with ALVAC based vector expressing 1-HV-1 gpl20, gp4l, gag and protease 
followed by boosting with rgp 120 in HTV-1 seronegative volunteers (Evans et al., 1999), 
and priming with ALVAC-HIV-1 gp16O and boosting with rgpl20 in FIIV-1 uninfected 
adults (Clements-Mann et al., 1998). More frequent and long-lived (6 months after the 
last immunisation) FIIV-1 CD8+ CTLs and/or neutralising antibodies were induced by 
priming with a live recombinant viral vector followed by a booster with recombinant 
ITV-1 envelope proteins, than by immunising with live recombinant vector or 
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recombinant HIV-1 envelope protein alone. It is encouraging that Cli responses 
induced by the ALVAC-IIIV-1MN Env/Gag/protease vaccine can recognise viruses 
belonging to genetically diverse MV-1 clades in HIV-1 uninfected volunteers (Ferrari et 
al., 1997), and that sera from recipients of a vaccine consisting of ALVAC based 
recombinant vector vCP205 and rgp120 from H1V-1 sF2 displayed neutralising activity 
against several HIV-1 primary isolates from clades B and C (Verrier et al., 2000). One 
can expect that protection against the wide range of HIV isolates affecting the 
populations of worldwide geographic regions might be achieved by formulating live 
recombinant HIV vaccines consisting of multiple HIV-1 genes from a number of HIV-1 
isolates, together with a rgp 120 booster regimen. However, subsequent phase ifi trials 
with those HIV-1 live recombinant vaccines are necessary to evaluate the efficacy in 
preventing HIV infection in uninfected vaccinees, or in slowing disease progression 
among vaccinees who become infected. Furthermore, the level and types of immune 
responses that were induced by the vaccines compared with the protective efficacy must 
be investigated. 
Several other live viral vectors for HIV vaccine research are also actively being 
developed and applied in the SIV/macaque model. Recombinant adenovirus vaccines 
have the feature of targeting antigen-presenting dendritic cells (Zhong et al., 2000), and 
have been shown to be highly immunogenic in non-human primates (Sullivan et al., 
2000). A recombinant adenoviral vector expressing SW Env elicited SW-specific 
humoral, cellular and mucosal responses, resulting in decreased viral loads following 
vaginal challenge with SWMAC25I (Buge et al., 1997). Replication-deficient adenoviral 
vectors expressing HIV Env could induce HIV-specific humoral and CTL responses in 
immunised mice (Bruce et al., 1999). 
Crotty et al. (1999) showed that recombinant poliovirus vectors expressing SW p17 and 
gp4l proteins could induce mucosal, cellular and humoral immune responses in 
immunised cynomolgus macaques. Subsequent studies demonstrated that vaccination 
with a Sabin poliovirus vector cocktail expressing SW gag, poi, env, nef and tat proteins 
successfully induced complete protection in 2 of 7 immunised macaques against vaginal 
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challenge with pathogenic SW251 (Crotty et al., 2001). This successful primate 
protection using a viral library cocktail vaccination approach suggests that immunisation 
with an array of defined antigenic sequences could be an effective strategy to induce 
protection against diverse HLV stains. 
Other studies have shown that recombinant rabies virus-based vectors expressing HIV- 1 
envelope glycoproteins from a laboratory-adapted HIV-1 strain (NL4-3) and a primary 
HTV-1 isolate (89.6) could induce humoral immune responses against HIV-1 gp160 
(Schnell et al., 2000), and cross-reactive CTLs against a variety of different HIV-1 
envelope proteins from different HIV-1 isolates in immunised mice (McGettigan et al., 
2001). An attenuated propagation-defective HSV vector expressing SW Env and Nef 
antigens was demonstrated to be able to induce anti-SW envelope antibody responses, 
and protection against intrarectal challenge with pathogenic SIVMAc239 in 2 of 7 
immunised rhesus monkeys (Murphy et al., 2000). The sequential immunisation of 
cynomolgus monkeys with recombinant semliki forest virus and MVA both expressing 
SIVMAC32H Rev and Tat, at four weeks intervals, could also induce protection against 
disease caused by intravenous challenge with SIVMAC32H (Osterhaus et al., 1999). 
A few bacterial vectors are being developed and used for the development of HIV 
vaccines, including attenuated strains of Salmonella typhimurium, Bacille Calmette-
Guérin (BCG) (an avirulent strain of Mycobacterium bovis) and Listeria monocyto genes. 
Recombinant Salmonella-based vectors expressing HIV-1 gp120 were able to induce 
antibody responses, with the absence of CTL responses detected, in immunised mice 
(Fouts et al., 1995). Another non-viral vector expressing FIIV antigens that is in 
development is Listeria (Frankel et al., 1995). Primary study showed that a 
hyperattenuated Listeria monocyto genes vector expressing HIV antigens could induce 
H[V specific CD8+ T cell responses in immunised mice (Friedman et al., 2000). Several 
SW genes including nef, gag, and env have been expressed by recombinant BCG strains. 
Immunisation of mice via mucosal or parenteral routes with those recombinant BCG 
vectors expressing SW proteins induced specific IgA antibodies as well as specific IgG 
and CTh responses (Lim et al., 1997, Lagrandene et al., 1998). Subsequently, 
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immunisation of rhesus macaques of recombinant BCG constructs expressing SW Gag, 
Pol, Env and Nef proteins elicited SW specific IgA and IgG antibodies, and CTh 
responses as well as T cell proliferation, which demonstrated that recombinant BCG 
vectors can induce concomitant humoral and cellular immune responses to SW (Leung 
et al., 2000). 
1.5.3 Whole inactivated HIV-1 
One of the first vaccine approaches tested in the SW/macaque model was formalin-
inactivated whole SW particles. Early studies showed that macaques immunized with 
inactivated SW could be protected against intravenous challenge with up to 1000 animal 
infectious doses of pathogenic SW strains grown in human cells, which generated 
considerable enthusiasm for the feasibility of generating an AIDS vaccine (Desrosiers et 
al., 1989; Murphey-Corb et al., 1989). Enthusiasm waned, however, when it was 
reported that it was the result of immune response to direct towards xenoantigens in the 
vaccine preparations rather than toward epitopes of SW (Stott 1991; Cranage et al., 
1993). Antibodies to human cell surface molecules and HLA molecules, which are 
incorporated into the viral envelope during the process of budding from an infected cell, 
might be responsible for mediating such protection (Arthur et al., 1992). This was 
further supported by the observations that immunised animals were not protected against 
challenge with SWMAC grown in monkey peripheral blood mononuclear cells (Cranage 
et al., 1993), and the fact that macaques immunised with liLA class H molecules 
purified from human cells can induce protection against intravenous challenge with 
infectious SW grown in human cells (Arthur et al., 1995). 
Because there are potential risks associated with incomplete inactivation of the virus 
stock and the failures of early SW vaccine preparations, research devoted to developing 
whole inactivated 1-RV-1 as a primary vaccination strategy has been limited. In addition, 
inactivating HP/-i without disrupting or losing potential neutralising epitopes (such as 
shedding of gp120 from virions) poses another difficulty to develop an inactivated whole 
HIV-1 vaccine. Chemical inactivation of HIV and SW particles by 2,2'-dithi odipyri dine, 
and production of replication defective SWMNE mutants by genetic modification, was 
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demonstrated to be able to preserve antigenic structure on the surfaces of SIVMNE and 
HIVMN (Arthur et al., 1998; Rossio et al., 1998; Gorelick et al., 1999). A recent study 
showed that the combined use of heat and formaldehyde could inactive REV-i. 
Moreover, these virus preparations were able to enhance the binding capacity to 
monoclonal antibodies directed towards conformation-dependent neutralisation epitopes, 
suggesting greater exposure of the epitopes following treatment (Grovit-Ferbas et al., 
2000). These data indicate that it may be possible for development of inactivated HIV-1 
vaccines without disrupting or losing potential epitopes which can induce both h'umoral 
and cellular immune responses. 
1.5.4 Live attenuated HIV-1 vaccines 
The live attenuated HIV-1 vaccines refer to a live HIV-1 virus from which one or more 
disease-promoting genes have been deleted. Live attenuated SW vaccines have achieved 
the most impressive vaccination results to date in inducing protection against infection 
with pathogenic virus. In 1992, Daniel et al. provided a landmark study which 
extensively prompted the attenuated vaccine approach. In his study, 6 rhesus monkeys 
infected with a nef deleted SW (SWMAc239neO remained healthy in the context of both 
virus burdens and CD4+ lymphocyte concentration for more than 3 years after 
inoculation with the mutated virus, indicating that deletion of auxiliary genes of the virus 
can be the means for creating a safe live attenuated vaccine to protect against AIDS. 
Most importantly, 4 Rhesus monkeys vaccinated with SWMAC239Anef were completely 
protected against intravenous challenge with wild-type, pathogenic SW MAC by all criteria 
including no decline of CD4+ lymphocytes, low virus burdens as with the attenuated 
virus observed before challenge and no evidence of wild-type SW MAC virus in the 
immunised monkeys. Later, a live attenuated SWMAc2393 produced by deletion of nef, 
vpr and upstream sequences (US) in the U3 region of Long terminal repeats (LTR) of 
SIVMAC239 was also demonstrated to be able to induce protection against intravenous 
challenge with pathogenic SIVMAC25I (Wyand et al., 1996), SHJVDHI2 (Shibata et al., 
1997), or SHIV89.6 and SHIVSME660 (Wyand et al., 1999) in immunised rhesus 
monkeys. In addition to inducing protection against intravenous challenge, a live 
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attenuated SIVMACC8 with deletion of a 12bp in the nef/3'-LTR could protect immunised 
macaques against infection with intrarectal challenge with either pathogenic SIVMACJ5 
and SHIV composed of SIVMAc239 expressing the HXBc2 env, tat and rev genes 
(Cranage et al., 1997) or pathogenic SIVSM (Nilsson et al., 1998), suggesting that a live 
attenuated SIV could induce protection against mucosal challenge with pathogenic virus. 
In a recent study, sequential immunisation of macaques with two different attenuated 
vaccines SHW-4Anefvpu (vaccine-1) and SIllVppctvpu (vaccine-H) induced long-term 
(during 85 weeks observation period) virus-specific immune responses and conferred 
protection against AIDS caused by intravenous challenge with heterologous simian 
human immunodeficiency virus SIRV89.6P in the context of controlling virus replication. 
All four immunised rhesus macaques developed binding antibodies against both the 
vaccine-I and -II envelope glycoproteins but neutralising antibodies only against vaccine-
I. Vaccine virus-specific CTLs recognised homologous as well as heterologous 
pathogenic SHTVs. These results showed that the graded immunisation schedule can 
induce an effective immune response that was associated with protection against AIDS 
caused by a pathogenic heterologous SHIV (Kumar et al., 2001b). It has been 
demonstrated that the protection induced by this class of vaccine in immunised 
macaques was associated with development of either CD8+ CTL (Cranage et al., 1997; 
Joag et al., 1998; Kumar et al., 2001b), or the production of specific neutralising 
antibodies (Wyand et al., 1996), suggesting both cell-mediated immunity and humoral 
immunity were involved in protective immunity (Johnson et al., 1998). 
However, the major concern regarding the development of a live attenuated HIV vaccine 
relates to safety concerns, including reversion of the vaccine strain to virulence and 
recombination with endogenous retroviral sequences to produce new infectious and 
potentially pathogenic virus. For instance, an in vitro study showed that deleted HIV-1 
vaccine strains can evolve into fast-replicating variants by multiplication of remaining 
sequence motifs and therefore their safety are not guaranteed (Berkhout et al., 1999). 
Baba et al. (1995) was the first to report that an attenuated SIV with multiple deletions in 
nef, vpr and the negative regulatory element (NRE) was demonstrated to be pathogenic 
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in orally exposed neonatal macaques. Subsequently, it has been showed that this 
attenuated SW was also pathogenic in orally or intravenously vaccinated infant 
macaques as well as in intravenously immunised adult macaques (Baba et al., 1999). 
Therefore, attention has been drawn to the development of more highly attenuated SW 
vaccines by deleting several areas of accessory genes including nef, vpr, vpx, vif and 
upstream sequences (US) in the U3 region (Desrosiers et al., 1998), and nef, vpr, vpx, vif, 
tat and rev (Guan et al., 2001). However, greater attenuation is also likely to decrease 
the probability of inducing protective immunity, as demonstrated by the fact that 
antiviral immunity was inversely associated with degree of attenuation in immunised 
rhesus macaques (Lohman et al., 1994). Thus these highly attenuated constructs need to 
be evaluated for their long-term safety as well as ability to induce protective immune 
responses as SIV vaccine candidates. Given the lack of a suitable animal model to 
evaluate attenuation of HIV strains, it will be challenging to develop attenuated HIV 
strains that combine both efficacy and safety. 
1.5.5 Virus-like particle -based vaccines 
Virus-like particles (VLP) are non-infectious HIV-1 look-alike particles that contain the 
viral proteins required for virion assembly, but do not contain the viral RNA genome. 
These non-replicating, conformationally correct particles can have multiple antigenic 
components, and therefore have the potential to elicit broadly directed immune 
responses. The gag precursor protein pr55 of Fly and SW can self assemble in budding 
noninfectious virus-like particles in the absence of other viral components (Peters et al., 
1997; Notka et al., 1999; Paliard et al., 2000). Immunisation of rhesus macaques with 
recombinant FIIV-1IIIB derived chimeric pr55(gag)/gpl2O VLP induced Gag- and Env-
specific humoral responses and CTL activities, but was unable to provide any protection 
against challenge with SHT\TmB (Wagner et al., 1998). Similar results occurred in 
macaques vaccinated with SW pr55 VLP modified by either inserting HIV-1 gp160 
derived peptides into the pr55 precursor, or integrating the complete HIV-1 gp120 into 
the particle membrane. Immunised animals became infected following challenge with 
SHIV, although SW specific humoral and cellular immune responses were induced. 
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However, macaques immunised with pr55 VLP presenting complete gp120 managed to 
clear virus faster than nonimmunised controls, which is correlated with the accelerated 
appearance of neutralising antibodies postchallenge (Notka et al., 1999). Paliard et al. 
(2000) demonstrated that HIV-1 derived pr55 \TLP  could induce CTh responses against 
multiple HIV-1 pr55 epitopes in immunised rhesus macaques. Importantly, these CTLs 
could recognise naturally processed peptides and were long lived (>8.5 months). These 
results suggested that HIV derived pr55 VLPs may be a good HTV vaccine candidate in 
combination with approaches priming humoral immune responses, which is desirable for 
an effective HIV vaccine. 
The yeast-derived virus-like particle immunogen, Typ17/p24 VIP (p24-VLP) expressing 
HIV-1 p24 and p17, is the only VLP-based vaccine which has entered human clinical 
trials in seronegative volunteers (Weber et al., 1995) as well as in HIV-1 infected 
individuals as a potential therapeutic vaccine (Kelleher 1998; Klein et al., 1997; Peters et 
al., 1997). The Ty transposon found in yeast (Saccharomyces cerevisiae) encodes the 
protein p1, which has the capacity to self-assemble into particles. When p24 gag proteins 
are fused to the carboxy terminus of the p1 protein, the resulting fusion proteins 
assemble into 50 nm virus-like particles that can be purified and used as an antigen. 
Weber et al. (1995) conducted a phase I trial. Sixteen healthy male subjects were 
subcutaneously immunised with either 100 .tg or 500 .tg p24-VLP three times at weeks 
0, 4 and 12 and 500 j.tg intramuscular injection for the fourth immunisation. HIV-1 p24 
antibodies were detected in 4 (25%) subjects after the third immunisation and in 11 
(70%) subjects after the fourth injection. However, no p24 specific CTL responses were 
elicited. This study indicated that p24 VLP vaccine is immunogenic and well tolerated in 
healthy people. 
1.5.6 Peptide-based vaccines 
Peptide-based vaccines refer to chemically synthesised pieces of HIV-1 proteins 
(peptides) known to stimulate HIV-1-specific immunity, which are highly safe as an 
immunogen. In some studies, this class of vaccine has been presented as lipopeptides, a 
synthetic peptide bound to fatty acids. These fatty acids make it easier for the peptides to 
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enter the cells (Pialoux et al., 2001). As discussed in section 1.2, the major problem to 
overcome in the development of an effective vaccine is extraordinary genetic diversity of 
HIV-1. Therefore peptide-based vaccines may be able to induce broadly immune 
response against infection with different HIV-1 strains by providing multiple epitopes in 
a single vaccine (Pialoux et al., 2001; Toledo, 2001). 
Studies in animal models showed that peptide vaccines were safe and immunogenic 
(Mortara et al., 1998). Immunisation of guinea-pigs with a HIV-1MN principal 
neutralising domain (PND) peptide based vaccine covalently conjugated to 
Pseudomonas aeruginosa toxin subunit A (TA), generated neutralising antibodies 
against the homologous strain HUV - 1MN and two heterologous strains HIV-1111B and HTV-
'RF (Cryz et al., 1995). This result suggested that a peptide-based H1V vaccine could 
generate broad antibody responses against homologous and heterologous HIV-1 strains. 
Peptide-based vaccines have been extensively evaluated in human phase I clinical trials. 
Most peptide-based vaccines have been based on the peptide sequences of the HIV-1 V3 
loop (Cryz et al., 1995; Rubinstein et al., 1995; Gorse et al., 1996; Kelleher et al., 1997; 
Toledo 2001). It was demonstrated that the immunisation route could affect the 
immunogenicity of a prototype synthetic HIV-1MN V3 region peptide vaccine. In one 
phase I trial, HIV-1 uninfected healthy adult volunteers were immunised intramuscularly 
with 20, 100 or 500 pg of vaccine formulated with alum adjuvant on days 0, 28, and 168. 
The results showed that the vaccine was safe and well-tolerated. Induction of binding 
antibody to V3 peptide was vaccine dose-related and was detected in 9 of 10 subjects in 
500 pg dose group. V3 peptide stimulated lymphocyte proliferation was detected in 15 
of 20 subjects tested after vaccination (Gorse et al., 1996). However, in an other phase 
1/lI trial, 24 HIV-1 seronegative men were subcutaneously immunised with the 100 or 
500 pg HIV-1MN V3 peptide vaccine at 0, 1, and 6 months. Antibodies against the 
immunogen were only detected in 4 immunised subjects. Lymphoproliferative responses 
to immunogen were demonstrated in only 7 of 19 vaccine recipients tested (3 from 500 
jig group and 4 from 100 .tg group) (Kelleher et al., 1997). Recently, it was 
demonstrated that this HIV-1 MN V3 peptide vaccine, when encapsulated in 
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biodegradable micro-spheres composed of co-polymers of lactic and glycolic acids and 
administered by the oral route, failed to induce humoral, cellular, or mucosal immune 
responses in a phase I clinical trial (Lambert et al., 2001). 
Cli responses have received great attention in the context of controlling the viral load 
and progression from HIV-1 infection to disease (Pontesilli et al., 1998), but it seems 
that a synthetic vaccine consisting of a single CTL epitope is unlikely to be 
immunogenic in vivo (Brander et al., 1996). Therefore, peptide vaccines consisting of 
multi-epitopes including FIIV-1 CTL epitopes to elicit a defined spectrum of Cli-
specificities as well as humoral immune responses have been investigated (Woodberry et 
al., 1999; Toledo et al., 2001). Two studies showed that peptide epitope vaccines 
consisting of HIV-1 gpl20 epitopes for Th cell, CTLs and B cells (Bartlett et al., 1998) 
or Gag CTL epitopes known to be restricted by HLA-A33, -B8, -B27, -B35, and -Bw62 
(Seth et al., 2000b), used as a therapeutic vaccine, may not be a sufficiently potent 
immunogen to significantly augment HIV-1-specific CTLs and to decrease virus load in 
H1V-1-seropositive individuals. This may be due to non-generation of optimal immune 
responses. Studies in seropositive persons which demonstrated cross-dade recognition 
of defined HIV-1 Cli epitopes in HIV-1 Gag (Bertoleti et al., 1998; Lynch et al., 1998), 
Env (Wilson et al., 1998) and Gag precursor pr55 (McAdam et al., 1998) may raise the 
possibility that a Gag-Env based vaccine may be able to induce broad immune responses 
against different lilY-i strains. In a phase I trial, the efficacy of a six lipopeptide mixture 
including two Gag peptides, one Env peptides and three Nef peptides, as a vaccine 
immunogen was investigated. Twenty-eight healthy HTV-1 seronegative volunteers 
received the lipopeptides, with or without the adjuvant QS-21. The results showed that 
the vaccine was safe and well tolerated. Specific IgG antibodies against the Nef and Gag 
proteins were detected in 25 out of 28 volunteers (89%). The T cell proliferation 
response to at least one peptide was detected in 19 (79%) of the 24 subjects tested, with 
the majority had induced a multispecific proliferative response, that is, cells from 
volunteers proliferated to two (5 of 19), three (5 of 19), four (3 of 19) or five peptides (1 
of 19). Anti-HIV CD8+ cytotoxic lymphocytes could be tested in 24 volunteers, with the 
polyepitopic responses were detected in 7 of 13 responders. Cytotoxic responses against 
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the whole Nef proteins from HIV-11 (dade B) were found in 3 of 4 tested volunteers, 
with cross-reactions to the proteins from HIV-1MN (dade B) and HIEVlB angui (dade A) 
strains detected in one of two tested volunteers (Pialoux et al., 2001). These results 
demonstrated that these lipopeptides could induce both HIV-1 specific cellular and 
humoral immune responses in vaccinated healthy volunteers and might be a promising 
candidate for an AIDS vaccine. 
1.5.7 DNA vaccines 
DNA vaccines are naked DNA (purified DNA alone, with no other molecules) that 
encodes for one or several 1HV-1 proteins. The administration of DNA vaccine would 
offer advantages in terms of the vaccine's simplicity and stability, and theoretically 
should result in the production of antigenic proteins in a natural form and thus have 
raised hopes for generating long-lived, broad humoral and cell-mediated immunity. 
Several experimental 11IV-1 DNA prototype vaccines have been developed including 
DNA constructs encoding HIV-1 structural proteins Env (Wang et al., 1993; 1995; 
Lekutis et al., 1997; Shiver et al., 1997; Cherpelis et al., 2001; Ross et al., 2001), Gag 
(Gorelick et al., 2000a; 2000b; zur Megede et al., 2000; Yoshizawa et al., 2001), Env 
and Gag (Yasutomi et al., 1996), and reverse transcriptase (RT) (Isaguliants et al., 2000). 
DNA constructs have been made encoding HIV regulatory and/or accessory proteins Nef 
(Moureau C et al., 1999), Tat (Caselli et al., 1999; Cafaro et al., 2001), Nef, Rev and Tat 
(Hinkula et al., 1997; Calarota et al., 1998; Tahtinen et al., 2001) and Vif, Vpu and Nef 
(Ayyavoo et al., 2000); and structural and regulatory proteins Env and Rev (MacGregor 
et al., 1998; Kim et al., 2001a). 
The feasibility of HIV-1 DNA vaccines have been evaluated in animal models including 
mice and non-human primates (Wang et al., 1995; Lekutis et al., 1997; Calarota et al., 
1998; Gorelick et al., 2000a, 2000b; Isaguliants et al., 2000; Wang et al., 2000; Tahtinen 
et al., 2001). In rodent models, HIV-1 DNA vaccine immunisation could elicit potent 
IHIV-1 specific humoral (Moureau et al., 1999; Lu et al., 1995) or cellular immune 
responses (Wang et al., 1995; 1993; Yasutomi et al., 1996; Ayyavoo et al., 2000; 
Tahtinen et al., 2001). Importantly, successful elicitation of both humoral and cellular 
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immune responses (Wang et al., 1993; Hinkula et al., 1997; Shiver et al., 1997; Caselli 
et al., 1999; Isaguliants et al., 2000; zur Megede et al., 2000) as well as mucosal 
immune responses (Wang et al., 1997; Yoshizawa et al., 2001) was observed in 
immunised mice. It was found that the immunisation route could affect the strength of 
the immune response induced by DNA vaccine. A 3 to 75 fold stronger T cell response 
was seen in mice receiving DNA constructs encoding FIIV-1 regulatory genes nef, rev 
and tat epidermally, compared to that in animals receiving intramuscular injections 
(Hinkula et al., 1997). The immunogenecity of HIV-1 regulatory proteins Nef, Rev and 
Tat was compared in a recent study. It has been shown that the HIV-1 nef constructs 
were the most immunogenic raising both humoral and cell-mediated immune responses 
in immunised mice, compared to HIV-1 rev construct which only elicited CTh-response 
against the corresponding protein, whereas, HIV-1 tat construct was shown to be a poor 
immunogen in all respects (Tahtinen et al., 2001). 
Several viral challenge studies have been performed in non-human primates to evaluate 
the protective capacity of immune responses induced by DNA-based vaccines. 
Vaccination of chimpanzees with DNA constructs encoding HIV-1 proteins (Env, Rev 
and Gag/Pol) induced specific cellular and humoral immune responses. Animals 
immunised with DNA constructs were completely protected from infection following 
challenge with HIV-ls j (Boyer et al., 1997). However the meaningful interpretation of 
this result remains uncertain because HIV-ls i is nonpathogenic and does not replicate at 
high levels in chimpanzees (Nath et al., 2000; Kim et al., 2001a). Early studies in 
macaques elucidated that DNA vaccines encoding SW Env proteins or all of the 
structural and regulatory proteins have been unsuccessful in protecting against infection 
with SW following challenge, although either both neutralising antibody and cytotoxic 
T-lymphocyte responses (Lu et al., 1996) or Thl and Th2 cytokine responses as well as 
CD8+ CTLs (Haigwood et al., 1999) were observed in vaccinated animals. However, the 
loss of CD4+ T cells could be prevented in macaques immunised with SW mutant (a 
four amino acid deletion) nucleocapsid DNA constructs, with humoral immune 
responses but no cellular immune responses observed prior to challenge (Gorelick et al., 
2000a; 2000b). It was found that a DNA vaccine encoding HIV-1sFI62LW2 envelope 
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induced lymphoproliferative responses and potent neutralising antibodies in immunised 
rhesus macaques. To evaluate the protective role of the anti-HIV Env antibodies elicited 
by the DNA vaccine, the CD8+ T lymphocytes of vaccinated macaques were depleted by 
intravenous administrations of the anti-CD8 monoclonal antibodies prior to 
intravenously challenge with SHFV 162p4. The vaccinated animals showed lower peak 
viremia levels, rapidly cleared plasma virus and delayed seroconversion, compared to 
unvaccinated animals. These results demonstrated the protective role of anti-HTV-1-Env 
antibody responses induced by HIV-1 DNA vaccine (Cherpelis et al., 2001). Another 
study showed that protection from pathogenic virus challenge could be achieved in 3 of 
8 rhesus macaques immunised with a multicomponent DNA vaccines encoding I-IIV 
Env/Rev and SW Gag/Pol. Following challenge with pathogenic SIVMAc239 and 
subsequently SH[\1896p, three vaccinated animals exhibited no detectable virus, whereas 
control animals showed CD4+ cell loss, high viral burden and subsequently failed to 
thrive. Cellular immune responses were observed in the protected macaques, suggesting 
their important role in protection (Kim et al., 2001a). Therefore, it appeared that a DNA 
vaccine can induce both humoral and cellular immune responses in primates model and 
they all play an important protective role in immunised animals, suggesting that an 
effective I-IIV-1 vaccine should be able to provide both protective humoral and cellular 
immune responses. 
Different strategies have been investigated to boost the immune responses induced by 
DNA vaccine. A great deal of attention has focused on two strategies: prime/boost 
strategy and cytokine adjuvants. The prime/boost strategy includes boosting the immune 
response induced by DNA vaccine with recombinant proteins or live recombinant viral 
vectors. DNA immunisation alone can induce potent specific cellular immune responses 
but with only transient or low level neutralising antibody responses (Haigwood et al., 
1999; Verschoor et al., 1999). It has been demonstrated that relatively high titer 
neutralising antibody responses induced by DNA immunisation could be generated by 
employing a subsequent boost with a recombinant FIIV-1 protein (Letvin et al., 1997; 
Richmond et al., 1998; Putkonen et al., 1998; Yoshizawa et al., 2001). Moreover, it was 
found that immunisation with WV-i env DNA followed by a final immunisation with 
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HIVAHXBc2 env DNA plus recombinant HIV-1[IIB Env protein could completely protect 
immunised monkeys from infection after intravenous challenge with a chimeric virus 
SHIVHXBC2 (Letvin et al., 1997). The potent immunity and protection observed in this 
study suggest that a DNA prime/DNA plus protein boost regimen might be a potential 
vaccine strategy to prevent HIV-1 infection. 
The immune responses induced by 111EV-1 DNA vaccine can be enhanced by boosting 
with recombinant live vectors including modified vaccinia Ankara (MVA) (Hanke et at., 
1999; Allen et al., 2000); recombinant fowipox virus (Kent et al., 1998; Robinson et at., 
1999) and recombinant vaccinia vector (Fuller et at., 1997). A recent study showed that 
DNA vaccine (encoding multiple SW proteins including Gag, Pol, Vif, Vpx, and Vpr 
and HIV-189.6 Env, Tat and Rev) priming followed by boosting with a recombinant 
MVA encoding the SlY Gag and Pol and HIV-1 Env, led to robust CD8+ T cell response 
and prevent vaccinated macaques from developing disease following intrarectal 
challenge with a pathogenic SH1V89 .6 (Amara et al., 2001), indicating that recombinant 
live vectors appear to augment the cellular response primed by DNA vaccine. However, 
the degree to which boosting with either recombinant proteins or recombinant live 
vectors will increase the ability of vaccinated animals to control pathogenic virus 
challenges remains to be determined. 
Another strategy to increase humoral and cellular immune responses induced by DNA 
vaccine involves the co-administration of plasmid encoding cytokines or co-stimulatory 
molecules B7 molecules. Experiments in murine model showed the augmentation of 
DNA vaccine-induced HIV-i specific cellular immune response by co-administration of 
plasmids encoding cytokines including IL-2 (Xin et al., 1998); IL-12 (Kim et al., 1997, 
1999; Boyer et al., 2000b); IL-15 (Xin et al., 1999a); IL-18 (Billanut-Mulot et al., 2001); 
the combination of IL-12 and GM-CSF (Okada et al., 1997; Kim et al., 1999; Liu et al., 
2001); IL-2/IL-15 and TNF-a (Kim et al., 1998a); and co-stimulatory molecules B7 
(Kim et al., 1998b; Santra et al., 2000). The humoral immune response induced by DNA 
vaccine could be increased by co-administration with plasmids encoding cytokines 
including IL-2, IL-4; IL-5 and IL-10 (Kim et al., 1998a; 1999). Co-administration of 
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DNA with a plasmid encoding the chemokine RANTES or MIP-ict increased HIV-1 
specific antibody responses and CTL activities as well as mucosal immune responses 
(Lu et al., 1999; Xin et at., 1999b). However, there are limited data reported from 
studies in primates. Kim et al. (2001b) studied the effects of cytokine gene adjuvants to 
enhance the level of cell-mediated immune responses in rhesus macaques. DNA vaccine 
constructs encoding for HIIV env/rev and SW gag/pot proteins were co-delivered to 
animals with plasmids encoding for 1L-2, IFN-gamma or I1L-4 cytokines. The results 
showed that co-administration of 11L-2 and JFN-gamma DNA constructs resulted in 
enhancement of antigen-specific T cell- mediated immune responses. It was also 
demonstrated that plasmids encoding IL-211g, a fusion protein consisting of IL-2 and the 
Fc portion of IgG, which has 11L-2 functional activity and a prolonged half-life in vivo 
(Nickerson et al., 1996), can substantially augment immune response when co-
administrated with DNA vaccine. The study showed that Gag -specific CTLs amounted 
to 18-40% of total circulating CD8+ T cells in rhesus monkeys that received the DNA 
vaccines encoding SWMAC239 Gag and HIV-189.6p Env plus 11L-211g protein or plasmid, 
compared to 6-20% of total circulating CD8+ T cells in animals received DNA vaccines 
only, suggesting that the co-administration of 11L-2/Ig can substantially augment immune 
responses elicited by DNA vaccine in primates (Barouch et al., 2001b). 
Phase I trials to evaluate the safety and immunogenicity of DNA constructs as an HTV 
vaccine candidate have been conducted in HIV-1 uninfected healthy volunteers. An 
HIV-1 env/rev DNA vaccine was administered intramuscularly to HIIV-1-seronegative 
persons at a dose of 100 or 300 .tg at 0, 4, 8, and 24 weeks. Subjects who received the 
300 tg dose exhibited antigen-specific T cell immune responses. This study supports the 
premise that HIV-1 DNA vaccine antigens can stimulate immune responses in 
immunised volunteers, and further studies to enhance DNA vaccine immunogenicity are 
required (Boyer et al., 2000a). 
Notably, a phase I trial of the first DNA vaccine specifically designed to combat the 
dade A HIV-1 virus, which is the most prevalent strain in many parts of Africa, was 
officially launched in Oxford in 2000 and later in Kenya in 2001. The trial was 
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conducted in low risk healthy volunteers and is to evaluate the safety and 
immunogenicity of the DNA vaccine. Results are expected to be ready in about two 
years (Fazal et al., 2000). 
1.5.8 Prime/boost strategy 
A prime-boost strategy refers to a vaccination regimen involving a primary vaccination 
with one vaccine, typically a DNA vaccine or a recombinant vector vaccine to induce 
cellular immune responses, followed by booster shots of a subunit vaccine to stimulate 
antibody production (Letvin et al., 1997; Tartaglia et al., 1998; Cho et al., 2001). This 
strategy is under active investigation not only for the potential additional effects of the 
vaccine on eliciting more effective immunity against HP/-i infection, but also for the 
potential that vaccine combinations may augment the breadth of both humoral and 
cellular immune responses against ITIV-i infection. It has been demonstrated that 
immunisation with live recombinant viral vectors (e.g., vaccinia vector) or DNA 
vaccines, which allow de novo synthesis of antigens, elicit CD8+ CTL responses 
(Steinman et al., 1998; Cho 2000; Barouch et al., 2001b), and with recombinant proteins 
can induce neutralising antibodies (Graham et al., 1996; Connor et at., 1998; 
McCormack et al., 2000; Nitayaphan et at., 2000). FIIV-1 vaccination prime-boost 
strategies consist of priming with live virus vectors or 1IV-1 DNA vaccines expressing 
HIV-1 proteins and boosting with subunit proteins or recombinant viral vector vaccines 
expressing HIV-1 proteins, may induce more potent HIV-1 specific cellular immune 
responses as well as humoral immune responses, than that induced by immunisation with 
a DNA vaccine or a live recombinant vaccine alone (Amara et al., 2001; Cho et al., 
2001; Nilsson et al., 2001; Yoshizawa et at., 2001). Macaques vaccinated with a 
recombinant Semliki forest virus (SFV) expressing multiple SW structural and 
regulatory proteins and boosted with a recombinant MVA expressing the same SW 
proteins as the recombinant SFV vector efficiently induced both humoral and cellular 
immune responses (Nilsson et al., 2001). Pigtailed macaques primed with recombinant 
vaccinia virus expressing HIV-1 gp160 and boosted with HIV-1 gp120 proteins 
developed neutralising antibodies against multiple HIV-1 isolates (Cho et at., 2001). 
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To generate both cellular and humoral immune responses, a phase I trial for evaluating 
the regimen of priming with recombinant vaccinia vector expressing FIIV-1 9p160j and 
boosting with HIV-1 rgpl20sp, rgp120i, rgp120MN or rgp16OMN were conducted in 56 
vaccinia naïve subjects. Neutralising antibodies against homologous and heterologous 
I-HV-1 strains occurred in all vaccinees receiving live recombinant vaccinia vectors and 
rgp120 proteins. 26 out of 51 subjects tested demonstrated Env-specific CTLs. These 
results demonstrated that vaccination regimens in which one component elicits primarily 
CTLs and the other neutralising antibodies may offer the promise for the development of 
an effective HIV-1 vaccine strategy (Corey et al., 1998). 
To date, different prime- boost strategies have been tested including sequentially 
immunising with viral vectors and subunit proteins (Corey et al., 1998; Belshe 2001), 
naked DNA and subunit proteins (Letvin et al., 1997P; Putkonen P et al., 1998; 
Cherpelis et al., 2001), naked DNA and recombinant viral vector vaccines (Amara et al., 
2001); live attenuated HIV and live viral vector vaccines (Walther-Jallow et al., 2001), 
by combining two different recombinant viral vectors (Nilsson et al., 2001), and also 
triple combinations (naked DNA, recombinant viral vector and then purified subunit 
proteins) (Lockey et al., 2000). 
1.6 Conclusion 
Development of an effective vaccine against HIV-1 is an important goal in the fight 
against AIDS. The observed role of CTh in the control of HJV-1 replication suggests 
that it is essential for an effective HIV-1 vaccine to induce strong H1V-1 specific CTL 
responses. The vaccine should also be able to induce antibodies neutralising HIV 
primary isolates, and importantly be capable of generating immunity at the mucosal 
surfaces, the primary route of transmission. At present, in the absence of definitive 
information about the mechanisms of protective immunity, induction of these responses 
remains an initial benchmark by which to judge candidate HIV vaccines. 
Live attenuated vaccine has been shown to induce efficient protection against pathogenic 
virus challenge in primate model, but its safety has been questioned. Recombinant viral 
A83 
protein and whole inactivated viruses are limited by their inability to induce Cli-
response. In contrast, naked DNA and live recombinant vector approaches can induce 
cellular immune responses, but these immune response are unlikely to be of sufficient 
magnitude to achieve protective immunity against challenges with a pathogenic SIVIHIV 
strain. A great deal of attention has been focused on prime/boost strategies, which have 
shown that DNA or live recombinant viral vector priming followed by recombinant 
protein or live recombinant viral vector boosting, could significantly augment HIV-
1/SW specific immune responses. However, the safety and efficacy of regimens which 
induce immune responses correlating protection from HIV-1 infection of candidate HIV-
1 vaccines need to be validated in human clinical trials. Despite the improvements and 
encouraging developments which have taken place over the past several years, 
substantial progress is still needed to achieve the goal of developing a safe and effective 
HIV-1 vaccine. 
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